<nodes>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/index-banana.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/index-banana.html</Path>
		<FileBody>
			
			
			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_cho.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_vicenti.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_perlata.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_shake.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_cho.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			
			 &lt;div id=&quot;hometagVic&quot; class=&quot;rheum&quot;&gt;&lt;/div&gt;
			&lt;div id=&quot;hometagtextVic&quot; class=&quot;rheum&quot;&gt;To provide outstanding clinical care while advancing the discipline of Rheumatology through cutting edge research and training of the next generation of academic rheumatologists.&lt;/div&gt;
			
			&lt;script type=&quot;text/javascript&quot; src=&quot;http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;
			
			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');
			
			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');
			    
			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }
			    
			    var $next = $active.next();
			
			    $active.addClass('last&#45;active');
			
			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}
			
			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});
			
			&lt;/script&gt;
			
			
			
			&lt;!&#45;&#45; 
			
			&lt;p&gt; &#45;&#45;&gt;
			 
			 
			&lt;div class=&quot;news mod&quot;&gt; 
			                &lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
						&lt;div id=&quot;allNews&quot;&gt;
			&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			
			
			
			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Fellowship Spotlight&lt;/h4&gt;
			&lt;ul&gt;&lt;li&gt;
			Information and &lt;b&gt;&lt;a href=&quot;&quot;&gt;links&lt;/a&gt;&lt;/b&gt; go &lt;b&gt;here&lt;/b&gt;!  &lt;/li&gt;&lt;/ul&gt;
			&lt;/div&gt;
			
			
			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;                
			&lt;h4&gt;Calendar&lt;/h4&gt;
						
			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/index-new.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/index-new.html</Path>
		<FileBody>
			
			
			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_cho.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_vicenti.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_perlata.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_shake.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_cho.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			
			 &lt;div id=&quot;hometagVic&quot;&gt;&lt;/div&gt;
			&lt;div id=&quot;hometagtextVic&quot;&gt;Tag line or brief mission statement here that could be as long and as detailed or complex or simple as this.&lt;/div&gt;
			
			&lt;script type=&quot;text/javascript&quot; src=&quot;http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;
			
			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');
			
			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');
			    
			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }
			    
			    var $next = $active.next();
			
			    $active.addClass('last&#45;active');
			
			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}
			
			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});
			
			&lt;/script&gt;
			
			
			
			&lt;!&#45;&#45; 
			
			&lt;p&gt; &#45;&#45;&gt;
			 
			 
			&lt;div class=&quot;news mod&quot;&gt; 
			                &lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
						&lt;div id=&quot;allNews&quot;&gt;
			&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			
			
			
			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Fellowship Spotlight&lt;/h4&gt;
			&lt;ul&gt;&lt;li&gt;
			Information and &lt;b&gt;&lt;a href=&quot;&quot;&gt;links&lt;/a&gt;&lt;/b&gt; go &lt;b&gt;here&lt;/b&gt;!  &lt;/li&gt;&lt;/ul&gt;
			&lt;/div&gt;
			
			
			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;                
			&lt;h4&gt;Calendar&lt;/h4&gt;
						
			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/index-old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/index-old.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;table width=&quot;528&quot; border=&quot;1&quot;&gt;
			&lt;tr&gt;
			    &lt;td height=&quot;123&quot;&gt;&lt;img src=&quot;images/faculty/wofsy2.jpg&quot; width=&quot;163&quot; height=&quot;200&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/wofsy.htm&quot;&gt;David Wofsy MD&lt;/a&gt; received in 2012 the designation of Master by the &lt;a href=&quot;http://www.rheumatology.org/membership/awards/awards_physiciansscientists.asp&quot;&gt;American College of Rheumatology&lt;/a&gt;, which is one of the highest honors the College bestows.&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;images/faculty/graf.JPG&quot; width=&quot;169&quot; height=&quot;199&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;div align=&quot;left&quot;&gt;
			      &lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/graf.htm&quot;&gt;Jonathan Graf,  MD&lt;/a&gt; received the 2012 &lt;em&gt;Within Our Reach&lt;/em&gt; Clinical Trials Award from the&lt;a href=&quot;http://www.rheumatology.org/foundation/about.asp&quot;&gt; Rheumatology Research Foundation&lt;/a&gt;. Within  Our Reach is dedicated to finding a cure  for Rheumatoid Arthritis.&lt;/p&gt;
			&lt;/div&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			
			
			  &lt;tr&gt;
			    &lt;td height=&quot;123&quot;&gt;&lt;img src=&quot;images/faculty/schwartz2.jpg&quot; width=&quot;171&quot; height=&quot;203&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;In 2012, Dr.  Nina Schwartz received an annual Special Recognition Award from the &lt;a href=&quot;http://meded.ucsf.edu/acf&quot;&gt;UCSF  Association of the Clinical Faculty&lt;/a&gt;.&amp;nbsp; Dr.  Schwartz is a volunteer faculty for the UCSF Division of Rheumatology. She has  been a fixture in our educational program for students, residents and fellows  for over 20 years.&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;158&quot; height=&quot;103&quot;&gt;&lt;p&gt;&lt;img src=&quot;images/faculty/katsumoto2.jpg&quot; alt=&quot;&quot; width=&quot;171&quot; height=&quot;160&quot; /&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;354&quot;&gt;&lt;div align=&quot;left&quot;&gt;
			      &lt;div align=&quot;left&quot;&gt;
			        &lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/katsumoto.htm&quot;&gt;Tamiko Katsumoto, MD&lt;/a&gt; is honored as the Jo Rae Wright Early Career Investigator Award recipient for 2012.&lt;/p&gt;
			      &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/faculty/weiss2a.JPG&quot; alt=&quot;&quot; width=&quot;170&quot; height=&quot;211&quot; /&gt;&lt;br /&gt;
			    &lt;/p&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/weiss.htm&quot;&gt;Arthur Weiss, MD, PhD&lt;/a&gt; is the recipient of the &lt;a href=&quot;http://academicaffairs.ucsf.edu/mentoring/awards.php&quot;&gt;2012 UCSF  Lifetime Mentoring Award.&lt;/a&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&lt;img src=&quot;images/faculty/katsumoto2.jpg&quot; alt=&quot;&quot; width=&quot;171&quot; height=&quot;160&quot; /&gt;&lt;br /&gt;
			    &lt;/p&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/katsumoto.htm&quot;&gt;Tamiko Katsumoto, MD&lt;/a&gt; has been chosen to receive the Laura Bechtel Junior Faculty  Award in recognition of her research.&amp;nbsp;Tamiko&amp;rsquo;s research is providing  insights into disease pathogenesis and new directions in the treatment of  scleroderma lung disease and asthma. &lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/faculty/weiss2a.JPG&quot; alt=&quot;&quot; width=&quot;170&quot; height=&quot;211&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;div align=&quot;left&quot;&gt;
			      &lt;div align=&quot;left&quot;&gt;
			        &lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/weiss.htm&quot;&gt;Arthur Weiss, MD,   PhD&lt;/a&gt; is the recipient of the &lt;a href=&quot;http://www.aai.org/Alerts/Awards/CareerAwardRecipients&#45;01&#45;wider.html&quot;&gt;2012   AAI Lifetime Achievement Award&lt;/a&gt; for outstanding research and career   achievements.&lt;/p&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;a class=&quot;style1&quot;
			href=&quot;http://www.ucsf.edu/news/2011/07/10275/ucsf&#45;medical&#45;center&#45;named&#45;top&#45;10&#45;hospital&#45;11th&#45;consecutive&#45;year&quot;&gt;US News and World Report&amp;rsquo;s Best Hospitals &lt;/a&gt;ranks UCSF Rheumatology in the top 10 in the United States.&lt;br&gt;
			    &lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/index.html</Path>
		<FileBody>
			
			
			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/group_2012.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/andy_gross.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/hands_home.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/mat_loubian.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/retreat_2008.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/dall_era.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/knee_home.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/group_2012.jpg&quot; /&gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			
			 &lt;!&#45;&#45;&lt;div id=&quot;hometagVic&quot; style=&quot;width:220px;height:150px&quot;&gt;&lt;/div&gt;
			&lt;div id=&quot;hometagtextVic&quot; style=&quot;width:220px&quot;&gt;&lt;/div&gt;&#45;&#45;&gt;
			
			&lt;script type=&quot;text/javascript&quot; src=&quot;http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;
			
			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');
			
			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');
			
			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }
			
			    var $next = $active.next();
			
			    $active.addClass('last&#45;active');
			
			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}
			
			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});
			
			&lt;/script&gt;
			
			
			
			&lt;!&#45;&#45;
			
			&lt;p&gt; &#45;&#45;&gt;
			&lt;h4&gt;Mission Statement&lt;/h4&gt;
			&lt;p&gt;To provide outstanding clinical care while advancing the discipline of Rheumatology through cutting edge research and training of the next generation of academic rheumatologists.&lt;/p&gt;
			
			&lt;div class=&quot;news mod&quot;&gt;
				&lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
							&lt;div id=&quot;allNews&quot;&gt;
					&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;
				&lt;/div&gt;
			&lt;/div&gt;
			
			
			
			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Fellowship Spotlight&lt;/h4&gt;
			&lt;p style=&quot;width:340px&quot;&gt;We have matched three excellent residents for the 2017 fellowship year!&lt;/p&gt;
			&lt;ul&gt;
				&lt;!&#45;&#45;&lt;li&gt;&lt;a href=&quot;/faculty/index.html?key=7e4fdef0fe0606ffda3a16629b518d8a&amp;name=WOFSY%2CDAVID&quot; target=&quot;_blank&quot;&gt;David Wofsy, MD&lt;/a&gt; received in 2012 the designation of Master by the &lt;a href=&quot;http://www.rheumatology.org/membership/awards/awards_physiciansscientists.asp&quot; target=&quot;_blank&quot;&gt;American College of Rheumatology&lt;/a&gt;, which is one of the highest honors the College bestows.&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/faculty/index.html?key=8b413233a93e914828059f859a6a1b23&amp;name=GRAF%2CJONATHAN+D&quot; target=&quot;_blank&quot;&gt;Jonathan Graf, MD&lt;/a&gt; received the 2012 Within Our Reach Clinical Trials Award from the &lt;a href=&quot;http://www.rheumatology.org/foundation/about.asp&quot;&gt;Rheumatology Research Foundation&lt;/a&gt;. Within Our Reach is dedicated to finding a cure for Rheumatoid Arthritis.&lt;/li&gt;
				&lt;li&gt;In 2012, Dr. Nina Schwartz received an annual Special Recognition Award from the &lt;a href=&quot;http://meded.ucsf.edu/acf&quot; target=&quot;_blank&quot;&gt;UCSF Association of the Clinical Faculty&lt;/a&gt;. Dr. Schwartz is a volunteer faculty for the UCSF Division of Rheumatology. She has been a fixture in our educational program for students, residents and fellows for over 20 years.&lt;/li&gt;&#45;&#45;&gt;
				&lt;li&gt;&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/christinea.jpg&quot; style=&quot;margin&#45;bottom:10px;&quot; class=&quot;imgLeft&quot;&gt;Christine Anastasiou, MD&lt;br&gt;&lt;/li&gt;&lt;br clear=all&gt;
				&lt;li&gt;&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/sarahfrench.jpg&quot; style=&quot;margin&#45;bottom:10px;&quot; class=&quot;imgLeft&quot;&gt;Sarah French, MD&lt;br&gt; &lt;/li&gt;&lt;br clear=all&gt;
				&lt;li&gt;&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/lucyliu.jpg&quot; class=&quot;imgLeft&quot;&gt;Lucy Liu, MD, MPH&lt;br&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/div&gt;
			
			
			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;
			&lt;h4&gt;Calendar&lt;/h4&gt;
						
			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/index.html.bak
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/index.html.bak</Path>
		<FileBody>
			
			
			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_cho.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_vicenti.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_perlata.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_shake.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/home_cho.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			
			 &lt;div id=&quot;hometagVic&quot;&gt;&lt;/div&gt;
			&lt;div id=&quot;hometagtextVic&quot;&gt;Tag line or brief mission statement here that could be as long and as detailed or complex or simple as this.&lt;/div&gt;
			
			&lt;script type=&quot;text/javascript&quot; src=&quot;http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;
			
			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');
			
			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');
			    
			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }
			    
			    var $next = $active.next();
			
			    $active.addClass('last&#45;active');
			
			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}
			
			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});
			
			&lt;/script&gt;
			
			
			
			&lt;!&#45;&#45; 
			
			&lt;p&gt; &#45;&#45;&gt;
			 
			 
			&lt;div class=&quot;news mod&quot;&gt; 
			                &lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
						&lt;div id=&quot;allNews&quot;&gt;
			&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			
			
			
			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Fellowship Spotlight&lt;/h4&gt;
			&lt;ul&gt;&lt;li&gt;
			Information and &lt;b&gt;&lt;a href=&quot;&quot;&gt;links&lt;/a&gt;&lt;/b&gt; go &lt;b&gt;here&lt;/b&gt;!  &lt;/li&gt;&lt;/ul&gt;
			&lt;/div&gt;
			
			
			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;                
			&lt;h4&gt;Calendar&lt;/h4&gt;
						
			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/index.html~</Path>
		<FileBody>
			
			
			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/group_2012.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/andy_gross.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/hands_home.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/mat_loubian.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/retreat_2008.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/dall_era.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/knee_home.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/homepage/group_2012.jpg&quot; /&gt;
			
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			
			 &lt;!&#45;&#45;&lt;div id=&quot;hometagVic&quot; style=&quot;width:220px;height:150px&quot;&gt;&lt;/div&gt;
			&lt;div id=&quot;hometagtextVic&quot; style=&quot;width:220px&quot;&gt;&lt;/div&gt;&#45;&#45;&gt;
			
			&lt;script type=&quot;text/javascript&quot; src=&quot;http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js&quot;&gt;&lt;/script&gt;
			&lt;script type=&quot;text/javascript&quot;&gt;
			
			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');
			
			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');
			    
			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }
			    
			    var $next = $active.next();
			
			    $active.addClass('last&#45;active');
			
			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}
			
			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});
			
			&lt;/script&gt;
			
			
			
			&lt;!&#45;&#45; 
			
			&lt;p&gt; &#45;&#45;&gt;
			&lt;h4&gt;Mission Statement&lt;/h4&gt;
			&lt;p&gt;To provide outstanding clinical care while advancing the discipline of Rheumatology through cutting edge research and training of the next generation of academic rheumatologists.&lt;/p&gt;
			 
			&lt;div class=&quot;news mod&quot;&gt; 
			                &lt;h4&gt;News &amp; Highlights&lt;/h4&gt;
						&lt;div id=&quot;allNews&quot;&gt;
			&lt;span class=&quot;allNews&quot;&gt;&lt;a href=&quot;/about/news.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			
			
			
			 &lt;div class=&quot;pod highlights unitLeft fellows&quot;&gt;
			&lt;h4&gt;Fellowship Spotlight&lt;/h4&gt;
			&lt;p style=&quot;width:340px&quot;&gt;We have matched three excellent residents for the 2013 fellowship year!&lt;/p&gt;
			&lt;ul&gt;
				&lt;!&#45;&#45;&lt;li&gt;&lt;a href=&quot;/faculty/index.html?key=7e4fdef0fe0606ffda3a16629b518d8a&amp;name=WOFSY%2CDAVID&quot; target=&quot;_blank&quot;&gt;David Wofsy, MD&lt;/a&gt; received in 2012 the designation of Master by the &lt;a href=&quot;http://www.rheumatology.org/membership/awards/awards_physiciansscientists.asp&quot; target=&quot;_blank&quot;&gt;American College of Rheumatology&lt;/a&gt;, which is one of the highest honors the College bestows.&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/faculty/index.html?key=8b413233a93e914828059f859a6a1b23&amp;name=GRAF%2CJONATHAN+D&quot; target=&quot;_blank&quot;&gt;Jonathan Graf, MD&lt;/a&gt; received the 2012 Within Our Reach Clinical Trials Award from the &lt;a href=&quot;http://www.rheumatology.org/foundation/about.asp&quot;&gt;Rheumatology Research Foundation&lt;/a&gt;. Within Our Reach is dedicated to finding a cure for Rheumatoid Arthritis.&lt;/li&gt;
				&lt;li&gt;In 2012, Dr. Nina Schwartz received an annual Special Recognition Award from the &lt;a href=&quot;http://meded.ucsf.edu/acf&quot; target=&quot;_blank&quot;&gt;UCSF Association of the Clinical Faculty&lt;/a&gt;. Dr. Schwartz is a volunteer faculty for the UCSF Division of Rheumatology. She has been a fixture in our educational program for students, residents and fellows for over 20 years.&lt;/li&gt;&#45;&#45;&gt;
				&lt;li&gt;Sancia Ferguson, MD  Tulane Resident&lt;/li&gt;
				&lt;li&gt;Alison Bays, MD University of Washington Resident&lt;/li&gt;
				&lt;li&gt;Cristina Lanata, MD  Georgetown/Washington Hospital Center, D.C., Chief Resident&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/div&gt;
			
			
			&lt;div class=&quot;pod calendarHm unitLeft&quot;&gt;                
			&lt;h4&gt;Calendar&lt;/h4&gt;
						
			&lt;div id=&quot;allEvents&quot;&gt;
			&lt;span class=&quot;allEvents&quot;&gt;&lt;a href=&quot;/about/calendar.html&quot;&gt;View all »&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
						&lt;/div&gt;
			&lt;/div&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;left&quot;&gt;&amp;nbsp;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Home ./rheumatology/indexbak.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/indexbak.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;table width=&quot;528&quot; height=&quot;1572&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td height=&quot;214&quot;&gt;&lt;img src=&quot;file:///Z|/rheumatology/images/faculty/weiss2a.JPG&quot; width=&quot;170&quot; height=&quot;211&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;div align=&quot;left&quot;&gt;
			      &lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/weiss.htm&quot;&gt;Arthur Weiss, MD,   PhD&lt;/a&gt; received the &lt;a href=&quot;http://sabre.ucsf.edu/executive/arthur_weiss.html&quot;&gt;2012   AAI Lifetime Achievement Award&lt;/a&gt; for outstanding research and career   achievements.&lt;/p&gt;
			    &lt;/div&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			 
			 
			  &lt;tr&gt;
			    &lt;td height=&quot;123&quot;&gt;&lt;img src=&quot;images/faculty/chung3.jpg&quot; alt=&quot;&quot; width=&quot;168&quot; height=&quot;239&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;The &lt;a href=&quot;http://www.vasculitisfoundation.org/research&quot;&gt;Vasculitis Foundation&lt;/a&gt; has approved &lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/chung.htm&quot;&gt;Dr. Sharon  Chung&amp;rsquo;s&lt;/a&gt; study &amp;ldquo;Exome sequencing in  granulomatosis with polyangiitis&amp;rdquo; for funding for one year.&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;158&quot; height=&quot;103&quot;&gt;&lt;p&gt;&lt;img src=&quot;images/faculty/yazdany2.jpg&quot; alt=&quot;&quot; width=&quot;166&quot; height=&quot;237&quot; /&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;354&quot;&gt;&lt;div align=&quot;left&quot;&gt;
			      &lt;div align=&quot;left&quot;&gt;
			        &lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/yazdany.htm&quot;&gt;Dr. Jinoos  Yazdany&lt;/a&gt; has won the 2011 &lt;a href=&quot;http://www.lupus.org/webmodules/webarticlesnet/templates/new_researchlfa.aspx?articleid=2646&amp;amp;zoneid=31&quot;&gt;Mary  Betty Stevens Young Investigator Award&lt;/a&gt; from the Lupus Foundation of America  for her research in systemic lupus erythematosus.&lt;/p&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&lt;img src=&quot;images/faculty/criswell2a.jpg&quot; alt=&quot;&quot; width=&quot;168&quot; height=&quot;230&quot; /&gt;&lt;br /&gt;
			    &lt;/p&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/criswell.htm&quot;&gt;Lindsey  A. Criswell, MD, MPH&amp;nbsp;&lt;/a&gt;has been appointed as Chief of the Division of  Rheumatology &amp;shy; Parnassus/Mt. Zion, effective July 1, 2011.&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&lt;img src=&quot;images/faculty/chung3.jpg&quot; alt=&quot;&quot; width=&quot;168&quot; height=&quot;239&quot; /&gt;&lt;br /&gt;
			    &lt;img src=&quot;images/faculty/Zikherman2.jpg&quot; alt=&quot;&quot; width=&quot;167&quot; height=&quot;161&quot; /&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			    &lt;p&gt;&amp;nbsp;&lt;/p&gt;
			    &lt;p&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/chung.htm&quot;&gt;Sharon Chung, MD, MAS&lt;/a&gt; and &lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/zikherman.htm&quot;&gt;Julie Zikherman, MD&lt;/a&gt; have been selected as the 2011 recipients of the &lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/awards.html&quot;&gt;Ephraim P. Engleman Award for Excellence in the Field of Arthritis Research&lt;/a&gt;.&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;images/faculty/imboden.JPG&quot; alt=&quot;&quot; width=&quot;166&quot; height=&quot;172&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/about/faculty/imboden.htm&quot;&gt;John Imboden, MD&lt;/a&gt; was named in 2011 as a &lt;a href=&quot;http://medicine.ucsf.edu/masters/current.html&quot;&gt;UCSF Department of Medicine Master Clinician&lt;/a&gt;,  an honor that was previously bestowed on Drs. Kenneth Sack and  Kenneth Fye in the Rheumatology Division.&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;a class=&quot;style1&quot; 
			href=&quot;http://www.ucsf.edu/news/2011/07/10275/ucsf&#45;medical&#45;center&#45;named&#45;top&#45;10&#45;hospital&#45;11th&#45;consecutive&#45;year&quot;&gt;US News and World Report&amp;rsquo;s Best Hospitals &lt;/a&gt;ranks UCSF Rheumatology in the top 10 in the United States.&lt;br&gt;
			    &lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Administration ./rheumatology/about/admin.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/admin.html</Path>
		<FileBody>
			
			&lt;table&gt;
			&lt;thead&gt;&lt;tr&gt;
			&lt;td&gt;Name&lt;/td&gt;
			&lt;td&gt;Title&lt;/td&gt;
			&lt;td&gt;Email&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/thead&gt;
			&lt;tbody&gt;
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;  	Moffitt&#45;Long Hospital
			&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;513 Parnassus Avenue,
			Room S&#45;847, Box 0500,
			San Francisco, CA 94143&#45;0500,
			(415) 502&#45;2279&lt;/i&gt;&lt;/td&gt;
			&lt;/tr&gt;
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Tony Barlow&lt;/td&gt;
				    &lt;td&gt;Manager&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Tony.Barlow@ucsf.edu&quot;&gt;Tony.Barlow@ucsf.edu &lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
			
				    &lt;tr&gt;
				    &lt;td&gt;Estrella Garcia&lt;/td&gt;
				    &lt;td&gt;Pre&#45;award Support&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Estrella.Garcia@ucsf.edu&quot;&gt;Estrella.Garcia@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
			
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Catherine Ross&lt;/td&gt;
				    &lt;td&gt;Post&#45;award Support&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:CRoss@medicine.ucsf.edu&quot;&gt;CRoss@medicine.ucsf.edu&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
			
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;Ambulatory Care Clinic&lt;/td&gt;
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;400 Parnassus Avenue, Plaza Level, San Francisco, CA 94143&#45;0326, (415) 353&#45;2497&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Darlene Young&lt;/td&gt;
				    &lt;td&gt;Practice Manager&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:DarleneLee.Young@ucsfmedctr.org&quot;&gt;DarleneLee.Young@ucsfmedctr.org&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
			
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;San Francisco General Hospital&lt;/td&gt;
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;Building 30, Room 3300, Box 0868, 1001 Potrero Avenue, San Francisco, CA 94110&#45;0868
			&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
			    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Aida Maluto&lt;/td&gt;
				    &lt;td&gt;Administrative Assistant&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:AidaMulato@ucsf.edu&quot;&gt;AidaMulato@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
			
				    &lt;tr&gt;
				    &lt;td&gt;Nyya Lark&#45;Wilson&lt;/td&gt;
				    &lt;td&gt;Division Administrator&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Nyya.Lark&#45;Wilson@ucsf.edu&quot;&gt;Nyya.Lark&#45;Wilson@ucsf.edu &lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
			
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;San Francisco VA Medical Center&lt;/td&gt;
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;Arthritis/Immunology Section, 4150 Clement Street, San Francisco, CA 94121&#45;1601
			&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
			    &lt;tr class=&quot;even&quot;&gt;
			
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Venecia Jacobs&lt;/td&gt;
				    &lt;td&gt;Research Analyst &amp; Fellowship Coordinator&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Venecia.Jacobs@ucsf.edu&quot;&gt;Venecia.Jacobs@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
			
				    &lt;/table&gt;
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Administration ./rheumatology/about/admin.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/admin.html~</Path>
		<FileBody>
			
			&lt;table&gt;
			&lt;thead&gt;&lt;tr&gt;
			&lt;td&gt;Name&lt;/td&gt;
			&lt;td&gt;Title&lt;/td&gt;
			&lt;td&gt;Email&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/thead&gt;
			&lt;tbody&gt;
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;  	Moffitt&#45;Long Hospital
			&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;533 Parnassus Avenue, 
			Room U&#45;384, Box 0633, 
			San Francisco, CA 94143&#45;0633, 
			(415) 502&#45;2279&lt;/i&gt;&lt;/td&gt;
			&lt;/tr&gt;
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Tony Barlow&lt;/td&gt;
				    &lt;td&gt;Manager&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Tony.Barlow@ucsf.edu&quot;&gt;Tony.Barlow@ucsf.edu &lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
				    &lt;tr&gt;
				    &lt;td&gt;Gracie Bernacki&lt;/td&gt;
				    &lt;td&gt;Administrative Assistant&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Gracie.Bernacki@ucsf.edu&quot;&gt;Gracie.Bernacki@ucsf.edu &lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Katrina Pickett&lt;/td&gt;
				    &lt;td&gt;Pre&#45;award Support&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Katrina.Pickett@ucsf.edu&quot;&gt;Katrina.Pickett@ucsf.edu&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
				    
				    &lt;tr&gt;
				    &lt;td&gt;Benjamin Hobson&lt;/td&gt;
				    &lt;td&gt;Post&#45;award Support&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:BHobson@medicine.ucsf.edu&quot;&gt;BHobson@medicine.ucsf.edu&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
				    
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;Ambulatory Care Clinic&lt;/td&gt;
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;400 Parnassus Avenue, Plaza Level, San Francisco, CA 94143&#45;0326, (415) 353&#45;2497&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Darlene Young&lt;/td&gt;
				    &lt;td&gt;Practice Manager&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:DarleneLee.Young@ucsfmedctr.org
			&quot;&gt;DarleneLee.Young@ucsfmedctr.org&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;San Francisco General Hospital&lt;/td&gt;
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;Building 30, Room 3300, Box 0868, 1001 Potrero Avenue, San Francisco, CA 94110&#45;0868
			&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
			    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Aida Maluto&lt;/td&gt;
				    &lt;td&gt;Administrative Assistant&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:AidaMulato@ucsf.edu&quot;&gt;AidaMulato@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
				    &lt;tr&gt;
				    &lt;td&gt;Barbara Murgado&lt;/td&gt;
				    &lt;td&gt;Division Administrator&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Barbara.Murgado@ucsf.edu&quot;&gt;Barbara.Murgado@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
			
			&lt;tr class=&quot;sub&quot;&gt;
			&lt;td colspan=&quot;3&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span class=&quot;white&quot;&gt;San Francisco VA Medical Center&lt;/td&gt;
			&lt;tr&gt;&lt;td colspan=&quot;3&quot;&gt;&lt;i&gt;Arthritis/Immunology Section, 4150 Clement Street, San Francisco, CA 94121&#45;1601 
			&lt;/span&gt; &lt;/strong&gt;&lt;/em&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
			    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Denise Go&lt;/td&gt;
				    &lt;td&gt;Fellowship Coordinator&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Denise.Go@ucsf.edu&quot;&gt;Denise.Go@ucsf.edu &lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
				    &lt;tr&gt;
				    &lt;td&gt;Venecia Jacobs&lt;/td&gt;
				    &lt;td&gt;Administrative Assistant&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Venecia.Jacobs@ucsf.edu &quot;&gt;Venecia.Jacobs@ucsf.edu&lt;/a&gt;&lt;/td&gt;
				    &lt;/tr&gt;
				    
				    &lt;tr class=&quot;even&quot;&gt;
				    &lt;td&gt;Joan Tanaka&lt;/td&gt;
				    &lt;td&gt;Administrative Assistant&lt;/td&gt;
				    &lt;td&gt;&lt;a href=&quot;mailto:Joan.Tanaka@ucsf.edu&quot;&gt;Joan.Tanaka@ucsf.edu&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;
				    &lt;/table&gt;
				    
			
			
			&lt;a href=&quot;rheumatology_contact_list2.pdf&quot; target=&quot;_blank&quot;&gt;&lt;h2&gt;Complete Rheumatology Contact List (pdf)&lt;/h2&gt;&lt;/a&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
calendar.html ./rheumatology/about/calendar.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/calendar.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Campuses ./rheumatology/about/campuses.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/campuses.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;UCSF’s Division of Rheumatology spans four campuses and includes three hospital sites at UCSF: Parnassus Heights campus –including Moffitt&#45;Long Hospital, Fort Miley Veterans Administration Center in San Francisco’s outer Richmond district, San Francisco General Hospital in the Mission district, and the Institute for Health Policy Studies at Laurel Heights.&lt;/p&gt;
			
			&lt;p&gt;Although physically separated, the clinical programs are highly integrated and interactive.  The programs at these sites provide comprehensive and consultative clinical care to patients with rheumatologic diseases in the outpatient and inpatient settings. We provide care to patients with the wide spectrum of illnesses that characterize the rheumatologic diseases such as rheumatoid arthritis, systemic lupus erythematosus and the vasculitides.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Message from the Chiefs ./rheumatology/about/chiefs.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/chiefs.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Division of Rheumatology is dedicated to delivering outstanding patient care in the diagnosis and treatment of rheumatic diseases in a premier academic environment. &lt;/p&gt;
			
			&lt;p&gt;At the core of our division is our fellowship program where trainees and faculty interact closely to make UCSF rheumatology a world leader in research and education. Our Division spans four sites including UCSF Medical Center, the San Francisco Veteran’s Administration Medical Center, San Francisco General Hospital and the UCSF Laurel Heights campus.  Together we seek to foster an environment of discovery, innovation, excellence and collaboration within our program.&lt;/p&gt;
			
			&lt;p&gt;Our research activities span a wide range of disciplines, including basic research in immunology, genetics, epidemiology, and health services research, and we are increasingly expanding our translational research activities, including clinical trials and other bench&#45;to&#45;bedside research.  We receive substantial support for our research and training programs from the NIH and other funding sources, and our program also benefits from important philanthropic support.  We have a long history of superb clinical scholars and clinician educators, and we have developed several sub&#45;specialty clinics that provide expert care to patients with rare or difficult to treat rheumatic diseases and provide opportunities for translational and other novel research activities.&lt;/p&gt;
			
			&lt;p&gt;We hope you enjoy learning about our division!&lt;/p&gt;
			
			
			&lt;p&gt;Sincerely,&lt;/p&gt;
			&lt;p class=&quot;introduction&quot;&gt;Lindsey A. Criswell, MD, MPH, DSc&lt;br/&gt;
			Chief, UCSF Medical Center&lt;br/&gt;
			&lt;br/&gt;
			David I. Daikh, MD, PhD&lt;br/&gt;
			Chief, VA Medical Center&lt;br/&gt;
			&lt;br/&gt;
			John Imboden, MD&lt;br/&gt;
			Chief, SFGH&lt;br/&gt;
			&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
History ./rheumatology/about/history.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/history.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Since 1948, the UCSF Division of Rheumatology has served the needs of patients, trainees, and the professional and academic research community at large with the highest quality patient care, education, and research opportunities. &lt;/p&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/retreat_2007.jpg&quot; class=&quot;image&quot; style=&quot;margin&#45;bottom:20px&quot;/&gt;
			&lt;p&gt;The first research studies on the relationship between rheumatoid factor and diagnosis of rheumatoid arthritis were headed by Dr. Wally Epstein in 1957, establishing the Division’s very first research laboratory.  In 1958, the UCSF Division of Rheumatology’s Research Training Program began and enrolled its first trainee, Jeffrey Fessel.  Dr. Fessel went on to become San Francisco Kaiser Hospital’s Chief of the Department of Medicine and Director of the Residency Training Program.  Since its creation in 1958, 145 men and women have trained in the Division of Rheumatology’s Research Training Program.  Originally there were three rheumatology training programs: one at each of the three campuses.  In 1987 the three programs were merged and a single integrated program was formed in which trainees rotated between all three sites.  In 1992, Dr. David Wofsy became the head of the training program and served in that capacity until 2005, when Dr. David Daikh succeeded him.  &lt;/p&gt;
			
			&lt;p&gt;The history of UCSF Division of Rheumatology would not be complete without mention of one of our most distinguished members, &lt;a href=&quot;ephengleman.pdf&quot;&gt;Dr. Ephraim Engleman&lt;/a&gt;. As one of the first physicians to receive training in the new subspecialty of rheumatology, Dr. “Eph” Engleman opened the first rheumatology clinic at UCSF in 1947.  His influence at UCSF over many years has been substantial.  In addition to his activities in rheumatology, he has served as President of the Executive Medical Board of UCSF and as the first President and Co&#45;Founder of the Association of Clinical Faculty at UCSF.  Dr. Engleman was also influential in establishing the &lt;a href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;Rosalind Russell Medical Research Center for Arthritis&lt;/a&gt; at UCSF and has acted as its director since 1979. This center has been hugely instrumental in supporting research and fellowship training at UCSF.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Honors &amp; Awards ./rheumatology/about/honors.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/honors.html</Path>
		<FileBody>
			
			&lt;p&gt;&lt;b&gt;Laura Bechtel Junior Faculty Award&lt;/b&gt;
			&lt;ul style=&quot;margin&#45;top:&#45;10px;&quot;&gt;&lt;li&gt;2009&#45;12: Julie Zikherman, MD
			&lt;/li&gt;&lt;li&gt;2012&#45;13: Tamiko Katsumoto, MD
			&lt;/li&gt;&lt;li&gt;2013&#45; 14: Gabriela Schmajuk, MD
			&lt;/li&gt;&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;Ephraim P. Engleman Award for Excellence in the Field of Arthritis Research
			&lt;/b&gt;
			&lt;ul style=&quot;margin&#45;top:&#45;10px;&quot;&gt;
			&lt;li&gt;2003: Jennifer Gorman, MD &amp; Mehrdad Matloubian, MD, PhD&lt;/li&gt;
			&lt;li&gt;2004: Mary Beth Humphrey, MD, PhD
			&lt;/li&gt;&lt;li&gt;2005: Leonard L. Dragone, MD
			&lt;/li&gt;&lt;li&gt;2006: Maria Dall'Era, MD &amp; Jonathan D. Graf, MD
			&lt;/li&gt;&lt;li&gt;2008: Kenneth J. Scalapino, MD &amp; Jinoos Yazdany, MD, MPH
			&lt;/li&gt;&lt;li&gt;2011: Sharon A. Chung, MD, MAS &amp; Julie Zikherman, MD
			&lt;/li&gt;&lt;li&gt;2012: Jennifer Barton, MD &amp; Gabriela Schmajuk, MD
			&lt;/li&gt;&lt;li&gt;2013: Mary E. Margaretten, MD MAS
			&lt;/li&gt;&lt;li&gt;2014: Robert Su, MD
			&lt;/li&gt;&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;Ira M. Goldstein Award for Outstanding Teaching in Rheumatology  &lt;/b&gt;
			&lt;ul style=&quot;margin&#45;top:&#45;10px;&quot;&gt;
			&lt;li&gt;1999: David I. Daikh, MD, PhD&lt;/li&gt;
			&lt;li&gt;2000: Kenneth E. Sack, MD
			&lt;/li&gt;&lt;li&gt;2001: John C. Davis, Jr., MD
			&lt;/li&gt;&lt;li&gt;2002: Kenneth H. Fye, MD
			&lt;/li&gt;&lt;li&gt;2003: John Imboden, MD
			&lt;/li&gt;&lt;li&gt;2004: Mary Nakamura, MD
			&lt;/li&gt;&lt;li&gt;2005: Wallace Epstein, MD
			&lt;/li&gt;&lt;li&gt;2006: Kerstin Morehead, MD
			&lt;/li&gt;&lt;li&gt;2007: Maria Dall'Era, MD
			&lt;/li&gt;&lt;li&gt;2008: Jinoos Yazdany, MD, MPH
			&lt;/li&gt;&lt;li&gt; 2009: Julia Charles, MD, PhD
			&lt;/li&gt;&lt;li&gt;2010: Jonathan D. Graf, MD
			&lt;/li&gt;&lt;li&gt;2011: John Imboden, MD
			&lt;/li&gt;&lt;li&gt;2012: Julie Baker&#45;LePain, MD
			&lt;/li&gt;&lt;li&gt; 2013: Andrew J. Gross, MD
			&lt;/li&gt;&lt;li&gt;2014: Gabriela Schmajuk, MD
			&lt;/li&gt;&lt;li&gt;2015: Lianne Gensler, MD
			&lt;/li&gt;&lt;li&gt;2016: Sarah Goglin, MD
			&lt;/li&gt;&lt;li&gt;2017: Mary Margaretten, MD
			&lt;/li&gt;&lt;/ul&gt;
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
About Us ./rheumatology/about/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/index.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Welcome to the Division of Rheumatology at the University of California, San Francisco!&lt;/p&gt;
			
			&lt;p&gt;&lt;i&gt;“Anyone who has spent time in association with the Rheumatology Division at UCSF has experienced the sense that it is a special institution.  This partly stems from the remarkable breadth of talent and involvement in research, education and clinical care encompassed by the faculty and fellows.  But it is also clearly related to all of the people who make up rheumatology at UCSF –the shared collegiality and commitment to excellence that defines the culture of the Division across all its several sites.” &lt;/i&gt;&lt;/p&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/hands.jpg&quot; class=&quot;imgLeft&quot;/&gt;
			&lt;div style=&quot;text&#45;align:right;margin&#45;top:24px;&quot;&gt;&#45; &lt;b&gt;David I. Daikh M.D., Ph.D.&lt;/b&gt;&lt;br /&gt;Associate Professor of Medicine&lt;br /&gt;Director, Rheumatology Fellowship Training Program&lt;/div&gt;&lt;br /&gt;
			
			&lt;p&gt;Our long tradition of commitment to excellence in the field of rheumatology continues as we train the next generation of academic rheumatology leaders and provide the highest quality patient care.
			&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
News Archives ./rheumatology/about/news.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/news.html</Path>
		<FileBody>
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Visiting Professors ./rheumatology/about/professors.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/professors.html</Path>
		<FileBody>
			
			&lt;p&gt;&lt;b&gt;Jean S. &amp; Ephraim P. Engleman Visiting Professors of Rheumatology&lt;/b&gt;
			&lt;ul style=&quot;margin&#45;top:&#45;10px;&quot;&gt;&lt;li&gt;1997: William Koopman, MD, University of Alabama
			&lt;/li&gt;&lt;li&gt;1998: Bevra Hahn, MD, University of California Los Angeles 1999: Allen C. Steere, MD, Tufts University School of Medicine 2000: John D. Stobo, MD, University of Texas
			&lt;/li&gt;&lt;li&gt;2001: Michael B. Brenner, MD, Brigham and Women's Hospital 2002: James O'Dell, MD, University of Nebraska
			&lt;/li&gt;&lt;li&gt;2003: Betty A. Diamond, MD, Albert Einstein College of Medicine 2004: Steven Goldring, MD, Harvard Medical School
			&lt;/li&gt;&lt;li&gt;2005: Peter K. Gregersen, MD, NYU School of Medicine
			&lt;/li&gt;&lt;li&gt;2006: Daniel Kastner, MD, PhD, NIAMS
			&lt;/li&gt;&lt;li&gt;2008: V. Michael Holers, MD, University of Colorado
			&lt;/li&gt;&lt;li&gt;2010: Laurie Glimcher, MD, Harvard Medical School
			&lt;/li&gt;&lt;li&gt;2012: Antony Rosen, MD, Johns Hopkins University
			&lt;/li&gt;&lt;li&gt;2013: Gary Koretzky, MD, PD, University of Pennsylvania
			&lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;&lt;b&gt;Wallace V. Epstein Visiting Professors of Rheumatology&lt;/b&gt;
			&lt;ul style=&quot;margin&#45;top:&#45;10px;&quot;&gt;&lt;li&gt;2003: John M. Esdaile, MD, University of British Columbia 2004: David Felson, MD, Boston University
			&lt;/li&gt;&lt;li&gt;2005: Donald A. Berry, PhD, University of Texas
			&lt;/li&gt;&lt;li&gt;2006: Maria Suarez&#45;Almazor, MD, University of Texas 2007: Sherine Gabriel, MD, Mayo Clinic
			&lt;/li&gt;&lt;li&gt;2009: David S. Pisetsky, MD, PhD, Duke University
			&lt;/li&gt;&lt;li&gt;2010: David Borenstein, MD, George Washington University Medical Center 2011: Lenore M. Buckley, MD, MPH, Virginia Commonwealth University 2012: None
			&lt;/li&gt;&lt;li&gt;2013: Bevra Hahn, MD, University of California at Los Angeles
			&lt;/li&gt;&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Volunteers ./rheumatology/about/volunteers.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/about/volunteers.html</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatoid Arthritis Clinic ./rheumatology/care/arthritis.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/arthritis.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Comprehensive evaluations are conducted in a multidisciplinary clinic that includes rheumatologists and a plastic surgeon specializing in the correction of hand deformities. &lt;/p&gt;
			
			
			
			&lt;p&gt;Patients seen in this clinic are monitored systematically over time, including their responses to the latest therapies. Because many of the patients in this clinic have complex systemic disease, the rheumatologists in this clinic also work closely with colleagues in multiple departments at UCSF to address all the needs of these patients. This includes the orthopaedic surgeons at UCSF who specialize in hand, shoulder, knee, and foot/ankle deformities as well as joint replacement in immunosuppressed patients. The Rheumatoid Arthritis Clinic
			is the gateway to the UCSF Rheumatoid Arthritis Cohort, the largest clinical study of rheumatoid arthritis patients in the western United States. Clinical studies are ongoing, investigating multiple aspects of rheumatoid arthritis, including patient outcomes and responses to new therapies in patients with difficult to manage disease. For more information,
			please contact &lt;a href=&quot;/faculty/index.html?key=498948be744cb4aa804822b22b68b78a&amp;name=GROSS%2CANDREW+J&quot;&gt;Dr. Gross&lt;/a&gt; at (415) 353&#45;4967.&lt;/p&gt;
			
			&lt;h3&gt;Rheumatoid Arthritis Medication Guides&lt;/h3&gt;
			
			&lt;a href=&quot;/care/docs/RA_MedicineGuide_English.pdf&quot;&gt;English PDF&lt;/a&gt;&lt;br/&gt;
			&lt;a href=&quot;/care/docs/RA_MedicineGuide_Mandarin.pdf&quot;&gt;Chinese PDF&lt;/a&gt;&lt;br/&gt;
			&lt;a href=&quot;/care/docs/RA_MedicineGuide_Spanish.pdf&quot;&gt;Spanish PDF&lt;/a&gt;&lt;br/&gt;
			&lt;br/&gt;
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/rheumatoid_arthritis/index.html&quot; target=&quot;_blank&quot;&gt;Rheumatoid Arthritis Clinic website&lt;/a&gt;.
			&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatoid Arthritis Clinic ./rheumatology/care/arthritis.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/arthritis.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Comprehensive evaluations are conducted in a multidisciplinary clinic that includes rheumatologists and a plastic surgeon specializing in the correction of hand deformities. &lt;/p&gt;
			
			
			
			&lt;p&gt;Patients seen in this clinic are monitored systematically over time, including their responses to the latest therapies. Because many of the patients in this clinic have complex systemic disease, the rheumatologists in this clinic also work closely with colleagues in multiple departments at UCSF to address all the needs of these patients. This includes the orthopaedic surgeons at UCSF who specialize in hand, shoulder, knee, and foot/ankle deformities as well as joint replacement in immunosuppressed patients. The Rheumatoid Arthritis Clinic
			is the gateway to the UCSF Rheumatoid Arthritis Cohort, the largest clinical study of rheumatoid arthritis patients in the western United States. Clinical studies are ongoing, investigating multiple aspects of rheumatoid arthritis, including patient outcomes and responses to new therapies in patients with difficult to manage disease. For more information,
			please contact &lt;a href=&quot;/faculty/index.html?key=498948be744cb4aa804822b22b68b78a&amp;name=GROSS%2CANDREW+J&quot;&gt;Dr. Gross&lt;/a&gt; at (415) 353&#45;4967.&lt;/p&gt;
			
			&lt;h3&gt;Educational PDF Materials&lt;/h3&gt;
			
			&lt;a href=&quot;/care/docs/RA_MedicineGuide_English.pdf&quot;&gt;English PDF&lt;/a&gt;&lt;br/&gt;
			&lt;a href=&quot;/care/docs/RA_MedicineGuide_Mandarin.pdf&quot;&gt;Mandarin PDF&lt;/a&gt;&lt;br/&gt;
			&lt;a href=&quot;/care/docs/RA_MedicineGuide_Spanish.pdf&quot;&gt;Spanish PDF&lt;/a&gt;&lt;br/&gt;
			&lt;br/&gt;
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/rheumatoid_arthritis/index.html&quot; target=&quot;_blank&quot;&gt;Rheumatoid Arthritis Clinic website&lt;/a&gt;.
			&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
General Rheumatology ./rheumatology/care/general.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/general.html</Path>
		<FileBody>
			
			&lt;p&gt;General Rheumatology at UCSF Medical Center is one of the top 10 hospitals in the nation in rheumatology, according to the annual ranking by U.S. News &amp; World Report. Our renowned rheumatologists specialize in treating a wide variety of diseases affecting muscles, bones and joints.  We bring together experts from several specialties, including rheumatology, orthopaedic surgery, dermatology and plastic surgery to diagnose and treat the more than 100 types of arthritis conditions. More than 6,000 patient visits are recorded at the clinic each year. Several of our physicians consistently appear in lists of Best Doctors in San Francisco and Best Doctors in America.&lt;/p&gt;
			
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/rheumatology_clinic/&quot;&gt;UCSF Medical Center Rheumatology Clinic website&lt;/a&gt;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./rheumatology/care/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/index.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The Clinical Program in Rheumatology at UCSF is dedicated to patient care, teaching, and clinical research.&lt;/p&gt;&lt;p&gt;  There are over 5,000 visits per year to the Rheumatology clinic where patients from diverse ethnic and socioeconomic backgrounds receive state&#45;of&#45;the&#45;art care from outstanding clinicians.  Several of our physicians consistently appear in lists of Best Doctors in San Francisco and Best Doctors in America.  Superb clinical teaching and research combine to make this one of the most sought after Rheumatology training programs in the country.
			&lt;/p&gt;
			&lt;h2&gt;Locations&lt;/h2&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.ucsfhealth.org/clinics/rheumatology/index.html&quot;&gt;UCSF Medical Center Rheumatology&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.sanfrancisco.va.gov/&quot;&gt;SFVA Medical Center&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.sfdph.org/dph/comupg/oservices/medSvs/sfgh/SFGHPatientVisitor.asp&quot;&gt;SFGH Medical Center&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/shoulder.jpg&quot; class=&quot;imgLeft&quot;/&gt;
			&lt;div style=&quot;margin&#45;top:50px&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;&lt;i&gt;“Given its small size, Rheumatology is well represented, even over&#45;represented, in the Department of Medicine’s &lt;a href=&quot;http://medicine.ucsf.edu/masters/masters.html&quot; target=&quot;_blank&quot;&gt;Council of Master Clinicians&lt;/a&gt;.”&lt;/i&gt;&lt;/p&gt;
			
			&lt;div style=&quot;text&#45;align:right;margin&#45;top:&#45;24px;&quot;&gt;&#45; &lt;b&gt;Ephraim P. Engleman, M.D.&lt;/b&gt;&lt;/div&gt;
			&lt;/div&gt;
			&lt;div style=&quot;margin&#45;top:100px&quot;&gt;
			
			&lt;/div&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Lupus Clinic ./rheumatology/care/lupus.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/lupus.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Lupus Clinic focuses on the evaluation and management of Systemic Lupus Erythematosus, with a particular emphasis on moderate to severe forms of the disease. Clinic providers have expertise in treating refractory, difficult to treat manifestations including lupus nephritis and severe arthritis and rashes. Because lupus is a disease that can involve multiple body systems, Lupus Clinic physicians work closely with other UCSF specialists including nephrologists, dermatologists, and neurologists to ensure that patients receive comprehensive care. Lupus is a chronic condition that requires close monitoring and physician collaboration throughout a patient’s lifetime. Clinic providers are dedicated to providing personalized care of the highest quality to our patients with lupus.&lt;/p&gt;
			
			&lt;p&gt;The UCSF Lupus Clinic is one of 22 national lupus centers participating in the Lupus Clinical Trials Consortium, collecting prospective information on lupus for the largest database of its kind. Clinic providers are actively engaged in the design and conduct of clinical trials in lupus sponsored by the National Institutes of Health (NIH), the Autoimmunity Centers of Excellence, and the Immune Tolerance Network. Patients are given the opportunity to participate in trials of novel and state&#45;of &#45;the&#45;art medications. Clinic providers are also leading a variety of other projects including the California Lupus Surveillance Project and the design and implementation of quality indicators for the treatment and monitoring of patients with lupus.&lt;/p&gt;
			
			&lt;p&gt;The Co&#45; Directors of the UCSF Lupus Clinic are Dr. Maria Dall’Era and Dr. Jinoos Yazdany.&lt;/p&gt;
			
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/lupus/index.html&quot; target=&quot;_blank&quot;&gt;Lupus Clinic website&lt;/a&gt;.
			&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Scleroderma Clinic ./rheumatology/care/scleroderma.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/scleroderma.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Scleroderma Clinic focuses on patients with systemic sclerosis (also known as scleroderma), mixed connective tissue disease, Sjögren’s syndrome and inflammatory myositis. &lt;/p&gt;
			
			&lt;p&gt;Patients seen in this clinic will benefit from the diverse expertise of UCSF physicians. Within this multidisciplinary clinic, a dermatologist specializing in autoimmune
			disease, Dr. Kari Connolly, sees patients along with the rheumatologists. In addition, the clinic’s physicians work closely with colleagues in the UCSF Interstitial Lung Disease Clinic and the Heart Failure Clinic, enrolling patients in clinical studies of autoimmune lung disease and pulmonary hypertension. For more information, please contact &lt;a href=&quot;/faculty/index.html?key=498948be744cb4aa804822b22b68b78a&amp;name=GROSS%2CANDREW+J&quot;&gt;Dr. Gross&lt;/a&gt; at (415) 353&#45;4967.&lt;/p&gt;
			
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a target=&quot;_blank&quot; href=&quot;http://www.ucsfhealth.org/clinics/scleroderma/index.html&quot;&gt;UCSF Scleroderma Clinic website&lt;/a&gt;.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Sjogren's Syndrome ./rheumatology/care/sjogren.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/sjogren.html</Path>
		<FileBody>
			
			&lt;p&gt;Cjögren’s Syndrome Patients who have or may have Sjögren’s Syndrome may be evaluated at the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/sjogrens_syndrome/index.html&quot; target=&quot;_blank&quot;&gt;UCSF Medical Center Sjögren's Syndrome Clinic&lt;/a&gt;, which is the only such clinic on the West coast. Evaluation is provided by a multidisciplinary team including oral medicine specialists, ophthalmologists and optometrists in coordination with rheumatologists.
			 &lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Ankylosing Spondylitis ./rheumatology/care/spondylitis.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/spondylitis.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Ankylosing Spondylitis (AS) Clinic specializes in the diagnosis and treatment of AS. &lt;/p&gt;
			
			&lt;p&gt;The clinic employs the latest diagnostic techniques, with particular focus on identifying disease at its earliest stage using specialized AS physical examination techniques and MRI protocols. Treatment of AS features the newest pharmacologic therapies. The AS clinic
			places additional emphasis on non&#45;pharmacologic treatments, and patients are encouraged to work with UCSF physical therapists in this clinic to guide them through optimized exercises for this disease. Lianne Gensler, MD, the director of the AS clinic, is a member of the Spondyloarthritis Research and Treatment Network (SPARTAN) and is actively involved in the study of this disease. &lt;/p&gt;&lt;p&gt;UCSF is one of only four sites in the United States enrolling patients in an NIH&#45;sponsored
			study examining the genetics of AS and the impact of genetics on disease severity. For more information, please contact &lt;a href=&quot;/faculty/index.html?key=bc5b1e3f809e1eac458c90f77451d8bd&amp;name=GENSLER%2CLIANNE+S.&quot;&gt;Dr. Gensler&lt;/a&gt; at (415) 353&#45;2305.&lt;/p&gt;
			
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/ankylosing_spondylitis/index.html&quot; target=&quot;_blank&quot;&gt;Ankylosing Spondylitis website&lt;/a&gt;.
			
			&lt;/p&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Vasculitis Clinic ./rheumatology/care/vasculitis.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/care/vasculitis.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Vasculitis Clinic specializes in the evaluation and management of all forms of systemic vasculitis, including giant cell arteritis,Takayasu’s arteritis, granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis), microscopic polyangiitis, Churg&#45;Strauss syndrome, and polyarteritis nodosa.&lt;/p&gt;
			
			&lt;p&gt;Dr. Sharon Chung directs this clinic and works closely with UCSF pulmonologists, nephrologists, dermatologists, ophthalmologists, as well as neuromuscular specialists to diagnose patients and treat these intensively complex diseases. The UCSF Vasculitis Clinic is a participating member of the Vasculitis Clinical Research Consortium, a network of 11 clinical sites across North America conducting clinical research studies in systemic vasculitis. Currently, the clinic is leading state&#45;of&#45;the&#45;art genetic studies and is participating in diagnostic studies of vasculitis. For more information, please contact &lt;a href=&quot;/faculty/index.html?key=214ecee2bb05a12e95c5802e7a2ed5fa&amp;name=CHUNG%2CSHARON+A.&quot;&gt;Dr. Chung&lt;/a&gt; at (415) 514&#45;1673.&lt;/p&gt;
			
			
			
			&lt;p&gt;For patients who are interested in making an appointment, please visit the &lt;a target=&quot;_blank&quot; href=&quot;http://www.ucsfhealth.org/clinics/vasculitis/index.html&quot;&gt;UCSF Vasculitis Clinic website&lt;/a&gt;.
			
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Career Info ./rheumatology/education/career.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/career.html</Path>
		<FileBody>
			
			&lt;a href=&quot;http://www.rheumatology.org/careers/&quot;&gt;
				&lt;p&gt;American College of Rheumatology Career Connection&lt;/p&gt;
			&lt;/a&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Continuing Medical Education ./rheumatology/education/cme.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/cme.html</Path>
		<FileBody>
			
			&lt;p&gt;The UCSF rheumatology program, under the direction of Drs. Mary Nakamura and David Wofsy, runs a highly successful annual national CME program for rheumatology trainees and others preparing for rheumatology board certification or re&#45;certification. The brochure from the most recent course in 2016 can be viewed here: &lt;a href=&quot;http://www.ucsfcme.com/2017/MDM17F01/MDM17F01.pdf&quot;&gt;Rheumatology Board Review and Clinical Update.&lt;/a&gt;. Rheumatology faculty members are regular participants in CME courses sponsored by UCSF (e.g. last year Dr. Lin Shen lectured in 3 UCSF CME courses).&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Program ./rheumatology/education/fellowship.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/fellowship.html</Path>
		<FileBody>
			
			&lt;p&gt;The rheumatology fellowship training program is integrated across the three primary hospital sites.  The three sites participate equally in the fellowship training program in that all trainees spend an equal amount of time at all three sites during their first year of intensive clinical training and faculty at all three sites actively participate in fellow training. The ACGME&#45;accredited program is approved for 4 positions annually and generally accepts 3&#45;4 first year fellows per year; 100% of these are graduates of ACGME&#45;accredited internal medicine training programs.  Dr. David Daikh is the Program Director who coordinates training activities with the clinic chiefs at the three hospitals and organizes curriculum conferences with Drs. Imboden and Gross.   The program emphasizes strong research training during fellowship and fellows participate in supervised research during the majority of their second year, as well as during a third, non&#45;ACGME year of training.  The program is widely viewed as one of the top rheumatology training programs in the country and has been very successful in attracting outstanding trainees from UCSF and other leading medicine programs in the U.S.  During the past five years, 100% of trainees have passed their American Board of Internal Medicine specialty exam and at least one UCSF fellow has been selected for one of ten national ACR Outstanding Fellow Awards (3 of 10 awardees in 2008).&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Education ./rheumatology/education/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/index.html</Path>
		<FileBody>
			&lt;p&gt;The rheumatology division has placed a high priority on providing outstanding rheumatology training at all levels, including medical students, internal medicine residents and rheumatology fellows.&lt;/p&gt;
			
			&lt;p&gt;The educational programs of the division involve teaching activities in the medical school, graduate school, internship and residency programs and at the subspecialty fellowship level. We actively participate in continuing medical education programs for physicians in practice. Our success in these areas has been underscored by the number of teaching awards our faculty members have received and our regular recruitment of outstanding UCSF medicine residents to our fellowship program.  Our highly regarded subspecialty training program in rheumatology aims to produce rheumatologists of the highest caliber.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Educational Materials ./rheumatology/education/materials.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/materials.html</Path>
		<FileBody>
			
			&lt;p&gt;&lt;i&gt;Additional info will be coming soon for this section.&lt;/i&gt;&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Medical Students ./rheumatology/education/medical.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/medical.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The rheumatology division is very active in education within the UCSF School of Medicine and the Department of Medicine.&lt;/p&gt;
			
			&lt;p&gt;Division faculty at all three hospital sites actively engage in medical school teaching in formal School of Medicine (SOM) classes and clerkships and in informal teaching of students in rheumatology clinics.  Division faculty have a number of leadership roles in SOM education.  Andy Gross organizes the small group discussion sessions and Mary Nakamura organizes rheumatology lectures for the second year Infection, Inflammation and Immunity (I3) course.  David Daikh serves on the UCSF Academy of Medical Educators Educational Scholarship Committee.  He was also a member of the SOM Advanced Studies Committee that reviewed the 4th year curriculum (2009&#45;2010) and served on the SOM Clinical Studies Steering Committee (2010&#45;2011).&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Residency Program ./rheumatology/education/residency.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/residency.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The division devotes significant energy to resident education and training.&lt;/p&gt;
			
			&lt;p&gt;A major educational emphasis of the division is the three&#45;hospital rheumatology elective, where many medicine residents (and UCSF medical students) receive education in musculoskeletal medicine and the rheumatic diseases.  This elective, which is perennially the highest rated medicine subspecialty elective, is coordinated by Lianne Gensler.   Rheumatology faculty and fellows at all three sites also regularly provide formal lectures as part of the DOM residency curriculum.  In addition, John Imboden and Jon Graf at SFGH and Mary Nakamura and David Daikh at SFVAMC regularly serve as medicine teaching attendings on the inpatient resident services.   Rheumatology faculty have also been recognized campus&#45;wide for their teaching ability over the past five years.  Ken Sack (2006) and John Imboden (2011) were selected as a UCSF Master Clinician and David Daikh was elected to the UCSF Academy of Medical Educators (2008).  Individual faculty members are also active in supervising and mentoring graduate students in basic science departments, including Drs. Weiss, Matloubian and Peterlin.  Dr. Daikh has also been involved in development of competency&#45;based GME curriculum development at the national level, including lecturing on this topic in curriculum and professional development workshops for training program directors for the Associate of Specialty Professionals (ASP) and the ACR.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research Training Program ./rheumatology/education/rtrain.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/rtrain.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;&lt;/p&gt;
			
			&lt;p&gt;For over 20 years the division has held a NIH T32 training program in Rheumatology and Clinical Immunology that links several important areas of medical science into a coherent interdisciplinary program whose primary goal is to train future medical scientists and leaders in rheumatology and immunology.  Areas of focus, with key faculty mentors in each area, include basic sciences, health services research and clinical trials.  Faculty in all of these areas are functionally integrated within the UCSF Rheumatology Program, with a high degree of collaboration between faculty at the various sites.  The training program is also integrated with the graduate program in Microbiology/Immunology.  Twelve of the participating faculty on the rheumatology training grant also have appointments in the graduate program in Immunology or includes faculty from other basic science departments; for example, Drs. Abbul Abbas (Pathology), Jeff Bluestone (Diabetes) and Mike McCune (Experimental Medicine). Thus the program provides broad opportunities for advanced research training.  The training program includes formal course work consistent with trainees’ specific training on a particular research project.  Trainees from the UCSF Rheumatology and Clinical Immunology Training Program have gone on to positions of prominence in this and related fields around the country.  The ongoing impact of this program is reflected in the success of its most recent graduates.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Alumni ./rheumatology/education/fellowship/alumni.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/fellowship/alumni.html</Path>
		<FileBody>
			
			&lt;h2&gt;2008&lt;/h2&gt;
			&lt;p&gt;More information coming soon!&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
How to Apply ./rheumatology/education/fellowship/apply.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/fellowship/apply.html</Path>
		<FileBody>
			
			&lt;p&gt;The UCSF Rheumatology fellowship program participates in the &lt;a href=&quot;http://www.nrmp.org/fellow/index.html&quot;&gt;NRMP Specialties Matching Service&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;Applications are made through the &lt;a href=&quot;https://www.aamc.org/students/medstudents/eras/fellowship_applicants/&quot;&gt;Electronic Residency Application System&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;Questions about fellowship applications can be directed to:&lt;br&gt; 
			&lt;b&gt;Denise Go&lt;/b&gt; or &lt;b&gt;Dr. David Daikh&lt;/b&gt;, at (415) 750&#45;2104.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Current Fellows ./rheumatology/education/fellowship/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/fellowship/fellows.html</Path>
		<FileBody>
			
			&lt;h3&gt;First&#45;Year Fellows&lt;/h3&gt;
			
			
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;center&gt;&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/christinea.jpg&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Christine Anastasiou&lt;/p&gt;&lt;/div&gt;
			
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/sarahfrench.jpg&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Sarah French&lt;/p&gt;&lt;/div&gt;
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/lucyliu.jpg&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Lucy Liu&lt;/p&gt;&lt;/div&gt;
			
			
			&lt;br clear=all&gt;&lt;br clear=all&gt;
			
			&lt;h3&gt;Second&#45;Year Fellows&lt;/h3&gt;
			
			
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/dequattro.png&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Kim DeQuattro&lt;/p&gt;&lt;/div&gt;
			
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mandal.png&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Jenny Mandal&lt;/p&gt;&lt;/div&gt;
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/ying.png&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;David Ying&lt;/p&gt;&lt;/div&gt;
			
			
			&lt;br clear=all&gt;&lt;br clear=all&gt;
			
			&lt;h3&gt;Third&#45;Year Fellows&lt;/h3&gt;
			
			
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/kashif.png&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Kashif Jafri&lt;/p&gt;&lt;/div&gt;
			
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/patterson2.png&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Sarah Patterson&lt;/p&gt;&lt;/div&gt;
			
			&lt;div style=&quot;float:left;margin:15px;&quot;&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/katie.png&quot; &gt;
						&lt;p class=&quot;caption&quot;&gt;Katie Wysham&lt;/p&gt;&lt;/div&gt;
			
			
			&lt;br clear=all&gt;&lt;br clear=all&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Current Fellows ./rheumatology/education/fellowship/fellows.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/fellowship/fellows.html~</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/fellows/JamesAndrews.JPG&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot; style=&quot;width:298px;&quot;&gt;James Andrew&lt;/p&gt;
			
			&lt;p&gt;&lt;/p&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/fellows/PattyChen.JPG&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot; style=&quot;width:298px;&quot;&gt;Patty Chen&lt;/p&gt;
			&lt;p&gt;&lt;/p&gt;
			
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/fellows/SarahGoglin.JPG&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot; style=&quot;width:298px;&quot;&gt;Sarah Goglin&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Career Info ./rheumatology/education/medical/career.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/medical/career.html~</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Electives ./rheumatology/education/medical/electives.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/medical/electives.html</Path>
		<FileBody>
			
			&lt;a href=&quot;med_student_elective.pdf&quot; target=&quot;_blank&quot;&gt;&lt;p&gt;Rheumatology Medical Student Elective (pdf)&lt;/p&gt;&lt;/a&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Electives ./rheumatology/education/residency/electives.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/residency/electives.html</Path>
		<FileBody>
			
			&lt;a href=&quot;resident_elective.pdf&quot; target=&quot;_blank&quot;&gt;
				&lt;p&gt;Rheumatology Resident Elective (pdf)&lt;/p&gt;
			&lt;/a&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Conference Schedule ./rheumatology/education/residency/schedule.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/education/residency/schedule.html</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./rheumatology/faculty/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/faculty/index.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
Faulty Interests ./rheumatology/faculty/interests.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/faculty/interests.html</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./rheumatology/faculty/profiles.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/faculty/profiles.html</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Publications ./rheumatology/faculty/publications.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/faculty/publications.html~</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Resources ./rheumatology/faculty/resources.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/faculty/resources.html</Path>
		<FileBody>
			
			&lt;h3&gt;Internal&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;2013&#45;14_inpatient_attending_schedule.pdf&quot; target=&quot;new&quot;&gt;Inpatient Attending Schedule (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;
			&lt;h3&gt;External&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://www.rheumatology.org/&quot; target=&quot;new&quot;&gt;American College of Rheumatology&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://www.abim.org/specialty/rheumatology.aspx&quot; target=&quot;new&quot;&gt;American Board of Internal Medicine, Rheumatology&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Volunteer Faculty ./rheumatology/faculty/volunteer.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/faculty/volunteer.html</Path>
		<FileBody>
			
			&lt;h2&gt;Parnassus Heights Campus&lt;/h2&gt;
			
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:Gerson.Bernhard@ucsf.edu&quot;&gt;Gerson Bernhard, MD &lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:ncarteron@netscape.net&quot;&gt;Nancy Carteron, MD&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:davisjmd@sutterhealth.org&quot;&gt;James Alan Davis&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:rkdixit@norcalarthritis.com&quot;&gt;Rajiv Dixit, MD&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:rbdixit@norcalarthritis.com&quot;&gt;Rashmi Dixit, MD&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:kmorehe@yahoo.com&quot;&gt;Kerstin Morehead, MD&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:ldmdoc@gmail.com&quot;&gt;Lester Miller, MD&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:nina.d.schwartz@kp.org&quot;&gt;Nina Schwartz, MD&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			
			
			&lt;h2&gt;San Francisco Veteran’s Administration Hospital&lt;/h2&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:gregory.bell157@gmail.com&quot;&gt;Gregory Bell, MD
				&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;mailto:sandra_tong@affymax.com&quot;&gt;Sandra Tong, MD
			&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;mailto:Nina.D.Schwartz@kp.org&quot;&gt;Nina Schwartz, MD
			&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;mailto:stone_jolton@comcast.net&quot;&gt;David Stone, MD&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			
			
			
			&lt;h2&gt;San Francisco General Hospital&lt;/h2&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;mailto:davis.john@gene.com&quot;&gt;John Davis, MD
			&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;mailto:tracey.robinson@sbcglobal.net&quot;&gt;Tracey Robinson, MD
			&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;mailto:Stone_Jolton@comcast.net&quot;&gt;David Stone, MD
			&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;mailto:davidwu6@aol.com&quot;&gt;David Wu, MD&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Giving ./rheumatology/giving/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/giving/index.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Philanthropy plays a vital role in the Division of Rheumatology.  It allows us to invest in the people and infrastructure that enable research into the causes and means of prevention for rheumatic diseases such as Rheumatoid Arthritis, SLE, Scleroderma, Vasculitis, Ankylosing Spondylitis, Osteoarthritis, and other chronic immunologic and inflammatory diseases.  The research informs the care we provide in our many specialty clinics.&lt;/p&gt;
			&lt;p&gt;We are fortunate to be the home of the Rosalind Russell Medical Research Center for Arthritis.  Established in 1978 by an act of Congress to posthumously honor the stage and screen actress Rosalind Russell whose advocacy focused national attention on the need for research into these diseases, the organization now raises funds to support research and training in the Division of Rheumatology.  Visit the &lt;a href=&quot;http://russellenglemancenter.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;Rosalind Russell Medical Research Center for Arthritis website&lt;/a&gt; to learn more. &lt;/p&gt;
			
			&lt;h3&gt;How You Can Help&lt;/h3&gt;
			&lt;p&gt;There are many ways to support the Division of Rheumatology at UCSF in its mission to provide outstanding cutting edge clinical care, to advance the discipline through clinical and basic research, and to train the next generation of rheumatologists.  Donations from patients, family, and friends are key to furthering this mission.  If you are interested in learning more, please contact Jacqui Lang@ucsf.edu at (415) 476&#45;3341 or at &lt;a href=&quot;mailto:Jacqui.Lang@ucsf.edu&quot;&gt;Jacqui.Lang@ucsf.edu&lt;/a&gt; or &lt;a href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_GeneralGivingForm&amp;Primary=Arthritis&quot; target=&quot;_blank&quot;&gt;donate online&lt;/a&gt;. &lt;/p&gt; 
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
$custom[entity] Search ./rheumatology/news/search.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/news/search.html</Path>
		<FileBody>
			/* &lt;![CDATA[ */
			
			#ucsfheadercontainer {
			  width: 100%;
			  background&#45;color: #000000;
			}
			td{
			    border:hidden;
			padding:1px;
			}
			
			
			/* ]]&gt; */
					</FileBody>
	</node>
	<node>
		<Fname>
Awards ./rheumatology/old/about/awards.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/awards.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;2&quot;&gt;&lt;U&gt;Laura Bechtel Junior Faculty Award&lt;/U&gt;&lt;/font&gt;&lt;/strong&gt;&lt;br /&gt;
			  &lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=&quot;2&quot;&gt;&amp;middot; 2009&#45;12: &lt;/font&gt;&lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; size=&quot;2&quot;&gt;Julie Zikherman, MD&lt;/font&gt;&lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=&quot;2&quot;&gt;&lt;br /&gt;
			&lt;/font&gt;&lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; size=&quot;2&quot;&gt;&amp;middot; 2012&#45;13: Tamiko Katsumoto, MD&lt;/font&gt;&lt;/p&gt;
			&lt;br /&gt;
			&lt;p&gt;&lt;strong&gt;&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;2&quot;&gt;&lt;U&gt;Ephraim P. Engleman Award for Excellence in the Field of Arthritis Research&lt;/U&gt;&lt;/font&gt;&lt;/strong&gt;&lt;br /&gt;
			  &lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=&quot;2&quot;&gt;&amp;middot; 2003: Jennifer Gorman, MD &amp;amp; Mehrdad Matloubian, MD, PhD&lt;br /&gt;
			  &lt;/font&gt;&lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; size=&quot;2&quot;&gt;&amp;middot; 2004: Mary Beth Humphrey, MD, PhD&lt;br /&gt;
			&amp;middot; 2005: Leonard L. Dragone, MD&lt;br /&gt;
			&amp;middot; 2006: Maria Dall'Era, MD &amp;amp; Jonathan D. Graf, MD&lt;br /&gt;
			&amp;middot; 2008: Kenneth J. Scalapino, MD &amp;amp; Jinoos Yazdany, MD, MPH&lt;br /&gt;
			&amp;middot; 2011: Sharon A. Chung, MD, MAS &amp;amp; Julie Zikherman, MD&lt;/font&gt;&lt;br /&gt;
			&lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; size=&quot;2&quot;&gt;&amp;middot; 2012: Jennifer Barton, MD &amp;amp; Gabriela Schmajuk, MD&lt;/font&gt;&lt;/p&gt;
			&lt;P&gt;&lt;br /&gt;
			  &lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;2&quot;&gt;&lt;strong&gt;&lt;U&gt;Ira M. Goldstein Award for Outstanding Teaching in Rheumatology&lt;/U&gt;&lt;/strong&gt;&lt;br /&gt;
			&amp;middot; 1999: David I. Daikh, MD, PhD&lt;br /&gt;
			&amp;middot; 2000: Kenneth E. Sack, MD&lt;br /&gt;
			&amp;middot; 2001: John C. Davis, Jr., MD&lt;br /&gt;
			&amp;middot; 2002: Kenneth H. Fye, MD&lt;br /&gt;
			&amp;middot; 2003: John Imboden, MD&lt;br /&gt;
			&amp;middot; 2004: Mary Nakamura, MD &lt;br /&gt;
			&amp;middot; 2005: Wallace Epstein, MD&lt;br /&gt;
			&amp;middot; 2006: Kerstin Morehead, MD&lt;br /&gt;
			&amp;middot; 2007: Maria Dall'Era, MD&lt;br /&gt;
			&amp;middot; 2008: Jinoos Yazdany, MD, MPH&lt;br /&gt;
			&amp;middot; 2009: Julia Charles, MD, PhD&lt;br /&gt;
			&amp;middot; 2010: Jonathan D. Graf, MD&lt;/font&gt;&lt;br /&gt;
			&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;2&quot;&gt;&amp;middot; 2011: John Imboden, MD&lt;br /&gt;
			&amp;middot; 2012: Julie Baker&#45;LePain, MD&lt;/font&gt;&lt;/P&gt;
			&lt;br&gt;
			  
						&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;		</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./rheumatology/old/about/faculty.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/faculty.html</Path>
		<FileBody>
			
			&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=2&gt;&lt;B&gt;&lt;FONT 
			color=#000000 size=&quot;4&quot;&gt;Faculty By Location &lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;
			&lt;ul&gt;
			  &lt;li&gt;&lt;a href=&quot;#Moffit&quot;&gt;MOFFITT&#45;LONG HOSPITAL&lt;/a&gt;&lt;/li&gt;
			  &lt;li&gt;&lt;a href=&quot;#VA&quot;&gt;VA MEDICAL CENTER&lt;/a&gt;&lt;/li&gt;
			  &lt;li&gt;&lt;a href=&quot;#SFGH&quot;&gt;SAN FRANCISCO GENERAL HOSPITAL&lt;/a&gt;&lt;/li&gt;
			  &lt;li&gt;&lt;a href=&quot;#ACC&quot;&gt;AMBULATORY CARE CLINIC&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;table width=&quot;659&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;315&quot;&gt;&lt;p&gt;    
			      &lt;p&gt;&lt;a name=&quot;Moffit&quot;&gt;&lt;/a&gt; &lt;strong&gt;&lt;font size=&quot;5&quot;&gt;MOFFITT&#45;LONG&lt;/font&gt;&lt;br&gt; 
			        533 Parnassus Avenue&lt;br&gt;
			  San Francisco, CA&lt;/strong&gt;&lt;strong&gt;      &lt;/strong&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/barton.htm&quot;&gt;Jennifer Barton, MD&lt;/a&gt;&lt;br&gt;
			      Assistant Adjunct Professor 
			      
			      &lt;p&gt;&lt;a href=&quot;faculty/chaganti.htm&quot;&gt;R. Krishna Chaganti , MD, MS&lt;/a&gt;&lt;br&gt;
			  Assistant Clinical Professor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/chung.htm&quot;&gt;Sharon A. Chung, MD, MAS&lt;/a&gt;&lt;br&gt;
			  Assistant Adjunct Professor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/connolly.htm&quot;&gt;M. Kari Connolly, MD&lt;/a&gt;&lt;br&gt;
			&#45;Clinical Professor of Dermatology and Medicine&lt;br&gt;
			&#45;Director, Autoimmune Clinic&lt;br&gt;
			&#45;Co&#45;Director, Immunodermatology Laboratory&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/criswell.htm&quot;&gt;Lindsey A. Criswell, MD, MPH&lt;/a&gt;&lt;br&gt;
			        &#45;Chief, Division of Rheumatology, Parnassus Campus&lt;br /&gt;
			        &#45;Professor in Residence, Divisions  of Rheumatology and Medical Genetics&lt;br /&gt;
			&#45;Professor of Orofacial Sciences, Department of Orofacial Sciences&lt;br /&gt;
			&#45;Kenneth H. Fye, MD, Endowed Chair in Rheumatology
			      &lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/dallera.htm&quot;&gt;Maria Dall'Era , MD&lt;/a&gt;&lt;br&gt;
			  &#45;Associate Professor of Clinical Medicine&lt;br&gt;
			  &#45;Director, Rheumatology Clinical Research Center&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/engleman.htm&quot;&gt;Ephraim P. Engleman, MD&lt;/a&gt;&lt;br&gt;
			  &#45;Professor of Clinical Medicine&lt;br&gt;
			  &#45;Director, Rosalind Russell Medical Research Center for Arthritis&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/epstein.htm&quot;&gt;Wallace Epstein, MD&lt;/a&gt;&lt;br&gt;
			  Professor of Medicine, Emeritus      &lt;/p&gt;
			      &lt;p&gt;Koh Fujinaga, PhD&lt;br /&gt;
			      Adjunct Instructor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/gensler.htm&quot;&gt;Lianne S. Gensler , MD&lt;/a&gt;&lt;br&gt;
			&#45;Assistant Clinical Professor&lt;br&gt;
			&#45;Director, Ankylosing Spondylitis Clinic&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/gross.htm&quot;&gt;Andrew J. Gross, MD&lt;/a&gt;&lt;br&gt;
			  &#45;Associate Clinical Professor&lt;br&gt;
			  &#45;Director of Clinical Programs in Rheumatology&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/hsu.html&quot;&gt;Lyn Hsu, PhD&lt;/a&gt;&lt;br /&gt;
			Adjunct Instructor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/julian.htm&quot;&gt;Laura J. Julian, PhD&lt;/a&gt;&lt;br&gt;
			  Assistant Adjunct Professor&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;328&quot;&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/katsumoto.htm&quot;&gt;Tamiko Katsumoto, MD&lt;/a&gt;&lt;br /&gt;
			        Assistant Adjunct Professor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/katz.htm&quot;&gt;Patricia P. Katz, PhD&lt;/a&gt;&lt;br&gt;
			        Professor in Residence of Medicine and Health Policy&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/levine.htm&quot;&gt;Jon Levine, MD, PhD&lt;/a&gt;&lt;br&gt;
			  Professor of Medicine, Neuroscience and Oral Surgery&lt;/p&gt;
			      &lt;p&gt;&lt;A href=&quot;faculty/margaretten.htm&quot;&gt;Mary Margaretten, MD&lt;/A&gt;&lt;FONT color=#000000&gt;&lt;BR&gt;
			Assistant Adjunct Professor&lt;/FONT&gt;&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/matloubian.htm&quot;&gt;Mehrdad Matloubian, MD, PhD&lt;/a&gt;&lt;br&gt;
			  Associate Professor in Residence&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/peterlin.htm&quot;&gt;B. Matija Peterlin, MD&lt;/a&gt;&lt;br&gt;
			  &#45;Professor in Residence of Medicine, Microbiology and Immunology&lt;br /&gt;
			  &#45;Finland Distinguished Professor (FIDIPRO)
			      &lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/phee.htm&quot;&gt;Hyewon Phee, PhD&lt;/a&gt;&lt;br&gt;
			  Assistant Adjunct Professor &lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/sack.htm&quot;&gt;Kenneth E. Sack, MD&lt;/a&gt;&lt;br&gt;
			  Professor of Clinical Medicine, Emeritus &lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/weiss.htm&quot;&gt;Arthur Weiss, MD, PhD&lt;/a&gt;&lt;br&gt;
			  &#45;Ephraim Engleman Distinguished Professor&lt;br&gt;
			  &#45;Investigator, Howard Hughes Medical Institute&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/yazdany.htm&quot;&gt;Jinoos Yazdany, MD, MPH&lt;/a&gt;&lt;br&gt;
			  Assistant Adjunct Professor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/yelin.htm&quot;&gt;Edward H. Yelin, PhD&lt;/a&gt;&lt;br&gt;
			  Professor in Residence of Medicine and Health Policy&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/zhu.htm&quot;&gt;Jing Zhu, PhD&lt;/a&gt;&lt;br&gt;
			  Assistant Adjunct Professor&lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/zikherman.htm&quot;&gt;Julie Zikherman, MD&lt;/a&gt;&lt;br&gt;
			  Assistant Adjunct Professor&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&lt;strong&gt;&lt;font size=&quot;5&quot;&gt;&lt;a name=&quot;VA&quot;&gt;&lt;font color=&quot;#000000&quot;&gt;VA &lt;/font&gt;&lt;/a&gt;&lt;font color=&quot;#000000&quot;&gt; MEDICAL CENTER&lt;/font&gt;&lt;/font&gt;&lt;br&gt;
			            &lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;Arthritis/Immunology Section&lt;BR&gt;
			          4150 Clement Street&lt;BR&gt;
			        San Francisco, CA&lt;/FONT&gt;
			      &lt;/strong&gt; &lt;/p&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/baker.htm&quot;&gt;Julie Baker&#45;LePain, MD, PhD&lt;/a&gt;&lt;br /&gt;
			        Adjunct Instructor      &lt;/P&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/daikh.htm&quot;&gt;David Daikh, MD, PhD&lt;/a&gt;&lt;br&gt;
			&#45;Associate Professor of Clinical Medicine&lt;br&gt;
			&#45;Chief, Division of Rheumatology, VA Medical Center&lt;/P&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/fang.htm&quot;&gt;Celia J. Fang, MD&lt;/a&gt;&lt;br /&gt;
			      Assistant Adjunct Professor&lt;/P&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/nakamura.htm&quot;&gt;Mary C. Nakamura, MD&lt;/a&gt;&lt;br&gt;
			Associate Professor of Medicine&lt;/P&gt;
			      &lt;P&gt;&lt;FONT color=#000000&gt;&lt;a href=&quot;faculty/schmajuk.html&quot;&gt;Gabriela Schmajuk, MD&lt;/a&gt;&lt;br&gt;
			      Adjunct Instructor&lt;/FONT&gt; &lt;/P&gt;
			      &lt;P&gt;&lt;font color=&quot;#000000&quot;&gt;&lt;a href=&quot;faculty/seaman.htm&quot;&gt;William E. Seaman, MD&lt;/a&gt;&lt;br /&gt;
			Professor of Medicine and Microbiology/Immunology&lt;/font&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/wofsy.htm&quot;&gt;David Wofsy, MD&lt;/a&gt;&lt;br&gt;
			  &#45;George A. Zimmermann Distinguished Professor of Rheumatology&lt;br&gt;
			  &#45;Associate Dean of Admissions, UCSF School of Medicine &lt;/P&gt;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&lt;a name=&quot;SFGH&quot;&gt;&lt;/a&gt; &lt;strong&gt;&lt;font size=&quot;5&quot;&gt;SFGH&lt;/font&gt;&lt;br&gt;
			            &lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;Building 30, Room 3300&lt;BR&gt;
			          1001 Potrero Avenue&lt;BR&gt;
			        San Francisco, CA&lt;/FONT&gt;
			      &lt;/strong&gt; &lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;faculty/bajpai.html&quot;&gt;Urmila  Bajpai, MD, PhD&lt;/a&gt;&lt;br /&gt;
			Adjunct Instructor of Medicine&lt;/p&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/graf.htm&quot;&gt;Jonathan D. Graf, MD&lt;/a&gt;&lt;br&gt;
			Assistant Clinical Professor&lt;/P&gt;
			      &lt;P&gt;&lt;a href=&quot;faculty/imboden.htm&quot;&gt;John Imboden, MD&lt;/a&gt;&lt;br&gt;
			&#45;Professor of Medicine&lt;br&gt;
			&#45;Chief, Rheumatology Division, SFGH&lt;br /&gt;
			&#45;Alice Betts Endowed Chair for Research in Arthritis
			      &lt;/P&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			      &lt;p&gt;&lt;strong&gt;&lt;a name=&quot;ACC&quot;&gt;&lt;font color=&quot;#000000&quot; size=&quot;4&quot;&gt;AMBULATORY CARE CLINIC&lt;/font&gt;&lt;/a&gt;&lt;br&gt;
			            &lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;Clinical Faculty&lt;BR&gt;
			          400 Parnassus Avenue&lt;BR&gt;
			        San Francisco, CA&lt;/FONT&gt;
			        &lt;/strong&gt;
			      &lt;/p&gt;
			      &lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;FONT color=#990000&gt;Gerson C. Bernhard, MD&lt;/FONT&gt;&lt;/B&gt;&lt;BR&gt;
			        Clinical Professor&lt;/FONT&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;FONT color=#990000&gt;Nancy L. Carteron, MD&lt;/FONT&gt;&lt;/B&gt;&lt;BR&gt;
			        Associate Clinical Professor&lt;/FONT&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;FONT color=#990000&gt;Andrew C. Chan, MD, PhD&lt;/FONT&gt;&lt;/B&gt;&lt;BR&gt;
			        Associate Clinical Professor&lt;/FONT&gt;      &lt;/P&gt;
			      &lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;FONT 
			color=#990000&gt;Rajiv K. Dixit, MD&lt;/FONT&gt;&lt;/B&gt;&lt;BR&gt;
			Clinical Professor&lt;/FONT&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;FONT color=#990000&gt;Rashmi B. Dixit, MD&lt;/FONT&gt;&lt;/B&gt;&lt;BR&gt;
			Associate Clinical Professor&lt;/FONT&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;2&quot;&gt;&lt;b&gt;&lt;font color=&quot;#990000&quot;&gt;Fiona Donald, MD&lt;/font&gt;&lt;/b&gt;&lt;br /&gt;
			Assistant Clinical Professor&lt;/font&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;2&quot;&gt;&lt;b&gt;&lt;font color=&quot;#990000&quot;&gt;Lester D. Miller, MD&lt;/font&gt;&lt;/b&gt;&lt;br /&gt;
			Associate Clinical Professor&lt;/font&gt;&lt;/P&gt;
			      &lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;FONT color=#990000&gt;Nina B. Schwartz, MD&lt;/FONT&gt;&lt;/B&gt;&lt;BR&gt;
			  Associate Clinical Professor&lt;/FONT&gt;&lt;/P&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
			      &lt;P&gt;&amp;nbsp;&lt;/P&gt;
			      &lt;P&gt;&amp;nbsp;&lt;/P&gt;
			      &lt;P&gt;&amp;nbsp;&lt;/P&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			&lt;p&gt;
			&lt;p&gt;
			&lt;p&gt;
			&lt;p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&amp;nbsp; &lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Fellows ./rheumatology/old/about/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/fellows.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;table width=&quot;652&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;135&quot;&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td width=&quot;501&quot;&gt;&lt;FONT color=#000000 size=6&gt;&lt;STRONG&gt;&lt;U&gt;1st Year Fellows&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/ashouri2.jpg&quot; width=&quot;136&quot; height=&quot;190&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=style1&gt;Judy Ashouri, MD&lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: UCSF &lt;BR&gt;
			  Internship/Residency: Stanford University&lt;BR&gt;
			    &lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/carlson2.jpg&quot; width=&quot;134&quot; height=&quot;167&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=style1&gt;Adam Carlson, MD &lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: University of Virginia&lt;BR&gt;
			  Internship/Residency: UCSF&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/su2.jpg&quot; width=&quot;136&quot; height=&quot;140&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;Robert Su, MD &lt;BR&gt;
			      &lt;BR&gt;
			      &lt;span class=&quot;style1&quot;&gt;Medical School: UCSF &lt;br /&gt;
			Internship/Residency: Stanford University&lt;/span&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;SPAN class=style1&gt;&lt;FONT color=#000000 size=6&gt;&lt;STRONG&gt;&lt;U&gt;2nd Year Fellows&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/matzkies1a.jpg&quot; alt=&quot;&quot; width=&quot;133&quot; height=&quot;172&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=style1&gt;Franziska Matzkies, MD&lt;br /&gt;
			        &lt;br /&gt;
			Medical School:  Friedrich&#45;Alexander University, Germany&lt;br /&gt;
			Internship/Residency: Cedars&#45;Sinai Medical Center, Los Angeles, CA&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/reimert1.jpg&quot; alt=&quot;&quot; width=&quot;136&quot; height=&quot;167&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;span class=&quot;style1&quot;&gt;Matthew Reimert, MD &lt;br /&gt;
			        &lt;br /&gt;
			Medical School: Keck School of Medicine of the University of Southern California&lt;br /&gt;
			Internship/Residency: California Pacific Medical Center&lt;/span&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/taher1a.jpg&quot; alt=&quot;&quot; width=&quot;135&quot; height=&quot;165&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;Pedram Taher, MD &lt;br /&gt;
			      &lt;br /&gt;
			Medical School: Azad University, Najafabad Branch, Iran&lt;br /&gt;
			Internship/Residency: Alameda County Medical Center, Highland, Oakland, CA&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT color=#000000 size=6&gt;&lt;STRONG&gt;&lt;U&gt;3rd Year Fellows&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/richman1.jpg&quot; alt=&quot;&quot; width=&quot;134&quot; height=&quot;162&quot; /&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;span class=&quot;style1&quot;&gt;Nicole Richman, MD &lt;br /&gt;
			        &lt;br /&gt;
			Medical School: George Washington University School of Medicine &lt;br /&gt;
			Internship/Residency: University of Illinois at Chicago&lt;/span&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Fellows ./rheumatology/old/about/fellows.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/fellows.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;table width=&quot;652&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;135&quot;&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td width=&quot;501&quot;&gt;&lt;FONT color=#000000 size=6&gt;&lt;STRONG&gt;&lt;U&gt;1st Year Fellows&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/belek2.jpg&quot; width=&quot;133&quot; height=&quot;163&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=style1&gt;Ann Mary Belek , MD&lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: University of Kentucky College of Medicine &lt;BR&gt;
			  Internship/Residency: UCSF&lt;BR&gt;
			    &lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/goldengatebridge.jpg&quot; width=&quot;133&quot; height=&quot;140&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=style1&gt;Nicole Richman, MD &lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: George Washington University School of Medicine &lt;BR&gt;
			  Internship/Residency: University of Illinois at Chicago&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/tarter2.jpg&quot; width=&quot;134&quot; height=&quot;168&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;Laura Tarter, MD &lt;BR&gt;
			      &lt;BR&gt;
			      Medical School: Harvard Medical School &lt;BR&gt;
			    Internship/Residency: UCSF&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;SPAN class=style1&gt;&lt;FONT color=#000000 size=6&gt;&lt;STRONG&gt;&lt;U&gt;2nd Year Fellows&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/gratton1.jpg&quot; width=&quot;134&quot; height=&quot;171&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=style1&gt;Sarah Gratton, MD&lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: Stanford University&lt;BR&gt;
			  Internship/Residency: UCSF&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/malladi2.jpg&quot; width=&quot;135&quot; height=&quot;181&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;Arundathi Malladi, MD &lt;BR&gt;
			      &lt;BR&gt;
			      Medical School: Baylor College of Medicine &lt;BR&gt;
			    Internship/Residency: Baylor College of Medicine&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/respicio1.jpg&quot; width=&quot;135&quot; height=&quot;146&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;Guada Respicio, MD &lt;BR&gt;
			      &lt;BR&gt;
			      Medical School: St. George's University School of Medicine &lt;BR&gt;
			Internship/Residency: University of Connecticut School of Medicine&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT color=#000000 size=6&gt;&lt;STRONG&gt;&lt;U&gt;3rd Year Fellows&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/bajpai1.jpg&quot; width=&quot;134&quot; height=&quot;142&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT color=#000000&gt;Urmila Bajpai &lt;/FONT&gt;&lt;SPAN class=style1&gt;&lt;FONT 
			color=#000000&gt;, MD&lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: &lt;/FONT&gt;&lt;/SPAN&gt;&lt;FONT 
			color=#000000&gt;University of Massachusetts &lt;SPAN 
			class=style1&gt;&lt;BR&gt;
			    Internship/Residency: &lt;/SPAN&gt;Boston University&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/goldengatebridge.jpg&quot; width=&quot;134&quot; height=&quot;141&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT color=#000000&gt;&lt;SPAN class=style1&gt;Julie Baker&#45;LePain, MD, PhD&lt;BR&gt;
			&lt;BR&gt;
			Medical School: Duke University School of Medicine&lt;BR&gt;
			Internship/Residency: University of North Carolina&lt;/SPAN&gt;&lt;U&gt;&lt;/U&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/moberg1.jpg&quot; width=&quot;134&quot; height=&quot;144&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT color=#000000&gt;Philip Moberg, MD&lt;BR&gt;
			        &lt;BR&gt;
			        Medical School: UCSF&lt;BR&gt;
			    Internship/Residency: UCSF&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/fellows/goldengatebridge.jpg&quot; width=&quot;134&quot; height=&quot;141&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT color=#000000&gt;&lt;FONT color=#000000&gt;Terrence Rooney, MD&lt;BR&gt;
			          &lt;BR&gt;
			          Medical School: Royal College of Surgeons in Ireland&lt;BR&gt;
			Internship/Residency: Connolly Hospital, Dublin, Irelan&lt;/FONT&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
People &amp; Mission ./rheumatology/old/about/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/index.html</Path>
		<FileBody>
						
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;p class=&quot;style1&quot;&gt;Mission
			&lt;p&gt;The missions of the Divisions of Rheumatology at UCSF are to provide outstanding cutting edge clinical care, to advance the discipline through clinical and basic research, and to train the next generation of academic rheumatologists. Our programs are located at three campuses of UCSF: the Parnassus Heights campus, the location of the Moffitt&#45;Long Hospital; the Fort Miley Veterans Administration Center in the outer Richmond district; and the San Francisco General Hospital in the Mission District. Although physically separated, the programs are highly integrated and interactive. 
			
			&lt;P&gt;The &lt;A href=&quot;../care&quot;&gt;&lt;U&gt;clinical programs&lt;/U&gt;&lt;/A&gt; at all three sites provide comprehensive and consultative clinical care to patients with rheumatologic diseases in the outpatient and inpatient settings. We provide care to patients with a wide spectrum illnesses that characterize the rheumatologic diseases such as rheumatoid arthritis, systemic lupus erythematosus and the vasculitides. Our clinical services provide and have helped develop cutting edge new therapies.&lt;/P&gt;
			&lt;P&gt;The research programs span the spectrum of the most fundamental research questions that underlie the pathogenesis of rheumatologic diseases to research involving clinical trials of new therapies as well as studies of health care delivery systems. We now have unprecedented opportunities in basic research and in the availability of new therapeutics to address questions related to rheumatologic diseases. As a consequence we are experiencing a large expansion of our research programs. These comprehensive research programs are being funded by a wide range of sources including the National Institutes of Health, the Arthritis Foundation, the Howard Hughes Medical Institute, philanthropic efforts and industry. Philanthropic support of research efforts and educational programs is coordinated by &lt;A href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot;&gt;&lt;U&gt;The Rosalind Russell Medical Research Center for Arthritis&lt;/U&gt;&lt;/A&gt; which was established and sited at UCSF by an act of Congress.&lt;/P&gt;
			&lt;P&gt;The &lt;A href=&quot;../education&quot;&gt;&lt;U&gt;educational programs&lt;/U&gt;&lt;/A&gt; of the division involve teaching activities in the medical school, graduate school, internship and residency programs and at the subspecialty fellowship level. We actively participate in continuing medical educational programs for physicians in practice. Our highly regarded subspecialty training program in rheumatology aims to produce outstanding scientists and physicians in the subspecialty of rheumatology.&lt;/P&gt;
			&lt;p&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
About Us ./rheumatology/old/about/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/index.html~</Path>
		<FileBody>
						
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;p class=&quot;style1&quot;&gt;Mission
			&lt;p&gt;The missions of the Divisions of Rheumatology at UCSF are to provide outstanding cutting edge clinical care, to advance the discipline through clinical and basic research, and to train the next generation of academic rheumatologists. Our programs are located at three campuses of UCSF: the Parnassus Heights campus, the location of the Moffitt&#45;Long Hospital; the Fort Miley Veterans Administration Center in the outer Richmond district; and the San Francisco General Hospital in the Mission District. Although physically separated, the programs are highly integrated and interactive. 
			
			&lt;P&gt;The &lt;A href=&quot;../care&quot;&gt;&lt;U&gt;clinical programs&lt;/U&gt;&lt;/A&gt; at all three sites provide comprehensive and consultative clinical care to patients with rheumatologic diseases in the outpatient and inpatient settings. We provide care to patients with a wide spectrum illnesses that characterize the rheumatologic diseases such as rheumatoid arthritis, systemic lupus erythematosus and the vasculitides. Our clinical services provide and have helped develop cutting edge new therapies.&lt;/P&gt;
			&lt;P&gt;The research programs span the spectrum of the most fundamental research questions that underlie the pathogenesis of rheumatologic diseases to research involving clinical trials of new therapies as well as studies of health care delivery systems. We now have unprecedented opportunities in basic research and in the availability of new therapeutics to address questions related to rheumatologic diseases. As a consequence we are experiencing a large expansion of our research programs. These comprehensive research programs are being funded by a wide range of sources including the National Institutes of Health, the Arthritis Foundation, the Howard Hughes Medical Institute, philanthropic efforts and industry. Philanthropic support of research efforts and educational programs is coordinated by &lt;A href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot;&gt;&lt;U&gt;The Rosalind Russell Medical Research Center for Arthritis&lt;/U&gt;&lt;/A&gt; which was established and sited at UCSF by an act of Congress.&lt;/P&gt;
			&lt;P&gt;The &lt;A href=&quot;../education&quot;&gt;&lt;U&gt;educational programs&lt;/U&gt;&lt;/A&gt; of the division involve teaching activities in the medical school, graduate school, internship and residency programs and at the subspecialty fellowship level. We actively participate in continuing medical educational programs for physicians in practice. Our highly regarded subspecialty training program in rheumatology aims to produce outstanding scientists and physicians in the subspecialty of rheumatology.&lt;/P&gt;
			&lt;p&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Administration ./rheumatology/old/about/staff.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/staff.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;table width=&quot;429&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;104&quot;&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td width=&quot;309&quot;&gt;&lt;font size=&quot;6&quot;&gt;ADMINISTRATION&lt;/font&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;MOFFITT&#45;LONG HOSPITAL&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;&lt;/SPAN&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;533 Parnassus Avenue&lt;O:P&gt;&lt;br&gt;
			    Room U&#45;384&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;O:P&gt;, Box 0633 &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;O:P&gt;&lt;BR&gt;
			&lt;/O:P&gt;San Francisco, CA&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt; 94143&#45;0633&lt;br&gt;
			(415) 502&#45;2279
			&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/barlow.jpg&quot; width=&quot;104&quot; height=&quot;131&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Tony Barlow&lt;O:P&gt;&lt;BR&gt;
			&lt;/O:P&gt;Manager&lt;O:P&gt;&lt;BR&gt;
			Tony.Barlow@ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/bernacki.jpg&quot; width=&quot;104&quot; height=&quot;104&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=MsoNormal&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Gracie Bernacki&lt;O:P&gt;&lt;BR&gt;
			  &lt;/O:P&gt;Administrative Assistant&lt;BR&gt;
			  &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Gracie.Bernacki@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/lew.jpg&quot; width=&quot;103&quot; height=&quot;125&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Linda Lew&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;Research Analyst&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Linda.Lew@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;A&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;MBULATORY&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt; C&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;ARE CLINIC &lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			          &lt;B&gt;400 Parnassus Avenu&lt;/B&gt;&lt;STRONG&gt;e, Plaza Level&lt;/STRONG&gt;&lt;BR&gt;
			&lt;B&gt;San Francisco, CA 94143&#45;0326&lt;br&gt;
			&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;(415) 353&#45;2497&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/young.jpg&quot; width=&quot;105&quot; height=&quot;113&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Darlene Young, RN &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;br&gt;
			    Practice Manager&lt;br&gt;
			    DarleneLee.Y&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;oung@ucsfmedctr.org&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;BR&gt;
			      &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;SAN FRANCISCO GENERAL HOSPITAL&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			              &lt;B&gt;Building 30, Room 3300&lt;br&gt;
			Box 0868         &lt;/B&gt;&lt;BR&gt;
			        &lt;B&gt;1001 Potrero Avenue&lt;/B&gt;&lt;BR&gt;
			        &lt;B&gt;San Francisco, CA&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt; &lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;9&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;4110&#45;0868&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;&lt;BR&gt;
			&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/p&gt;
			      &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/maluto.jpg&quot; width=&quot;104&quot; height=&quot;121&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Aida Maluto&lt;BR&gt;
			      Administrative Assistant&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;AidaMulato@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/murgado.JPG&quot; width=&quot;103&quot; height=&quot;90&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=MsoNormal&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Barbara Murgado&lt;O:P&gt;&lt;BR&gt;
			  &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Division Administrator&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;&lt;BR&gt;
			  &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;Barbara.M&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;urgado&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;@&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;ucsf.edu &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER&lt;/SPAN&gt;&lt;/B&gt;&lt;BR&gt;
			&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;Arthritis/Immunology Section&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			&lt;B&gt;4150 Clement Street&lt;/B&gt;&lt;BR&gt;
			&lt;B&gt;San Francisco, &lt;/B&gt;&lt;strong&gt;CA &lt;/strong&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;strong&gt;94121&#45;1601 &lt;/strong&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Denise Go&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Fellowship Coordinator&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;br&gt;
			    Denise.Go@ucsf.edu
			    &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Venecia Jacobs&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;BR&gt;
			&lt;/O:P&gt;Administrative Analyst&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Venecia.Jacobs@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Joan Tanaka &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;Administrative &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Assistant&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Joan.Tanaka@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Staff ./rheumatology/old/about/staff.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/staff.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;table width=&quot;429&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;104&quot;&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td width=&quot;309&quot;&gt;&lt;font size=&quot;6&quot;&gt;ADMINISTRATION&lt;/font&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;MOFFITT&#45;LONG HOSPITAL&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;&lt;/SPAN&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;533 Parnassus Avenue&lt;O:P&gt;&lt;br&gt;
			    Room U&#45;384&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;O:P&gt;, Box 0633 &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;O:P&gt;&lt;BR&gt;
			&lt;/O:P&gt;San Francisco, CA&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt; 94143&#45;0633&lt;br&gt;
			(415) 502&#45;2279
			&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/barlow.jpg&quot; width=&quot;104&quot; height=&quot;131&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Tony Barlow&lt;O:P&gt;&lt;BR&gt;
			&lt;/O:P&gt;Manager&lt;O:P&gt;&lt;BR&gt;
			Tony.Barlow@ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/bernacki.jpg&quot; width=&quot;104&quot; height=&quot;104&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=MsoNormal&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Gracie Bernacki&lt;O:P&gt;&lt;BR&gt;
			  &lt;/O:P&gt;Administrative Assistant&lt;BR&gt;
			  &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Gracie.Bernacki@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/lew.jpg&quot; width=&quot;103&quot; height=&quot;125&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Linda Lew&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;Research Analyst&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;&lt;/O:P&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Linda.Lew@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;A&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;MBULATORY&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt; C&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;ARE CLINIC &lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			          &lt;B&gt;400 Parnassus Avenu&lt;/B&gt;&lt;STRONG&gt;e, Plaza Level&lt;/STRONG&gt;&lt;BR&gt;
			&lt;B&gt;San Francisco, CA 94143&#45;0326&lt;br&gt;
			&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;(415) 353&#45;2497&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;TBN&lt;br&gt;
			    &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Practice Manager&lt;BR&gt;
			      &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;SAN FRANCISCO GENERAL HOSPITAL&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			              &lt;B&gt;Building 30, Room 3300&lt;br&gt;
			Box 0868         &lt;/B&gt;&lt;BR&gt;
			        &lt;B&gt;1001 Potrero Avenue&lt;/B&gt;&lt;BR&gt;
			        &lt;B&gt;San Francisco, CA&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt; &lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;9&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;4110&#45;0868&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;B&gt;&lt;BR&gt;
			&lt;/B&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/p&gt;
			      &lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/maluto.jpg&quot; width=&quot;104&quot; height=&quot;121&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Aida Maluto&lt;BR&gt;
			      Administrative Assistant&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;AidaMulato@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&lt;img src=&quot;../images/administration/murgado.JPG&quot; width=&quot;103&quot; height=&quot;90&quot;&gt;&lt;/td&gt;
			    &lt;td&gt;&lt;P class=MsoNormal&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Barbara Murgado&lt;O:P&gt;&lt;BR&gt;
			  &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Division Administrator&lt;O:P&gt;&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;&lt;BR&gt;
			  &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;Barbara.M&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;urgado&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;@&lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;O:P&gt;ucsf.edu &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER&lt;/SPAN&gt;&lt;/B&gt;&lt;BR&gt;
			&lt;B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;Arthritis/Immunology Section&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 13.5pt&quot;&gt;&lt;BR&gt;
			&lt;B&gt;4150 Clement Street&lt;/B&gt;&lt;BR&gt;
			&lt;B&gt;San Francisco, &lt;/B&gt;&lt;strong&gt;CA &lt;/strong&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;strong&gt;94121&#45;1601 &lt;/strong&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Denise Go&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;Fellowship Coordinator&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt; mso&#45;bidi&#45;font&#45;weight: bold&quot;&gt;&lt;br&gt;
			    Denise.Go@ucsf.edu
			    &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Venecia Jacobs&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;BR&gt;
			&lt;/O:P&gt;Administrative Analyst&lt;O:P&gt;&lt;/O:P&gt;&lt;O:P&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Venecia.Jacobs@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Joan Tanaka &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;O:P&gt;&lt;BR&gt;
			    &lt;/O:P&gt;Administrative &lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Assistant&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;&lt;BR&gt;
			&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;Joan.Tanaka@&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;SPAN 
			style=&quot;FONT&#45;SIZE: 10pt; mso&#45;bidi&#45;font&#45;size: 12.0pt&quot;&gt;ucsf.edu &lt;/SPAN&gt;&lt;/FONT&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			  &lt;tr&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			    &lt;td&gt;&amp;nbsp;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Visiting Professors ./rheumatology/old/about/visit.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/visit.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;SPAN&gt;&lt;B&gt;&lt;U&gt;Jean S. &amp;amp; Ephraim P. Engleman Visiting Professors &lt;/U&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;U&gt;&lt;B&gt;of Rheumatology&lt;/B&gt;&lt;/U&gt;&lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;SPAN&gt;1997: William Koopman, MD, University of Alabama&lt;BR&gt;
			  1998: &lt;/SPAN&gt;Bevra Hahn, MD, &lt;ST1:PLACE&gt;&lt;ST1:PLACETYPE&gt;University&lt;/ST1:PLACETYPE&gt; of &lt;ST1:PLACENAME&gt;California&lt;/ST1:PLACENAME&gt;&lt;/ST1:PLACE&gt; &lt;ST1:CITY&gt;&lt;ST1:PLACE&gt;Los Angeles&lt;/ST1:PLACE&gt;&lt;/ST1:CITY&gt;&lt;BR&gt;
			  &lt;SPAN&gt;1999: &lt;/SPAN&gt;Allen C. Steere, MD, &lt;ST1:PLACE&gt;&lt;ST1:PLACENAME&gt;Tufts&lt;/ST1:PLACENAME&gt; &lt;ST1:PLACETYPE&gt;University&lt;/ST1:PLACETYPE&gt; &lt;ST1:PLACETYPE&gt;School&lt;/ST1:PLACETYPE&gt;&lt;/ST1:PLACE&gt; of Medicine&lt;BR&gt;
			  &lt;SPAN&gt;2000: &lt;/SPAN&gt;John D. Stobo, MD, &lt;ST1:PLACE&gt;&lt;ST1:PLACETYPE&gt;University&lt;/ST1:PLACETYPE&gt; of &lt;ST1:PLACENAME&gt;Texas&lt;/ST1:PLACENAME&gt;&lt;/ST1:PLACE&gt;&lt;BR&gt;
			  &lt;SPAN&gt;2001: &lt;/SPAN&gt;Michael B. Brenner, MD, Brigham and Women's Hospital&lt;BR&gt;
			  &lt;SPAN&gt;2002: &lt;/SPAN&gt;James O'Dell, MD, &lt;ST1:PLACE&gt;&lt;ST1:PLACETYPE&gt;University&lt;/ST1:PLACETYPE&gt; of &lt;ST1:PLACENAME&gt;Nebraska&lt;/ST1:PLACENAME&gt;&lt;/ST1:PLACE&gt;&lt;BR&gt;
			  &lt;SPAN&gt;2003: Betty A. Diamond, MD, &lt;/SPAN&gt;&lt;ST1:PLACE&gt;&lt;ST1:PLACENAME&gt;Albert&lt;/ST1:PLACENAME&gt; &lt;ST1:PLACENAME&gt;Einstein&lt;/ST1:PLACENAME&gt; &lt;ST1:PLACETYPE&gt;College&lt;/ST1:PLACETYPE&gt;&lt;/ST1:PLACE&gt; of Medicine&lt;BR&gt;
			  2004: Steven Goldring, MD, Harvard Medical School&lt;BR&gt;
			  2005: Peter K. Gregersen, MD, NYU School of Medicine&lt;BR&gt;
			  2006: Daniel Kastner, MD, PhD, NIAMS&lt;BR&gt;
			  2008: V. Michael Holers, MD, University of Colorado&lt;br /&gt;
			  2010: Laurie Glimcher, MD, Harvard Medical School&lt;br /&gt;
			  2012: Antony Rosen, MD, Johns Hopkins University&lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;U&gt;Wallace V. Epstein Visiting Professors of Rheumatology&lt;/U&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;2003: John M. Esdaile, MD, &lt;ST1:PLACE&gt;&lt;ST1:PLACETYPE&gt;University&lt;/ST1:PLACETYPE&gt; of &lt;ST1:PLACENAME&gt;British Columbia&lt;BR&gt;
			  2004: David Felson, MD, Boston University&lt;BR&gt;
			  2005: Donald A. Berry, PhD, University of Texas&lt;/ST1:PLACENAME&gt;&lt;/ST1:PLACE&gt;&lt;BR&gt;
			  &lt;ST1:PLACE&gt;&lt;ST1:PLACENAME&gt;2006: Maria Suarez&#45;Almazor, MD, University of Texas&lt;BR&gt;
			2007: Sherine Gabriel, MD, Mayo Clinic&lt;/ST1:PLACENAME&gt;&lt;/ST1:PLACE&gt;&lt;br&gt;
			2009: David S. Pisetsky, MD, PhD, Duke University&lt;br /&gt;
			2010: David Borenstein, MD, George Washington University Medical Center&lt;br /&gt;
			2011: Lenore M. Buckley, MD, MPH, Virginia Commonwealth University
			&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;BR&gt;
			&lt;/FONT&gt;&lt;/P&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Lupus Program ./rheumatology/old/about/visit.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/visit.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			Your content goes here.&lt;p&gt;
			
			You can edit the page title by changing the text within the quotes on the line that begins &lt;code&gt;$title = &lt;/code&gt; in the code view above.
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./rheumatology/old/about/faculty/bajpai.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/faculty/bajpai.html</Path>
		<FileBody>
			
			
			&lt;!DOCTYPE HTML PUBLIC &quot;&#45;//W3C//DTD HTML 4.01 Transitional//EN&quot;
			&quot;http://www.w3.org/TR/html4/loose.dtd&quot;&gt;
			&lt;html&gt;
			&lt;head&gt;
			&lt;meta http&#45;equiv=&quot;Content&#45;Type&quot; content=&quot;text/html; charset=iso&#45;8859&#45;1&quot;&gt;
			&lt;title&gt;Untitled Document&lt;/title&gt;
			&lt;/head&gt;
			
			&lt;body&gt;
			&lt;table width=&quot;458&quot; height=&quot;114&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;148&quot;&gt;&lt;img src=&quot;../../images/faculty/bajpai3.jpeg&quot; width=&quot;228&quot; height=&quot;341&quot;&gt;&lt;/td&gt;
			    &lt;td width=&quot;294&quot;&gt;&lt;p&gt;&lt;strong&gt;Urmila Bajpai, MD, PhD&lt;/strong&gt;&lt;br&gt;
			  Adjunct Instructor of Medicine &lt;/p&gt;
			      &lt;p&gt; &lt;br&gt;
			  &lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;table width=&quot;458&quot; height=&quot;227&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;448&quot;&gt;&lt;p&gt;University of California, San Francisco&lt;br&gt;
			      1001 Potrero Ave., SFGH 30&#45;3300&lt;br&gt;
			      Box 0868&lt;br&gt;
			      San Francisco, CA 94143&#45;0868&lt;br&gt;
			      &lt;br&gt;
			        p: 415&#45;206&#45;6640&lt;br&gt;
			        f: 415&#45;648&#45;8425&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Education&lt;/strong&gt;&lt;br&gt;
			  Dr. Bajpai received her Ph.D in immunology from  Tufts University Sackler School of Biomedical Sciences in 2000 and her M.D.  from University of Massachusetts Medical School in 2004. She completed internal  medicine residency at Boston Medical Center in Boston, Massachusetts (2007) and  received her fellowship training in Rheumatology at the University of California,  San Francisco (2010). &lt;/p&gt;
			      &lt;p&gt;&lt;br&gt;
			        &lt;strong&gt;Licensure and Certification &lt;/strong&gt;&lt;br&gt;
			        Board certification, Rheumatology (2010) &lt;br&gt;
			Board certification, Internal Medicine (2007) &lt;br&gt;
			Medical License, State of California &lt;/p&gt;
			      &lt;p&gt;&lt;br&gt;
			        &lt;strong&gt;Research Interests &lt;/strong&gt;&lt;br&gt;
			        Understanding the  pathogenesis of autoimmune diseases like rheumatoid arthritis (RA) is  challenging due to the great number of potentially influential environmental  and genetic factors. An established critical pathway in autoimmune disease and  RA is the failure of regulatory T cells to control pathologic chronic  inflammation. An improved  understanding of the underlying mechanisms of regulatory T cell function in RA  will be crucial for delineating RA pathogenesis and, ultimately, for designing  more targeted and effective therapeutic interventions.&lt;br&gt;
			        &lt;br&gt;
			Dr.Bajpai&amp;rsquo;s current  work focuses on Fc Receptor Like&#45;3 (FcRL3), a transmembrane receptor expressed  on regulatory T cells. A genetic single nucleotide polymorphism (SNP) in FcRL3 is  thought to lead to increase risk for development of RA and other autoimmune  diseases. FcRL3 has only recently been discovered and, despite the proposed  genetic link between FcRL3 and various autoimmune diseases, its biology is only  poorly understood. Utilizing the UCSF RA Cohort, translational studies are  underway to determine the relevance of FcRL3 genetic polymorphisms and surface expression  on regulatory T cells to rheumatoid arthritis onset and progression.&lt;/p&gt;
			&lt;p&gt;&lt;br&gt;
			        &lt;strong&gt;Peer Reviewed Publications&lt;/strong&gt;&lt;br&gt;
			        L.  Swainson, J. Mold, &lt;strong&gt;U. Bajpai,&lt;/strong&gt; and M.  McCune. (2010) Expression of the autoimmune susceptibility gene FcRL3 on human  regulatory T cells is associated with dysfunction and high levels of programmed  cell death&#45;1.&lt;em&gt; J I&lt;/em&gt;&lt;em&gt;mmunol&lt;/em&gt; 184: 3639&#45;47. &lt;br&gt;
			        &lt;br&gt;
			        &lt;strong&gt;Bajpai, UD,&lt;/strong&gt; Zhang, K., Teutsch, M., Sen, R., Wortis, HH. (2000) Bruton&amp;rsquo;s tyrosine  kinase links the B cell receptor to nuclear factor&#45;kB activation.&amp;nbsp; &lt;em&gt;Journal  of Experimental Medicine.&lt;/em&gt;&amp;nbsp;  191(10):1735&#45;44.&lt;br&gt;
			Novina, C., Kumar S., &lt;strong&gt;Bajpai, U&lt;/strong&gt;.,  Cheriyath, V., Zhang, K., Pillai, S., Wortis, HH., Roy, AL. (1999) Regulation  of nuclear localization and transcriptional activity of TFII&#45;I by Bruton&amp;rsquo;s  Tyrosine Kinase.&amp;nbsp; &lt;em&gt;Molecular and Cellular Biology.&lt;/em&gt;&amp;nbsp;  19(7):5014&#45;24.&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Abstracts (Selected)&lt;/strong&gt;&lt;br&gt;
			  &lt;strong&gt;Bajpai, U.,&lt;/strong&gt; Swainson, L, Mold, J., Imboden, J., McCune, JM.&amp;nbsp; (2010) &amp;ldquo;FcRL3 expression on regulatory T  cells in Rheumatoid Arthritis&amp;rdquo;.FASEB Meeting &amp;ndash; Immunoreceptors. Aspen,  Colorado. &lt;br&gt;
			  &lt;br&gt;
			  &lt;strong&gt;Bajpai, U.,&lt;/strong&gt; Swainson, L, Mold, J., Imboden, J., McCune, JM.&amp;nbsp; (2010) &amp;ldquo;FcRL3 expression on regulatory T  cells in Rheumatoid Arthritis&amp;rdquo;. Midwinter Conference of Immunologists.  Monterey, CA.&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;/body&gt;
			&lt;/html&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./rheumatology/old/about/faculty/hsu.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/faculty/hsu.html</Path>
		<FileBody>
			
			
			&lt;!DOCTYPE HTML PUBLIC &quot;&#45;//W3C//DTD HTML 4.01 Transitional//EN&quot;
			&quot;http://www.w3.org/TR/html4/loose.dtd&quot;&gt;
			&lt;html&gt;
			&lt;head&gt;
			&lt;meta http&#45;equiv=&quot;Content&#45;Type&quot; content=&quot;text/html; charset=iso&#45;8859&#45;1&quot;&gt;
			&lt;title&gt;Untitled Document&lt;/title&gt;
			&lt;/head&gt;
			
			&lt;body&gt;
			&lt;table width=&quot;458&quot; height=&quot;114&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;148&quot;&gt;&lt;img src=&quot;../../images/faculty/hsu1.jpg&quot; width=&quot;273&quot; height=&quot;312&quot;&gt;&lt;/td&gt;
			    &lt;td width=&quot;294&quot;&gt;&lt;p&gt;&lt;strong&gt;Lyn Hsu, Ph.D.&lt;br&gt;
			    &lt;/strong&gt;Adjunct Instructor&lt;br&gt;
			  &lt;/p&gt;
			      &lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;table width=&quot;458&quot; height=&quot;227&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;448&quot;&gt;&lt;p&gt;Department  of Medicine/Rheumatology&lt;br&gt;
			University of California, San    Francisco&lt;br&gt;
			513  Parnassus, S&#45;1024, Box 0795&lt;br&gt;
			San    Francisco, CA 94143&#45;0795 &lt;/p&gt;
			      &lt;p&gt;E&#45;mail: &lt;a href=&quot;mailto:lih&#45;yun.hsu@ucsf.edu&quot;&gt;lih&#45;yun.hsu@ucsf.edu&lt;/a&gt;&lt;br&gt;
			        Lab  Phone: (415) 476&#45;4116&lt;br&gt;
			        Fax:  (415) 502&#45;5081&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Education&lt;br&gt;
			  &lt;/strong&gt;&#45;&#45;2003:  Dept. of Molecular Biology and Genetics, Graduate Program in Immunology, The Johns Hopkins   University.&lt;br&gt;
			  &#45;&#45;1994:  M.S., Institute of Molecular Medicine, School  of Medicine, National Taiwan University, Taiwan.&lt;br&gt;
			  &#45;&#45;1992:  B.S., Department of Medical Technology, China    Medical University, Taiwan.     &lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Research Interests&lt;br&gt;
			&lt;/strong&gt;My  main research interest is to understand how dysregulated signal transduction in  immune cells is associated with the development of various autoimmune  diseases.&amp;nbsp; In particular, I am interested  in studying the potential roles of tyrosine kinase ZAP&#45;70, a Syk family  tyrosine kinase associated with the z subunit of  the T cell receptor in T cell autoimmunity.&amp;nbsp;  Recently, I have compared a hypomorphic ZAP&#45;70 mutant mouse with an  interesting mouse model called SKG mouse, which spontaneously develops  inflammatory arthritis. My study has suggested that alterations in T cell  repertoire may contribute to susceptibility to autoimmunity versus autoimmune  disease.&amp;nbsp; Using several ZAP&#45;70 mutant  mice, my ongoing studies are aiming to better understand the molecular  mechanisms that contribute to the development of autoimmune arthritis or  protect from the development from the autoimmunity.&amp;nbsp; In addition, I am also interested in  developing other ZAP&#45;70 mouse models in which T cell signaling may be perturbed  in different ways, leading to either immune dysregulation or autoimmunity.&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Publications&lt;/strong&gt;&lt;br&gt;
			  1.&lt;strong&gt; &lt;/strong&gt;Liang, H.&#45;E., Hsu, L.&#45;Y., Cado, D., Cowell, L., Kelsoe, G  and Schlissel, M.S. (2002) &amp;ldquo;Dispensable&amp;rdquo;  Portion of RAG2 is necessary for efficient V&#45;to&#45;DJ rearrangement during B and T Cell  development. &lt;em&gt;Immunity&lt;/em&gt; 17, 639&#45;651.&lt;br&gt;
			  &lt;br&gt;
			2. Hsu, L.&#45;Y.,&lt;strong&gt; &lt;/strong&gt;Lauring,  J.,&lt;strong&gt; &lt;/strong&gt;Liang,  H.&#45;E., Greenbaum, S., Cado, D., Zhuang, Y., Schlissel, M.S. (2003) A conserved transcriptional enhancer regulates RAG gene expression in developing B cells. &lt;em&gt;Immunity&lt;/em&gt; 19, 105&#45;117.&lt;br&gt;
			&lt;br&gt;
			3. Borghesi, L., Hsu, L.&#45;Y., Miller, J.P., Anderson, M., Herzenberg, L., Herzenberg, L., Schlissel, M.S., Allman,  D., Gerstein, R.M. (2004) B lineage&#45;specific regulation of V(D)J recombinase  activity is established in common lymphoid progenitors. &lt;em&gt;J Exp&amp;nbsp;  Med 199, 491&#45;502.&lt;/em&gt;&lt;br&gt;
			&lt;br&gt;
			4. Hsu, L.&#45;Y., Liang, H.&#45;E., Johnson, K., Kang, C., Schlissel, M.S. (2004)  Pax5 activates immunoglobulin heavy chain V to DJ rearrangement in transgenic thymocytes. &lt;em&gt;J Exp&amp;nbsp; Med 199,  825&#45;830.&lt;/em&gt;&lt;br&gt;
			&lt;br&gt;
			5.  Liang, H.&#45;E., Hsu, L.&#45;Y., Cado, D., Schlissel,  M.S. (2004) Variegated transcriptional activation of the  immunoglobulin kappa locus in pre&#45;b cells contributes to the allelic exclusion of  light&#45;chain expression. &lt;em&gt;Cell 118, 19&#45;29.&lt;/em&gt;&lt;br&gt;
			&lt;br&gt;
			6. Au&#45;Yeung, B. B., Deindl, S., Hsu, L.&#45;Y.,&lt;strong&gt; &lt;/strong&gt;Palacios, E. H., Levin, S. E., Kuriyan,  J., Weiss, A. (2009) The structure,  regulation, and function of ZAP&#45;70.&amp;nbsp;&lt;em&gt;Immunol  Rev 228, 41&#45;57.&lt;br&gt;
			&lt;/em&gt;&lt;br&gt;
			7. Hsu, L.&#45;Y.,&lt;strong&gt; &lt;/strong&gt;Tan, Y.X., Xiao, Z., Malissen, M., Weiss, A. (2009) A hypomorphic allele ZAP&#45;70 reveals a distinct thymic threshold for autoimmune disease  versus autoimmune reactivity. &lt;em&gt;J Exp&amp;nbsp; Med 206,  2527&#45;2541.&lt;/em&gt;&lt;/p&gt;
			&lt;p&gt;8. Wang, H*, Kadlecek, T.A.*, Au&#45;Yeung, B. B.*, Sj&amp;ouml;lin  Goodfellow, H.E.*, Hsu, L.&#45;Y.*, Freedman, T.S., Weiss,&lt;br&gt;
			(2010) ZAP&#45;70: an essential kinase in T cell signaling.  Cold Spring Harb Perspect Biol May 2010; 2:a002279. (* these authors contribute  equally to this work.)&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&lt;br&gt;
			  &lt;br&gt;
			&lt;/p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;/body&gt;
			&lt;/html&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./rheumatology/old/about/faculty/schmajuk.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/about/faculty/schmajuk.html</Path>
		<FileBody>
			
			
			&lt;!DOCTYPE HTML PUBLIC &quot;&#45;//W3C//DTD HTML 4.01 Transitional//EN&quot;
			&quot;http://www.w3.org/TR/html4/loose.dtd&quot;&gt;
			&lt;html&gt;
			&lt;head&gt;
			&lt;meta http&#45;equiv=&quot;Content&#45;Type&quot; content=&quot;text/html; charset=iso&#45;8859&#45;1&quot;&gt;
			&lt;title&gt;Untitled Document&lt;/title&gt;
			&lt;/head&gt;
			
			&lt;body&gt;
			&lt;table width=&quot;458&quot; height=&quot;114&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;148&quot;&gt;&lt;img src=&quot;../../images/faculty/schmajuk2.jpg&quot; width=&quot;193&quot; height=&quot;273&quot;&gt;&lt;/td&gt;
			    &lt;td width=&quot;294&quot;&gt;&lt;p&gt;&lt;strong&gt;Gabriela Schmajuk, MD&lt;BR&gt;
			    &lt;/strong&gt;Adjunct Instructor of Medicine &lt;/p&gt;
			      &lt;p&gt; &lt;br&gt;
			  &lt;/p&gt;
			    &lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;table width=&quot;458&quot; height=&quot;227&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;448&quot;&gt;&lt;p&gt;San Francisco VA Medical Center&lt;br&gt;
			4150 Clement Street 111R&lt;br&gt;
			San Francisco, CA 94121&lt;br&gt;
			    &lt;/p&gt;
			      &lt;p&gt;Dr. Schmajuk graduated from Harvard University with a  B.A. in biochemistry in 1999. She received her M.D. degree from University of  Pennsylvania School of Medicine in 2003.&amp;nbsp;  She completed her internal medicine residency at Brigham and Women's  Hospital in Boston and her fellowship training in Rheumatology at Stanford  University. She also received a Master's in Epidemiology from Stanford in 2009.&lt;/p&gt;
			      &lt;p&gt;&lt;strong&gt;Licensure and  Certification&lt;/strong&gt;&lt;br&gt;
			Board certification, Rheumatology (2008)&lt;br&gt;
			Board certification, Internal Medicine (2006)&lt;br&gt;
			Medical License, State of California      &lt;/p&gt;
			      &lt;p&gt;&lt;strong&gt;Research Interests&lt;/strong&gt;&lt;br&gt;
			      Interests include quality of care, quality measurement,  pharmacoepidemiology in the rheumatic diseases.&lt;/p&gt;
			      &lt;p&gt;&lt;strong&gt;Publications&lt;/strong&gt;&lt;br&gt;
			      Schmajuk G, Sierakowska H, Kole R, Antisense  oligonucleotides with different backbones: Modification of splicing pathways  and efficacy of uptake. J Biol Chem. 1999 Jul 30;274(31):21783&#45;9.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME,  Setoguchi S, Avorn J, Levin R, Solomon DH. Treatment of Older Adult Patients  Diagnosed With Rheumatoid Arthritis: Improved but Not Optimal. Arthritis Rheum.&lt;br&gt;
			        2007 Aug 15;57(6):928&#45;34.&lt;/p&gt;
			      &lt;p&gt;Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean  CH, Wofsy D, Yelin E. Systemic Lupus Erythematosus Quality Indicators Project  Expert Panels. A quality indicator set for systemic lupus erythematosus.  Arthritis Rheum. 2009 Mar 15;61(3):370&#45;7.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Bush TM, Burkham J, Krishnan E, Chung L.  Characterizing systemic sclerosis in Northern California: focus on Asian and  Hispanic patients. Clin Exp Rheumatol. 2009 May&#45;Jun;27(3 Suppl 54):22&#45;5.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Genovese MC. First report of idiopathic  granulomatous mastitis treated with methotrexate monotherapy. J Rheumatol. 2009  Jul;36(7):1559.&lt;/p&gt;
			      &lt;p&gt;Sainani KL, Schmajuk G, Liu V. A caution on interpreting  odds ratios [Letter]. Sleep 2009; 32: 976.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Chakravarty E. Arthritis: in the eye of the  beholder?&lt;br&gt;
			        [Editorial]. J Rheumatol. 2009 Sep;36(9):1858&#45;60.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Krishnan E. Real or perceived conflicts of  interest in comparative effectiveness research [Abstract].&amp;nbsp; 2009 ACR/ARHP Annual Scientific Meeting in  Philadelphia, PA, Oct 2009.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Yazdany J, Trupin L, Yelin E.&amp;nbsp; Hydroxychloroquine use in a community&#45;based  cohort of patients with systemic lupus erythematosus.&lt;br&gt;
			        Arthritis Care Res (Hoboken). 2010 Mar;62(3):386&#45;92.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Yelin E, Chakravarty E, Nelson L, Panopolis  P, Yazdany J.&lt;br&gt;
			        Osteoporosis Screening, Prevention and Treatment in  Systemic Lupus&lt;br&gt;
			        Erythematosus: Application of the Systemic Lupus  Erythematosus Quality Indicators. Arthritis Care Res (Hoboken). 2010  Jul;62(7):993&#45;1001.&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Yazdany J. Drug monitoring in Systemic Lupus&lt;br&gt;
			        Erythematosus: A Systematic Review. Seminars in Arthritis  and Rheum.&lt;br&gt;
			        2010 Oct 26. [Epub ahead of print]&lt;/p&gt;
			      &lt;p&gt;Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ,  Chakravarty EF, Schwarz EB. Contraceptive Counseling and Use Among Women with  Systemic Lupus Erythematosus:&amp;nbsp; A Gap in  Health Care Quality? Arthritis Care Res (Hoboken). 2010 Nov 15. [Epub ahead of  print]&lt;/p&gt;
			      &lt;p&gt;Gillis J, Panopalis P, Schmajuk G, Ramsey&#45;Goldman R,  Yazdany J.&lt;br&gt;
			        Quality Indicators for Pregnancy and Reproductive Health  in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). Arthritis Care  Res (Hoboken). 2011 Jan;63(1):17&#45;30&lt;/p&gt;
			      &lt;p&gt;Schmajuk G, Trivedi A, Solomon DH, Yelin E, Trupin L,  Chakravarty EF, Yazdany J. Receipt of disease&#45;modifying anti&#45;rheumatic drugs  among patients with rheumatoid arthritis in Medicare managed care plans.&lt;br&gt;
			      JAMA. 2011 Feb 2; 305(5):480&#45;486.&lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;/body&gt;
			&lt;/html&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Lupus Clinic ./rheumatology/old/care/clinic.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/care/clinic.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			The UCSF Lupus Clinic is dedicated to providing the highest quality care to patients living with lupus. Our primary mission is to provide state&#45;of&#45;the&#45;art, personal care for all of our patients. Lupus is an autoimmune disease that can attack any organ system in the body including the joints, skin, kidneys, blood vessels, nervous system, and heart. Because lupus is a chronic disease, a large part of our efforts is devoted to educating patients and their families about their particular disease characteristics in order for them to take the best possible care of their health over the long run. The Lupus Clinic is located at 400 Parnassus Ave, Plaza level. The Director of the Lupus Clinic is Dr. Maria Dall'Era. Other Lupus Clinic providers include Drs. Jinoos Yazdany and Rachel Kaiser. If you feel that you would benefit from a referral to the Lupus Clinic, please contact us at (415) 476&#45;3735.&lt;br&gt;
			
			&lt;br&gt;
			&lt;img src=&quot;../images/LupusCliniccrop500.jpg&quot;&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Lupus Clinic ./rheumatology/old/care/clinic.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/care/clinic.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			The UCSF Lupus Clinic is dedicated to providing the highest quality care to patients living with lupus. Our primary mission is to provide state&#45;of&#45;the&#45;art, personal care for all of our patients. Lupus is an autoimmune disease that can attack any organ system in the body including the joints, skin, kidneys, blood vessels, nervous system, and heart. Because lupus is a chronic disease, a large part of our efforts is devoted to educating patients and their families about their particular disease characteristics in order for them to take the best possible care of their health over the long run. The Lupus Clinic is located at 400 Parnassus Ave, Plaza level. The Director of the Lupus Clinic is Dr. Maria Dall'Era. Other Lupus Clinic providers include Drs. Jinoos Yazdany and Rachel Kaiser. If you feel that you would benefit from a referral to the Lupus Clinic, please contact us at (415) 476&#45;3735.
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./rheumatology/old/care/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/care/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;The Clinical Program in Rheumatology at UCSF is dedicated to patient care, teaching, and clinical research. There are over 5,000 visits per year to the Rheumatology clinic where patients from diverse ethnic and socioeconomic backgrounds receive state&#45;of&#45;the&#45;art care from outstanding clinicians. Several of our physicians consistently appear in lists of Best Doctors in San Francisco and Best Doctors in America. Superb clinical teaching and research combine to make this one of the most sought after Rheumatology training programs in the country.&lt;/FONT&gt;&lt;/p&gt;
			&lt;p&gt;Click here for the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/rheumatology/index.html&quot;&gt;Rheumatology clinics at the UCSF Medical Center.&lt;/a&gt;&lt;/p&gt;
			&lt;p&gt;Click here for the &lt;a href=&quot;http://www.ucsfhealth.org/clinics/arthritis_and_joint_replacement_center/index.html&quot;&gt;Arthritis &amp;amp; Joint Replacement Center at the UCSF Medical Center&lt;/a&gt;.&lt;/p&gt;
			&lt;p&gt;Click here for &lt;a href=&quot;websites1.pdf&quot;&gt;useful websites for patients seeking information about rheumatologic disease&lt;/a&gt;.&lt;br /&gt;
			&lt;/p&gt;
			&lt;table width=&quot;857&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;520&quot;&gt;&lt;h2&gt; Parnassus Campus &lt;/h2&gt;
			      &lt;p&gt; &lt;strong&gt;Rheumatology Faculty Practice at Parnassus &lt;/strong&gt;&lt;/p&gt;
			      &lt;p&gt; Ambulatory Care Clinic&lt;br&gt;
			      400 Parnassus, Plaza level&lt;br&gt;
			      San Francisco , CA 94143&#45;0326&lt;/p&gt;
			      &lt;ul&gt;
			        &lt;li&gt; For scheduling new or follow&#45;up appointments, please call (415) 353&#45;2497.&lt;/li&gt;
			        &lt;li&gt;Click here&lt;a href=&quot;https://www.ucsfhealth.org/appointments/rheumatology/index.html&quot;&gt; to request an appointment&lt;/a&gt; on&#45;line.&lt;/li&gt;
			        &lt;li&gt; &lt;FONT color=#000000&gt;Fax referrals to (415) 353&#45;2530.&lt;/FONT&gt;&lt;/li&gt;
			        &lt;li&gt; &lt;a href=&quot;../care/clinic.html&quot;&gt;Lupus Patients&lt;/a&gt;, please telephone (415) 476&#45;3735. &lt;/li&gt;
			      &lt;/ul&gt;
			      &lt;p&gt; &lt;strong&gt;New Patients&lt;/strong&gt; are asked to bring the following to their first appointment: &lt;/p&gt;
			      &lt;ul&gt;
			        &lt;li&gt; Referring physician&amp;rsquo;s chart notes and test results &lt;/li&gt;
			        &lt;li&gt; Patient's insurance card(s) &lt;/li&gt;
			        &lt;li&gt; Insurance authorization letter (if needed) &lt;/li&gt;
			        &lt;li&gt; At this first appointment patient will be asked to provide demographic information &lt;/li&gt;
			      &lt;/ul&gt;
			    &lt;p align=&quot;center&quot;&gt;&lt;img src=&quot;../images/rhuemfaculty1.JPG&quot; width=&quot;222&quot; height=&quot;186&quot;&gt;&lt;/p&gt;
			    &lt;p align=&quot;center&quot;&gt;&lt;EM&gt;(from left to right) R. Krishna Chaganti, M, Andrew Gross, MD, &lt;/EM&gt;&lt;EM&gt;Lianne Gensler, MD, and Kenneth Sack, MD &lt;/EM&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;321&quot;&gt;&lt;p&gt;&lt;img src=&quot;../images/parnassus1.jpg&quot; width=&quot;200&quot; height=&quot;135&quot;&gt;&lt;/p&gt;
			    &lt;p&gt;&lt;strong&gt; Parking, Directions &amp;amp; Maps &lt;/strong&gt;&lt;/p&gt;
			    &lt;p&gt; Parking: Parking is available in the seven&#45;level Millberry Union Garage at 500 Parnassus Ave. There are two garage entrances, one on the north side of Parnassus Avenue and another on Irving Street, just east of Third Avenue. Current rates are posted on the &lt;a href=&quot;http://www.campuslifeservices.ucsf.edu/transportation/parking/public/parnassus/&quot;&gt;UCSF Parking and Transportation&lt;/a&gt; web site.&lt;/p&gt;
			    &lt;p&gt;&lt;a href=&quot;http://www.ucsf.edu/maps/directions&#45;to&#45;ucsf&#45;medical&#45;center/&quot;&gt; Directions&lt;/a&gt;&lt;/p&gt;
			    &lt;p&gt;&lt;a href=&quot;http://www.ucsf.edu/pdf/maps/ucsf_parnassus.pdf&quot;&gt; Map&lt;/a&gt; (pdf file) &lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./rheumatology/old/care/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/care/index.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;The Clinical Program in Rheumatology at UCSF is dedicated to patient care, teaching, and clinical research. There are over 5,000 visits per year to the Rheumatology clinic where patients from diverse ethnic and socioeconomic backgrounds receive state&#45;of&#45;the&#45;art care from outstanding clinicians. Several of our physicians consistently appear in lists of Best Doctors in San Francisco and Best Doctors in America. Superb clinical teaching and research combine to make this one of the most sought after Rheumatology training programs in the country.&lt;/FONT&gt;&lt;/p&gt;
			&lt;p&gt;Click here for &lt;a href=&quot;websites1.pdf&quot;&gt;useful websites for patients seeking information about rheumatologic disease&lt;/a&gt;.&lt;br /&gt;
			&lt;/p&gt;
			&lt;table width=&quot;857&quot; border=&quot;1&quot;&gt;
			  &lt;tr&gt;
			    &lt;td width=&quot;520&quot;&gt;&lt;h2&gt; Parnassus Campus &lt;/h2&gt;
			      &lt;p&gt; &lt;strong&gt;Rheumatology Faculty Practice at Parnassus &lt;/strong&gt;&lt;/p&gt;
			      &lt;p&gt; Ambulatory Care Clinic&lt;br&gt;
			      400 Parnassus, Plaza level&lt;br&gt;
			      San Francisco , CA 94143&#45;0326&lt;/p&gt;
			      &lt;ul&gt;
			        &lt;li&gt; For appointments, please telephone (415) 353&#45;2497.&lt;/li&gt;
			        &lt;li&gt; &lt;FONT color=#000000&gt;Fax referrals to (415) 353&#45;2530.&lt;/FONT&gt;&lt;/li&gt;
			        &lt;li&gt; &lt;strong&gt;Lupus patients&lt;/strong&gt;, please telephone (415) 476&#45;3735. &lt;/li&gt;
			      &lt;/ul&gt;
			      &lt;p&gt; &lt;strong&gt;New Patients&lt;/strong&gt; are asked to bring the following to their first appointment: &lt;/p&gt;
			      &lt;ul&gt;
			        &lt;li&gt; Referring physician&amp;rsquo;s chart notes and test results &lt;/li&gt;
			        &lt;li&gt; Patient's insurance card(s) &lt;/li&gt;
			        &lt;li&gt; Insurance authorization letter (if needed) &lt;/li&gt;
			        &lt;li&gt; At this first appointment patient will be asked to provide demographic information &lt;/li&gt;
			      &lt;/ul&gt;
			    &lt;p align=&quot;center&quot;&gt;&lt;img src=&quot;../images/rhuemfaculty1.JPG&quot; width=&quot;222&quot; height=&quot;186&quot;&gt;&lt;/p&gt;
			    &lt;p align=&quot;center&quot;&gt;&lt;EM&gt;(from left to right) R. Krishna Chaganti, M, Andrew Gross, MD, &lt;/EM&gt;&lt;EM&gt;Lianne Gensler, MD, and Kenneth Sack, MD &lt;/EM&gt;&lt;/p&gt;&lt;/td&gt;
			    &lt;td width=&quot;321&quot;&gt;&lt;p&gt;&lt;img src=&quot;../images/parnassus1.jpg&quot; width=&quot;200&quot; height=&quot;135&quot;&gt;&lt;/p&gt;
			    &lt;p&gt;&lt;strong&gt; Parking, Directions &amp;amp; Maps &lt;/strong&gt;&lt;/p&gt;
			    &lt;p&gt; Parking: Parking is available in the seven&#45;level Millberry Union Garage at 500 Parnassus Ave. There are two garage entrances, one on the north side of Parnassus Avenue and another on Irving Street, just east of Third Avenue. Current rates are posted on the &lt;a href=&quot;http://www.campuslifeservices.ucsf.edu/transportation/parking/public/parnassus/&quot;&gt;UCSF Parking and Transportation&lt;/a&gt; web site.&lt;/p&gt;
			    &lt;p&gt;&lt;a href=&quot;http://www.ucsf.edu/maps/directions&#45;to&#45;ucsf&#45;medical&#45;center/&quot;&gt; Directions&lt;/a&gt;&lt;/p&gt;
			    &lt;p&gt;&lt;a href=&quot;http://www.ucsf.edu/pdf/maps/ucsf_parnassus.pdf&quot;&gt; Map&lt;/a&gt; (pdf file) &lt;/p&gt;&lt;/td&gt;
			  &lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Fellowship Training Program ./rheumatology/old/education/fellowship.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/education/fellowship.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;The Rheumatology Fellowship Program at UCSF integrates clinical and research activities of the Divisions of Rheumatology located at each of the three UCSF training hospitals: San Francisco General Hospital, Moffitt&#45;Long Hospital, and the San Francisco Veterans Administration Medical Center. The program consists of one year of extensive clinical training, followed by one to two years of research experience and further clinical training. &lt;/FONT&gt;&lt;/P&gt;
			&lt;DIV align=center&gt;&lt;img src=&quot;../images/groupphoto2002.jpg&quot; width=&quot;337&quot; height=&quot;258&quot;&gt;&lt;BR&gt;
			    &lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;Rheumatology Fellows Retreat 2002&lt;/FONT&gt; &lt;/DIV&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;B&gt;&lt;U&gt;Description of the Program&lt;br&gt;
			&lt;/U&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;The inclusion of all three teaching hospitals of the University of California, San Francisco, in the Rheumatology Fellowship Program assures fellows an exposure to a large and diverse patient population and to a faculty with broad clinical and scientific expertise. Fifteen full&#45;time faculty members comprise the Divisions of Rheumatology. In addition, we have close associations with faculty in related areas, including allergy, pediatrics, radiology, orthopedics, rehabilitative medicine, microbiology/immunology, and epidemiology. Twenty additional part&#45;time clinical faculty members play an important role as attending physicians in the outpatient clinics and on the inpatient consult services. &lt;/FONT&gt;
			&lt;DIV align=center&gt;&lt;img src=&quot;../images/groupphoto2001.jpg&quot; width=&quot;371&quot; height=&quot;217&quot;&gt;&lt;BR&gt;
			    &lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;Rheumatology Fellows Retreat 2001&lt;/FONT&gt; &lt;/DIV&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;B&gt;&lt;U&gt;Clinical Training in Rheumatology&lt;br&gt;
			&lt;/U&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;First year fellows spend four months on the inpatient consultation service at each of the three teaching hospitals and participate in four outpatient clinics. Members of the faculty supervise each of these activities. &lt;/FONT&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;Following each outpatient clinic there is a conference that serves as a forum to discuss interesting patients. Participants at these conferences include rheumatology faculty members, orthopedic surgeons, and bone radiologists. &lt;/FONT&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;During all three years of the training program, fellows and faculty members participate in regularly scheduled teaching exercises. These include a weekly conference covering basic pathophysiology and clinical topics, a monthly journal club, and research conferences with participation by all three teaching hospitals. &lt;/FONT&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;The second and third years are devoted primarily to intensive training in laboratory or clinical research, but fellows continue to follow their own patients one&#45;half day per week in an outpatient clinic. Research may be conducted at any of the three teaching hospitals and, under some circumstances, in divisions outside of rheumatology. Candidates are not required to elect an area of research prior to entering the Fellowship Training Program. The selection can be made during the first year of the program. In addition to the activities within the Division of Rheumatology, UCSF offers a rich environment in contemporary biomedical research. Basic science seminars and graduate courses are readily available to the trainee. &lt;/FONT&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;Fellows choosing a career in clinical rheumatology continue their outpatient clinical responsibilities at the three teaching hospitals. In addition, they spend their second year on rotations through pediatric rheumatology, radiology, allergy/immunology, dermatology, and occupational medicine. Fellows become board eligible at the end of their second year. &lt;/FONT&gt;&lt;/P&gt;
			&lt;DIV align=center&gt;&lt;img src=&quot;../images/retreatcollage2002.jpg&quot; width=&quot;280&quot; height=&quot;307&quot;&gt; &lt;BR&gt;
			    &lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;Rheumatology Fellows Retreat 2002&lt;/FONT&gt; &lt;/DIV&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;B&gt;&lt;U&gt;Research Activities&lt;br&gt;
			&lt;/U&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;Research training opportunities in the UCSF Rheumatology Division are exceptionally broad. This page summarizes briefly the research activities of the rheumatology faculty at each of the three UCSF teaching hospitals. In addition to the specific research experiences under the direction of members of the Rheumatology Divisions, the University of California, San Francisco offers a large number of courses and ongoing seminars to supplement and enhance training in biomedical research. &lt;/FONT&gt;
			&lt;P align=justify&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;&lt;B&gt;&lt;U&gt;Applications&lt;br&gt;
			&lt;/U&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;Selection of fellows is coordinated by co&#45;Directors Drs. David Daikh and David Wofsy at the following address:&lt;BR&gt;
			  &lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;BR&gt;
			  VA Medical Center&lt;BR&gt;
			  4150 Clement St. (111R)&lt;BR&gt;
			  San Francisco, CA 94121&lt;BR&gt;
			  (415) 750&#45;2104 &lt;/FONT&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;Application requires the completion of the application form and the submission of three letters of recommendation. Interview is by invitation. Applicants will be notified of the need for an interview within three weeks of the submission of the application and the receipt of letters of recommendation. &lt;/FONT&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000 size=2&gt;To request an application, please send e&#45;mail to &lt;A 
			href=&quot;mailto:Denise.Go@ucsf.edu&quot;&gt;Denise.Go@ucsf.edu&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Education ./rheumatology/old/education/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/education/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p&gt;The educational programs of the division involve teaching activities in the medical school, graduate school, internship and residency programs and at the subspecialty fellowship level. We actively participate in continuing medical educational programs for physicians in practice. Our highly regarded subspecialty training program in rheumatology aims to produce outstanding scientists and physicians in the subspecialty of rheumatology.&lt;/p&gt;
			&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;A 
			href=&quot;https://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM11F01&quot;&gt;&lt;strong&gt;Rheumatology Board Review 2010 (Course # MDM11F01)&lt;/strong&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/p&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=3&gt;&lt;STRONG&gt;&lt;U&gt;GRADUATE EDUCATION PROGRAMS&lt;/U&gt;&lt;/STRONG&gt;&lt;/FONT&gt; &lt;/p&gt;
			&lt;UL type=disc&gt;
			  &lt;LI&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt; COLOR: windowtext&quot;&gt;&lt;A 
			href=&quot;http://www.ucsf.edu/bms/&quot;&gt;Biomedical Sciences Graduate Program (BMS)&lt;/A&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;
			  &lt;LI&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt&quot;&gt;&lt;A 
			href=&quot;http://www.ucsf.edu/immuno/&quot;&gt;Immunology Graduate Program&lt;/A&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt;
			  &lt;LI&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;B&gt;&lt;SPAN style=&quot;FONT&#45;SIZE: 10pt&quot;&gt;&lt;A 
			href=&quot;http://www.ucsf.edu/pibs/&quot;&gt;Program in Biological Sciences (PIBS)&lt;/A&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/FONT&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;p&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;A 
			href=&quot;https://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM10F01&quot;&gt;&lt;BR&gt;
			&lt;/A&gt;&lt;/FONT&gt;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Philanthropy/Rosalind Russell Center ./rheumatology/old/giving/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/giving/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			Your content goes here.&lt;p&gt;
			
			You can edit the page title by changing the text within the quotes on the line that begins &lt;code&gt;$title = &lt;/code&gt; in the code view above.
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Internal ./rheumatology/old/internal/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/internal/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P align=justify&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;strong&gt;&lt;b&gt;&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;4&quot;&gt;Journal Club&lt;/font&gt;&lt;/b&gt;&#45;&#45;The&lt;/strong&gt;&lt;a href=&quot;journalclub2011b.pdf&quot;&gt; 2011 Journal Club &lt;/a&gt;is organized by Dr. Lindsey Criswell for doctors, fellows, residents, students, interns and volunteer clinical faculty. It is held the last Tuesday every month.&lt;/FONT&gt;&lt;/P&gt;
			&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=justify&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;&lt;strong&gt;&lt;b&gt;&lt;font face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; 
			size=&quot;4&quot;&gt;Seminar Series&lt;/font&gt;&lt;/b&gt;&lt;/strong&gt;&#45;&#45;takes place on the second and third Tuesday of every month and is organized by Dr. Andrew Gross for first year fellows, residents, interns and students. Faculty discuss selected topics. Monthly conference schedules are available from Gracie Bernacki at 502&#45;2279 or Gracie.Bernacki@ucsf.edu&lt;/FONT&gt;&lt;/P&gt;
			&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p align=&quot;justify&quot;&gt;&lt;font 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=&quot;#000000&quot; size=&quot;2&quot;&gt;&lt;strong&gt;&lt;b&gt;&lt;font 
			size=&quot;4&quot;&gt;Clinical Case Conferences&lt;/font&gt;&lt;/b&gt;&#45;&#45;&lt;/strong&gt;takes place on the first Tuesday of each month and is organized by Dr. Andrew Gross for first year fellows, residents, interns and students.  (Click below to past presentations.)&lt;/font&gt;&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;&lt;font color=&quot;#000000&quot; size=&quot;2&quot; face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot;&gt;&lt;a href=&quot;clincase72010.pdf&quot;&gt;July 2010&lt;/a&gt;&lt;/font&gt; and &lt;a href=&quot;conf72010inflammatory.pdf&quot;&gt;Inflamatory Arthritis&lt;/a&gt;&#45;&#45;Ann Mary Belek &amp;amp; Andy Gross&lt;/li&gt;
			  &lt;li&gt;&lt;font color=&quot;#000000&quot; size=&quot;2&quot; face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot;&gt;&lt;a href=&quot;ccc22010.pdf&quot;&gt;February 2010&lt;/a&gt;&lt;/font&gt;&#45;&#45;Nicole Richman&lt;/li&gt;
			  &lt;li&gt;&lt;font color=&quot;#000000&quot; size=&quot;2&quot; face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot;&gt;&lt;a href=&quot;ccc12010.pdf&quot;&gt;January 2010&lt;/a&gt;&lt;/font&gt;&#45;&#45;Laura Tarter &amp;amp; Jon Graf&lt;/li&gt;
			  &lt;li&gt;&lt;font color=&quot;#000000&quot; size=&quot;2&quot; face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot;&gt;&lt;a href=&quot;ccc102009.pdf&quot;&gt;October 2009&lt;/a&gt;&lt;/font&gt;&#45;&#45;Laura Tarter &amp;amp; Andy Gross&lt;/li&gt;
			  
			  &lt;li&gt;&lt;font color=&quot;#000000&quot; size=&quot;2&quot; face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot;&gt;&lt;a href=&quot;ccc92009.pdf&quot;&gt;September 2009&lt;/a&gt;&lt;/font&gt;&#45;&#45;Sarah Graton&lt;br /&gt;
			  &lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&lt;a href=&quot;../reimbursement.pdf&quot;&gt;&lt;strong&gt;Reimbursement Policy for Rheumatology Parnassus Clinical Faculty&lt;/strong&gt;&lt;/a&gt; &lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Internal Resources ./rheumatology/old/internal/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/internal/index.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P align=justify&gt;&lt;B&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=4&gt;Seminar Series &amp;amp; Journal Club&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000&gt;&lt;A href=&quot;journalclub2009.pdf&quot;&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#990000 size=3&gt;&lt;STRONG&gt;&lt;font color=&quot;#000099&quot;&gt;The Journal Club 2009 &lt;/font&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;font color=&quot;#000099&quot;&gt;&lt;SPAN class=style2&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot;&gt;(click to see schedule)&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/font&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt;is organized by Dr. Lindsey Criswell for doctors, fellows, residents, students, interns and volunteer clinical faculty. It is held every last Tuesday of the month.&lt;/FONT&gt;&lt;/P&gt;
			&lt;P align=justify&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; 
			color=#000000&gt;&lt;SPAN class=style3&gt;&lt;strong&gt;The Seminar Serie&lt;/strong&gt;s&lt;/SPAN&gt;&lt;/FONT&gt;&lt;FONT 
			face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 size=2&gt; takes place every Tuesday and is organized by Dr. Andrew Gross for first year fellows, residents, interns and students. Faculty discuss selected topics. (Click below to see schedule.) &lt;/FONT&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;
			    &lt;DIV align=left&gt;
			      &lt;DIV align=left&gt;
			        &lt;DIV align=left&gt;
			          &lt;DIV align=left&gt;
			            &lt;DIV align=left&gt;
			              &lt;DIV align=left&gt;
			                &lt;DIV align=left&gt;
			                  &lt;DIV align=left&gt;
			                    &lt;DIV align=left&gt;
			                      &lt;DIV align=left&gt;
			                        &lt;DIV align=left&gt;
			                          &lt;DIV align=left&gt;
			                            &lt;DIV align=left&gt;
			                              &lt;DIV align=left&gt;
			                                &lt;DIV align=left&gt;
			                                  &lt;DIV align=left&gt;
			                                    &lt;DIV align=left&gt;
			                                      &lt;DIV align=left&gt;
			                                        &lt;DIV align=left&gt;
			                                          &lt;DIV align=left&gt;
			                                            &lt;DIV align=left&gt;
			                                              &lt;DIV align=left&gt;
			                                                &lt;DIV align=left&gt;
			                                                  &lt;DIV align=left&gt;
			                                                    &lt;DIV align=left&gt;
			                                                      &lt;DIV align=left&gt;
			                                                        &lt;DIV align=left&gt;
			                                                          &lt;DIV align=left&gt;
			                                                            &lt;DIV align=left&gt;
			                                                              &lt;DIV align=left&gt;
			                                                                &lt;DIV align=left&gt;
			                                                                  &lt;DIV align=left&gt;
			                                                                    &lt;DIV align=left&gt;
			                                                                      &lt;DIV align=left&gt;
			                                                                        &lt;DIV align=left&gt;
			                                                                          &lt;DIV align=left&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;A href=&quot;conf72009.pdf&quot;&gt;July 2009&lt;/A&gt;&lt;/FONT&gt;
			                                                                              &lt;DIV align=left&gt;
			                                                                                &lt;DIV align=left&gt;
			                                                                                  &lt;DIV align=left&gt;
			                                                                                    &lt;DIV align=left&gt;
			                                                                                      &lt;DIV align=left&gt;
			                                                                                        &lt;DIV align=left&gt;
			                                                                                          &lt;DIV align=left&gt;
			                                                                                            &lt;DIV align=left&gt;
			                                                                                              &lt;DIV align=left&gt;
			                                                                                                &lt;DIV align=left&gt;
			                                                                                                  &lt;DIV align=left&gt;
			                                                                                                    &lt;DIV align=left&gt;
			                                                                                                      &lt;DIV align=left&gt;
			                                                                                                        &lt;DIV align=left&gt;
			                                                                                                          &lt;DIV align=left&gt;
			                                                                                                            &lt;DIV align=left&gt;
			                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                                                                                                          &lt;DIV 
			align=left&gt;&lt;/DIV&gt;
			                                                                                                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                &lt;/DIV&gt;
			                                                                                                                              &lt;/DIV&gt;
			                                                                                                                            &lt;/DIV&gt;
			                                                                                                                          &lt;/DIV&gt;
			                                                                                                                        &lt;/DIV&gt;
			                                                                                                                      &lt;/DIV&gt;
			                                                                                                                    &lt;/DIV&gt;
			                                                                                                                  &lt;/DIV&gt;
			                                                                                                                &lt;/DIV&gt;
			                                                                                                              &lt;/DIV&gt;
			                                                                                                            &lt;/DIV&gt;
			                                                                                                          &lt;/DIV&gt;
			                                                                                                        &lt;/DIV&gt;
			                                                                                                      &lt;/DIV&gt;
			                                                                                                    &lt;/DIV&gt;
			                                                                                                  &lt;/DIV&gt;
			                                                                                                &lt;/DIV&gt;
			                                                                                              &lt;/DIV&gt;
			                                                                                            &lt;/DIV&gt;
			                                                                                          &lt;/DIV&gt;
			                                                                                        &lt;/DIV&gt;
			                                                                                      &lt;/DIV&gt;
			                                                                                    &lt;/DIV&gt;
			                                                                                  &lt;/DIV&gt;
			                                                                                &lt;/DIV&gt;
			                                                                              &lt;/DIV&gt;
			                                                                          &lt;/DIV&gt;
			                                                                        &lt;/DIV&gt;
			                                                                      &lt;/DIV&gt;
			                                                                    &lt;/DIV&gt;
			                                                                  &lt;/DIV&gt;
			                                                                &lt;/DIV&gt;
			                                                              &lt;/DIV&gt;
			                                                            &lt;/DIV&gt;
			                                                          &lt;/DIV&gt;
			                                                        &lt;/DIV&gt;
			                                                      &lt;/DIV&gt;
			                                                    &lt;/DIV&gt;
			                                                  &lt;/DIV&gt;
			                                                &lt;/DIV&gt;
			                                              &lt;/DIV&gt;
			                                            &lt;/DIV&gt;
			                                          &lt;/DIV&gt;
			                                        &lt;/DIV&gt;
			                                      &lt;/DIV&gt;
			                                    &lt;/DIV&gt;
			                                  &lt;/DIV&gt;
			                                &lt;/DIV&gt;
			                              &lt;/DIV&gt;
			                            &lt;/DIV&gt;
			                          &lt;/DIV&gt;
			                        &lt;/DIV&gt;
			                      &lt;/DIV&gt;
			                    &lt;/DIV&gt;
			                  &lt;/DIV&gt;
			                &lt;/DIV&gt;
			              &lt;/DIV&gt;
			            &lt;/DIV&gt;
			          &lt;/DIV&gt;
			        &lt;/DIV&gt;
			      &lt;/DIV&gt;
			    &lt;/DIV&gt;
			  &lt;LI&gt;
			    &lt;DIV align=left&gt;
			      &lt;DIV align=left&gt;
			        &lt;DIV align=left&gt;
			          &lt;DIV align=left&gt;
			            &lt;DIV align=left&gt;
			              &lt;DIV align=left&gt;
			                &lt;DIV align=left&gt;
			                  &lt;DIV align=left&gt;
			                    &lt;DIV align=left&gt;
			                      &lt;DIV align=left&gt;
			                        &lt;DIV align=left&gt;
			                          &lt;DIV align=left&gt;
			                            &lt;DIV align=left&gt;
			                              &lt;DIV align=left&gt;
			                                &lt;DIV align=left&gt;
			                                  &lt;DIV align=left&gt;
			                                    &lt;DIV align=left&gt;
			                                      &lt;DIV align=left&gt;
			                                        &lt;DIV align=left&gt;
			                                          &lt;DIV align=left&gt;
			                                            &lt;DIV align=left&gt;
			                                              &lt;DIV align=left&gt;
			                                                &lt;DIV align=left&gt;
			                                                  &lt;DIV align=left&gt;
			                                                    &lt;DIV align=left&gt;
			                                                      &lt;DIV align=left&gt;
			                                                        &lt;DIV align=left&gt;
			                                                          &lt;DIV align=left&gt;
			                                                            &lt;DIV align=left&gt;
			                                                              &lt;DIV align=left&gt;
			                                                                &lt;DIV align=left&gt;
			                                                                  &lt;DIV align=left&gt;
			                                                                    &lt;DIV align=left&gt;
			                                                                      &lt;DIV align=left&gt;
			                                                                        &lt;DIV align=left&gt;
			                                                                          &lt;DIV align=left&gt;
			                                                                            &lt;DIV align=left&gt;
			                                                                              &lt;DIV align=left&gt;
			                                                                                &lt;DIV align=left&gt;
			                                                                                  &lt;DIV align=left&gt;
			                                                                                    &lt;DIV align=left&gt;
			                                                                                      &lt;DIV align=left&gt;
			                                                                                        &lt;DIV align=left&gt;
			                                                                                          &lt;DIV align=left&gt;
			                                                                                            &lt;DIV align=left&gt;
			                                                                                              &lt;DIV align=left&gt;
			                                                                                                &lt;DIV align=left&gt;
			                                                                                                  &lt;DIV align=left&gt;
			                                                                                                    &lt;DIV align=left&gt;
			                                                                                                      &lt;DIV align=left&gt;
			                                                                                                        &lt;DIV align=left&gt;
			                                                                                                          &lt;DIV align=left&gt;
			                                                                                                            &lt;DIV align=left&gt;
			                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                  &lt;DIV align=left&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;A href=&quot;conf82009.pdf&quot;&gt;August 2009&lt;/A&gt;&lt;/FONT&gt;&lt;/DIV&gt;
			                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                &lt;/DIV&gt;
			                                                                                                                              &lt;/DIV&gt;
			                                                                                                                            &lt;/DIV&gt;
			                                                                                                                          &lt;/DIV&gt;
			                                                                                                                        &lt;/DIV&gt;
			                                                                                                                      &lt;/DIV&gt;
			                                                                                                                    &lt;/DIV&gt;
			                                                                                                                  &lt;/DIV&gt;
			                                                                                                                &lt;/DIV&gt;
			                                                                                                              &lt;/DIV&gt;
			                                                                                                            &lt;/DIV&gt;
			                                                                                                          &lt;/DIV&gt;
			                                                                                                        &lt;/DIV&gt;
			                                                                                                      &lt;/DIV&gt;
			                                                                                                    &lt;/DIV&gt;
			                                                                                                  &lt;/DIV&gt;
			                                                                                                &lt;/DIV&gt;
			                                                                                              &lt;/DIV&gt;
			                                                                                            &lt;/DIV&gt;
			                                                                                          &lt;/DIV&gt;
			                                                                                        &lt;/DIV&gt;
			                                                                                      &lt;/DIV&gt;
			                                                                                    &lt;/DIV&gt;
			                                                                                  &lt;/DIV&gt;
			                                                                                &lt;/DIV&gt;
			                                                                              &lt;/DIV&gt;
			                                                                            &lt;/DIV&gt;
			                                                                          &lt;/DIV&gt;
			                                                                        &lt;/DIV&gt;
			                                                                      &lt;/DIV&gt;
			                                                                    &lt;/DIV&gt;
			                                                                  &lt;/DIV&gt;
			                                                                &lt;/DIV&gt;
			                                                              &lt;/DIV&gt;
			                                                            &lt;/DIV&gt;
			                                                          &lt;/DIV&gt;
			                                                        &lt;/DIV&gt;
			                                                      &lt;/DIV&gt;
			                                                    &lt;/DIV&gt;
			                                                  &lt;/DIV&gt;
			                                                &lt;/DIV&gt;
			                                              &lt;/DIV&gt;
			                                            &lt;/DIV&gt;
			                                          &lt;/DIV&gt;
			                                        &lt;/DIV&gt;
			                                      &lt;/DIV&gt;
			                                    &lt;/DIV&gt;
			                                  &lt;/DIV&gt;
			                                &lt;/DIV&gt;
			                              &lt;/DIV&gt;
			                            &lt;/DIV&gt;
			                          &lt;/DIV&gt;
			                        &lt;/DIV&gt;
			                      &lt;/DIV&gt;
			                    &lt;/DIV&gt;
			                  &lt;/DIV&gt;
			                &lt;/DIV&gt;
			              &lt;/DIV&gt;
			            &lt;/DIV&gt;
			          &lt;/DIV&gt;
			        &lt;/DIV&gt;
			      &lt;/DIV&gt;
			    &lt;/DIV&gt;
			  &lt;LI&gt;
			    &lt;DIV align=left&gt;
			      &lt;DIV align=left&gt;
			        &lt;DIV align=left&gt;
			          &lt;DIV align=left&gt;
			            &lt;DIV align=left&gt;
			              &lt;DIV align=left&gt;
			                &lt;DIV align=left&gt;
			                  &lt;DIV align=left&gt;
			                    &lt;DIV align=left&gt;
			                      &lt;DIV align=left&gt;
			                        &lt;DIV align=left&gt;
			                          &lt;DIV align=left&gt;
			                            &lt;DIV align=left&gt;
			                              &lt;DIV align=left&gt;
			                                &lt;DIV align=left&gt;
			                                  &lt;DIV align=left&gt;
			                                    &lt;DIV align=left&gt;
			                                      &lt;DIV align=left&gt;
			                                        &lt;DIV align=left&gt;
			                                          &lt;DIV align=left&gt;
			                                            &lt;DIV align=left&gt;
			                                              &lt;DIV align=left&gt;
			                                                &lt;DIV align=left&gt;
			                                                  &lt;DIV align=left&gt;
			                                                    &lt;DIV align=left&gt;
			                                                      &lt;DIV align=left&gt;
			                                                        &lt;DIV align=left&gt;
			                                                          &lt;DIV align=left&gt;
			                                                            &lt;DIV align=left&gt;
			                                                              &lt;DIV align=left&gt;
			                                                                &lt;DIV align=left&gt;
			                                                                  &lt;DIV align=left&gt;
			                                                                    &lt;DIV align=left&gt;
			                                                                      &lt;DIV align=left&gt;
			                                                                        &lt;DIV align=left&gt;
			                                                                          &lt;DIV align=left&gt;
			                                                                            &lt;DIV align=left&gt;
			                                                                              &lt;DIV align=left&gt;
			                                                                                &lt;DIV align=left&gt;
			                                                                                  &lt;DIV align=left&gt;
			                                                                                    &lt;DIV align=left&gt;
			                                                                                      &lt;DIV align=left&gt;
			                                                                                        &lt;DIV align=left&gt;
			                                                                                          &lt;DIV align=left&gt;
			                                                                                            &lt;DIV align=left&gt;
			                                                                                              &lt;DIV align=left&gt;
			                                                                                                &lt;DIV align=left&gt;
			                                                                                                  &lt;DIV align=left&gt;
			                                                                                                    &lt;DIV align=left&gt;
			                                                                                                      &lt;DIV align=left&gt;
			                                                                                                        &lt;DIV align=left&gt;
			                                                                                                          &lt;DIV align=left&gt;
			                                                                                                            &lt;DIV align=left&gt;
			                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                  &lt;DIV align=left&gt;
			                                                                                                                                    &lt;DIV align=left&gt;
			                                                                                                                                      &lt;DIV align=left&gt;
			                                                                                                                                        &lt;DIV align=left&gt;
			                                                                                                                                          &lt;DIV align=left&gt;
			                                                                                                                                            &lt;DIV align=left&gt;
			                                                                                                                                              &lt;DIV align=left&gt;
			                                                                                                                                                &lt;DIV align=left&gt;
			                                                                                                                                                  &lt;DIV align=left&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; color=#000000 
			size=2&gt;&lt;A href=&quot;conf92009.pdf&quot;&gt;September 2009&lt;/A&gt;&lt;/FONT&gt;&lt;/DIV&gt;
			                                                                                                                                                &lt;/DIV&gt;
			                                                                                                                                              &lt;/DIV&gt;
			                                                                                                                                            &lt;/DIV&gt;
			                                                                                                                                          &lt;/DIV&gt;
			                                                                                                                                        &lt;/DIV&gt;
			                                                                                                                                      &lt;/DIV&gt;
			                                                                                                                                    &lt;/DIV&gt;
			                                                                                                                                  &lt;/DIV&gt;
			                                                                                                                                &lt;/DIV&gt;
			                                                                                                                              &lt;/DIV&gt;
			                                                                                                                            &lt;/DIV&gt;
			                                                                                                                          &lt;/DIV&gt;
			                                                                                                                        &lt;/DIV&gt;
			                                                                                                                      &lt;/DIV&gt;
			                                                                                                                    &lt;/DIV&gt;
			                                                                                                                  &lt;/DIV&gt;
			                                                                                                                &lt;/DIV&gt;
			                                                                                                              &lt;/DIV&gt;
			                                                                                                            &lt;/DIV&gt;
			                                                                                                          &lt;/DIV&gt;
			                                                                                                        &lt;/DIV&gt;
			                                                                                                      &lt;/DIV&gt;
			                                                                                                    &lt;/DIV&gt;
			                                                                                                  &lt;/DIV&gt;
			                                                                                                &lt;/DIV&gt;
			                                                                                              &lt;/DIV&gt;
			                                                                                            &lt;/DIV&gt;
			                                                                                          &lt;/DIV&gt;
			                                                                                        &lt;/DIV&gt;
			                                                                                      &lt;/DIV&gt;
			                                                                                    &lt;/DIV&gt;
			                                                                                  &lt;/DIV&gt;
			                                                                                &lt;/DIV&gt;
			                                                                              &lt;/DIV&gt;
			                                                                            &lt;/DIV&gt;
			                                                                          &lt;/DIV&gt;
			                                                                        &lt;/DIV&gt;
			                                                                      &lt;/DIV&gt;
			                                                                    &lt;/DIV&gt;
			                                                                  &lt;/DIV&gt;
			                                                                &lt;/DIV&gt;
			                                                              &lt;/DIV&gt;
			                                                            &lt;/DIV&gt;
			                                                          &lt;/DIV&gt;
			                                                        &lt;/DIV&gt;
			                                                      &lt;/DIV&gt;
			                                                    &lt;/DIV&gt;
			                                                  &lt;/DIV&gt;
			                                                &lt;/DIV&gt;
			                                              &lt;/DIV&gt;
			                                            &lt;/DIV&gt;
			                                          &lt;/DIV&gt;
			                                        &lt;/DIV&gt;
			                                      &lt;/DIV&gt;
			                                    &lt;/DIV&gt;
			                                  &lt;/DIV&gt;
			                                &lt;/DIV&gt;
			                              &lt;/DIV&gt;
			                            &lt;/DIV&gt;
			                          &lt;/DIV&gt;
			                        &lt;/DIV&gt;
			                      &lt;/DIV&gt;
			                    &lt;/DIV&gt;
			                  &lt;/DIV&gt;
			                &lt;/DIV&gt;
			              &lt;/DIV&gt;
			            &lt;/DIV&gt;
			          &lt;/DIV&gt;
			        &lt;/DIV&gt;
			      &lt;/DIV&gt;
			    &lt;/DIV&gt;
			  &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;&lt;font size=&quot;4&quot;&gt;Rheumatology Administration&lt;/font&gt;:&lt;/strong&gt;&lt;a href=&quot;../reimbursement.pdf&quot;&gt; Reimbursement Policy for Parnassus Clinical Faculty&lt;/a&gt; &lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Research ./rheumatology/old/research/#clinical.html#
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/#clinical.html#</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=2&gt;&lt;SPAN 
			style=&quot;COLOR: #003333; mso&#45;bidi&#45;font&#45;size: 9.0pt&quot;&gt;*** Research activities of the Division can also be viewed on the &lt;U&gt;&lt;A href=&quot;faculty.html&quot;&gt;bio&#45;sketches of individual faculty members.&lt;/A&gt;&lt;/U&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;STRONG&gt;M. Kari Connolly, MD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Scleroderma&quot;&gt;The UCSF Scleroderma Database and Tissue Bank&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Scleroderma_Lung&quot;&gt;The Scleroderma Lung Study&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Anti_TGFb&quot;&gt;Anti&#45;TGFb in scleroderma patients &lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Anti_TGFb&quot;&gt;Immune tolerance therapy in pemphigus patients&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Lindsey A. Criswell, MD, MPH&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Lupus&quot;&gt;Lupus Genetics Research Project&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Lupus&quot;&gt;Rheumatoid Arthritis Genetics Research Project&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Mother&quot;&gt;Mother&#45;Child Immunogenetic Study&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Maria Dall'Era , MD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Davis_Natural_History&quot;&gt;The Natural History, Pathogenesis, and Disease Analysis of Systemic Lupus Erythematosus&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Davis_Relationships&quot;&gt;Relationships among Disease Status, Immune Markers, Cognitive Functioning, and Psychiatric Symptoms in Systemic Lupus Erythematosus (SLE)&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Edward Yelin, PhD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;http://medicine.ucsf.edu/rheum/mcrc/&quot;&gt;Multidisiplinary Clinical Research Center Program (MCRC)&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=center&gt;***************************************************&lt;/P&gt;
			&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research &#45;&#45; Clinical &lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by M. Kari Connolly, M.D.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Connolly_Scleroderma&gt;&lt;/A&gt;&lt;STRONG&gt;The UCSF Scleroderma Database and Tissue Bank.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This study is open to all patients with scleroderma. A one&#45;page information sheet is completed and signed.&amp;nbsp; This form can be downloaded at &lt;A 
			href=&quot;http://www.dermatology.ucsf.edu/autoimmune/&quot;&gt;http://www.dermatology.ucsf.edu/autoimmune/&lt;/A&gt; and then returned by fax or mail to the address below.&amp;nbsp; The information is entered into a computer database. Based on the information, together with what studies are active, patients may be contacted for study participation which could include: blood draws, skin biopsies and/or other studies.&amp;nbsp; &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Scleroderma Research Foundation 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. (Dermatologist/Rheumatologist) 
			  &lt;LI&gt;Call and leave info on machine: 415&#45;502&#45;5358 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Connolly_Scleroderma_Lung&gt;&lt;/A&gt;&lt;STRONG&gt;The Scleroderma Lung Study.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This is a two&#45;year study that looks at the affect of daily oral cytoxan for one year versus placebo on lung disease in scleroderma patients.&amp;nbsp; This study is open to patients with scleroderma (systemic sclerosis) for less than 7 years with symptomatic lung involvement (short of breath going up one flight of steps). &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: The NIH 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. 
			  &lt;LI&gt;Research coordinator: 415&#45;502&#45;6229 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Connolly_Anti_TGFb&gt;&lt;/A&gt;&lt;STRONG&gt;Anti&#45;TGFb in scleroderma patients.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This study is in the planning stages.&amp;nbsp; This study will be a phase II trial of anti&#45;TGF&#45;b in scleroderma patients (4 IV infusions 6&#45;weeks apart over 6 months.).&amp;nbsp; The goal of this experimental therapy is to soften skin and improve fibrosis. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Genzyme, Inc. 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Immune tolerance therapy in pemphigus patients.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This a phase I trial of synthetic desmoglein 3 (the immuno dominant antigen for pemphigus) in stable, active pemphigus vulgaris patients. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Peptimmune, Inc. 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. 
			  &lt;LI&gt;Research coordinator: 415&#45;502&#45;6229 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by Lindsey Ann Criswell, M.D., M.P.H.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Criswell_Lupus&gt;&lt;STRONG&gt;Lupus Genetics Research Project &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;Any patient with a diagnosis of systemic lupus (SLE) is welcome to participate in this study. This ongoing study is investigating the genes that may predispose an individual to develop lupus. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigator: Lindsey Criswell, M.D., M.P.H. 
			  &lt;LI&gt;Contact: toll free 888&#45;223&#45;3067 x1 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Criswell_RA&gt;&lt;STRONG&gt;Rheumatoid Arthritis Genetics Research Project &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;Any patient with a diagnosis of rheumatoid arthritis (RA) is welcome to participate in this study. This ongoing study is investigating the genes that may predispose an individual to develop rheumatoid arthritis. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigator: Lindsey Criswell, M.D., M.P.H. 
			  &lt;LI&gt;Contact: toll&#45;free 888&#45;223&#45;3067 x4 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Criswell_Mother&gt;&lt;STRONG&gt;Mother&#45;Child Immunogenetic Study &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;This study involves a collaboration with the UC Berkeley School of Public Health to investigate the role that pregnancy plays in rheumatoid arthritis (RA) and lupus (SLE). Criteria for participation include: (1) a diagnosis of RA or SLE, (2) at least one pregnancy resulting in a live birth, (3) at least one child must be willing to participate and over the age of 7, and (4) participation of the biological father is encouraged but not required. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigators: Lindsey Criswell, M.D., M.P.H. &amp;amp; Lisa Barcellos, Ph.D.(UC Berkeley) 
			  &lt;LI&gt;Contact: toll&#45;free 888&#45;223&#45;3067 x3 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by Maria Dall'Era, M.D.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Davis_Natural_History&gt;&lt;/A&gt;&lt;STRONG&gt;The Natural History, Pathogenesis, and Disease Analysis of Systemic Lupus Erythematosus&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;The purpose of this study is to learn more about the disease systemic lupus erythematosus (SLE). The goals of this research are 1) to evaluate patients with lupus to better understand how the disease begins and how it affects patients, 2) to follow patients during the course of the disease to understand how disease changes over time and, 3) to conduct research to develop better treatments for lupus. There is no cost for participation. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Rosalind Russell Center for Arthritis Research 
			  &lt;LI&gt;Investigator: Maria Dall'Era, M.D. &amp;amp; David Wofsy, M.D. 
			  &lt;LI&gt;Contact: Stephanie Morgan (415) 502&#45;1698 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Davis_Relationships&gt;&lt;/A&gt;&lt;STRONG&gt;Relationships among Disease Status, Immune Markers, Cognitive Functioning, and Psychiatric Symptoms in Systemic Lupus Erythematosus (SLE)&lt;BR&gt;
			  &lt;/STRONG&gt;The purpose of this study is to examine neuropsychiatric symptoms in SLE. The goals of this investigation are to (1) evaluate cognitive and psychiatric symptoms in SLE, (2) to examine the relationship among SLE disease status, immune functioning, cognitive functioning and psychiatric symptoms, and (3) to follow patients in order to understand how these neuropsychiatric symptoms change over time. Patients with and without a previous history of neuropsychiatric symptoms are invited to participate. There is no cost for participation, and treatment is not provided. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Investigators: Maria Dall'Era, M.D.&amp;amp; Laura J. Julian, Ph.D. 
			  &lt;LI&gt;Contact: Stephanie Morgan (415) 502&#45;1886 &amp;amp; Laura Julian (415) 221&#45;4810 x 3134 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;&lt;br&gt;
			
								</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Clinical Research Center ./rheumatology/old/research/center.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/center.html</Path>
		<FileBody>
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;#trials&quot;&gt;Clinical Trials&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#consortium&quot;&gt;Lupus Clinical Trials Consortium Patient Registry&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#surveillance&quot;&gt;The California Lupus Surveillance Project&lt;/a&gt;
			&lt;/ul&gt;&lt;br&gt;
			&lt;img src=&quot;../images/ClinicalResearchCenterCrop600.jpg&quot;&gt;&lt;br&gt;
			
			&lt;br&gt;
			
			&lt;b&gt;&lt;a name=&quot;trials&quot;&gt;Clinical Trials &lt;/a&gt;&lt;/b&gt;&lt;br&gt;
			&lt;br&gt;
			A clinical trial is a formal research study designed to test promising treatments for a disease. It represents the final stage of the long process of drug design and development. A clinical trial follows a very specific protocol that has been reviewed by a variety of individuals and groups including the United States Food and Drug Administration (FDA) and the UCSF Committee on Human Research. Through participation in clinical trials, lupus patients can help their physicians bring effective and safe treatments for lupus into clinical use.&lt;br&gt;
			At UCSF, we are currently conducting several important clinical trials of promising new agents in an effort to determine which may be the safest and most effective in the treatment of lupus. We feel privileged to be able to offer our patients access to new and state&#45;of&#45;the&#45;art treatments in the context of clinical trials. Our studies are funded by the National Institutes of Health and industry. Study protocols include research collaborations with other academic medical centers, the Autoimmune Centers of Excellence, and the Immune Tolerance Network. Please view our listing of active trials for more details about our currently enrolling &lt;a href=&quot;/research/clinical.html/&quot;&gt;clinical trials&lt;/a&gt;.&lt;br&gt;
			Patient participation in trials is vital to our success in bringing new therapies for lupus to daily clinical practice.  If you are interested in learning more about clinical trials in lupus or about any of the trials listed below, please contact us at (415) 502&#45;1886.&lt;br&gt;
			&lt;br&gt;
			Currently enrolling Clinical Trials to see&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/research/clinical.html#Abatacept&quot;&gt;Abatacept for patients with lupus nephritis (lupus kidney disease)&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/research/clinical.html#VitD&quot;&gt;Vitamin D for the treatment of lupus&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/research/clinical.html#Lovastatin&quot;&gt;Lovastatin for the treatment of rheumatoid arthritis&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;&lt;a name=&quot;consortium&quot;&gt;Lupus Clinical Trials Consortium Patient Registry&lt;/a&gt;&lt;/b&gt;&lt;br&gt;
			&lt;br&gt;
			We are proud to have been selected to be a part of the Lupus Clinical Trials Consortium, a non&#45;profit organization dedicated to improving the lives of lupus patients.  The Lupus Consortium is composed of 20 academic centers across the United States. For the first time in the history of lupus research, these 20 centers will be coordinating their efforts to create a longitudinal Lupus Registry.  Each center will be entering information into the Registry, resulting in one of the largest lupus databases in existence. The information we collect in this registry will help us to answer many fundamental questions about lupus including (1) Which medications are effective for which features of lupus? (2) How do lupus disease manifestations change over the course of time (3) How does lupus differ in various racial/ethnic groups and in different geographical areas?&lt;br&gt;
			While registries such as this have been commonly utilized in other conditions such as cancer and heart disease, they have never before been used for lupus.  We are thrilled that lupus is finally getting the attention it deserves, and we feel that this is an extraordinary opportunity to advance our understanding of lupus and its treatment.&lt;br&gt;
			The registry is an observational study, so no special treatments or drugs will be given. Importantly, no extra patient visits will be required outside of regularly scheduled clinic visits.&lt;br&gt;
			Dr. Maria Dall'era is the Center Director and Dr. Jinoos Yazdany is the Clinical Director for the UCSF Lupus Clinical Trials Consortium patient registry. Dr. David Wofsy is the Senior Investigator of this Registry. If you would like to learn more about this registry, please contact Ms. Stephanie Wangler at 415&#45;476&#45;3735.&lt;br&gt;
			&lt;br&gt;
			
			&lt;b&gt;&lt;a name=&quot;surveillance&quot;&gt;The California Lupus Surveillance Project&lt;/a&gt;&lt;/b&gt;&lt;br&gt;
			&lt;br&gt;
			The California Lupus Surveillance Project (CLSP) is a population based effort to determine the true incidence and prevalence of lupus within San Francisco and San Mateo Counties in the San Francisco bay area. This project is being sponsored by the Centers for Disease Control and Prevention (CDC), and is being performed in conjunction with the California Department of Public Health. Dr. Maria Dall'era is the pricipal Investigator of this project.&lt;br&gt;
			The purpose of the CLSP is to document how many people are living with lupus and how quickly new cases are developing in a defined area over a defined period of time.  It will also help us understand the public health burden that lupus presents. We will ultimately develop a deeper understanding of the manifestations of lupus and how lupus affects various racial and ethnic groups.&lt;br&gt;
			Acting as public health agents under the auspices of the California Department of Public Health, we will identify as many hospitals and practitioners as possible who are providing care to potential cases of lupus. Providers contacted will include rheumatologists, nephrologists, and dermatologists. In addition, patient advocacy groups will also help identify patients and their healthcare providers. Once these providers and hospitals are identified, lupus cases will be validated through medical record review. Trained data abstractors will review medical records and document the presence of the criteria needed to enter a patient into the lupus registry. Other information important to public health surveillance will be collected as well.&lt;br&gt;
			For more information about the California Lupus Surveillance Project, please call Ms. Lidia Espino at 415&#45;502&#45;5108.
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatology Clinical Research Center ./rheumatology/old/research/center.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/center.html~</Path>
		<FileBody>
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;#trials&quot;&gt;Clinical Trials&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#consortium&quot;&gt;Lupus Clinical Trials Consortium Patient Registry&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#surveillance&quot;&gt;The California Lupus Surveillance Project&lt;/a&gt;
			&lt;/ul&gt;&lt;br&gt;
			&lt;img src=&quot;../images/ClinicalResearchCenterCrop600.jpg&quot;&gt;&lt;br&gt;
			
			&lt;br&gt;
			
			&lt;b&gt;&lt;a name=&quot;trials&quot;&gt;Clinical Trials &lt;/a&gt;&lt;/b&gt;&lt;br&gt;
			&lt;br&gt;
			A clinical trial is a formal research study designed to test promising treatments for a disease. It represents the final stage of the long process of drug design and development. A clinical trial follows a very specific protocol that has been reviewed by a variety of individuals and groups including the United States Food and Drug Administration (FDA) and the UCSF Committee on Human Research. Through participation in clinical trials, lupus patients can help their physicians bring effective and safe treatments for lupus into clinical use.&lt;br&gt;
			At UCSF, we are currently conducting several important clinical trials of promising new agents in an effort to determine which may be the safest and most effective in the treatment of lupus. We feel privileged to be able to offer our patients access to new and state&#45;of&#45;the&#45;art treatments in the context of clinical trials. Our studies are funded by the National Institutes of Health and industry. Study protocols include research collaborations with other academic medical centers, the Autoimmune Centers of Excellence, and the Immune Tolerance Network. Please view our listing of active trials for more details about our currently enrolling &lt;a href=&quot;/research/clinical.html/&quot;&gt;clinical trials&lt;/a&gt;.&lt;br&gt;
			Patient participation in trials is vital to our success in bringing new therapies for lupus to daily clinical practice.  If you are interested in learning more about clinical trials in lupus or about any of the trials listed below, please contact us at (415) 502&#45;1886.&lt;br&gt;
			&lt;br&gt;
			Currently enrolling Clinical Trials to see&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/research/clinical.html#Abatacept&quot;&gt;Abatacept for patients with lupus nephritis (lupus kidney disease)&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/research/clinical.html#VitD&quot;&gt;Vitamin D for the treatment of lupus&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/research/clinical.html#Lovastin&quot;&gt;Lovastatin for the treatment of rheumatoid arthritis&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;&lt;a name=&quot;consortium&quot;&gt;Lupus Clinical Trials Consortium Patient Registry&lt;/a&gt;&lt;/b&gt;&lt;br&gt;
			&lt;br&gt;
			We are proud to have been selected to be a part of the Lupus Clinical Trials Consortium, a non&#45;profit organization dedicated to improving the lives of lupus patients.  The Lupus Consortium is composed of 20 academic centers across the United States. For the first time in the history of lupus research, these 20 centers will be coordinating their efforts to create a longitudinal Lupus Registry.  Each center will be entering information into the Registry, resulting in one of the largest lupus databases in existence. The information we collect in this registry will help us to answer many fundamental questions about lupus including (1) Which medications are effective for which features of lupus? (2) How do lupus disease manifestations change over the course of time (3) How does lupus differ in various racial/ethnic groups and in different geographical areas?&lt;br&gt;
			While registries such as this have been commonly utilized in other conditions such as cancer and heart disease, they have never before been used for lupus.  We are thrilled that lupus is finally getting the attention it deserves, and we feel that this is an extraordinary opportunity to advance our understanding of lupus and its treatment.&lt;br&gt;
			The registry is an observational study, so no special treatments or drugs will be given. Importantly, no extra patient visits will be required outside of regularly scheduled clinic visits.&lt;br&gt;
			Dr. Maria Dall'era is the Center Director and Dr. Jinoos Yazdany is the Clinical Director for the UCSF Lupus Clinical Trials Consortium patient registry. Dr. David Wofsy is the Senior Investigator of this Registry. If you would like to learn more about this registry, please contact Ms. Stephanie Wangler at 415&#45;476&#45;3735.&lt;br&gt;
			&lt;br&gt;
			
			&lt;b&gt;&lt;a name=&quot;surveillance&quot;&gt;The California Lupus Surveillance Project&lt;/a&gt;&lt;/b&gt;&lt;br&gt;
			&lt;br&gt;
			The California Lupus Surveillance Project (CLSP) is a population based effort to determine the true incidence and prevalence of lupus within San Francisco and San Mateo Counties in the San Francisco bay area. This project is being sponsored by the Centers for Disease Control and Prevention (CDC), and is being performed in conjunction with the California Department of Public Health. Dr. Maria Dall'era is the pricipal Investigator of this project.&lt;br&gt;
			The purpose of the CLSP is to document how many people are living with lupus and how quickly new cases are developing in a defined area over a defined period of time.  It will also help us understand the public health burden that lupus presents. We will ultimately develop a deeper understanding of the manifestations of lupus and how lupus affects various racial and ethnic groups.&lt;br&gt;
			Acting as public health agents under the auspices of the California Department of Public Health, we will identify as many hospitals and practitioners as possible who are providing care to potential cases of lupus. Providers contacted will include rheumatologists, nephrologists, and dermatologists. In addition, patient advocacy groups will also help identify patients and their healthcare providers. Once these providers and hospitals are identified, lupus cases will be validated through medical record review. Trained data abstractors will review medical records and document the presence of the criteria needed to enter a patient into the lupus registry. Other information important to public health surveillance will be collected as well.&lt;br&gt;
			For more information about the California Lupus Surveillance Project, please call Ms. Lidia Espino at 415&#45;502&#45;5108.
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Research ./rheumatology/old/research/clinical.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/clinical.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=2&gt;&lt;SPAN 
			style=&quot;COLOR: #003333; mso&#45;bidi&#45;font&#45;size: 9.0pt&quot;&gt;*** Research activities of the Division can also be viewed on the &lt;U&gt;&lt;A href=&quot;faculty.html&quot;&gt;bio&#45;sketches of individual faculty members.&lt;/A&gt;&lt;/U&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;STRONG&gt;M. Kari Connolly, MD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Scleroderma&quot;&gt;The UCSF Scleroderma Database and Tissue Bank&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Scleroderma_Lung&quot;&gt;The Scleroderma Lung Study&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Anti_TGFb&quot;&gt;Anti&#45;TGFb in scleroderma patients&lt;/A&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Lindsey A. Criswell, MD, MPH&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Lupus&quot;&gt;Lupus Genetics Research Project&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Lupus&quot;&gt;Rheumatoid Arthritis Genetics Research Project&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Mother&quot;&gt;Mother&#45;Child Immunogenetic Study&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Maria Dall'Era , MD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;u&gt;&lt;a href=&quot;#Abatacept&quot;&gt;Abatacept for patients with lupus  nephritis (lupus kidney disease)&lt;/a&gt;&lt;/u&gt;   
			  &lt;LI&gt;&lt;u&gt;&lt;a href=&quot;#VitD&quot;&gt;Vitamin D for the treatment of lupus&lt;/a&gt;&lt;/u&gt;  
			  &lt;LI&gt;&lt;u&gt;&lt;a href=&quot;#Lovastatin&quot;&gt;Lovastatin for the  treatment of rheumatoid arthritis&lt;/a&gt;&lt;a href=&quot;#VitD&quot;&gt;&lt;/a&gt;&lt;/u&gt;  
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Edward Yelin, PhD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;mcrc/index.html&quot;&gt;Multidisiplinary Clinical Research Center Program (MCRC)&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=center&gt;***************************************************&lt;/P&gt;
			&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research &#45;&#45; Clinical &lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by M. Kari Connolly, M.D.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Connolly_Scleroderma&gt;&lt;/A&gt;&lt;STRONG&gt;The UCSF Scleroderma Database and Tissue Bank&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This study is open to select scleroderma patients who are willing to undergo skin biopsies and blood draws for research studies. In addition, clinical information is stored in a computer database that investigators may use for research studies and to contact subjects about future studies they may want to participate in.&amp;nbsp; &lt;/P&gt;
			&lt;UL&gt;&lt;LI&gt;Investigator: M. Kari Connolly, M.D.
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Connolly_Scleroderma_Lung&gt;&lt;/A&gt;&lt;STRONG&gt;The Scleroderma Lung Study.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This is a 2&#45;year study that compare the affect of daily oral cyclophosphamide (Cytoxan) for one year versus mycophenolate mofetil (Cellcept) twice daily for 2 years in patients with systemic sclerosis and interstitial lung disease.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: NIH 
			  &lt;LI&gt;Co&#45;investigator: M. Kari Connolly, M.D. 
			  &lt;LI&gt;Research coordinator: 415&#45;353&#45;2060&lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Connolly_Anti_TGFb&gt;&lt;/A&gt;&lt;STRONG&gt;Anti&#45;TGFb in scleroderma patients&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This study is in the planning stages and will involve the use of a topical preparation on scleroderma skin to block fibrosis.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: ISDIN 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by Lindsey A. Criswell, M.D., M.P.H.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Criswell_Lupus&gt;&lt;STRONG&gt;Lupus Genetics Research Project &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;Any patient with a diagnosis of systemic lupus (SLE) is welcome to participate in this study. This ongoing study is investigating the genes that may predispose an individual to develop lupus. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigator: Lindsey Criswell, M.D., M.P.H. 
			  &lt;LI&gt;Contact: toll free 888&#45;223&#45;3067 x1 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Criswell_RA&gt;&lt;STRONG&gt;Rheumatoid Arthritis Genetics Research Project &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;Any patient with a diagnosis of rheumatoid arthritis (RA) is welcome to participate in this study. This ongoing study is investigating the genes that may predispose an individual to develop rheumatoid arthritis. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigator: Lindsey Criswell, M.D., M.P.H. 
			  &lt;LI&gt;Contact: toll&#45;free 888&#45;223&#45;3067 x4 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Criswell_Mother&gt;&lt;STRONG&gt;Mother&#45;Child Immunogenetic Study &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;This study involves a collaboration with the UC Berkeley School of Public Health to investigate the role that pregnancy plays in rheumatoid arthritis (RA) and lupus (SLE). Criteria for participation include: (1) a diagnosis of RA or SLE, (2) at least one pregnancy resulting in a live birth, (3) at least one child must be willing to participate and over the age of 7, and (4) participation of the biological father is encouraged but not required. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigators: Lindsey Criswell, M.D., M.P.H. &amp;amp; Lisa Barcellos, Ph.D.(UC Berkeley) 
			  &lt;LI&gt;Contact: toll&#45;free 888&#45;223&#45;3067 x3 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by Maria Dall'Era, M.D.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;a name=&quot;OLE_LINK2&quot; id=&quot;OLE_LINK2&quot;&gt;&lt;/a&gt;&lt;a name=&quot;OLE_LINK1&quot; id=&quot;OLE_LINK1&quot;&gt;&lt;/a&gt;&lt;a name=&quot;Abatacept&quot; id=&quot;Abatacept&quot;&gt;&lt;strong&gt;Abatacept for patients  with lupus nephritis (lupus kidney disease)&lt;/strong&gt;&lt;/a&gt; &amp;nbsp;&amp;nbsp;&lt;br /&gt;
			  &lt;br /&gt;
			  &lt;strong&gt;Objective:&lt;/strong&gt; To test a  potential new therapy, abatacept, for patients with active lupus nephritis&lt;br /&gt;
			  &lt;strong&gt;Investigators:&lt;/strong&gt; Maria  Dall&amp;rsquo;Era, MD and David Wofsy, MD&lt;br /&gt;
			  &lt;strong&gt;Main Eligibility Criteria: &lt;/strong&gt;Active  lupus nephritis with kidney biopsy within past year&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;strong&gt;&lt;/strong&gt;&lt;br /&gt;
			&lt;strong&gt;Sponsor: National Institutes  of Health&lt;br /&gt;
			&lt;/strong&gt;&lt;/P&gt;
			&lt;p&gt;&lt;a name=&quot;VitD&quot; id=&quot;VitD&quot;&gt;&lt;strong&gt;Vitamin D for  the treatment of lupus&lt;u&gt;&lt;br /&gt;
			  &lt;br /&gt;
			&lt;/u&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;Objective&lt;/strong&gt;: To test the ability of  Vitamin D to reduce the symptoms and signs of lupus&lt;br /&gt;
			  &lt;strong&gt;Investigator: &lt;/strong&gt;Maria Dall&amp;rsquo;Era,  MD&lt;br /&gt;
			  &lt;strong&gt;Main Eligibility Criteria&lt;/strong&gt;:  Diagnosis of lupus&lt;br /&gt;
			&lt;strong&gt;Sponsor: National Institutes  of Health&lt;br /&gt;
			&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;&lt;a name=&quot;Lovastatin&quot; id=&quot;Lovastatin&quot;&gt;&lt;strong&gt;Lovastatin  for the treatment of rheumatoid arthritis&lt;/strong&gt;&lt;/a&gt;&lt;br /&gt;
			  &lt;br /&gt;
			  &lt;strong&gt;Objective: &lt;/strong&gt;To  test the ability of lovastatin to improve the signs and symptoms of rheumatoid  arthritis.&lt;br /&gt;
			  &lt;strong&gt;Investigator&lt;/strong&gt;:  Maria Dall&amp;rsquo;Era, MD&lt;br /&gt;
			&lt;strong&gt;Main Eligibility  Criteria&lt;/strong&gt;:&lt;/p&gt;
			&lt;ul&gt;
			  &lt;li&gt;Rheumatoid  Arthritis &lt;/li&gt;
			  &lt;li&gt;1 swollen (max 6) and 2 tender (max 8) joints &lt;/li&gt;
			  &lt;li&gt;If on corticosteroids, the dose must be stable  and &amp;le; 10mg/day (prednisone or equivalent) for at least 4 weeks. &lt;/li&gt;
			  &lt;li&gt;If on a DMARD (traditional or biologic), the  dose must be stable,&amp;nbsp; &lt;/li&gt;
			&lt;/ul&gt;
			&lt;p&gt;&lt;strong&gt;Sponsor: National  Institutes of Health&lt;/strong&gt;&amp;nbsp; &lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Research ./rheumatology/old/research/clinical.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/clinical.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P&gt;&lt;FONT face=&quot;Verdana, Arial, Helvetica, sans&#45;serif&quot; size=2&gt;&lt;SPAN 
			style=&quot;COLOR: #003333; mso&#45;bidi&#45;font&#45;size: 9.0pt&quot;&gt;*** Research activities of the Division can also be viewed on the &lt;U&gt;&lt;A href=&quot;faculty.html&quot;&gt;bio&#45;sketches of individual faculty members.&lt;/A&gt;&lt;/U&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;STRONG&gt;M. Kari Connolly, MD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Scleroderma&quot;&gt;The UCSF Scleroderma Database and Tissue Bank&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Scleroderma_Lung&quot;&gt;The Scleroderma Lung Study&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Anti_TGFb&quot;&gt;Anti&#45;TGFb in scleroderma patients &lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Connolly_Anti_TGFb&quot;&gt;Immune tolerance therapy in pemphigus patients&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Lindsey A. Criswell, MD, MPH&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Lupus&quot;&gt;Lupus Genetics Research Project&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Lupus&quot;&gt;Rheumatoid Arthritis Genetics Research Project&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Criswell_Mother&quot;&gt;Mother&#45;Child Immunogenetic Study&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Maria Dall'Era , MD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Davis_Natural_History&quot;&gt;The Natural History, Pathogenesis, and Disease Analysis of Systemic Lupus Erythematosus&lt;/A&gt;
			  &lt;LI&gt;&lt;A href=&quot;#Davis_Relationships&quot;&gt;Relationships among Disease Status, Immune Markers, Cognitive Functioning, and Psychiatric Symptoms in Systemic Lupus Erythematosus (SLE)&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Edward Yelin, PhD&lt;/STRONG&gt;&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;&lt;A href=&quot;http://medicine.ucsf.edu/rheum/mcrc/&quot;&gt;Multidisiplinary Clinical Research Center Program (MCRC)&lt;/A&gt; &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=center&gt;***************************************************&lt;/P&gt;
			&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research &#45;&#45; Clinical &lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by M. Kari Connolly, M.D.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Connolly_Scleroderma&gt;&lt;/A&gt;&lt;STRONG&gt;The UCSF Scleroderma Database and Tissue Bank.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This study is open to all patients with scleroderma. A one&#45;page information sheet is completed and signed.&amp;nbsp; This form can be downloaded at &lt;A 
			href=&quot;http://www.dermatology.ucsf.edu/autoimmune/&quot;&gt;http://www.dermatology.ucsf.edu/autoimmune/&lt;/A&gt; and then returned by fax or mail to the address below.&amp;nbsp; The information is entered into a computer database. Based on the information, together with what studies are active, patients may be contacted for study participation which could include: blood draws, skin biopsies and/or other studies.&amp;nbsp; &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Scleroderma Research Foundation 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. (Dermatologist/Rheumatologist) 
			  &lt;LI&gt;Call and leave info on machine: 415&#45;502&#45;5358 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Connolly_Scleroderma_Lung&gt;&lt;/A&gt;&lt;STRONG&gt;The Scleroderma Lung Study.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This is a two&#45;year study that looks at the affect of daily oral cytoxan for one year versus placebo on lung disease in scleroderma patients.&amp;nbsp; This study is open to patients with scleroderma (systemic sclerosis) for less than 7 years with symptomatic lung involvement (short of breath going up one flight of steps). &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: The NIH 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. 
			  &lt;LI&gt;Research coordinator: 415&#45;502&#45;6229 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Connolly_Anti_TGFb&gt;&lt;/A&gt;&lt;STRONG&gt;Anti&#45;TGFb in scleroderma patients.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This study is in the planning stages.&amp;nbsp; This study will be a phase II trial of anti&#45;TGF&#45;b in scleroderma patients (4 IV infusions 6&#45;weeks apart over 6 months.).&amp;nbsp; The goal of this experimental therapy is to soften skin and improve fibrosis. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Genzyme, Inc. 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;STRONG&gt;Immune tolerance therapy in pemphigus patients.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;This a phase I trial of synthetic desmoglein 3 (the immuno dominant antigen for pemphigus) in stable, active pemphigus vulgaris patients. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Peptimmune, Inc. 
			  &lt;LI&gt;Investigator: M. Kari Connolly, M.D. 
			  &lt;LI&gt;Research coordinator: 415&#45;502&#45;6229 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by Lindsey Ann Criswell, M.D., M.P.H.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Criswell_Lupus&gt;&lt;STRONG&gt;Lupus Genetics Research Project &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;Any patient with a diagnosis of systemic lupus (SLE) is welcome to participate in this study. This ongoing study is investigating the genes that may predispose an individual to develop lupus. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigator: Lindsey Criswell, M.D., M.P.H. 
			  &lt;LI&gt;Contact: toll free 888&#45;223&#45;3067 x1 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Criswell_RA&gt;&lt;STRONG&gt;Rheumatoid Arthritis Genetics Research Project &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;Any patient with a diagnosis of rheumatoid arthritis (RA) is welcome to participate in this study. This ongoing study is investigating the genes that may predispose an individual to develop rheumatoid arthritis. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigator: Lindsey Criswell, M.D., M.P.H. 
			  &lt;LI&gt;Contact: toll&#45;free 888&#45;223&#45;3067 x4 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Criswell_Mother&gt;&lt;STRONG&gt;Mother&#45;Child Immunogenetic Study &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
			&lt;P&gt;This study involves a collaboration with the UC Berkeley School of Public Health to investigate the role that pregnancy plays in rheumatoid arthritis (RA) and lupus (SLE). Criteria for participation include: (1) a diagnosis of RA or SLE, (2) at least one pregnancy resulting in a live birth, (3) at least one child must be willing to participate and over the age of 7, and (4) participation of the biological father is encouraged but not required. Participation can be completed by mail and involves completing a questionnaire, consent form, as well as providing a small saliva sample.&lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: National Institute of Health (NIH) 
			  &lt;LI&gt;Investigators: Lindsey Criswell, M.D., M.P.H. &amp;amp; Lisa Barcellos, Ph.D.(UC Berkeley) 
			  &lt;LI&gt;Contact: toll&#45;free 888&#45;223&#45;3067 x3 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P align=center&gt;&lt;STRONG&gt;Research by Maria Dall'Era, M.D.&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;&lt;A name=Davis_Natural_History&gt;&lt;/A&gt;&lt;STRONG&gt;The Natural History, Pathogenesis, and Disease Analysis of Systemic Lupus Erythematosus&lt;/STRONG&gt;&lt;/P&gt;
			&lt;P&gt;The purpose of this study is to learn more about the disease systemic lupus erythematosus (SLE). The goals of this research are 1) to evaluate patients with lupus to better understand how the disease begins and how it affects patients, 2) to follow patients during the course of the disease to understand how disease changes over time and, 3) to conduct research to develop better treatments for lupus. There is no cost for participation. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Sponsor: Rosalind Russell Center for Arthritis Research 
			  &lt;LI&gt;Investigator: Maria Dall'Era, M.D. &amp;amp; David Wofsy, M.D. 
			  &lt;LI&gt;Contact: Stephanie Morgan (415) 502&#45;1698 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;P&gt;&lt;A name=Davis_Relationships&gt;&lt;/A&gt;&lt;STRONG&gt;Relationships among Disease Status, Immune Markers, Cognitive Functioning, and Psychiatric Symptoms in Systemic Lupus Erythematosus (SLE)&lt;BR&gt;
			  &lt;/STRONG&gt;The purpose of this study is to examine neuropsychiatric symptoms in SLE. The goals of this investigation are to (1) evaluate cognitive and psychiatric symptoms in SLE, (2) to examine the relationship among SLE disease status, immune functioning, cognitive functioning and psychiatric symptoms, and (3) to follow patients in order to understand how these neuropsychiatric symptoms change over time. Patients with and without a previous history of neuropsychiatric symptoms are invited to participate. There is no cost for participation, and treatment is not provided. &lt;/P&gt;
			&lt;UL&gt;
			  &lt;LI&gt;Investigators: Maria Dall'Era, M.D.&amp;amp; Laura J. Julian, Ph.D. 
			  &lt;LI&gt;Contact: Stephanie Morgan (415) 502&#45;1886 &amp;amp; Laura Julian (415) 221&#45;4810 x 3134 &lt;/LI&gt;
			&lt;/UL&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research ./rheumatology/old/research/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			The research programs span the spectrum of the most fundamental research 
			questions that underlie the pathogenesis of rheumatologic diseases to research 
			involving clinical trials of new therapies as well as studies of health care 
			delivery systems. We now have unprecedented opportunities in basic research and 
			in the availability of new therapeutics to address questions related to 
			rheumatologic diseases. As a consequence we are experiencing a large expansion 
			of our research programs. These comprehensive research programs are being funded 
			by a wide range of sources including the National Institutes of Health, the 
			Arthritis Foundation, the Howard Hughes Medical Institute, philanthropic efforts 
			and industry. Philanthropic support of research efforts and educational programs 
			is coordinated by &lt;A href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot;&gt;&lt;U&gt;The Rosalind Russell Medical Research Center for Arthritis&lt;/U&gt;&lt;/A&gt; which was established and sited at UCSF by an act of Congress.&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Lupus Program ./rheumatology/old/research/lupus.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/lupus.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P&gt;&lt;B&gt;&lt;FONT color=#000000&gt;Mission Statement&lt;br&gt;
			&lt;/FONT&gt;&lt;/B&gt;&lt;FONT color=#000000&gt;The UCSF Lupus Program is composed of a multi&#45;disciplinary group of health care professionals who share a common vision: to find safer, more effective therapies for lupus and to improve the quality of life of patients living with lupus. Supporting this vision, the Lupus Collaboration has established several important goals: &lt;/FONT&gt;
			&lt;ul&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To provide pediatric and adult patients with the highest quality clinical care &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To give pediatric and adult patients access to promising new therapies through clinical trials &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To understand the basic immunologic processes underlying lupus &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To elucidate the role of genetics in the development of lupus &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To understand and treat problems with memory, concentration, and thinking in lupus patients &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To study the socioeconomic impact of lupus on individual patients and their families &lt;/FONT&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;b&gt;&lt;i&gt;The UCSF Lupus Clinic&lt;/i&gt;&lt;/b&gt; (&lt;a href=&quot;/care/clinic.html&quot;&gt;Click here&lt;/a&gt;)
			&lt;P&gt;&lt;B&gt;&lt;I&gt;Lupus Immunology&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			UCSF investigators actively working in the area of lupus immunology are Drs. Arthur Weiss, David Wofsy, David Daikh, and Leonard Dragone. Disorders of the immune system can often lead to autoimmune diseases such as lupus. These inve&lt;FONT color=#000000&gt;stigators are involved in defining the basic biochemical mechanisms that regulate normal immune responses and in understanding how disorders in such mechanisms contribute to the development of lupus. &lt;/FONT&gt; &lt;/P&gt;
			&lt;P&gt;&lt;B&gt;&lt;I&gt;Genetic Epidemiology&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			  Dr. Lindsey Criswell and her group are working to better understand the genetic and environmental causes of autoimmune diseases&lt;FONT color=#000000&gt;, such as lupus, in order to discover better treatments and eventually cures for people living with an autoimmune disease. For more information about her research studies please call her research coordinator toll free at 1&#45;888&#45;223&#45;3067 (ext. 1), or visit her website at: &lt;/FONT&gt;&lt;A 
			href=&quot;http://medicine.ucsf.edu/lupus/&quot;&gt;&lt;u&gt;http://medicine.ucsf.edu/lupus/&lt;/u&gt;&lt;/A&gt;
			&lt;P&gt;&lt;U&gt;&lt;B&gt;&lt;/B&gt;&lt;/U&gt;&lt;B&gt;&lt;I&gt;Health Services and Outcome Research&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			  Investigators actively working in the area of health services and outcomes research include Dr. Ed Yelin and Dr. Patty Katz. Drs. &lt;FONT color=#000000&gt;Katz and Yelin have established a large cohort of approximately 1,000 adults with lupus, the Lupus Outcomes Study (LOS). Dr. Katz is using data from the LOS to examine disability among individuals with lupus, including factors that may predispose people to disability and potential psychological outcomes of disability.Dr. Yelin is using the LOS data to study the determinants of work loss among patients with lupus and to evaluate how the growth of managed care is affecting their access to healthcare, including access to rheumatologists. &lt;/FONT&gt;
			&lt;P&gt;&lt;B&gt;&lt;I&gt;Pediatric Lupus&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			  Dr. Emily von Scheven and Dr. Diana Milojevic lead the UCSF Pediatric Rheumatology Clinical Research Program. This program is committed to the ethical conduct of research that improves the understanding a&lt;FONT color=#000000&gt;nd treatment of childhood and adolescent lupus. Current studies focus on childhood osteoporosis, anti&#45;phospholipid antibody syndrome, and prevention of premature atherosclerosis. For further information regarding these and other studies in pediatric lupus, please contact the study coordinator at (415) 502&#45;7685. &lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;FONT color=#000000&gt;&lt;B&gt;Acknowledgments&lt;/B&gt; &lt;/FONT&gt;
			&lt;P&gt;&lt;FONT color=#000000&gt;Support for UCSF Lupus Program endeavors comes from the &lt;a href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot;&gt;Rosalind Russell Medical Research Center for Arthritis&lt;/a&gt;, the National Institute of Allergy and Infectious Diseases, the Lupus Clinical Trials Consortium, and the State of California.&lt;/FONT&gt;
			    &lt;!&#45;&#45; Content End&#45;&#45;&gt;
			&lt;/P&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Lupus Program ./rheumatology/old/research/lupus.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/lupus.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;P&gt;&lt;B&gt;&lt;FONT color=#000000&gt;Mission Statement&lt;br&gt;
			&lt;/FONT&gt;&lt;/B&gt;&lt;FONT color=#000000&gt;The UCSF Lupus Program is composed of a multi&#45;disciplinary group of health care professionals who share a common vision: to find safer, more effective therapies for lupus and to improve the quality of life of patients living with lupus. Supporting this vision, the Lupus Collaboration has established several important goals: &lt;/FONT&gt;
			&lt;ul&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To provide pediatric and adult patients with the highest quality clinical care &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To give pediatric and adult patients access to promising new therapies through clinical trials &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To understand the basic immunologic processes underlying lupus &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To elucidate the role of genetics in the development of lupus &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To understand and treat problems with memory, concentration, and thinking in lupus patients &lt;/FONT&gt;
			  &lt;/li&gt;
			  &lt;li&gt;&lt;FONT color=#000000&gt;To study the socioeconomic impact of lupus on individual patients and their families &lt;/FONT&gt;&lt;/li&gt;
			&lt;/ul&gt;
			Patient information regarding &lt;a href=&quot;/care/clinic.html&quot;&gt;The UCSF Lupus  Clinic&lt;/a&gt;
			
			&lt;P&gt;&lt;B&gt;&lt;I&gt;Lupus Immunology&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			UCSF investigators actively working in the area of lupus immunology are Drs. Arthur Weiss, David Wofsy, David Daikh, and Leonard Dragone. Disorders of the immune system can often lead to autoimmune diseases such as lupus. These inve&lt;FONT color=#000000&gt;stigators are involved in defining the basic biochemical mechanisms that regulate normal immune responses and in understanding how disorders in such mechanisms contribute to the development of lupus. &lt;/FONT&gt; &lt;/P&gt;
			&lt;P&gt;&lt;B&gt;&lt;I&gt;Genetic Epidemiology&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			  Dr. Lindsey Criswell and her group are working to better understand the genetic and environmental causes of autoimmune diseases&lt;FONT color=#000000&gt;, such as lupus, in order to discover better treatments and eventually cures for people living with an autoimmune disease. For more information about her research studies please call her research coordinator toll free at 1&#45;888&#45;223&#45;3067 (ext. 1), or visit her website at: &lt;/FONT&gt;&lt;A 
			href=&quot;http://medicine.ucsf.edu/lupus/&quot;&gt;&lt;u&gt;http://medicine.ucsf.edu/lupus/&lt;/u&gt;&lt;/A&gt;
			&lt;P&gt;&lt;U&gt;&lt;B&gt;&lt;/B&gt;&lt;/U&gt;&lt;B&gt;&lt;I&gt;Health Services and Outcome Research&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			  Investigators actively working in the area of health services and outcomes research include Dr. Ed Yelin and Dr. Patty Katz. Drs. &lt;FONT color=#000000&gt;Katz and Yelin have established a large cohort of approximately 1,000 adults with lupus, the Lupus Outcomes Study (LOS). Dr. Katz is using data from the LOS to examine disability among individuals with lupus, including factors that may predispose people to disability and potential psychological outcomes of disability.Dr. Yelin is using the LOS data to study the determinants of work loss among patients with lupus and to evaluate how the growth of managed care is affecting their access to healthcare, including access to rheumatologists. &lt;/FONT&gt;
			&lt;P&gt;&lt;B&gt;&lt;I&gt;Pediatric Lupus&lt;/i&gt;&lt;/B&gt;&lt;BR&gt;
			  Dr. Emily von Scheven and Dr. Diana Milojevic lead the UCSF Pediatric Rheumatology Clinical Research Program. This program is committed to the ethical conduct of research that improves the understanding a&lt;FONT color=#000000&gt;nd treatment of childhood and adolescent lupus. Current studies focus on childhood osteoporosis, anti&#45;phospholipid antibody syndrome, and prevention of premature atherosclerosis. For further information regarding these and other studies in pediatric lupus, please contact the study coordinator at (415) 502&#45;7685. &lt;/FONT&gt;&lt;/P&gt;
			&lt;P&gt;&lt;FONT color=#000000&gt;&lt;B&gt;Acknowledgments&lt;/B&gt; &lt;/FONT&gt;
			&lt;P&gt;&lt;FONT color=#000000&gt;Support for UCSF Lupus Program endeavors comes from the &lt;a href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot;&gt;Rosalind Russell Medical Research Center for Arthritis&lt;/a&gt;, the National Institute of Allergy and Infectious Diseases, the Lupus Clinical Trials Consortium, and the State of California.&lt;/FONT&gt;
			    &lt;!&#45;&#45; Content End&#45;&#45;&gt;
			&lt;/P&gt;
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 2 ./rheumatology/old/research/mcrc/#project2.html#
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/#project2.html#</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			Project 2:  Body Composition and Disability in RA and SLE&lt;br&gt;
			(PI:  Patricia Katz, PhD)
			&lt;/b&gt;
			&lt;/center&gt;
			 &lt;p&gt;
			
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/project2&#45;1.jpg&quot; align=left style=&quot;padding&#45;right: 8px&quot;&gt;
			
			The overarching aim of this study is to estimate the role of body composition in the development of functional limitations and disability in both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), within the context of a well&#45;established model of disablement. Use of this model will facilitate a greater understanding of the role of body composition in the development of disability, taking into account other disease, therapeutic, demographic, psychosocial, and behavioral factors that may contribute to or protect from disability. This project also represents the first attempt to characterize disability among persons with SLE across a wide range of life activities using the &quot;valued life activities&quot; model of disability.  Specific aims are to: (1) examine the role of body composition in development of functional limitations and disability in SLE and RA, using an existing model of disablement; (2) identify risk and protective factors that interact with body composition in the development of functional limitations and disability, or the maintenance of function and avoidance of disability, in RA and SLE; and (3) estimate the prevalence and incidence of disability in a wide range of life activities in a large group of individuals with SLE. 
			&lt;p&gt;
			Subjects for the proposed study are members of the existing UCSF RA Panel and Lupus Outcomes Study (LOS). Existing study protocols include annual telephone interviews with the cohorts through 2008, with an additional two years proposed in the Methodology Core of this application.  The proposed study builds upon this by adding project&#45;specific measures to the annual telephone interviews, and adding two in&#45;person assessments at the UCSF General Clinical Research Center (GCRC) for a subset of subjects from each cohort.  At the GCRC visit, we are conducting an assessment of body composition, conducting testing of muscle strength and physical function, obtaining blood samples for measurement of inflammatory and other markers, obtaining an estimate of habitual physical activity, and performing a cognitive function evaluation. Analyses, combining interview and home visit data, focus on 3 major areas &amp;mdash; (1) describing body composition findings in the 2 cohorts, (2) estimating the relationship between body composition and functional limitations and disability in the 2 cohorts; and (3) identifying factors that may modify or mediate the relationship between body composition and either functional limitations or disability. Analyses seek to identify the correlation between self&#45;reported information from interview data (e.g., body mass index calculated from self&#45;reported height and weight) with that gathered from the GCRC assessment.  The findings from this study will provide information that can assist in identifying individuals with RA and SLE who may be at greatest risk of disability, and estimating the effect of intervening factors on the development of disability.
			
			&lt;P&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			Data collection and management for this project are being handled by the Methodology Core Unit. Data for this project are collected both in the telephone interviews and through in&#45;person visits to the UCSF CTSI Clinical Research Center (CRC). From the telephone interview of the Lupus Outcomes Study, we submitted a manuscript addressing specific aim 3, estimating the prevalence and incidence of disability in a wide range of life activities. This manuscript was published Arthritis Care &amp; Research (see section E). 
			&lt;p&gt;
			We are recruiting a sample of individuals from both the RA Panel and the Lupus Outcomes Study who live in the greater Bay Area to participate in the CRC visit. In April 2007, we began to collect data in the CRC. Data being collected include assessments of body composition by DEXA, disability by self&#45;report questionnaires, functional limitations by muscle strength testing and performance tests, cognitive function by an extensive battery, and psychological status by a psychiatric screening interview. In addition, blood is collected to assess systemic inflammation as well as disease&#45;specific markers. 
			&lt;p&gt;
			As of 1/06/09, 197 subject visits have been completed, 90 from the RA Panel and 107 from the Lupus Outcomes Study. An additional 7 and 13 visits are currently scheduled for individuals  from the RA Panel and LOS, respectively. We are still behind in the number of visits we had hoped to complete. The primary reason that subjects have given for non&#45;participation is difficulty traveling to the University. This difficulty was compounded during a large portion of 2008 because of the high gas prices. Of the 58 individuals from the LOS and 74 from the RA Panel who have declined participation, almost 50% of each group reported that transportation problems were the reason they could not participate. We will continue to try to recruit participants for the CRC visits.
			&lt;p&gt;
			We presented preliminary data from the LOS cohort as part of a symposium on body composition and rheumatic disease at the 2008 annual meeting of the American College of Rheumatology.
			&lt;p&gt;
			One of the research assistants who conducted study visits left the University in December 2008. His replacement was hired and completed training by February 2008. We reported difficulties obtaining scheduling in the CRC in the last progress report; those difficulties have been resolved.
			
			
			&lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Methodology Core Unit ./rheumatology/old/research/mcrc/core copy.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/core copy.html</Path>
		<FileBody>
			
			
			&lt;center&gt;
			&lt;b&gt;
			Methodology Core Unit&lt;br&gt;
			(PI:  Patricia Katz, PhD;&lt;br&gt; 
			Associate Director: Stuart Gansky, PhD; &lt;br&gt;
			Project Director, Laura Trupin, MPH)
			&lt;/b&gt;
			&lt;P&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/core1.jpg&quot;&gt;
			&lt;/center&gt;
			&lt;p&gt;
			
			The Methodology Core Unit of the UCSF Multidisciplinary Clinical Research Center (MCRC) serves as the hub for all MCRC projects and activities. The primary goal of the MCRC Methodology Core Unit is to advance clinical research at UCSF in outcomes of rheumatic conditions, building upon the existing structure developed through the MAMDC and other extramural funding.  The specific aims of the Methodology Core are to:  provide methodological and biostatistical support and oversight to MCRC projects and other projects using MCRC data sources; coordinate data collection and management of data used for MCRC projects and the research base, including protocol development, staff training and monitoring, interviewing and other data collection, data management, data analysis, and quality control; play an active role in education of fellows and junior faculty in topics related to rheumatic disease; and advance the knowledge base in rheumatology and clinical research methodology both on the UCSF campus and nationally through outreach and dissemination efforts.  
			&lt;p&gt;
			The Methodology core serves the four full projects and D&amp;F project of the MCRC, as well as the research base of the MCRC and the UCSF campus as a whole. The unit provides service to the MCRC projects by guiding all aspects of study design, protocol and instrument development, data management and statistical analysis.  Two research projects, described below, are also being undertaken in the Methodology Core, as well, both of which serve the MCRC projects and research base.  For the projects using primary data sources, the Methodology Core handles such data support services as training and supervision of interview staff.  The Methodology Core actively promotes cross&#45;disciplinary clinical research in the MCRC research base through one&#45;on&#45;one meetings of Methodology Core faculty with fellows and junior faculty, and through participation of Methodology Core faculty in established forums such as the Rheumatology Journal Club, the Department of Medicine Clinical Fellows program and the UCSF Institute for Health Policy Study's Postdoctoral Fellowship program.  Finally, the Methodology Core Unit serves the UCSF research community through its sponsorship of a quarterly lecture series and through Methodology Core faculty serving in an advisory role to several other longitudinal projects in chronic conditions, including asthma, COPD, and infertility.
			&lt;p&gt;
			
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			The Methodology Core coordinates data collection for two primary data sources, both of which are longitudinal studies that are being used in MCRC projects:
			&lt;ul&gt;
			&lt;li&gt; Lupus outcomes Study (LOS). To date, 1,149 individuals have been enrolled in the LOS; diagnoses for all have been confirmed by medical record review. The LOS is currently in the 6th wave of annual interviews. The annual re&#45;interview rate has averaged 93%. 728 individuals completed the 2007 interview. As of this writing, 684 individuals have completed the 2008 interview, and we have enrolled 102 new participants in the past year. The 2009 interview has been designed and data collection will commence in the next month.
			&lt;li&gt; Rheumatoid Arthritis Panel Study (RA Panel). The RA Panel began in 1982 with individuals enrolled from community rheumatology practices. To date, 1,447 persons have been enrolled in the LOS. The primary data source is annual telephone interviews. The Panel has been replenished several times. Average annual reinterview rates are 93%. 423 individuals completed the 2007 interview. As of this writing, 333 individuals have completed the 2008 interview. The 2009 interview has been designed, and data collection will begin in early Spring.
			&lt;/ul&gt;
			&lt;p&gt;
			The Core Unit also is responsible for the development and implementation for a protocol in which 200 persons from the RA Panel and Lupus Outcomes Study are assessed at the General Clinical Research Center of UCSF (now part of the Clinical and Translational Science Institute, or CTSI). Data collection began for this protocol in 2007. To date, 192 individuals have completed the CTSI assessment, 87 with RA and 105 with lupus. We anticipate completing the enrollment and initial assessments in the next month and beginning the follow&#45;up assessments later this year.
			&lt;p&gt;
			Finally, we have made substantial progress on one of the Core Unit projects outlined in the initial proposal &amp;mdash; the development and validation of a self&#45;reported proxy for SLICC/ACR&#45;Damage lndex (SDI) &amp;mdash;  and laid the groundwork for the second Core Unit project, establishing cut&#45;points for depression in rheumatic disease. For the SDI proxy project, the data collection through the UCSF Lupus Clinic has proven to be more time consuming than initially anticipated. We have thus far obtained complete data on 38 patients, approximately half the total needed for the analysis. For the depression project, we have recently completed enough enrollment through the CTSI to permit analysis of the appropriate cut&#45;points for the CES&#45;D scale in lupus and for the Geriatric Depression Score (GDS) in RA. All participants in the CTSI study receive a psychiatric screening interview, as well as the CES&#45;D or GDS. This will enable us to confirm the existing cutpoints for these instruments, or propose new cut&#45;points. We will be using statistical methodology developed by a statistician working with Dr. Katz on a non&#45;MCRC project.
			&lt;p&gt;
			The Methodology Core Unit faculty and staff have also continued to support the development of the Rheumatoid Arthritis Cohort Study, (PI, Dr. John Imboden, Chief of the Division of Rheumatology at SF General Hospital). The Core Unit assisted in the design of the telephone survey instrument, trained the survey interviewers, designed the database and continues to handle data management for the study. As of 12/31/08, there were a total of 224 persons with RA enrolled at San Francisco General Hospital and 203 at UCSF, for a total of 427. Enrollment continues at the two hospitals' outpatient clinics. As enrollees present for clinical care, the research assistant obtains the patients. consent to be interviewed by telephone. To date, 170 telephone interviews have been conducted &amp;mdash; 108 in English, 33 in Spanish, and 29 in Cantonese.
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Methodology Core Unit ./rheumatology/old/research/mcrc/core.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/core.html</Path>
		<FileBody>
			
			
			&lt;center&gt;
			&lt;b&gt;
			Methodology Core Unit&lt;br&gt;
			(PI:  Patricia Katz, PhD;&lt;br&gt; 
			 
			&lt;/b&gt;
			&lt;P&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/core1.jpg&quot;&gt;
			&lt;/center&gt;
			&lt;p&gt;
			
			
			
			&lt;p&gt;
			
			&lt;b&gt;A. Specific Aims&lt;/b&gt;
			&lt;p&gt;The study aims have not changed.  
			&lt;p&gt;
			The Methodology Core Unit of the UCSF Multidisciplinary Clinical Research Center (MCRC) serves as the hub for all MCRC projects and activities. The primary goal of the MCRC Methodology Core Unit is to advance clinical research at UCSF in outcomes of rheumatic conditions, building upon the existing structure developed through the MAMDC and other extramural funding.  
			&lt;p&gt;
			The specific aims of the Methodology Core are to:  
			&lt;p&gt;
			1) Provide methodological and biostatistical support and oversight to MCRC projects and other projects using MCRC data sources; 
			&lt;p&gt;
			2) Coordinate data collection and management of data used for MCRC projects and the research base, including protocol development, staff training and monitoring, interviewing and other data collection, data management, data analysis, and quality control; 
			&lt;p&gt;
			3) Play an active role in education of fellows and junior faculty in topics related to rheumatic disease; and, 
			&lt;p&gt;
			4) Advance the knowledge base in rheumatology and clinical research methodology both on the UCSF campus and nationally through outreach and dissemination efforts.  
			&lt;p&gt;
			The Methodology core serves the four full projects and D&amp;F project of the MCRC, as well as the research base of the MCRC and the UCSF campus as a whole. The unit provides service to the MCRC projects by guiding all aspects of study design, protocol and instrument development, data management and statistical analysis.  
			&lt;p&gt;
			Two research projects are also being undertaken in the Methodology Core, as well, both of which serve the MCRC projects and research base.   The projects are: 
			&lt;p&gt;
			1) Development and validation of a proxy for SLICC/ACR&#45;DI that can be administered by interview.
			&lt;p&gt;
			2) Validation of the Geriatric Depression Scale, Short Form, among persons with RA and validation or development of a cut&#45;point that can be used as a proxy for a clinical diagnosis for depression.  This project will be expanded to examine the same questions regarding the CES&#45;D among individuals with lupus.
			&lt;p&gt;
			&lt;b&gt;B. Studies and Results&lt;/b&gt;
			The Methodology Core coordinates data collection for two primary data sources, both of which are longitudinal studies that are being used in MCRC projects:
			&lt;p&gt;
			1) Lupus outcomes Study (LOS).  We have now enrolled a total of 1,204 individuals in the LOS, completing recruitment as planned.  Diagnoses for all participants have been confirmed by medical record review. The LOS is currently in the eighth wave of annual interviews. The annual re&#45;interview rate for the first seven waves averaged 93% (95% excluding deceased subjects). 866 individuals completed an interview in 2009, including 814 continuing and 52 new subjects. As of January, 2011, 707 individuals have completed the 2010 interview; interviews for this wave continue until March 2011.  Since the cohort inception, we have conducted 6,671 interviews (average 5.5/participant). We will begin the ninth wave of interviews in early 2011.
			&lt;p&gt;
			2)	Rheumatoid Arthritis Panel Study (RA Panel). The RA Panel began in 1982 with individuals enrolled from community rheumatology practices. To date, 1,447 persons have been enrolled in the RA Panel. The primary data source is annual telephone interviews. The RA Panel has been replenished several times. Average annual re&#45;interview rates are consistently 93%. 357 individuals completed the 2009 interview. As of this writing, 200 individuals have completed the 2010 interview; these will continue until March 2011. We will begin the 2011 interview this spring.
			&lt;p&gt;
			The Core Unit was also responsible for the development and implementation for a protocol in which active participants in the RA Panel and Lupus Outcomes Study are assessed at the UCSF Clinical and Translational Science Institute (CTSI). Data collection began for this protocol in 2007. To date, 312 individuals have completed the baseline CTSI assessment: 145 with RA and 167 with SLE. In the past year, we have conducted 128 follow&#45;up assessments on these participants: 57 with RA and 71 with SLE.  
			&lt;p&gt;
			The Methodology Core Unit faculty and staff continue to support the development and management of the Rheumatoid Arthritis Cohort Study, (PI, Dr. John Imboden, Chief of the Division of Rheumatology at SF General Hospital). As of December 31, 2010, there were a total of 644 patients enrolled in the study: 290 from SF General Hospital and 354 at UCSF. Enrollment continues at the two hospitals' outpatient clinics. The RA Cohort is itself the basis for a new project, funded by AHRQ with ARRA funds, entitled &quot;RA Medication Summary Guides for Vulnerable Populations.&quot; The goal of this project, which is led by Dr. Yelin and managed by the MCRC Methodology Core Unit, is to adapt existing guides for low literate and immigrant populations.  Incorporating input from physicians, interpreters, and patients, we will develop a decision aid tool for physicians to use with their patients, and then conduct a pilot trial of both the adapted guides and the decision aid tool. Since September 2010, we have completed the first phase of the study &#45; conducting focus groups with patients, physicians, and interpreters to gather input on the existing summary guides. The adapted guides and decision aid tool will be developed in the next few months and the pilot test will begin in summer 2011.  The methodological and study management expertise in the MCRC Methodology Core Unit has been instrumental in getting this project up and running as quickly as it has.
			&lt;p&gt;
			We are nearing completion on both methodology projects outlined in the initial proposal of the Methodology Core Unit: i) development and validation of a self&#45;reported proxy for SLICC/ACR&#45;Damage lndex (SDI) and ii) establishment of cut&#45;points for depression in rheumatic disease. For the SDI proxy study, we completed data collection and conducted analyses of both criterion validity (using data on 57 UCSF lupus clinic data) and construct validity (using data collected in 728 LOS interviews). In addition, we compared our new proxy measure, named Brief Instrument of Lupus Damage (BILD), with a recently developed instrument, the Lupus Damage Index Questionnaire (LDIQ). We found good agreement between most BILD items and corresponding SDI items, and a moderately high rank correlation between the measures overall (0.59), very similar to the published correlation between SDI and LDIQ. In addition, higher BILD scores were associated with poorer self&#45;rated health and functional status, greater unemployment and work disability, and increased health care utilization. We submitted the manuscript describing our results, and received a response of 'revise and resubmit', based on a concern that the criterion validity sample was too small. Subsequent to that, we have re&#45;opened enrollment at a new clinic and have completed the criterion validity study on an additional 20 patients. We plan to complete this second phase of data collection (aiming for a total of 30 new patients), re&#45;analyze the data and resubmit the manuscript in the coming months.
			&lt;p&gt;
			For the depression project, the manuscript establishing cut&#45;points for the CES&#45;D scale in lupus patients is now in press in Arthritis Care and Research. Of the 150 persons with SLE in the study, 26% met criteria for any mood disorder and 17% met criteria for MDD. Optimal threshold estimations suggested a CES&#45;D cut score of 24 and above, which yielded adequate sensitivity and specificity in detecting MDD (88% and 93%, respectively) and correctly classified 92% of participants. To detect the presence of any mood disorder, the analysis identified a cut score of 20 and above which yielded sensitivity and specificity of 87%, correctly classifying 87%. This manuscript represents the first such validation and classification of the CES&#45;D in the lupus population. As such, we anticipate that the work will be used frequently both by our research group and by other researchers interested in depression in SLE. For the RA depression cut&#45;point study, we have recently enrolled sufficient participants through the CTSI to permit analysis of the appropriate screening cut&#45;points for the Geriatric Depression Score (GDS) in RA, and will follow the same methodology used for the CES&#45;D cut&#45;point study for SLE. 
			&lt;p&gt;
			&lt;b&gt;C. Significance&lt;/b&gt;
			The Methodology Core Unit is at the center of the UCSF MCRC activities.  Throughout the tenure of the MCRC, it has been extremely productive in its aims of protocol development, data collection, and data analysis, and in supporting publications using the RA Panel, LOS, and RA Cohort.  Since the funding for the MCRC began, the weekly research meetings and monthly seminars held by Methodology Core Unit faculty have been central to the training of two medical students, four pre&#45;doctoral fellows, and 14 post&#45;doctoral fellows, several of whom have recently advanced to faculty positions here. 
			&lt;p&gt;
			&lt;b&gt;D. Plans&lt;/b&gt;
			In the next year, the Core Unit will continue to do all protocol development and implementation for the UCSF MCRC, including protocols for the LOS and RA Panel interviews and the CTSI assessments. We will complete revisions on the BILD manuscript. We also anticipate completing the RA depression cut&#45;point analysis and submitting a manuscript for that study.
			&lt;p&gt;
			&lt;b&gt;E. Publications&lt;/b&gt;
			
			&lt;b&gt;2006&lt;/b&gt;
			
			&lt;p&gt;
			Freemer MM, King TE, Criswell LA.  Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus.  Annals of the Rheumatic Diseases  2006; 65(5): 581&#45;4.  PMCID PMC1798144
			&lt;p&gt;
			Janssens A, Steyerberg E, Jiang Y, Habbema J, van Duijn C, Criswell LA.  Value of the HLA&#45;DRB1 shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile.  Journal of Rheumatology  2006; 33(12): 2383&#45;9.
			&lt;p&gt;
			Katz PP, Morris A, Yelin EH.  Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis.  Annals of the Rheumatic Diseases  2006; 65(6): 763&#45;9.  PMCID PMC1798183
			&lt;p&gt;
			Katz PP.  Childbearing decisions and family size among women with rheumatoid arthritis.  Arthritis Care &amp; Research  2006; 55(2):217&#45;23
			&lt;p&gt;
			&lt;b&gt;2007&lt;/b&gt;
			
			&lt;p&gt;
			Kinder BW, Freemer MM, King Jr. TE, Lum RF, Taylor K, Jeff Edberg, Bridges Jr. SL, Jr, Criswell LA.  Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.  Arthritis &amp; Rheumatism  2007; 56(8): 2679&#45;86.  PMCID PMC2875177
			&lt;p&gt;
			Yelin EH, Trupin LS, Katz PP, Criswell LA, Yazdany J, Gillis J, Panopalis P.  Work dynamics among persons with SLE.  Arthritis Rheum (Arthritis Care Res)  2007; 57(1): 56&#45;63.  PMCID PMC2875125
			&lt;p&gt;
			Yelin EH, Trupin LS, Katz PP, Criswell LA, Yazdany J, Gillis J, Panopalis P.  Impact of HMOs and fee&#45;for&#45;service on health care utilization among persons with SLE.  Arthritis Rheum (Arthritis Care Res)  2007; 57(3): 508&#45;15.  PMCID PMC2875127
			&lt;p&gt;
			Yazdany J, Gillis J, Trupin LS, Katz PP, Panopalis P, Criswell LA, Yelin EH.  Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in a large observational cohort of subjects with systemic lupus erythematosus.  Arthritis Rheum (Arthritis Care Res)  2007; 57(4): 593&#45;600.  PMCID PMC2875170
			&lt;p&gt;
			Gillis J, Yazdany J, Trupin LS, Julian LJ, Panopalis P, Criswell LA, Katz PP, Yelin EH.  Medicaid and access to care among persons with SLE.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2007; 57(4): 601&#45;7.  PMCID PMC2875126
			&lt;p&gt;
			Katz PP, Morris A.  Use of accommodations for valued life activities: prevalence and effects on disability scores.  Arthritis Rheum (Arthritis Care Res)  2007; 57(5):730&#45;7.  PMCID PMC2875140
			&lt;p&gt;
			Panopalis P, Julian LJ, Yazdany J, Gillis J, Trupin LD, Hersh A, Criswell LS, Katz PP, Yelin EH.  Impact of memory impairment on employment status in persons with systemic lupus erythematosus.  Arthritis Rheum (Arthritis Care Res)  2007; 57(8): 1453&#45;60.  PMCID PMC2875137
			&lt;p&gt;
			Chung SA, Criswell LA.  PTPN22: its role in SLE and autoimmunity.  Autoimmunity  2007: 40 (8): 582&#45;90.  PMCID PMC2875134
			&lt;p&gt;
			Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, Williams A, Beck S, Kyogoku C, Moser K, Gaffney P, Gregersen PK, Criswell LA, Harley JB, Behrens TW. Specific combinations of HLA&#45;DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. European Journal of Human Genetics 2007: 15(8): 823&#45;30.  PMID only 17406641
			&lt;p&gt;
			Thorburn CM, Prokunina&#45;Olsson L, Sterba KA, Lum RF, Seldin MF, Alarcon&#45;Riquelme ME, Criswell LA.  Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus.  Genes &amp; Immunity  2007; 8(4): 279&#45;87.  PMCID PMC2925679
			&lt;p&gt;
			Remmers EF, Plenge RM, Lee, AT, Graham RR, Hom G, Behrens TW, de Bakker PIW, Le JM, Lee H&#45;S, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.  New England Journal of Medicine  2007; 357(10): 977&#45;86.  PMCID PMC2630215
			&lt;p&gt;
			Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LRL, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW, Gillett C, Burtt N, Graham DSC, Onofrio R, Petri M, Gunnarsson I, Svenungsson E, Ronnblom L, Nordmark G, Gregersen PK, Moser K, Gaffney PM, Criswell LA, Vyse TJ, Syv(!!editedcontent!!)nen A&#45;C, Bohjanen PR, Daly MJ, Behrens TW, Altshuler D.  Three functional variants of interferon regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.  Proceedings of the National Academy of Sciences USA  2007; 104(16): 6758&#45;63.  PMCID PMC1847749
			&lt;p&gt;
			Katz PP, Morris A.  Time use patterns among women with rheumatoid arthritis: association with functional limitations and psychological status.  Rheumatology  2007; 46(6):490&#45;5.  PMCID PMC2875174
			&lt;p&gt;
			Yazdany J, Gillis JZ, Trupin L, Katz P, Panopalis P, Criswell LA, Yelin E.  Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus.  Arthritis Rheum 2007; 57(4): 593&#45;600. PMCID: PMC2875170
			&lt;p&gt;.
			&lt;b&gt;2008&lt;/b&gt;
			&lt;p&gt;
			Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP.  Validation of the Systemic Lupus Erythematosus Activity Questionnaire in a large observational cohort.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2008; 59(1):136&#45;43.  PMID only 18163398
			&lt;p&gt;
			Katz PP, Morris A, Trupin LS, Yazdany J, Yelin EH.  Disability in valued life activities among individuals with systemic lupus erythematosus.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2008; 59(4): 465&#45;73.  PMCID PMC2875191
			&lt;p&gt;
			Katz PP, Morris A, Yelin EH.  Subclinical disability in valued life activities among individuals with rheumatoid arthritis.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2008; 59(10):1416&#45;23.  PMCID PMC2754406
			&lt;p&gt;
			
			Panopalis P, Yazdany J, Gillis J, Julian LJ, Trupin LS, Hersh A, Criswell LA, Katz PP, Yelin EH.  Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2008; 59(12):1788&#45;95.  PMCID PMC2875149
			Trupin LS, Tonner MC, Yazdany J, Julian LJ, Criswell LA, Katz PP, Yelin EH.  The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus.  Journal of Rheumatology  2008; 35(9):1782&#45;8.  PMCID PMC2875144
			&lt;p&gt;
			Harley JB, Alarcon&#45;Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD.  Genome&#45;wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.  Nature Genetics  2008: 40(2): 204&#45;10.  PMID only 18204446
			&lt;p&gt;
			Musone SL, Taylor KE, Lu T, Nititham J, Ferreira RC, Ortmann W, Shiffrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok P&#45;Y, Criswell LA.  Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus.  Nature Genetics  2008; 40(9): 1062&#45;4.  NIHMSID #200733
			&lt;p&gt;
			
			Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira R, Pant PVK, Ballinger DG, Kosoy R, Demirci FY, Kamboh I, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa&#45;Dahlquist S, Petri M, Manzi S, Seldin MF, Ronnblom L, Syvanen A&#45;C, Criswell LA, Gregersen PK, Behrens TW.  Association of systemic lupus erythematosus with C8orf13/BLK and ITGAM/ITGAX.  New England Journal of Medicine  2008; 358(9): 900&#45;9.  NIHMSID #200738
			&lt;p&gt;
			
			Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA.  Specificity of the STAT4 genetic association for severe disease manifestations of SLE.  PLoS Genetics  2008; 4(5): e1000084. 1&#45;9.  PMCID PMC2377340
			&lt;p&gt;
			
			Morris A, Yelin EH, Wong B, Katz PP.  Patterns of psychosocial risk and long&#45;term outcomes in rheumatoid arthritis.  Psychology, Health &amp; Medicine  2008; 13(5): 529&#45;44.  PMCID PMC2875155
			&lt;p&gt;
			
			Katz P, Morris A, Trupin L, Yazdany J, Yelin E.  Disability in valued life activities among individuals with systemic lupus erythematosus. Arthritis Rheum (Arthritis Care Res) 2008; 59: 465&#45;473. PMCID: PMC2875191.
			&lt;p&gt;
			&lt;b.&gt;2009&lt;/b&gt;
			
			&lt;p&gt;
			Kaiser R, Cleveland CM, Criswell LA.  Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi&#45;ethnic cohort.  Annals of the Rheumatic Diseases  2009; 68(2):238&#45;41.  PMCID PMC2875136
			&lt;p&gt;
			Chung SA, Tian C, Taylor KE, Lee AT, Ortmann WA, Hom G, Graham R, Nititham J, Kelly JA, Morrisey J, Wu H, Yin H, Alarcon&#45;Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, Manzi S, Petri M, Gregersen PK, Langefeld CD, Behrens TW, Seldin MF, Criswell LA.  Substructure in European&#45;derived populations is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus.  Arthritis &amp; Rheumatism  2009; 60(8): 2448&#45;56.  PMCID PMC2739103
			&lt;p&gt;
			Julian LJ, Yelin EH, Yazdany J, Panopalis P, Trupin LS, Criswell LA, Katz PP.  Depression, medication adherence, and service utilization in systemic lupus erythematosus.  Arthritis Rheum (Arthritis Care Res)  2009; 61(2): 240&#45;6.  PMCID PMC2875189
			&lt;p&gt;
			Yelin EH, Tonner C, Trupin LS, Panopalis P, Yazdany J, Julian LJ, Katz PP, Criswell LA.  Work loss and work entry among persons with SLE: comparisons to a national, matched sample.  Arthritis Rheum (Arthritis Care Res)  2009; 61(2): 247&#45;58.  PMCID PMC2875188
			&lt;p&gt;
			
			Yazdany J, Panopalis P, Gillis J, Schmajuk G, MacLean C, Wofsy D, Yelin EH.  A quality indicator set for systemic lupus erythematosus.  Arthritis Rheum (Arthritis Care &amp; Research)  2009; 61(3): 370&#45;7.  PMCID PMC2748348
			&lt;p&gt;
			
			Katz PP, Yelin EH, Patel V, Huang XY, Chiou CF.  Patient&#45;reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community&#45;based rheumatologists.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2009; 61(5): 593&#45;9.  PMCID PMC2747783
			&lt;p&gt;
			
			Margaretten ME, Yelin EH, Imboden J, Graf J, Barton J, Katz PP, Julian LJ.  Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis.  Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)  2009; 61(11): 1586&#45;91.  PMCID PMC2835470
			&lt;p&gt;
			
			Kaiser R, Barton JL, Chang MN, Catanese JJ, Li YN, Begovich A, Criswell LA.  Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta&#45;analysis.  Genes &amp; Immunity  2009;10(5): 495&#45;502.  PMCID PMC2766554
			&lt;p&gt;
			
			Richman IB, Chung SA, Taylor KE, Kosoy R, Tian C, Ortmann WA, Nititham J, Lee AT, Rutman S, Petri M, Manzi S, Behrens TW, Gregersen PK, Seldin MF, Criswell LA.  European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent.  Genes &amp; Immunity  2009: Oct 22  [Epub ahead of print].  NIHMSID #200727
			&lt;p&gt;
			
			Katz PP, Morris A, Gregorich S, Yazdany J, Eisner M, Yelin EH, Blanc P.  Valued life activity disability play a significant role in self&#45;rated health among adults with chronic health conditions.  Journal of Clinical Epidemiology  2009; 62(2): 158&#45;66.  PMCID PMC2633356
			&lt;p&gt;
			
			Liu K, Li QZ, Delgado&#45;Vega AM, Abelson AK, Sanchez E, Kelly JA, Li L, Liu Y, Zhou J, Yan M, Ye Q, Liu S, Xie C, Zhou XJ, Chung SA, Pons&#45;Estel B, Witte T, de Ram-n E, Bae SC, Barizzone N, Sebastiani GD, Merrill JT, Gregersen PK, Gilkeson GG, Kimberly RP, Vyse TJ, Kim I, D'Alfonso S, Martin J, Harley JB, Criswell LA, Wakeland EK, Alarc-n&#45;Riquelme ME, Mohan C.  Kallikrien genes are associated with lupus and glomerular basement membrane&#45;specific antibody&#45;induced nephritis in mice and humans.  Journal of Clinical Investigation  2009; 119 (4): 911&#45;23.   PMCID PMC2662554
			&lt;p&gt;
			Barton JL, Criswell LA, Kaiser R, Chen YH, Schillinger D.  Systematic review and metaanalysis of patient selfreport versus trained assessor joint counts in rheumatoid arthritis.  J Rheumatol  2009; 36(12): 2635&#45;41.  PMCID PMC2874463
			&lt;p&gt;
			
			Barton JL.  Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.  Patient Prefer Adherence  2009; 3: 335&#45;44.  PMCID PMC2792871
			
			&lt;p&gt;
			Hersh A, Von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Criswell L, Katz P, Yelin E.  Differences in long&#45;term disease activity and treatment of adult patients with childhood and adult&#45;onset systemic lupus erythematosus.  Arthritis &amp; Rheumatism (Arthritis Care and Research)  2009; 61(1):13&#45;20.  PMCID PMC2875186
			&lt;p&gt;
			
			&lt;b&gt;2010&lt;/b&gt;
			&lt;p&gt;
			Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D.  Patient&#45;physician discordance in assessments of global disease severity in rheumatoid arthritis.  Arthritis Care Res  2010; 62(6): 857&#45;64.  PMCID PMC2885009
			&lt;p&gt;
			Demas KL, Keenan BT, Solomon DH, Yazdany J, Costenbader KH.  Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators.  Semin Arthritis Rheum  2010; 40(3): 193&#45;200.  PMCID PMC2932869
			&lt;p&gt;
			Gillis JZ, Panopalis P, Schmajuk G, Ramsey&#45;Goldman R, Yazdany J.  Quality indicators for pregnancy and reproductive health in systemic lupus erythematosus.  Arthritis Care Res  2010; Aug 23.
			&lt;p&gt;
			Hersh AO, Trupin LS, Yazdany J, Panopalis P, Julian LJ, Katz PP, Criswell LA, Yelin EH.  Childhood&#45;onset disease predicts mortality in an adult cohort of patients with systemic lupus erythematosus.  Arthritis Care Res  2010; Mar 16.
			&lt;p&gt;
			Katz PP, Gregorich S, Yazdany J, Trupin LS, Julian LJ, Yelin EH, Criswell LA.  Obesity and its measurement in a community&#45;based sample of women with systemic lupus erythematosus.  Arthritis Care Res  2010; Sep 7.
			&lt;p&gt;
			Margaretten ME, Barton JL, Julian LJ, Katz PP, Trupin LS, Imboden J, Yelin EH.  Socioeconomic determinants of depression and disability in patients with rheumatoid arthritis.  Arthritis Care Res  2010; Sep 7. [Epub ahead of print]
			&lt;p&gt;
			Panopalis P, Gillis JZ, Yazdany J, Trupin LS, Hersh AO, Julian LJ, Criswell LA, Katz PP, Yelin EH.  Frequent use of the emergency department among persons with systemic lupus erythematosus.  Arthritis Care Res  2010; 62(3): 401&#45;8.
			&lt;p&gt;
			Richman IB, Chung SA, Taylor KE, Kosoy R, Tian C, Ortmann WA, Nititham J, Lee AT, Rutman S, Petri M, Manzi S, Behrens TW, Gregersen PK, Seldin MF, Criswell LA. European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent. Genes Immun. 2010 Sep;11(6):515&#45;21. Epub 2009 Oct 22.
			&lt;p&gt;
			Schmajuk G, Yazdany J, Trupin LS, Yelin EH.  Hydroxychloroquine treatment in a community&#45;based cohort of patients with systemic lupus erythematosus.   Arthritis Care Res 2010; 62(3): 386&#45;92.
			&lt;p&gt;
			Schmajuk G, Yazdany J.  Drug monitoring in systemic lupus erythematosus: a systematic review.  Semin Arthritis Rheum  2010; Oct 26.  [Epub ahead of print]
			&lt;p&gt;
			Schmajuk G, Yelin EH, Chakravarty E, Nelson LM, Panopolis P, Yazdany J.  Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.  Arthritis Care Res  2010; 62(7): 993&#45;1001.
			&lt;p&gt;
			Tonner MC, Trupin LS, Yazdany J, Criswell LA, Katz PP, Yelin EH.  The role of community and individual characteristics in physician visits for persons with systemic lupus erythematosus.  Arthritis Care Res 2010; 62(6): 888&#45;95.  NIHMSID 186853
			&lt;p&gt;
			Yazdany J, Tonner MC, Trupin LS, Panopalis P, Gillis JZ, Hersh AO, Julian LJ, Katz PP, Criswell LA, Yelin EH.  Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study.  Arthritis Research &amp; Therapy  2010; 12(3): 124.  PMCID PMC2911868
			&lt;p&gt;
			Yazdany J, Trupin LS, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, Schwarz EB.  Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?  Arthritis Care Res  2010; Nov 15.  [Epub ahead of print]
			&lt;p&gt;
			Yazdany J, Yelin EH.  Health&#45;related quality of life and employment among persons with systemic lupus erythematosus.  Rheum Dis Clin North Am  2010; 36(1): 15&#45;32, vii.
			&lt;p&gt;
			&lt;b&gt;In press.&lt;/b&gt;
			&lt;p&gt;
			Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, Jacob CO, Alarcon&#45;Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, SLEGEN, Petri M, Demerci Y, Kamboh MI, Manzi S, Gregersen PK, Langefeld CD, Behrens TW, Criswell LA.  Anti&#45;dsDNA autoantibody production identifies genetic subsets of systemic lupus erythematosus.  PLoS Genetics.  In press.
			&lt;p&gt;
			
			Julian LJ, Tonner MC, Gregorich S, Yazdany J, Yelin EH, Trupin LS, Criswell LA, Katz PP.  Using the CES&#45;D to screen for depression in SLE.  Arthritis Care &amp; Research.  In press.
			&lt;p&gt;
			
			Julian LJ, Tonner MC, Yelin EH, Yazdany J, Trupin LS, Criswell LA, Katz PP.  Cardiovascular predictors of depression in SLE.   Arthritis Care &amp; Research.  In press.
			&lt;p&gt;
			
			Taylor KE, Chung SA, Graham RR, Ortmann W, Lee AT, Langefeld CD, Jacob CO, Alarcon&#45;Riquelme ME, Tsao BP, Moser KL, Gaffney PM, Harley JB, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA.  Risk alleles for systemic lupus erythematosus in a large case&#45;control collection and associations with clinical subphenotypes.  PLoS Genetics.  In press.
			&lt;p&gt;
			&lt;b&gt;F. Project&#45;Generated Resources&lt;/b&gt;
			&lt;p&gt;
			Not applicable
			&lt;p&gt;
			
			&lt;b&gt;Gender and Minority Inclusion&lt;/b&gt;
			&lt;p&gt;
			See attached tables.
			
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Methodology Core Unit ./rheumatology/old/research/mcrc/core.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/core.html~</Path>
		<FileBody>
			
			
			&lt;center&gt;
			&lt;b&gt;
			Methodology Core Unit&lt;br&gt;
			(PI:  Patricia Katz, PhD;&lt;br&gt; 
			Associate Director: Stuart Gansky, PhD; &lt;br&gt;
			Project Director, Laura Trupin, MPH)
			&lt;/b&gt;
			&lt;P&gt;
			&lt;img src=&quot;/rheum/images/mcrc/core1.jpg&quot;&gt;
			&lt;/center&gt;
			&lt;p&gt;
			
			The Methodology Core Unit of the UCSF Multidisciplinary Clinical Research Center (MCRC) serves as the hub for all MCRC projects and activities. The primary goal of the MCRC Methodology Core Unit is to advance clinical research at UCSF in outcomes of rheumatic conditions, building upon the existing structure developed through the MAMDC and other extramural funding.  The specific aims of the Methodology Core are to:  provide methodological and biostatistical support and oversight to MCRC projects and other projects using MCRC data sources; coordinate data collection and management of data used for MCRC projects and the research base, including protocol development, staff training and monitoring, interviewing and other data collection, data management, data analysis, and quality control; play an active role in education of fellows and junior faculty in topics related to rheumatic disease; and advance the knowledge base in rheumatology and clinical research methodology both on the UCSF campus and nationally through outreach and dissemination efforts.  
			&lt;p&gt;
			The Methodology core serves the four full projects and D&amp;F project of the MCRC, as well as the research base of the MCRC and the UCSF campus as a whole. The unit provides service to the MCRC projects by guiding all aspects of study design, protocol and instrument development, data management and statistical analysis.  Two research projects, described below, are also being undertaken in the Methodology Core, as well, both of which serve the MCRC projects and research base.  For the projects using primary data sources, the Methodology Core handles such data support services as training and supervision of interview staff.  The Methodology Core actively promotes cross&#45;disciplinary clinical research in the MCRC research base through one&#45;on&#45;one meetings of Methodology Core faculty with fellows and junior faculty, and through participation of Methodology Core faculty in established forums such as the Rheumatology Journal Club, the Department of Medicine Clinical Fellows program and the UCSF Institute for Health Policy Study's Postdoctoral Fellowship program.  Finally, the Methodology Core Unit serves the UCSF research community through its sponsorship of a quarterly lecture series and through Methodology Core faculty serving in an advisory role to several other longitudinal projects in chronic conditions, including asthma, COPD, and infertility.
			&lt;p&gt;
			
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			The Methodology Core coordinates data collection for two primary data sources, both of which are longitudinal studies that are being used in MCRC projects:
			&lt;ul&gt;
			&lt;li&gt; Lupus outcomes Study (LOS). To date, 1,149 individuals have been enrolled in the LOS; diagnoses for all have been confirmed by medical record review. The LOS is currently in the 6th wave of annual interviews. The annual re&#45;interview rate has averaged 93%. 728 individuals completed the 2007 interview. As of this writing, 684 individuals have completed the 2008 interview, and we have enrolled 102 new participants in the past year. The 2009 interview has been designed and data collection will commence in the next month.
			&lt;li&gt; Rheumatoid Arthritis Panel Study (RA Panel). The RA Panel began in 1982 with individuals enrolled from community rheumatology practices. To date, 1,447 persons have been enrolled in the LOS. The primary data source is annual telephone interviews. The Panel has been replenished several times. Average annual reinterview rates are 93%. 423 individuals completed the 2007 interview. As of this writing, 333 individuals have completed the 2008 interview. The 2009 interview has been designed, and data collection will begin in early Spring.
			&lt;/ul&gt;
			&lt;p&gt;
			The Core Unit also is responsible for the development and implementation for a protocol in which 200 persons from the RA Panel and Lupus Outcomes Study are assessed at the General Clinical Research Center of UCSF (now part of the Clinical and Translational Science Institute, or CTSI). Data collection began for this protocol in 2007. To date, 192 individuals have completed the CTSI assessment, 87 with RA and 105 with lupus. We anticipate completing the enrollment and initial assessments in the next month and beginning the follow&#45;up assessments later this year.
			&lt;p&gt;
			Finally, we have made substantial progress on one of the Core Unit projects outlined in the initial proposal &amp;mdash; the development and validation of a self&#45;reported proxy for SLICC/ACR&#45;Damage lndex (SDI) &amp;mdash;  and laid the groundwork for the second Core Unit project, establishing cut&#45;points for depression in rheumatic disease. For the SDI proxy project, the data collection through the UCSF Lupus Clinic has proven to be more time consuming than initially anticipated. We have thus far obtained complete data on 38 patients, approximately half the total needed for the analysis. For the depression project, we have recently completed enough enrollment through the CTSI to permit analysis of the appropriate cut&#45;points for the CES&#45;D scale in lupus and for the Geriatric Depression Score (GDS) in RA. All participants in the CTSI study receive a psychiatric screening interview, as well as the CES&#45;D or GDS. This will enable us to confirm the existing cutpoints for these instruments, or propose new cut&#45;points. We will be using statistical methodology developed by a statistician working with Dr. Katz on a non&#45;MCRC project.
			&lt;p&gt;
			The Methodology Core Unit faculty and staff have also continued to support the development of the Rheumatoid Arthritis Cohort Study, (PI, Dr. John Imboden, Chief of the Division of Rheumatology at SF General Hospital). The Core Unit assisted in the design of the telephone survey instrument, trained the survey interviewers, designed the database and continues to handle data management for the study. As of 12/31/08, there were a total of 224 persons with RA enrolled at San Francisco General Hospital and 203 at UCSF, for a total of 427. Enrollment continues at the two hospitals' outpatient clinics. As enrollees present for clinical care, the research assistant obtains the patients. consent to be interviewed by telephone. To date, 170 telephone interviews have been conducted &amp;mdash; 108 in English, 33 in Spanish, and 29 in Cantonese.
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
D &amp;amp; F Project ./rheumatology/old/research/mcrc/dandf.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/dandf.html</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			D &amp; F Project:  Neuropsychiatric Symptoms and MRI Markers in LSE Patients with APLA&lt;br&gt;
			(PI:  Laura Julian, PhD; Co&#45;PI:  Roland Henry, PhD)
			&lt;/b&gt;
			&lt;p&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/df&#45;1.jpg&quot;&gt;
			
			&lt;/center&gt;
			&lt;p&gt;
			
			&lt;b&gt;Abstract from Original Proposal:&lt;/b&gt;&lt;br&gt;
			
			Systemic lupus erythematosus (SLE) is a disabling autoimmune condition with multi&#45;organ system involvement. Recently central nervous system (CNS) involvement has emerged as a major cause of morbidity in SLE. Patients with SLE have an increased risk for cerebrovascular disease (CVD), and the presence of antiphospholipid antibodies (APLAs) is a recognized risk factor.  APLAs are also associated with cognitive dysfunction and markers on magnetic resonance imaging (MRI) studies, even in the absence of other overt neurological signs.  Cognitive dysfunction and depression are among the most common manifestations within the neuropsychiatric SLE spectrum.  In SLE, etiologies of these symptoms remain unclear, although preliminary studies in multiple sclerosis, and extant literature in CVD suggest that these symptoms are associated with structural changes in frontal brain regions visible by MRI studies. The current study is a cross&#45;sectional investigation of MRI markers, APLA, depression and cognitive dysfunction in SLE. Aim 1 of this study is to evaluate the relationships among depression and cognitive dysfunction among SLE patients with and without APLAs. Aim 2 of this investigation is to evaluate the contributions of APLA and MRI markers on depression and cognitive dysfunction. Diffusion Tensor Imaging (DTI) is an increasingly utilized MRI technology used to detect microscopic structural changes in otherwise normal appearing brain matter. Although this technique has proven useful in comparable CNS conditions, this technique has not been studied in SLE. We are comparing the relative sensitivity of DTI and conventional MRI techniques (T2&#45;weighted MRI) in relation to APLA, cognitive dysfunction and depression.  Using this design we may begin to evaluate behavioral and serological markers, obtainable in the course of clinical care, that identify SLE patients with underlying CNS activity.  In addition, we may provide preliminary evidence of a model of depression and cognitive dysfunction in SLE precipitated by underlying frontal CNS changes. This D &amp; F project provides pilot data that will lay the foundation for future studies evaluating neuropathological bases of cognitive function and depression in SLE.  Such studies may guide the use of preventative interventions for SLE patients at risk for CVD.
			
			&lt;p&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;
			&lt;br&gt;
			We have currently enrolled a total of 50 of a proposed 68 patients.  Although results integrating APLA antibody status, cognitive functioning, and MRI markers are pending, we have begun preliminary analyses of specific aspects of our investigational model.  
			&lt;p&gt;
			&lt;b&gt;Project 1:  Diffusion Tensor Imaging, Cognitive Function, and Cerebrovascular Risk in SLE:&lt;/b&gt;  This is a preliminary analyses of the first 26 participants enrolled.  Using standardized criteria for cognitive impairment we found that at least 1/3 of our participants were impaired on at least 1 cognitive domain, most commonly impaired on measures of information processing speed.   Performance on cognitive measures was compared to DTI measures of white matter integrity (fractional anisotropy).  Poor patient performance on measures of executive functioning (1st quartile, see Figure 1) we associated with significantly poorer structural white matter integrity as measured by DTI (p&lt;0.05), no association among DTI and memory is observed in this preliminary analyses (Figure 2).  
			
			&lt;p align=center&gt;
			&lt;table style=&quot;border:solid; border&#45;color:black; border&#45;width:1px&quot; cellpadding=5 cellspacing=0&gt;&lt;tr&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px&quot;&gt;
			Figure 1: Diffusion Tensor Imaging and Executive 
			Functioning (Performance in Quartiles)
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px; border&#45;left:solid; border&#45;color:black;border&#45;width:1px&quot;&gt;
			Figure 2:
			Diffusion Tensor Imaging and Memory
			Functioning 
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			Additionally, although data on APLA status is not available at this time, we evaluated MRI markers of white matter structural integrity in the context of other relevant cerebrovascular (CV) risk factors, specifically hypertension (HTN) and hypercholesterolemia (CHOL).  Results suggest that participants with HTN or CHOL were observed to have decreased white matter structural integrity (HTN, p&lt;0.06; CHOL p&lt;0.05; See Figures 3 and 4).  
			&lt;p align=center&gt; 
			&lt;table style=&quot;border:solid; border&#45;color:black; border&#45;width:1px&quot; cellpadding=5 cellspacing=0&gt;&lt;tr&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px&quot;&gt;
			Figure 3: Diffusion Tensor Imaging and Hypertension 
			(HTN) status 
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px; border&#45;left:solid; border&#45;color:black;border&#45;width:1px&quot;&gt;
			Figure 4:
			Diffusion Tensor Imaging and 
			Hypercholesterolemia 
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;
			
			
			&lt;p&gt;
			
			In sum, our preliminary data has provided us with some specific relevant observations. First, that DTI appears to be a sensitive technique to detect alterations in normal appearing white matter in SLE, and that these alterations are associated with outcomes in cognitive functioning.  Specifically, DTI markers of white matter integrity were significantly associated with measures of executive functioning, hypothesized in this study to be the cognitive domain most associated with subcortical CV risk factors and APLA.  Second, that when evaluating other relevant risk factors for CV disease (HTN and CHOL), we found that the presence of other CV risk factors was also associated with decreased white matter integrity.  
			
			&lt;p&gt;
			In 2009, we will be evaluating all aspects of our investigational model (APLA, DTI, and cognitive functioning) as indicated in our specific aims and hypotheses.  
			
					</FileBody>
	</node>
	<node>
		<Fname>
D &amp;amp; F Project ./rheumatology/old/research/mcrc/dandf.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/dandf.html~</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			D &amp; F Project:  Neuropsychiatric Symptoms and MRI Markers in LSE Patients with APLA&lt;br&gt;
			(PI:  Laura Julian, PhD; Co&#45;PI:  Roland Henry, PhD)
			&lt;/b&gt;
			&lt;p&gt;
			&lt;img src=&quot;/rheumatology/images/mcrc/df&#45;1.jpg&quot;&gt;
			
			&lt;/center&gt;
			&lt;p&gt;
			
			&lt;b&gt;Abstract from Original Proposal:&lt;/b&gt;&lt;br&gt;
			
			Systemic lupus erythematosus (SLE) is a disabling autoimmune condition with multi&#45;organ system involvement. Recently central nervous system (CNS) involvement has emerged as a major cause of morbidity in SLE. Patients with SLE have an increased risk for cerebrovascular disease (CVD), and the presence of antiphospholipid antibodies (APLAs) is a recognized risk factor.  APLAs are also associated with cognitive dysfunction and markers on magnetic resonance imaging (MRI) studies, even in the absence of other overt neurological signs.  Cognitive dysfunction and depression are among the most common manifestations within the neuropsychiatric SLE spectrum.  In SLE, etiologies of these symptoms remain unclear, although preliminary studies in multiple sclerosis, and extant literature in CVD suggest that these symptoms are associated with structural changes in frontal brain regions visible by MRI studies. The current study is a cross&#45;sectional investigation of MRI markers, APLA, depression and cognitive dysfunction in SLE. Aim 1 of this study is to evaluate the relationships among depression and cognitive dysfunction among SLE patients with and without APLAs. Aim 2 of this investigation is to evaluate the contributions of APLA and MRI markers on depression and cognitive dysfunction. Diffusion Tensor Imaging (DTI) is an increasingly utilized MRI technology used to detect microscopic structural changes in otherwise normal appearing brain matter. Although this technique has proven useful in comparable CNS conditions, this technique has not been studied in SLE. We are comparing the relative sensitivity of DTI and conventional MRI techniques (T2&#45;weighted MRI) in relation to APLA, cognitive dysfunction and depression.  Using this design we may begin to evaluate behavioral and serological markers, obtainable in the course of clinical care, that identify SLE patients with underlying CNS activity.  In addition, we may provide preliminary evidence of a model of depression and cognitive dysfunction in SLE precipitated by underlying frontal CNS changes. This D &amp; F project provides pilot data that will lay the foundation for future studies evaluating neuropathological bases of cognitive function and depression in SLE.  Such studies may guide the use of preventative interventions for SLE patients at risk for CVD.
			
			&lt;p&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;
			&lt;br&gt;
			We have currently enrolled a total of 50 of a proposed 68 patients.  Although results integrating APLA antibody status, cognitive functioning, and MRI markers are pending, we have begun preliminary analyses of specific aspects of our investigational model.  
			&lt;p&gt;
			&lt;b&gt;Project 1:  Diffusion Tensor Imaging, Cognitive Function, and Cerebrovascular Risk in SLE:&lt;/b&gt;  This is a preliminary analyses of the first 26 participants enrolled.  Using standardized criteria for cognitive impairment we found that at least 1/3 of our participants were impaired on at least 1 cognitive domain, most commonly impaired on measures of information processing speed.   Performance on cognitive measures was compared to DTI measures of white matter integrity (fractional anisotropy).  Poor patient performance on measures of executive functioning (1st quartile, see Figure 1) we associated with significantly poorer structural white matter integrity as measured by DTI (p&lt;0.05), no association among DTI and memory is observed in this preliminary analyses (Figure 2).  
			
			&lt;p align=center&gt;
			&lt;table style=&quot;border:solid; border&#45;color:black; border&#45;width:1px&quot; cellpadding=5 cellspacing=0&gt;&lt;tr&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px&quot;&gt;
			Figure 1: Diffusion Tensor Imaging and Executive 
			Functioning (Performance in Quartiles)
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px; border&#45;left:solid; border&#45;color:black;border&#45;width:1px&quot;&gt;
			Figure 2:
			Diffusion Tensor Imaging and Memory
			Functioning 
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;
			&lt;p&gt;
			Additionally, although data on APLA status is not available at this time, we evaluated MRI markers of white matter structural integrity in the context of other relevant cerebrovascular (CV) risk factors, specifically hypertension (HTN) and hypercholesterolemia (CHOL).  Results suggest that participants with HTN or CHOL were observed to have decreased white matter structural integrity (HTN, p&lt;0.06; CHOL p&lt;0.05; See Figures 3 and 4).  
			&lt;p align=center&gt; 
			&lt;table style=&quot;border:solid; border&#45;color:black; border&#45;width:1px&quot; cellpadding=5 cellspacing=0&gt;&lt;tr&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px&quot;&gt;
			Figure 3: Diffusion Tensor Imaging and Hypertension 
			(HTN) status 
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;
			&lt;td valign=top style=&quot;font&#45;size:10px; border&#45;left:solid; border&#45;color:black;border&#45;width:1px&quot;&gt;
			Figure 4:
			Diffusion Tensor Imaging and 
			Hypercholesterolemia 
			&lt;br&gt;
			&lt;img src=&quot;images/fig1.gif&quot;&gt;
			&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;
			
			
			&lt;p&gt;
			
			In sum, our preliminary data has provided us with some specific relevant observations. First, that DTI appears to be a sensitive technique to detect alterations in normal appearing white matter in SLE, and that these alterations are associated with outcomes in cognitive functioning.  Specifically, DTI markers of white matter integrity were significantly associated with measures of executive functioning, hypothesized in this study to be the cognitive domain most associated with subcortical CV risk factors and APLA.  Second, that when evaluating other relevant risk factors for CV disease (HTN and CHOL), we found that the presence of other CV risk factors was also associated with decreased white matter integrity.  
			
			&lt;p&gt;
			In 2009, we will be evaluating all aspects of our investigational model (APLA, DTI, and cognitive functioning) as indicated in our specific aims and hypotheses.  
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Multidisciplinary Clinical Research Center ./rheumatology/old/research/mcrc/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/index.html</Path>
		<FileBody>
			
			
			&lt;center&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/home&#45;1.jpg&quot;&gt;
			&lt;/center&gt;
			&lt;b&gt;Center Aims and Structure&lt;/b&gt;
			&lt;br&gt;The broad aim of the UCSF Multidisciplinary Clinical Research Center Program (UCSF MCRC) is to improve outcomes for persons with various forms of rheumatic diseases by discovery of the medical, demographic, and contextual factors affecting those outcomes. This overarching aim is pursued by a comprehensive program of clinical research in the rheumatic diseases, including but not limited to that within the MCRC; by serving as a catalyst for such clinical research throughout UCSF; and by systematic training of clinical investigators in the rheumatic diseases.&lt;br /&gt;
			&lt;p&gt;The MCRC consists of an Administrative Unit, Methodology Core, four five&#45;year projects, and a three&#45;year Development and Feasibility (D&amp;amp;F) Study. The participants in the MCRC span three UCSF schools (Medicine, Nursing, and Dentistry) and UC, Davis and include representatives of nine discrete academic units, including the UCSF Clinical and Translational Science Institute (CTSI). The Center's Director and Associate Director are Drs. Edward Yelin and Lindsey Criswell, respectively. The Director and Project Director of the Core Unit are Dr. Patricia Katz and Ms. Laura Trupin, respectively. The activities of the MCRC are guided on a day&#45;to&#45;day basis by an Executive Committee. Strategic oversight of the Center is provided by Internal (UCSF) and External Advisory Committees.&lt;br /&gt;
			&lt;p&gt;The research in the MCRC is based on analysis of primary data on persons with two specific diseases, Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), and on analysis of secondary data on persons with a broader array of musculoskeletal conditions. The specific five&#45;year projects are: &amp;quot;The Interplay of Sociodemographic and Genetic Factors in SLE Health Disparities&amp;quot; (Dr. Lindsey Criswell, P.I.); &amp;quot;Body Composition and Disability in RA and SLE&amp;quot; (Dr. Patricia Katz, P.I.); &amp;quot;SLE and Employment: The Impact of Individual and Contextual Factors&amp;quot; (Dr. Edward Yelin, P.I.); and, &amp;quot;Do Mid&#45;Life Musculoskeletal Conditions Lead to Disability in the Elderly?&amp;quot; (Dr. Kenneth Covinsky, P.I.). The D&amp;amp;F study is: &amp;quot;Diffusion Tensor Imaging Correlates with Neuropsychiatric Symptoms in Patients with SLE and APLA&amp;quot; (Dr. Laura Julian, P.I.).&lt;br /&gt;
			&lt;p&gt;&lt;strong&gt;Progress since 5/1/2006 funding:&lt;/strong&gt;&lt;br /&gt;
			  Since the UCSF MCRC began funding,&amp;nbsp;73 publications. In addition,&amp;nbsp;70 abstracts have been presented at professional meetings, including the National Meeting of the American College of Rheumatology, ACMG Clinical Genetics Meeting, American Society of Human Genetics, International Congress on SLE, Pediatric Academic Society, EULAR Annual Meeting, and Health Care Quality and Outcomes Conference.
			&lt;p&gt;
			&lt;br&gt;
			&lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Center Aims and Structure ./rheumatology/old/research/mcrc/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/index.html~</Path>
		<FileBody>
			
			
			&lt;center&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/home&#45;1.jpg&quot;&gt;
			&lt;/center&gt;
			&lt;p&gt;
			The broad aim of the UCSF Multidisciplinary Clinical Research Center Program (UCSF MCRC) is to improve outcomes for persons with various forms of rheumatic diseases by discovery of the medical, demographic, and contextual factors affecting those outcomes.  This overarching aim is pursued by a comprehensive program of clinical research in the rheumatic diseases, including but not limited to that within the MCRC; by serving as a catalyst for such clinical research throughout UCSF; and by systematic training of clinical investigators in the rheumatic diseases.
			&lt;p&gt;
			The MCRC consists of an Administrative Unit, Methodology Core, four five&#45;year projects, and a three&#45;year Development and Feasibility (D&amp;F) Study.  The participants in the MCRC span three UCSF schools (Medicine, Nursing, and Dentistry) and UC, Davis and include representatives of nine discrete academic units, including the UCSF Clinical and Translational Science Institute (CTSI). The Center's Director and Associate Director are Drs. Edward Yelin and Lindsey Criswell, respectively.  The Director and Project Director of the Core Unit are Dr. Patricia Katz and Ms. Laura Trupin, respectively.  The activities of the MCRC are guided on a day&#45;to&#45;day basis by an Executive Committee.  Strategic oversight of the Center is provided by Internal (UCSF) and External Advisory Committees.
			&lt;p&gt;
			The research in the MCRC is based on analysis of primary data on persons with two specific diseases, Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), and on analysis of secondary data on persons with a broader array of musculoskeletal conditions. The specific five&#45;year projects are: &quot;The Interplay of Sociodemographic and Genetic Factors in SLE Health Disparities&quot; (Dr. Lindsey Criswell, P.I.); &quot;Body Composition and Disability in RA and SLE&quot; (Dr. Patricia Katz, P.I.); &quot;SLE and Employment: The Impact of Individual and Contextual Factors&quot; (Dr. Edward Yelin, P.I.); and, &quot;Do Mid&#45;Life Musculoskeletal Conditions Lead to Disability in the Elderly?&quot; (Dr. Kenneth Covinsky, P.I.). The D&amp;F study is: &quot;Diffusion Tensor Imaging Correlates with Neuropsychiatric Symptoms in Patients with SLE and APLA&quot; (Dr. Laura Julian, P.I.). 
			&lt;p&gt;
			
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			Since the UCSF MCRC began funding, &lt;a href=&quot;/research/mcrc/presentations.html&quot;&gt;37 papers from the MCRC faculty have been published or are in press&lt;/a&gt; and five more have been submitted for publication.  In addition, &lt;a href=&quot;/research/mcrc/presentations.html&quot;&gt;40 abstracts have been presented&lt;/a&gt; at professional meetings, including the National Meeting of the American College of Rheumatology, ACMG Clinical Genetics Meeting, American Society of Human Genetics, International Congress on SLE, Pediatric Academic Society, EULAR Annual Meeting, and Health Care Quality and Outcomes Conference. 
			&lt;p&gt;
			&lt;br&gt;
			&lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Research ./rheumatology/old/research/mcrc/presentations.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/presentations.html</Path>
		<FileBody>
			
			
			&lt;b&gt;Publications of the MCRC Faculty&lt;/b&gt;
			&lt;p&gt;
			&lt;b&gt;2006&lt;/b&gt;
			&lt;p&gt;
			Freemer MM, King TE, Criswell LA.  Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus.  Annals of the Rheumatic Diseases, 2006: 65(5): 581&#45;4.
			&lt;p&gt;
			Janssens A, Steyerberg E, Jiang Y, Habbema J, van Duijn C, Criswell L.  Value of the HLA&#45;DRB1 Shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile.  J Rheumatol 2006; 33: 2383&#45;9.
			&lt;p&gt;
			Katz P, Morris A, Yelin E. Prevalence and Predictors of Disability in Valued Life Activities among Individuals with Rheumatoid Arthritis. Ann Rheum Dis 2006; 65 763&#45;769.
			&lt;p&gt;
			Katz P. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2006; 5:217&#45;223.
			&lt;p&gt;
			Steinman M, McQuaid K, Covinsky K.  Age and rising rates of cyclooxygenase&#45;2 inhibitor use.  Results from a national survey.  J Gen Intern Med 2006;  21: 245&#45;250.
			&lt;p&gt;
			&lt;b&gt;2007&lt;/b&gt;
			&lt;p&gt;
			Gillis J, Yazdany J, Trupin L, Julian L, Panopalis P, Criswell L, Katz P, Yelin E. Medicaid and Access to Care among Persons with SLE.  Arthritis and Rheumatism (Arthritis Care and Research) 2007; 57: 601&#45;607.
			&lt;p&gt;
			Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, Williams A, Beck S, Kyogoku C, Moser K, Gaffney P, Gregersen PK, Criswell LA, Harley JB, Behrens TW.  Specific combinations of HLA&#45;DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE.  European Journal of Human Genetics, 2007: 15(8): 823&#45;30. [Epub 2007 Apr 4]
			&lt;p&gt;
			Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LRL, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW, Gillett C, Burtt N, Graham DSC, Onofrio R, Petri M, Gunnarsson I, Svenungsson E, R&amp;ouml;nnblom L, Nordmark G, Gregersen PK, Moser K, Gaffney PM, Criswell LA, Vyse TJ, Syv&amp;auml;nen A&#45;C, Bohjanen PR, Daly MJ, Behrens TW, Altshuler D.  Three functional variants of interferon regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.  Proceedings of the National Academy of Sciences USA, 2007: 104 (16): 6758&#45;63. [Epub 2007 Apr 5]
			&lt;p&gt;
			Katz P, Morris A.  Use of accommodations for valued life activities:  prevalence and effects on disability scores. Arthritis Rheum (Arthritis Care Res) 2007; 57:730&#45;737.
			&lt;p&gt;
			Katz P, Morris A.  Time use patterns among women with rheumatoid arthritis: association with functional limitations and psychological status.  Rheumatology 2007; 46:490&#45;495.
			&lt;p&gt;
			Kinder BW, Freemer MM, King, TE, Jr, Lum RF, Taylor K, Jeff Edberg, Bridges, SL, Jr, Criswell LA.  Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.  Arthritis and Rheumatism, 2007: 56(8): 2679&#45;2686.
			&lt;p&gt;
			Panopalis P, Julian L, Yazdany J, Gillis J, Trupin L, Hersh A, Criswell L, Katz P, Yelin E.  Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum (Arthritis Care Res) 2007; 57: 1453&#45;1460.
			&lt;p&gt;
			Remmers EF, Plenge RM, Lee, AT, Graham RR, Hom G, Behrens TW, de Bakker PIW, Le JM, Lee H&#45;S, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.  The New England Journal of Medicine, 2007: 357(10): 977&#45;86.
			&lt;p&gt;
			Thorburn CM, Prokunina&#45;Olsson L, Sterba KA, Lum RF, Seldin MF, Alarcon&#45;Riquelme ME, Criswell LA.  Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus.  Genes and Immunity, 2007: 8(4): 279&#45;87. [Epub 2007 Mar 8]
			&lt;p&gt;
			Yazdany J, Gillis J, Trupin L, Katz P, Criswell L, Yelin E. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in a large observational cohort of subjects with systemic lupus erythematosus.  Arthritis Rheum (Arthritis Care Res) 2007; 57: 508&#45;515.
			&lt;p&gt;
			Yazdany J, Gillis J, Trupin L, Katz P, Panopalis P, Criswell L, Yelin E. Rheumatology Subspecialty Care in a Large Observational Cohort of Subjects with Systemic Lupus Erythematosus.  Arthritis and Rheumatism (Arthritis Care and Research) 2007: 57: 593&#45;600.
			Yelin E, Trupin L, Katz P, Criswell L, Yazdany J, Gillis J, Panopalis P.  Work dynamics among persons with SLE.  Arthritis Rheum (Arthritis Care Res) 2007; 57: 56&#45;63.
			Yelin E, Trupin L, Katz P, Criswell L, Yazdany J, Gillis J, Panopalis P. Impact of HMOs and Fee&#45;for&#45;Service on Health Care Utilization among Persons with SLE. Arthritis Rheum (Arthritis Care Res) 2007; 57: 508&#45;515.
			&lt;p&gt;
			&lt;b&gt;2008&lt;/b&gt;
			&lt;p&gt;
			Boyd CM, Landefeld CS, Counsell SR, Palmer RM, Fortinsky RH, Kresevic D, Burant C, Covinsky KE.  Recovery of activities of daily living in older adults after hospitalization for acute medical illness.  J Am Geriatr Soc 2008; 56:2171&#45;2179
			&lt;p&gt;
			Covinsky KE, Lindquist K, Dunlop DD, Gill TM, Yelin E. Effect of arthritis in middle age on older&#45;age functioning. J Am Geriatr Soc. 2008; 56:23&#45;28.
			&lt;p&gt;
			Harley JB, Alarc&amp;oacute;n&#45;Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD.  A genome wide association study of systemic lupus erythematosus.  Nature Genetics, 2008: 40(2): 204&#45;10. [Epub 2008 Jan 20]
			&lt;p&gt;
			 
			Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira R, Pant PVK, Ballinger DG, Kosoy R, Demirci FY, Kamboh I, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantap&amp;auml;&amp;auml;&#45;Dahlquist S, Petri M, Manzi S, Seldin MF, R&amp;ouml;nnblom L, Syv&amp;auml;nen A&#45;C, Criswell LA, Gregersen PK, Behrens TW.  Association of systemic lupus erythematosus with C8orf13/BLK and ITGAM/ITGAX.  The New England Journal of Medicine, 2008: 358(9): 900&#45;9.  [Epub 2008 Jan 20].
			Kaiser R, Cleveland CM, Criswell LA.  Risk and protective factors for thrombosis in systemic lupus erythematosus:  results from a large, multi&#45;ethnic cohort.  Annals of the Rheumatic Diseases, 2008: 2008 Sep 9. [Epub ahead of print]
			&lt;p&gt;
			Katz P, Morris A, Yelin E.  Subclinical disability in valued life activities among individuals with rheumatoid arthritis. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research) 2008; 59:1416&#45;1423.
			Katz P, Morris A, Trupin L, Yazdany J, Yelin E.  Disability in valued life activities among individuals with systemic lupus erythematosus. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research) 2008; 59: 465&#45;473.
			Lee SJ, Go AS, Lindquist K, Bertenthal D, Covinsky KE. Chronic conditions and mortality among the oldest old. Am J Public Health. 2008; 98:1209&#45;1214.
			Morris A, Yelin EH, Wong B, Katz PP.  Patterns of psychosocial risk and long&#45;term outcomes in rheumatoid arthritis.  Psychology, Health &amp; Medicine 2008; 13:529&#45;544.
			Musone SL, Taylor KE, Lu T, Nititham J, Ferreira RC, Ortmann W, Shiffrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok P&#45;Y, Criswell LA.  Multiple Polymorphisms in the TNFAIP3 Region are Independently Associated with Systemic Lupus Erythematosus.  Nature Genetics, 01 August 2008; doi:10.1038/ng.202.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Trupin L, Hersh A, Criswell L, Katz P, Yelin E. The Economic Burden of Systemic Lupus Erythematosus: Healthcare Costs and Costs Associated with Changes in Work Productivity.  Arthritis and Rheumatism (Arthritis Care and Research) 2008; 59:1788&#45;1795.
			&lt;p&gt;
			Sands LP, Xu H, Craig BA, Eng C, Covinsky KE.  Predicting change in functional status over quarterly intervals for older adults enrolled in the PACE community&#45;based long&#45;term care program.  Aging Clin Exp Res  2008; 20:419&#45;427
			&lt;p&gt;
			Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA.  Specificity of the STAT4 genetic association for severe disease manifestations of SLE.  PLoS Genetics, 2008; 4 (5): e1000084.
			Trupin L, Tonner MC, Yazdany J, Julian LJ, Criswell LA, Katz PP, Yelin E.  The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus.  Journal of Rheumatology  2008; 35:1782&#45;1788.
			Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP.  Validation of the Systemic Lupus Erythematosus Activity Questionnaire in a large observational cohort. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research) 2008; 59:136&#45;143.
			 &lt;p&gt;
			&lt;B&gt;2009 or in press&lt;/b&gt;
			&lt;p&gt;
			Hersh A, Von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Criswell L, Katz P, Yelin E. Differences in Long&#45;Term Disease Activity and Treatment of Adult Patients with Childhood and Adult&#45;Onset Systemic Lupus Erythematosus. Arthritis and Rheumatism (Arthritis Care and Research),  in press.
			&lt;p&gt;
			Katz P, Morris A, Gregorich S, Yazdany J, Eisner M, Yelin E, Blanc P.  Valued life activity disability play a significant role in self&#45;rated health among adults with chronic health conditions.  Journal of Clinical Epidemiology (in press).
			Yazdany J, Panopalis P, Gillis J, Schmajuk G, MacLean C, Wofsy D, Yelin E. A Quality Indicator Set for Systemic Lupus Erythematosus.  Arthritis and Rheumatism (Arthritis Care and Research),  in press.
			&lt;p&gt;
			Yelin E, Tonner C,  Trupin L, Panopalis P, Yazdany J, Julian L, Katz P, Criswell L. Work Loss and Work Entry among Persons with SLE: Comparisons to a National, Matched Sample.   Arthritis Rheum (Arthritis Care Res), in press.
			&lt;p&gt;
			
			 &lt;a name=&quot;presentations&quot;&gt;&lt;/a&gt;
			&lt;b&gt;Presentations of UCSF MCRC Faculty&lt;/b&gt;
			&lt;p&gt;
			&lt;b&gt;2006&lt;/b&gt;
			&lt;p&gt;
			Barcellos L, Komorowski L, Graham R, Artim G, Seldin M, Harley J, Behrens T, Criswell L.  Parent of origin effects and HLA&#45;DRB1 risk in systemic lupus erythematosus.  Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. 
			&lt;p&gt;
			Begovich A, Chang M, Criswell L, Pfeiffer K, Bare L, Arellano A, Ho A, Lee W, Behlendorf D, Sun Y, Rowland C, Short M, Zoccoli M.  Development of a research genotyping assay for 5 SNPs associated with deep vein thrombosis and application to a study of antiphospholipid syndrome in patients with systemic lupus erythematosus.  Presented at the ACMG Annual Clinical Genetics Meeting, San Diego, CA, March 2006.
			&lt;p&gt;
			Chung S, Edwards T, Parsa A, Lum R, Taylor K, Seldin M, Ritchie M, Criswell L.  Novel associations between angiotensinogen and ACE polymorphisms and SLE risk: results of a family based analysis. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006.
			&lt;p&gt;
			Gillis J, Yazdany J, Panopalis P, Katz P, Yelin E.  Differential access to SLE care by Medicaid status. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S100, #106.
			&lt;p&gt;
			Hersh A, von Scheven E, Yelin E. Comparison of outcomes between patients with childhood and adult&#45;onset disease in a large observational cohort with systemic lupus erythematosus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006.
			&lt;p&gt;
			Julian L, Katz P, Trupin L, Criswell L, Yelin E.  Relationships among neuropsychological performance, patient reported cognitive symptoms, and depressive symptoms in systemic lupus erythematosus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S769, #1952.
			&lt;p&gt;
			Julian L, Katz P, Trupin L, Panopalis P, Gillis J, Yazdany J, Yelin E.  Cognitive functioning in systemic lupus erythematosus: impact of disease severity, manifestations, and medication effects. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S274, #578.
			&lt;p&gt;
			Julian L, Katz P, Trupin L, Yelin E.  Health related quality of life in the UCSF Lupus Outcomes Study: Impact of patient and disease characteristics. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S769, #1955.
			&lt;p&gt;
			Katz P, Morris A.  Body composition and disability in valued life activities in RA and lupus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S816, #2078.
			&lt;p&gt;
			Katz P, Morris A.  Prevalence of pre&#45;clinical disability among individuals with RA. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S507, #1211.
			&lt;p&gt;
			Katz P, Morris A.  Social impact of disease, disability, and depressive symptoms in RA. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S795, #2024.
			&lt;p&gt;
			Morris A, Wong B, Yelin E, Katz P.  Patterns of psychosocial risk and long term outcomes in rheumatoid arthritis. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S506, #1209.
			&lt;p&gt;
			Murphy L, Yelin E, Cisternas M, Foreman A, Pasta D, Helmick C.  Medical expenditures and earnings losses among persons with arthritis and other rheumatic conditions (AORC), United States, 2003. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S786, #2002.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Morris A, Katz P, Yelin E.  Cognitive function and health resource utilization in patients wih systemic lupus erythematosus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S119, #154.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Morris A, Katz P, Yelin E.  Cognitive function in systemic lupus erythematosus: impact on employment status. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S120, #155.
			&lt;p&gt;
			Thorburn C, Pawlikowska L, Taylor K, Woo J, Carlson E, Kwok P&#45;Y, Criswell L.  Confirmation of ESR1 polymorphism association with lupus nephritis in a multi&#45;ethnic case&#45;control cohort. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006.
			&lt;p&gt;
			Trupin L, Katz P, Yelin E.  Individual and neighborhood SES in physical functioning and depression in an SLE cohort. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S105, #119.
			&lt;p&gt;
			Yazdany J, Gillis J, Panopalis P, Julian L, Katz P, Yelin E.  Racial/ethnic differences in the prevalence and treatment of major depressive disorder in a large observational cohort of persons with SLE. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S274, #580.
			&lt;p&gt;
			 
			&lt;b&gt;2007&lt;/b&gt;
			&lt;p&gt;
			Katz P, Morris A, Yelin E, Trupin L.  Body mass index and disability in lupus.  Presented at the 8th International Congress on SLE; Shanghai, China; 05/23&#45;27/07.  Lupus  2007; 16(S1) &#45; abstract supplement: 199, #PO314.
			&lt;p&gt;
			Yelin E, Trupin L, Tonner C, Katz P.  Impact of personal&#45; and community&#45;level poverty on SLE activity, physical function, and depression.  Presented at the 8th International Congress on SLE; Shanghai, China; 05/23&#45;27/07.  Lupus  2007; 16(S1) &#45; abstract supplement: 200, #PO315.
			&lt;p&gt;
			Barcellos L, Clark S, Ramsay P, Quach H, Seldin M, Harley J, Moser K, Behrens T, Gaffney P, Criswell L.  High density SNP screening of the major histocompatibility complex in systemic lupus erythematosus families. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007.  Arthritis Rheum 2007; 56(supp): S753, #1972.
			&lt;p&gt;
			Chung S, Pawlikowska L, Chu C, Oksenberg J, Kwok P&#45;Y, Criswell L.  Investigating CD45 as a SLE susceptibility gene. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007.  Arthritis Rheum 2007; 56(supp): S352, #838.
			&lt;p&gt;
			Hersh A, von Scheven E, Panopalis P, Yazdany J, Gillis J, Trupin L, Julian L, Katz P, Yelin EH. Long&#45;term psychosocial and employment outcomes of children with systemic lupus erythematosus. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S138, #232.
			&lt;p&gt;
			Hersh A, von Scheven E, Yelin E. Long&#45;term psychosocial outcomes of children with systemic lupus erythematosus in a large observational cohort. Presented at annual meeting of the Pediatric Academic Society, May 2007. 
			&lt;p&gt;
			Julian L, Panopalis P, Yazdany J, Trupin L, Gillis J, Yelin E, Katz P.  Depression in SLE:  relationships with traditional and disease&#45;specific cardiovascular risk. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S513, #1277.
			&lt;p&gt;
			Kaiser R, Cleveland C, Criswell L.  Ethnicity and thrombosis in a large, ethnically&#45;diverse systemic lupus erythematosus (SLE) cohort. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007.
			&lt;p&gt;
			Morris A, Yelin E, Katz P.  Long&#45;term patterns of serious depression in a longitudinal study of individuals with rheumatoid arthritis. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S513, #1278.
			&lt;p&gt;
			Morris A, Yelin E, Wong B, Katz P.  Patterns of psychosocial risk and long&#45;term outcomes in rheumatoid arthritis.  Presented at the 5th Annual Health care Quality and Outcomes Conference, Oakland, CA  May 2007.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Hersh A, Trupin L, Katz P, Yelin E.  Direct healthcare costs of systemic lupus erythematosus and predictors of costs.  Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S81, #78.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Hersh A, Trupin L, Katz P, Yelin E.  Predictors of frequent emergency department use among persons with systemic lupus erythematosus. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S594, #1503.
			&lt;p&gt;
			Trupin L, Tonner C, Yazdany J, Julian L, Criswell L, Katz P, Yelin E.  Socioeconomic status in outcomes of systemic lupus erythematosus. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S506, #1256.
			&lt;p&gt;
			Yazdany J, Panopalis P, Gillis J, Trupin L, Julian L, Hersh A, Katz P, Yelin E.  Provision of preventive health services in SLE.  Oral presentation. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S806, #2118.
			&lt;p&gt;
			&lt;b&gt;2008&lt;/b&gt;
			&lt;p&gt;
			Criswell LA, Taylor KE, Tian C, Chung SA, Lee AT, Ortmann WA, Nititham JS, Petri MA, Manzi S, Gregersen PK, Behrens TW, Seldin MF.  Specific European ancestry contributes to subphenotypes of SLE [AB0147].  Presented at the European League Against Rheumatism (EULAR) meeting, Paris, France, June 2008; Ann Rheum Dis 2008;67(Suppl II): 597.
			&lt;p&gt;
			Richman IB, Barton J, Trupin L, Criswell LA.  The role of socioeconomic status and ethnicity in systemic lupus erythematosus outcomes.  Presented at the Health Disparities Symposium, University of California, San Francisco, San Francisco, CA, October 2008.
			&lt;p&gt;
			Chung SA, Taylor KE, Graham RR, Hom G, Ortmann WA, Lee AT, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA.  Genome&#45;wide association study of anti&#45;dsDNA autoantibody production in SLE.  Presented at the American College of Rheumatology meeting, San Francisco, CA, USA, October 2008.
			&lt;p&gt;
			Taylor KE, Graham RR, Hom G, Chung SA, Ortmann W, Lee AT, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA.  Cumulative effects of risk alleles on systemic lupus erythematosus susceptibility and subphenotypes.  Presented at the American Society of Human Genetics meeting, Philadelphia, PA, USA, November 2008.
			&lt;p&gt;
			Katz PP.  Body composition and disability in lupus.  Presented at annual scientific meeting of the American College of Rheumatology, San Francisco, CA, October 2008.
			&lt;p&gt;
			Julian, L.J., Katz, P.P., Lande, C., Trupin, L., Criswell, L.A., Yelin, E.H., Wofsy, D., Henry, R., (2008) Diffusion Tensor Imaging and Cognitive Functioning in Systemic Lupus Erythematosus.  Poster presented at the American College of Rheumatology, San Francisco, CA.
			&lt;p&gt;
			 
			Julian, L.J., Yelin, E., Yazdany, J., Panopalis, P., Trupin, L., Criswell, L., Katz, P. (2008)Depression, Medication Adherence, and Service Utilization in Systemic Lupus Erythematosus. Paper presented at the Association for Rheumatology Health Professionals.
			&lt;p&gt;
			Margaretten, M., Yelin, E., Imboden, J., Graf, J., Julian, L., (2008) Predictors of Depression in a Multi&#45;ethnic Cohort of Patients with Rheumatoid Arthritis.  Poster presented at the American College of Rheumatology, San Francisco, CA.
			
			&lt;p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Research ./rheumatology/old/research/mcrc/presentations.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/presentations.html~</Path>
		<FileBody>
			
			
			print &lt;&lt;&lt;END
			
			&lt;b&gt;Publications of the MCRC Faculty&lt;/b&gt;
			&lt;p&gt;
			&lt;b&gt;2006&lt;/b&gt;
			&lt;p&gt;
			Freemer MM, King TE, Criswell LA.  Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus.  Annals of the Rheumatic Diseases, 2006: 65(5): 581&#45;4.
			&lt;p&gt;
			Janssens A, Steyerberg E, Jiang Y, Habbema J, van Duijn C, Criswell L.  Value of the HLA&#45;DRB1 Shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile.  J Rheumatol 2006; 33: 2383&#45;9.
			&lt;p&gt;
			Katz P, Morris A, Yelin E. Prevalence and Predictors of Disability in Valued Life Activities among Individuals with Rheumatoid Arthritis. Ann Rheum Dis 2006; 65 763&#45;769.
			&lt;p&gt;
			Katz P. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2006; 5:217&#45;223.
			&lt;p&gt;
			Steinman M, McQuaid K, Covinsky K.  Age and rising rates of cyclooxygenase&#45;2 inhibitor use.  Results from a national survey.  J Gen Intern Med 2006;  21: 245&#45;250.
			&lt;p&gt;
			&lt;b&gt;2007&lt;/b&gt;
			&lt;p&gt;
			Gillis J, Yazdany J, Trupin L, Julian L, Panopalis P, Criswell L, Katz P, Yelin E. Medicaid and Access to Care among Persons with SLE.  Arthritis and Rheumatism (Arthritis Care and Research) 2007; 57: 601&#45;607.
			&lt;p&gt;
			Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, Williams A, Beck S, Kyogoku C, Moser K, Gaffney P, Gregersen PK, Criswell LA, Harley JB, Behrens TW.  Specific combinations of HLA&#45;DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE.  European Journal of Human Genetics, 2007: 15(8): 823&#45;30. [Epub 2007 Apr 4]
			&lt;p&gt;
			Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LRL, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW, Gillett C, Burtt N, Graham DSC, Onofrio R, Petri M, Gunnarsson I, Svenungsson E, R&amp;ouml;nnblom L, Nordmark G, Gregersen PK, Moser K, Gaffney PM, Criswell LA, Vyse TJ, Syv&amp;auml;nen A&#45;C, Bohjanen PR, Daly MJ, Behrens TW, Altshuler D.  Three functional variants of interferon regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.  Proceedings of the National Academy of Sciences USA, 2007: 104 (16): 6758&#45;63. [Epub 2007 Apr 5]
			&lt;p&gt;
			Katz P, Morris A.  Use of accommodations for valued life activities:  prevalence and effects on disability scores. Arthritis Rheum (Arthritis Care Res) 2007; 57:730&#45;737.
			&lt;p&gt;
			Katz P, Morris A.  Time use patterns among women with rheumatoid arthritis: association with functional limitations and psychological status.  Rheumatology 2007; 46:490&#45;495.
			&lt;p&gt;
			Kinder BW, Freemer MM, King, TE, Jr, Lum RF, Taylor K, Jeff Edberg, Bridges, SL, Jr, Criswell LA.  Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.  Arthritis and Rheumatism, 2007: 56(8): 2679&#45;2686.
			&lt;p&gt;
			Panopalis P, Julian L, Yazdany J, Gillis J, Trupin L, Hersh A, Criswell L, Katz P, Yelin E.  Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum (Arthritis Care Res) 2007; 57: 1453&#45;1460.
			&lt;p&gt;
			Remmers EF, Plenge RM, Lee, AT, Graham RR, Hom G, Behrens TW, de Bakker PIW, Le JM, Lee H&#45;S, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.  The New England Journal of Medicine, 2007: 357(10): 977&#45;86.
			&lt;p&gt;
			Thorburn CM, Prokunina&#45;Olsson L, Sterba KA, Lum RF, Seldin MF, Alarcon&#45;Riquelme ME, Criswell LA.  Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus.  Genes and Immunity, 2007: 8(4): 279&#45;87. [Epub 2007 Mar 8]
			&lt;p&gt;
			Yazdany J, Gillis J, Trupin L, Katz P, Criswell L, Yelin E. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in a large observational cohort of subjects with systemic lupus erythematosus.  Arthritis Rheum (Arthritis Care Res) 2007; 57: 508&#45;515.
			&lt;p&gt;
			Yazdany J, Gillis J, Trupin L, Katz P, Panopalis P, Criswell L, Yelin E. Rheumatology Subspecialty Care in a Large Observational Cohort of Subjects with Systemic Lupus Erythematosus.  Arthritis and Rheumatism (Arthritis Care and Research) 2007: 57: 593&#45;600.
			Yelin E, Trupin L, Katz P, Criswell L, Yazdany J, Gillis J, Panopalis P.  Work dynamics among persons with SLE.  Arthritis Rheum (Arthritis Care Res) 2007; 57: 56&#45;63.
			Yelin E, Trupin L, Katz P, Criswell L, Yazdany J, Gillis J, Panopalis P. Impact of HMOs and Fee&#45;for&#45;Service on Health Care Utilization among Persons with SLE. Arthritis Rheum (Arthritis Care Res) 2007; 57: 508&#45;515.
			&lt;p&gt;
			&lt;b&gt;2008&lt;/b&gt;
			&lt;p&gt;
			Boyd CM, Landefeld CS, Counsell SR, Palmer RM, Fortinsky RH, Kresevic D, Burant C, Covinsky KE.  Recovery of activities of daily living in older adults after hospitalization for acute medical illness.  J Am Geriatr Soc 2008; 56:2171&#45;2179
			&lt;p&gt;
			Covinsky KE, Lindquist K, Dunlop DD, Gill TM, Yelin E. Effect of arthritis in middle age on older&#45;age functioning. J Am Geriatr Soc. 2008; 56:23&#45;28.
			&lt;p&gt;
			Harley JB, Alarc&amp;oacute;n&#45;Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD.  A genome wide association study of systemic lupus erythematosus.  Nature Genetics, 2008: 40(2): 204&#45;10. [Epub 2008 Jan 20]
			&lt;p&gt;
			 
			Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira R, Pant PVK, Ballinger DG, Kosoy R, Demirci FY, Kamboh I, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantap&amp;auml;&amp;auml;&#45;Dahlquist S, Petri M, Manzi S, Seldin MF, R&amp;ouml;nnblom L, Syv&amp;auml;nen A&#45;C, Criswell LA, Gregersen PK, Behrens TW.  Association of systemic lupus erythematosus with C8orf13/BLK and ITGAM/ITGAX.  The New England Journal of Medicine, 2008: 358(9): 900&#45;9.  [Epub 2008 Jan 20].
			Kaiser R, Cleveland CM, Criswell LA.  Risk and protective factors for thrombosis in systemic lupus erythematosus:  results from a large, multi&#45;ethnic cohort.  Annals of the Rheumatic Diseases, 2008: 2008 Sep 9. [Epub ahead of print]
			&lt;p&gt;
			Katz P, Morris A, Yelin E.  Subclinical disability in valued life activities among individuals with rheumatoid arthritis. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research) 2008; 59:1416&#45;1423.
			Katz P, Morris A, Trupin L, Yazdany J, Yelin E.  Disability in valued life activities among individuals with systemic lupus erythematosus. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research) 2008; 59: 465&#45;473.
			Lee SJ, Go AS, Lindquist K, Bertenthal D, Covinsky KE. Chronic conditions and mortality among the oldest old. Am J Public Health. 2008; 98:1209&#45;1214.
			Morris A, Yelin EH, Wong B, Katz PP.  Patterns of psychosocial risk and long&#45;term outcomes in rheumatoid arthritis.  Psychology, Health &amp; Medicine 2008; 13:529&#45;544.
			Musone SL, Taylor KE, Lu T, Nititham J, Ferreira RC, Ortmann W, Shiffrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok P&#45;Y, Criswell LA.  Multiple Polymorphisms in the TNFAIP3 Region are Independently Associated with Systemic Lupus Erythematosus.  Nature Genetics, 01 August 2008; doi:10.1038/ng.202.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Trupin L, Hersh A, Criswell L, Katz P, Yelin E. The Economic Burden of Systemic Lupus Erythematosus: Healthcare Costs and Costs Associated with Changes in Work Productivity.  Arthritis and Rheumatism (Arthritis Care and Research) 2008; 59:1788&#45;1795.
			&lt;p&gt;
			Sands LP, Xu H, Craig BA, Eng C, Covinsky KE.  Predicting change in functional status over quarterly intervals for older adults enrolled in the PACE community&#45;based long&#45;term care program.  Aging Clin Exp Res  2008; 20:419&#45;427
			&lt;p&gt;
			Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA.  Specificity of the STAT4 genetic association for severe disease manifestations of SLE.  PLoS Genetics, 2008; 4 (5): e1000084.
			Trupin L, Tonner MC, Yazdany J, Julian LJ, Criswell LA, Katz PP, Yelin E.  The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus.  Journal of Rheumatology  2008; 35:1782&#45;1788.
			Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP.  Validation of the Systemic Lupus Erythematosus Activity Questionnaire in a large observational cohort. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research) 2008; 59:136&#45;143.
			 &lt;p&gt;
			&lt;B&gt;2009 or in press&lt;/b&gt;
			&lt;p&gt;
			Hersh A, Von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Criswell L, Katz P, Yelin E. Differences in Long&#45;Term Disease Activity and Treatment of Adult Patients with Childhood and Adult&#45;Onset Systemic Lupus Erythematosus. Arthritis and Rheumatism (Arthritis Care and Research),  in press.
			&lt;p&gt;
			Katz P, Morris A, Gregorich S, Yazdany J, Eisner M, Yelin E, Blanc P.  Valued life activity disability play a significant role in self&#45;rated health among adults with chronic health conditions.  Journal of Clinical Epidemiology (in press).
			Yazdany J, Panopalis P, Gillis J, Schmajuk G, MacLean C, Wofsy D, Yelin E. A Quality Indicator Set for Systemic Lupus Erythematosus.  Arthritis and Rheumatism (Arthritis Care and Research),  in press.
			&lt;p&gt;
			Yelin E, Tonner C,  Trupin L, Panopalis P, Yazdany J, Julian L, Katz P, Criswell L. Work Loss and Work Entry among Persons with SLE: Comparisons to a National, Matched Sample.   Arthritis Rheum (Arthritis Care Res), in press.
			&lt;p&gt;
			
			 &lt;a name=&quot;presentations&quot;&gt;&lt;/a&gt;
			&lt;b&gt;Presentations of UCSF MCRC Faculty&lt;/b&gt;
			&lt;p&gt;
			&lt;b&gt;2006&lt;/b&gt;
			&lt;p&gt;
			Barcellos L, Komorowski L, Graham R, Artim G, Seldin M, Harley J, Behrens T, Criswell L.  Parent of origin effects and HLA&#45;DRB1 risk in systemic lupus erythematosus.  Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. 
			&lt;p&gt;
			Begovich A, Chang M, Criswell L, Pfeiffer K, Bare L, Arellano A, Ho A, Lee W, Behlendorf D, Sun Y, Rowland C, Short M, Zoccoli M.  Development of a research genotyping assay for 5 SNPs associated with deep vein thrombosis and application to a study of antiphospholipid syndrome in patients with systemic lupus erythematosus.  Presented at the ACMG Annual Clinical Genetics Meeting, San Diego, CA, March 2006.
			&lt;p&gt;
			Chung S, Edwards T, Parsa A, Lum R, Taylor K, Seldin M, Ritchie M, Criswell L.  Novel associations between angiotensinogen and ACE polymorphisms and SLE risk: results of a family based analysis. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006.
			&lt;p&gt;
			Gillis J, Yazdany J, Panopalis P, Katz P, Yelin E.  Differential access to SLE care by Medicaid status. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S100, #106.
			&lt;p&gt;
			Hersh A, von Scheven E, Yelin E. Comparison of outcomes between patients with childhood and adult&#45;onset disease in a large observational cohort with systemic lupus erythematosus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006.
			&lt;p&gt;
			Julian L, Katz P, Trupin L, Criswell L, Yelin E.  Relationships among neuropsychological performance, patient reported cognitive symptoms, and depressive symptoms in systemic lupus erythematosus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S769, #1952.
			&lt;p&gt;
			Julian L, Katz P, Trupin L, Panopalis P, Gillis J, Yazdany J, Yelin E.  Cognitive functioning in systemic lupus erythematosus: impact of disease severity, manifestations, and medication effects. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S274, #578.
			&lt;p&gt;
			Julian L, Katz P, Trupin L, Yelin E.  Health related quality of life in the UCSF Lupus Outcomes Study: Impact of patient and disease characteristics. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S769, #1955.
			&lt;p&gt;
			Katz P, Morris A.  Body composition and disability in valued life activities in RA and lupus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S816, #2078.
			&lt;p&gt;
			Katz P, Morris A.  Prevalence of pre&#45;clinical disability among individuals with RA. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S507, #1211.
			&lt;p&gt;
			Katz P, Morris A.  Social impact of disease, disability, and depressive symptoms in RA. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S795, #2024.
			&lt;p&gt;
			Morris A, Wong B, Yelin E, Katz P.  Patterns of psychosocial risk and long term outcomes in rheumatoid arthritis. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S506, #1209.
			&lt;p&gt;
			Murphy L, Yelin E, Cisternas M, Foreman A, Pasta D, Helmick C.  Medical expenditures and earnings losses among persons with arthritis and other rheumatic conditions (AORC), United States, 2003. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S786, #2002.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Morris A, Katz P, Yelin E.  Cognitive function and health resource utilization in patients wih systemic lupus erythematosus. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S119, #154.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Morris A, Katz P, Yelin E.  Cognitive function in systemic lupus erythematosus: impact on employment status. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S120, #155.
			&lt;p&gt;
			Thorburn C, Pawlikowska L, Taylor K, Woo J, Carlson E, Kwok P&#45;Y, Criswell L.  Confirmation of ESR1 polymorphism association with lupus nephritis in a multi&#45;ethnic case&#45;control cohort. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006.
			&lt;p&gt;
			Trupin L, Katz P, Yelin E.  Individual and neighborhood SES in physical functioning and depression in an SLE cohort. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S105, #119.
			&lt;p&gt;
			Yazdany J, Gillis J, Panopalis P, Julian L, Katz P, Yelin E.  Racial/ethnic differences in the prevalence and treatment of major depressive disorder in a large observational cohort of persons with SLE. Presented at the annual meeting of the American College of Rheumatology, Washington DC, November 2006. Arthritis Rheum 2006; 54(supp): S274, #580.
			&lt;p&gt;
			 
			&lt;b&gt;2007&lt;/b&gt;
			&lt;p&gt;
			Katz P, Morris A, Yelin E, Trupin L.  Body mass index and disability in lupus.  Presented at the 8th International Congress on SLE; Shanghai, China; 05/23&#45;27/07.  Lupus  2007; 16(S1) &#45; abstract supplement: 199, #PO314.
			&lt;p&gt;
			Yelin E, Trupin L, Tonner C, Katz P.  Impact of personal&#45; and community&#45;level poverty on SLE activity, physical function, and depression.  Presented at the 8th International Congress on SLE; Shanghai, China; 05/23&#45;27/07.  Lupus  2007; 16(S1) &#45; abstract supplement: 200, #PO315.
			&lt;p&gt;
			Barcellos L, Clark S, Ramsay P, Quach H, Seldin M, Harley J, Moser K, Behrens T, Gaffney P, Criswell L.  High density SNP screening of the major histocompatibility complex in systemic lupus erythematosus families. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007.  Arthritis Rheum 2007; 56(supp): S753, #1972.
			&lt;p&gt;
			Chung S, Pawlikowska L, Chu C, Oksenberg J, Kwok P&#45;Y, Criswell L.  Investigating CD45 as a SLE susceptibility gene. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007.  Arthritis Rheum 2007; 56(supp): S352, #838.
			&lt;p&gt;
			Hersh A, von Scheven E, Panopalis P, Yazdany J, Gillis J, Trupin L, Julian L, Katz P, Yelin EH. Long&#45;term psychosocial and employment outcomes of children with systemic lupus erythematosus. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S138, #232.
			&lt;p&gt;
			Hersh A, von Scheven E, Yelin E. Long&#45;term psychosocial outcomes of children with systemic lupus erythematosus in a large observational cohort. Presented at annual meeting of the Pediatric Academic Society, May 2007. 
			&lt;p&gt;
			Julian L, Panopalis P, Yazdany J, Trupin L, Gillis J, Yelin E, Katz P.  Depression in SLE:  relationships with traditional and disease&#45;specific cardiovascular risk. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S513, #1277.
			&lt;p&gt;
			Kaiser R, Cleveland C, Criswell L.  Ethnicity and thrombosis in a large, ethnically&#45;diverse systemic lupus erythematosus (SLE) cohort. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007.
			&lt;p&gt;
			Morris A, Yelin E, Katz P.  Long&#45;term patterns of serious depression in a longitudinal study of individuals with rheumatoid arthritis. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S513, #1278.
			&lt;p&gt;
			Morris A, Yelin E, Wong B, Katz P.  Patterns of psychosocial risk and long&#45;term outcomes in rheumatoid arthritis.  Presented at the 5th Annual Health care Quality and Outcomes Conference, Oakland, CA  May 2007.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Hersh A, Trupin L, Katz P, Yelin E.  Direct healthcare costs of systemic lupus erythematosus and predictors of costs.  Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S81, #78.
			&lt;p&gt;
			Panopalis P, Yazdany J, Gillis J, Julian L, Hersh A, Trupin L, Katz P, Yelin E.  Predictors of frequent emergency department use among persons with systemic lupus erythematosus. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S594, #1503.
			&lt;p&gt;
			Trupin L, Tonner C, Yazdany J, Julian L, Criswell L, Katz P, Yelin E.  Socioeconomic status in outcomes of systemic lupus erythematosus. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S506, #1256.
			&lt;p&gt;
			Yazdany J, Panopalis P, Gillis J, Trupin L, Julian L, Hersh A, Katz P, Yelin E.  Provision of preventive health services in SLE.  Oral presentation. Presented at annual meeting of the American College of Rheumatology, Boston, MA, November 2007. Arthritis Rheum 2007; 56(supp): S806, #2118.
			&lt;p&gt;
			&lt;b&gt;2008&lt;/b&gt;
			&lt;p&gt;
			Criswell LA, Taylor KE, Tian C, Chung SA, Lee AT, Ortmann WA, Nititham JS, Petri MA, Manzi S, Gregersen PK, Behrens TW, Seldin MF.  Specific European ancestry contributes to subphenotypes of SLE [AB0147].  Presented at the European League Against Rheumatism (EULAR) meeting, Paris, France, June 2008; Ann Rheum Dis 2008;67(Suppl II): 597.
			&lt;p&gt;
			Richman IB, Barton J, Trupin L, Criswell LA.  The role of socioeconomic status and ethnicity in systemic lupus erythematosus outcomes.  Presented at the Health Disparities Symposium, University of California, San Francisco, San Francisco, CA, October 2008.
			&lt;p&gt;
			Chung SA, Taylor KE, Graham RR, Hom G, Ortmann WA, Lee AT, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA.  Genome&#45;wide association study of anti&#45;dsDNA autoantibody production in SLE.  Presented at the American College of Rheumatology meeting, San Francisco, CA, USA, October 2008.
			&lt;p&gt;
			Taylor KE, Graham RR, Hom G, Chung SA, Ortmann W, Lee AT, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA.  Cumulative effects of risk alleles on systemic lupus erythematosus susceptibility and subphenotypes.  Presented at the American Society of Human Genetics meeting, Philadelphia, PA, USA, November 2008.
			&lt;p&gt;
			Katz PP.  Body composition and disability in lupus.  Presented at annual scientific meeting of the American College of Rheumatology, San Francisco, CA, October 2008.
			&lt;p&gt;
			Julian, L.J., Katz, P.P., Lande, C., Trupin, L., Criswell, L.A., Yelin, E.H., Wofsy, D., Henry, R., (2008) Diffusion Tensor Imaging and Cognitive Functioning in Systemic Lupus Erythematosus.  Poster presented at the American College of Rheumatology, San Francisco, CA.
			&lt;p&gt;
			 
			Julian, L.J., Yelin, E., Yazdany, J., Panopalis, P., Trupin, L., Criswell, L., Katz, P. (2008)Depression, Medication Adherence, and Service Utilization in Systemic Lupus Erythematosus. Paper presented at the Association for Rheumatology Health Professionals.
			&lt;p&gt;
			Margaretten, M., Yelin, E., Imboden, J., Graf, J., Julian, L., (2008) Predictors of Depression in a Multi&#45;ethnic Cohort of Patients with Rheumatoid Arthritis.  Poster presented at the American College of Rheumatology, San Francisco, CA.
			
			&lt;p&gt;
			END;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 1 ./rheumatology/old/research/mcrc/project1.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project1.html</Path>
		<FileBody>
			
			&lt;center&gt;
			  &lt;p&gt;&lt;strong&gt;Project # 1&lt;br /&gt;
			    The Interplay of Sociodemographic and Genetic Factors in SLE Health Disparities&lt;br /&gt;
			  Lindsey Criswell, M.D., M.P.H., P.I.&lt;/strong&gt;&lt;br /&gt;&lt;/p&gt;&lt;/center&gt;
			    &lt;p&gt;&lt;strong&gt;A. Specific Aims&lt;/strong&gt;&lt;br /&gt;
			    The study aims have not changed. They are to: 1) Determine the relative contributions of demographic, socioeconomic, psychosocial, behavioral and genetic factors to health outcomes in systemic lupus erythematosus (SLE); and 2) Characterize changes in health outcomes over time and the contribution of these explanatory factors to temporal changes in outcome. A primary focus of this project is the relationship of ethnicity to SLE outcomes, and in particular understanding the roles of genetics and other factors (e.g. socioeconomic, psychosocial, etc.) as mediators of ethnic disparities in outcome. Our primary study population consists of approximately 1,000 SLE patients enrolled in the Lupus Outcome Study.  We use validated instruments to assess the following outcomes: general health status, disease activity and cumulative damage.  A unique feature of the current proposal is the depth and breadth of potentially important explanatory factors that are being considered. In addition to traditional risk factors, these include novel measures of ancestry (i.e., ancestry informative genetic markers). Due to the size and scope of this project, in conjunction with the rich resources and expertise of the MCRC, this project should substantially increase our understanding of health disparities in SLE and their underlying causes and guide efforts to remedy these disparities.&lt;br /&gt;
			    &lt;/p&gt;
			    &lt;p&gt;&lt;strong&gt;B. Studies and Results&lt;/strong&gt;&lt;br /&gt;
			    Progress relevant to this project has focused on the following areas:  1) collection of blood from current and new LOS enrollees; 2) collection of additional medical records to validate self&#45;reported outcome events obtained as part of the LOS annual interviews, particularly thromboses and other complications of the antiphospholipid syndrome (APS); 3) development of procedures for assigning SLICC/Damage Index (SDI) scores as a measure of damage; and 4) statistical analyses incorporating ancestry informative marker (AIM) data, other risk factors, and candidate gene data to identify important predictors of SLE outcomes.  Some of this progress is discussed as part of the Core Unit, and below we highlight our progress analyzing predictors of SLE outcomes, including our AIM and candidate gene data.&lt;/p&gt;
			    &lt;/p&gt;
			  &lt;p&gt;Progress on this project during the past year has benefitted enormously from the work of several trainees and mentees of Dr. Criswell&amp;rsquo;s, and their roles and contributions are highlighted here. Dr. Ilana Richman received a Pathways to Careers in Clinical and Translational Research (PACCTR) fellowship (part of the UCSF Clinical and Translational Science Institute) while she was a UCSF medical student. This fellowship allowed her to spend a year with Dr. Criswell, during which time she completed the Advanced Training in Clinical Research certificate program and initiated an ambitious research project directly relevant to MCRC project 1. Her initial work included a detailed analysis of the LOS data (n = 1,087 SLE patients) in which she examined ethnic differences in a range of SLE outcomes, as well as predictors of the observed outcome differences. Details of these results were presented previously and so are not repeated here.  Next, Ms. Richman extended this work to focus on the most ethnically diverse subgroup, Hispanics, and to further assess the contribution of ancestry and select candidate gene polymorphisms to several important SLE outcomes, including renal disease, age at diagnosis and SLE activity (measured by the SLAQ). In brief, 247 Hispanic SLE patients were evaluated and analysis of AIM data indicated that overall this group was comprised of 48% European ancestry, 39% Amerindian ancestry, 8% Asian ancestry and 5% African ancestry. In multivariate analysis, European ancestry was strongly associated with a decreased risk of renal disease (odds ratio, OR, 0.35, p = 0.004 per 25% increase in European ancestry) and with an increased age at SLE diagnosis ( = 4.8, p = 0.007 per 25% increase in European ancestry). In contrast, European (or other) ancestry was not significantly associated with disease activity as measured by the SLAQ. Covariates included sex, education level, insurance status/type, language, and disease duration (the latter not included for age at SLE diagnosis). The only significant predictor of the SLAQ was insurance type (private&#45;public) ( = &#45;4, p = 0.026). Given prior evidence that several gene polymorphisms may be associated with the risk of renal disease in SLE, we extended our analyses to include polymorphisms of STAT4, TNFAIP3 and ITGAM. Of interest, the rs1143679 variant of ITGAM was significantly associated with the risk of renal disease among our Hispanic population (OR = 2.1, p = 0.004), but the effect of ancestry remained significant in these extended models. This work was presented at the 2000 American College of Rheumatology (ACR) meeting (1). During the past year Ms. Richman spent an additional 3 months on a research elective in order to extend her work on this project. More specifically, in an expanded analysis including all major ethnic groups in our lupus cohort (1,910 SLE patients), Ms. Richman demonstrated that European ancestry has a strong protective effect on the development of renal disease. In multivariable logistic regression, a 10% increase in European ancestry was associated with a 15% reduction in the odds of having renal disease (OR 0.85, 95% CI 0.82&#45;0.87, p=1.9e&#45;30). Adjusting for other genetic ancestries, education, other SES indicators, or genes associated with renal disease did not substantively alter this relationship. This work was presented at the 2010 ACR and ASHG (American Society of Human Genetics) meetings (2) and a manuscript is currently in preparation. As a result of Ms. Richman&amp;rsquo;s work on this project she received the ACR Resident Award at the 2010 annual meeting.&lt;/p&gt;
			  &lt;p&gt;Dr. Sharon Chung, a junior faculty member and mentee of Dr. Criswell&amp;rsquo;s, along with Ms. Richman, have also made important progress in another area relevant to the overall goals of this project. They have utilized state of the art methods to characterize Caucasian patients for substructure within the European population to determine whether such substructure has an important influence on SLE disease manifestations and outcome.  Dr. Michael Seldin, Co&#45;Investigator for this project, is an international leader in the development of AIMs and methods that can be used to characterize such intra&#45;continental genetic variation. This work was inspired in part by the discovery of a gene, PTPN22 (3, 4), which has a strong impact on risk of SLE and also exhibits striking variation in frequency across Europe (high frequency in Northern Europe and low frequency in Southern Europe). Using a large set of SLE cases who were characterized for a set of AIMs that distinguished Northern from Southern European ancestry, Dr. Chung demonstrated that individuals with greater Northern European ancestry were more likely to have photosensitivity and discoid rash, whereas individuals with relatively less Northern European ancestry (i.e., greater Southern European ancestry) were more likely to have immunologic manifestations, such as dsDNA or anticardiolipin antibodies (5). Ms. Richman subsequently extended this work among a larger group of SLE patients (including 1,000 SLE patients from the UCSF collection) and a much larger set of genetic markers (n ~ 4,000). She utilized principal components analysis to characterize the ancestry of each individual (n ~ 1,600 total) for a series of principal components that correspond to geographic and genetic clusters within Europe. This novel work confirmed the initial ancestry associations reported by Dr. Chung and extended our understanding of associations of European ancestry with SLE outcomes. Ms. Richman presented these findings at the EULAR meeting in Copenhagen (June, 2009) and they published in Genes and Immunity (6). &lt;/p&gt;
			  &lt;p&gt;Other work relevant to the goals of this project include the identification of novel genetic risk factors that are associated specifically with certain SLE subphenotypes or outcomes. Dr. Chung has completed a genome wide association study of SLE in which she compared whole genome findings for two distinct serologic subgroups: anti&#45;dsDNA positive and anti&#45;dsDNA negative SLE. Overall this work indicates that many of the recently identified risk factors for SLE, such as STAT4, IRF5, and ITGAM SLE are, in fact, more accurately described as autoantibody propensity loci, since their associations with anti&#45;dsDNA positive SLE are far stronger than with anti&#45;dsDNA negative SLE.  A manuscript describing these findings was recently accepted for publication in PLoS Genetics (7). &lt;/p&gt;
			&lt;p&gt;Dr. Rachel Kaiser, a junior faculty member and mentee of Dr. Criswell&amp;rsquo;s, has been focusing on associations of ethnicity, genetics and other risk factors with another important outcome in SLE &#45; thrombosis. She published the largest and most comprehensive study to date of risk and protective factors for thrombosis in SLE (8) as well as a meta&#45;analysis of the Factor V Leiden mutation as a risk factor for thrombosis in SLE, which included newly generated data on &amp;gt; 1,000 SLE patients in our collection (9). Dr. Kaiser has also examined a large number of additional genetic polymorphisms that may influence thrombosis risk in SLE. She presented her findings at the 2009 ACR meeting in Philadelphia (10, 11) and a manuscript is in preparation. More recently Dr. Kaiser has examined the contribution of the HLA region to risk of thrombosis and antiphospholipid antibody production in SLE. This work was presented at the international Congress on Antiphospholipid Antibodies (12) and the 2010 ACR meeting (13) and a manuscript is in preparation. Dr. Kaiser is currently reviewing medical records obtained for LOS participants who have reported thromboses or other APS&#45;related events during one or more of their annual LOS interviews.  This will allow Dr. Kaiser to apply longitudinal methods of data analysis, substantially increasing her power to identify genetic and other risk factors for thrombosis in SLE. Finally, Drs. Kaiser and Criswell also published a review of genetics studies in SLE that is designed for the non&#45;genetics audience in order to help make the rapid developments in this field more accessible to the wider rheumatology scientific community (14).&lt;/p&gt;
			  &lt;p&gt;Lastly, Dr. Guada Respicio, a recent graduate of the UCSF rheumatology fellowship program worked with Dr. Criswell last year on a project examining ethnic differences in risk of arthritis among SLE patients, as well as other predictors for this important outcome. This work was presented at the 2010 ACR meeting (15). Drs. Respicio, Kaiser, Chung and Richman have all benefitted enormously from the rich resources and expertise of the extended MCRC investigative team at UCSF.&lt;/p&gt;
			  &lt;p&gt;&lt;br /&gt;
			    &lt;strong&gt;C. Significance&lt;br /&gt;
			    &lt;/strong&gt;SLE has the potential to cause serious morbidity and early mortality and is responsible for tremendous costs to affected individuals and society.  A striking feature of SLE is variation in health outcomes.  In particular, substantial research documents ethnic disparities in SLE risk and severity.  In spite of the magnitude of variation in SLE health outcomes, and the potential importance for patients, physicians and society, many questions remain about the underlying causes.  For example, it remains unclear whether ethnic disparities in SLE outcomes reflect primarily individual, social, environmental or genetic variation in risk or interactions among these factors.  Our lack of understanding is at least partially due to the challenges of assembling a sufficiently large and diverse cohort of SLE patients, measuring the full range of potentially important risk factors, and accurately assessing health outcomes.  The current proposal represents a unique combination of clinical and investigative resources that has been developed to address this critically important issue.&lt;/p&gt;
			  &lt;p&gt;&lt;br /&gt;
			    &lt;strong&gt;D. Plans&lt;/strong&gt;&lt;br /&gt;
			    During the coming year we will continue our efforts to document prospectively reported SLE outcomes in order to further support our longitudinal data analyses.  We will also be devoting substantial effort to completing the manuscripts described above that are currently in preparation.  Progress in the development of a SLICC/Damage Index will also be ongoing (as part of the MCRC Core) and will support our longitudinal data analyses. &lt;/p&gt;
			&lt;p&gt;&lt;br /&gt;
			  &lt;strong&gt;E. Publications&lt;/strong&gt;&lt;/p&gt;
			  &lt;p&gt;1.	Richman IB, Barton J, Trupin L, Petri MA, Yelin EH, Seldin MF, Criswell LA.  Genetic ancestry, socioeconomic status, and disease characteristics among Hispanics with systemic lupus erythematosus.  Presented at the American College of Rheumatology meeting, Philadelphia, PA, October 2009.&lt;/p&gt;
			  &lt;p&gt;2.	Richman IB, Taylor KE, Chung SA, Trupin L, Petri M, Yelin E, Graham RR, Lee A, Behrens TW, Gregersen PK, Seldin MF, Criswell LA.  European genetic ancestry protects against the development of renal disease in systemic lupus erythematosus.  Presented at the American College of Rheumatology (Atlanta, GA) and American Society of Human Genetics annual meetings (Washington, DC), November 2010.&lt;/p&gt;
			  &lt;p&gt;3.  Chung SA, Criswell LA.  PTPN22: its role in SLE and autoimmunity.  Autoimmunity, 2007: 40 (8): 582&#45;90.  PMID: 18075792&lt;/p&gt;
			  &lt;p&gt;4.	Criswell LA, Seldin MF.  Admixed populations and autoimmunity.  Arthritis and Rheumatism, 2008; 58(2):335&#45;337.  PMID: 18240252&lt;/p&gt;
			  &lt;p&gt;5.	Chung SA, Tian C, Taylor KE, Lee AT, Ortmann WA, Hom G, Graham R, Nititham J, Kelly JA, Morrisey J, Wu H, Yin H, Alarc&amp;oacute;n&#45;Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, Manzi S, Petri M, Gregersen PK, Langefeld CD, Behrens TW, Seldin MF, Criswell LA.  Substructure in European&#45;derived populations is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus.  Arthritis and Rheumatism, 2009; 60 (8): 2448&#45;56.  PMID: 19644962&lt;/p&gt;
			  &lt;p&gt;6.	Richman IB, Chung SA, Taylor KE, Kosoy R, Tian C, Ortmann WA, Nititham J, Lee AT, Rutman S, Petri M, Manzi S, Behrens TW, Gregersen PK, Seldin MF, Criswell LA.  European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent.  Genes and Immunity, 2010; 11(6): 515&#45;21.  PMID: 19847193&lt;/p&gt;
			  &lt;p&gt;7.	Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, Jacob CO, Alarc&amp;oacute;n&#45;Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, SLEGEN, Petri M, Demerci Y, Kamboh MI, Manzi S, Gregersen PK, Langefeld CD, Behrens TW, Criswell LA.  Anti&#45;dsDNA autoantibody production identifies genetic subsets of systemic lupus erythematosus.  PLoS Genetics, 2010: accepted for publication.&lt;/p&gt;
			  &lt;p&gt;8.	Kaiser R, Cleveland CM, Criswell LA.  Risk and protective factors for thrombosis in systemic lupus erythematosus:  results from a large, multi&#45;ethnic cohort.  Annals of the Rheumatic Diseases, 2009; 68 (2): 238 &#45; 41. [Epub 2008 Sep 9]  PMID: 18782792&lt;/p&gt;
			  &lt;p&gt;9.	Kaiser R, Barton JL, Chang MN, Catanese JJ,  Li YN,  Begovich A,  Criswell LA.  Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta&#45;analysis.  Genes and Immunity, 2009; 10 (5): 495&#45;502. [Epub 2009 May 7]  PMID: 19421222&lt;/p&gt;
			  &lt;p&gt;10.	Kaiser R, Li Y, Chang M, Catanese JJ, Begovich AB, Criswell LA.  Genetic risk factors for thrombosis in an ethnically diverse systemic lupus erythematosus (SLE) population.  Presented at the American College of Rheumatology meeting, Philadelphia, PA, October 2009.&lt;/p&gt;
			  &lt;p&gt;11. Kaiser R, Li Y, Chang M, Catanese JJ, Edberg JC, Alarcon GS, Begovich AB, Criswell LA.  Novel SNPs associated with systemic lupus erythematosus (SLE).  Presented at the American College of Rheumatology meeting, Philadelphia, PA, October 2009.&lt;/p&gt;
			  &lt;p&gt;12.	Kaiser R, Chung SA, Taylor KE,  Noble JA, Seldin MF, Criswell LA.  HLA&#45;DRB1*0701 is associated with thrombosis but not antiphospholipid antibody (aPL) production in systemic lupus erythematosus (SLE).  Presented at the International Congress on Antiphospholipid Antibodies, April 2010, Galveston, Texas. &lt;/p&gt;
			  &lt;p&gt;13.	Kaiser R, Chung SA, Taylor K, May SL, Ramsay PP, Quach HL, Quach DL, Lane JA, Noble JA, Seldin MF,, Barcellos L, Criswell LA.  Major histocompatibility complex associations with thrombosis and antiphospholipid antibody production in systemic lupus erythematosus.  Presented at the American College of Rheumatology annual meeting, November 2010, Atlanta, GA.&lt;/p&gt;
			  &lt;p&gt;14.	Kaiser R, Criswell LA.  Genetics research in systemic lupus erythematosus for clinicians: methodology, progress and controversies.  Current Opinion in Rheumatology, 2010; 22(2): 119&#45;25.&lt;/p&gt;
			  &lt;p&gt;15.	Respicio G, Cleveland C, Taylor KE, Criswell LA.  Arthritis in an ethnically diverse systemic lupus erythematosus population.  Presented at the American College of Rheumatology annual meeting, November 2010, Atlanta, GA.&lt;/p&gt;
			  &lt;p&gt;&lt;strong&gt;F. Project&#45;Generated Resources&lt;/strong&gt;&lt;br /&gt;
			Not applicable&lt;/p&gt;
			  &lt;p&gt;&lt;strong&gt;Gender and Minority Inclusion&lt;/strong&gt;&lt;/p&gt;
			  &lt;p&gt;See attached table.&lt;/p&gt;
			&lt;/center&gt;&lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 1 ./rheumatology/old/research/mcrc/project1.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project1.html~</Path>
		<FileBody>
			
			&lt;centeR&gt;
			&lt;b&gt;
			Project 1: The Interplay of Sociodemographic and Genetic Factors
			in SLE Health Disparities&lt;br&gt;
			(PI: Lindsey Criswell, MD, MPH)
			&lt;/b&gt;
			&lt;/center&gt;
			&lt;p&gt;
			&lt;img src=&quot;/rheum/images/mcrc/project1&#45;1.jpg&quot; style=&quot;padding&#45;left: 8px&quot; align=right&gt;
			Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease that has the potential to cause serious morbidity and early mortality and is responsible for tremendous costs to affected individuals and society.  A striking feature of SLE is variation in health outcomes.  In particular, substantial research documents ethnic disparities in SLE risk and severity.  In spite of the magnitude of variation in SLE health outcomes, and the potential importance for patients, physicians and society, many questions remain about the underlying causes.  For example, it remains unclear whether ethnic disparities in SLE outcomes reflect primarily individual, social, environmental or genetic variation in risk or interactions among these factors.  Our lack of understanding is at least partially due to the challenges of assembling a sufficiently large and diverse cohort of SLE patients, measuring the full range of potentially important risk factors, and accurately assessing health outcomes.  The current proposal represents a unique combination of clinical and investigative resources that has been developed to address this critically important issue.  Specifically, we will: 1) determine the relative contributions of demographic, socioeconomic, psychosocial, behavioral and genetic factors to health outcomes in SLE; and 2) characterize changes in health outcomes over time and the contribution of these explanatory factors to temporal changes in outcome.  A primary focus of this project will be the relationship of ethnicity to SLE outcomes, and in particular understanding the roles of genetics and other factors (e.g. socioeconomic, psychosocial, etc.) as mediators of ethnic disparities in outcome.  Our study population will be approximately 1,000 SLE patients enrolled in the Lupus Outcome Study.  We will use validated instruments to assess the following outcomes: general health status, disease activity and cumulative damage.  A unique feature of the current proposal is the depth and breath of potentially important explanatory factors that will be considered.  In addition to traditional risk factors, these include novel measures of community informative genetic markers.  Due to the size and scope of this project, in conjunction with the rich resources and expertise of the MCRC, this project should substantially increase our understanding of health disparities in SLE and their underlying causes and guide efforts to remedy these disparities.
			
			&lt;p&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;
			&lt;br&gt;
			Progress for this project has focused on four areas: 1) recruitment of additional non&#45;Caucasian SLE patients for enrollment into the LOS; 2) collection of blood from current and new LOS enrollees; 3) further development of the panel of ancestry informative markers (AIMS), in particular to allow for identification of European substructure (e.g., Northern vs. Southern Europe); 4) performance of genotyping for AIM data on specific subsets of SLE patients, and 5) development of procedures for assigning SLICC/Damage Index (SDI) scores as a measure of damage. Some of this progress is discussed as part of the Core Unit, and below we highlight our progress analyzing predictors of SLE outcomes, including our initial set of AIM data.
			&lt;P&gt;
			Progress on this project during the past year has benefitted enormously from the work of several trainees and mentees of Dr. Criswell's, and their roles and contributions are highlighted here. Ilana Richman, a UCSF medical student who has received a PACCTR fellowship that allows her to spend 12 months obtaining clinical research training and experience, has completed a detailed analysis of the LOS data (n = 1,087 SLE patients) in which she examined ethnic differences in a range of SLE outcomes, as well as predictors of the observed outcome differences. Ms. Richman presented these results at the UCSF Symposium on Health Disparities (Oct., 2008). In brief, highly significant (p . 0.0001) ethnic differences in SLE outcome were observed for age at SLE diagnosis, disease activity (SLAQ score), presence of renal disease, physical functioning (SF&#45;12 PCS score) and depression (CES&#45;D score). African American SLE patients had the highest disease activity, Asian patients had earlier onset disease and a higher prevalence of renal disease, and Hispanic patients had the highest prevalence of depression. There were also highly significant (p &lt; 0.0001) ethnic differences in several socioeconomic factors, including education level, poverty status and presence of public forms of insurance. Hispanic patients had the lowest education levels and African American patients were more likely to be poor and to have public forms of insurance. Multivariate analyses indicated that ethnic background remains a significant predictor of renal disease, age at SLE diagnosis and depressive symptoms even after controlling for age, sex, disease duration, income, education level, insurance status, and access to  rheumatologic care. The next steps for these analyses will be to incorporate the AIM data in order to more carefully account for ancestrally determined genetic variation as a predictor of SLE outcome. Preliminary work by Ms. Richman among a subset of African American SLE patients carefully characterized for ancestry using a large set of AIMs suggests that African ancestry may be associated with the development of renal disease and thrombosis. 
			&lt;P&gt;
			Dr. Sharon Chung, a junior faculty member and mentee of Dr. Criswell's, along with Ms. Richman, have also made  important progress in another area relevant to the overall goals of this project. More specifically, they are utilizing state of the art methods to characterize Caucasian patients for substructure within the European population to determine whether such substructure has an important influence on SLE disease manifestations and outcome. Dr. Michael Seldin, Co&#45;Investigator for this project, is an international leader in the development of AIMs and methods that can be used to characterize such intra&#45;continental genetic variation. This work is inspired in part by the discovery of a gene, PTPN22 (see publications 1 and 5 below), which has a strong 
			impact on risk of SLE and also exhibits striking variation in frequency across Europe (high frequency in Northern Europe and low frequency in Southern Europe). Dr. Chung recently completed an analysis in which a large group of SLE patients (members of the LOS as well as other case series) were characterized for a set of genetic markers that were utilized to identify population outliers (substantial non&#45;European ancestry) and also to characterize each individual according to the percent Northern (vs. Southern) European ancestry. She then examined whether the % Northern European ancestry was a significant predictor of specific disease manifestations. Of interest, she showed that individuals with greater Northern European ancestry were more
			likely to have photosensitivity and discoid rash, whereas individuals with relatively less Northern European ancestry (i.e., greater Southern European ancestry) were more likely to have immunologic manifestations, such as dsDNA or anticardiolipin antibodies. A manuscript describing these novel findings is under review at Arthritis and Rheumatism (9). Ms. Richman is now extending this work among a larger group of SLE patients (including 1,000 SLE patients from the UCSF collection) and a much larger set of genetic markers (n ~ 4,000). She will be utilizing principal components analysis to characterize the ancestry of each individual (n ~ 1,600
			total) for a series of principal components that correspond to geographic and genetic clusters within Europe.
			&lt;P&gt;
			Other recent work relevant to the goals of this project include the identification of several novel genes that influence the risk and/or outcome of SLE (2&#45;4, 6). Of particular interest is our recent discovery that the STAT4 gene influences not only the risk of SLE and rheumatoid arthritis, but has an important impact on the severity of SLE. In particular, the STAT4 gene is specifically associated with disease characterized by severe SLE manifestations, such as renal disease (lupus nephritis) and dsDNA antibody production (4).
			&lt;P&gt;
			Lastly, Rachel Kaiser, a junior faculty member and mentee of Dr. Criswell's, has recently completed work relevant to the goals of this project. She performed the largest and most comprehensive study to date of risk and protective factors for thrombosis in SLE (7). She has also recently completed a meta&#45;analysis of the Factor V Leiden mutation as a risk factor for thrombosis in SLE, which included newly generated data on 1,000 SLE patients in our collection (10). Dr. Kaiser's work and expertise in this area will greatly enhance our ability to examine this very important SLE outcome as part of our future work on this project.
			
			&lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 2 ./rheumatology/old/research/mcrc/project2.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project2.html</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			Project 2:  Body Composition and Disability in RA and SLE&lt;br&gt;
			(PI:  Patricia Katz, PhD)
			&lt;/b&gt;
			&lt;/center&gt;
			&lt;p&gt;
			
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/project2&#45;1.jpg&quot; align=&quot;right&quot; style=&quot;padding&#45;right: 8px&quot;&gt;
			
			&lt;center&gt;&lt;/center&gt;
			&lt;strong&gt;A. Specific Aims&lt;br /&gt;
			&lt;/strong&gt;Aims of the project have not changed.  
			  The major goals of the project are to:
			&lt;ol&gt;
			  &lt;li&gt;examine the role of body composition in development of functional limitations and disability in SLE and RA, using an existing model of disablement.
			  &lt;li&gt;identify factors that influence the relationships among body composition, functional limitations, and disability in RA and SLE.
			  &lt;li&gt;estimate the prevalence and incidence of disability in a wide range of life activities in a large group of individuals with SLE.
			&lt;/ol&gt; 
			&lt;strong&gt;  B. Studies and Results&lt;/strong&gt;
			  Data collection and management for this project are being handled by the Methodology Core Unit.  Project data are collected both in the telephone interviews and through in&#45;person visits to the UCSF CTSI Clinical Research Center (CRC).  We began to collect data in the CRC in April 2007.  Data being collected include assessments of body composition by DEXA, disability by self&#45;report questionnaires, functional limitations by muscle strength testing and performance tests, cognitive function by an extensive battery, and psychological status by a psychiatric screening interview.  In addition, blood is collected to assess systemic inflammation as well as disease&#45;specific markers.&lt;p&gt;
			  
			  We have recruited a sample of individuals from both the RA Panel and the Lupus Outcomes Study who live in the greater Bay Area to participate in the CRC visit.  Because recruitment from the RA Panel was less successful than we had hoped, we expanded our recruitment efforts to other RA cohorts at UCSF.  We completed baseline assessments of 167 individuals from the Lupus Outcomes Study, 100 individuals from the RA Panel, and 43 individuals with RA recruited from other sources, for a total of 310 total baseline visits.  We were not able to complete the number of visits we had proposed (200 from each cohort), but our analyses of the existing data suggest that we will have adequate power to examine relationships between body composition and disability.  The primary reasons for declines to participate were related to difficulty traveling to the university (36%) and scheduling difficulties (i.e., &quot;too busy: or unable to leave work, 30%).  We are in the process of final data cleaning and scoring for the baseline CRC visits.&lt;p&gt;
			  
			  We are currently conducting 2&#45;year follow&#45;up clinic visits.  As of December 1, 2010, we have completed 69 follow&#45;ups for the lupus cohort, with an additional 6 visits scheduled, and 57 follow&#45;ups for the RA cohort, with an additional 8 visits scheduled.  Only 1 individual thus far has declined follow&#45;up from the lupus cohort; for the RA cohort, 2 subjects have declined the visit, 1 was too ill to travel, and 3 have died.  Three individuals from the lupus cohort were deteremined to be ineligible for follow&#45;up, 2 because we could obtain DEXA assessments on them at baseline, and 1 because of language difficulties.&lt;p&gt;
			  
			  We have published one manuscript from the study:  &amp;quot;Obesity and its measurement in a community&#45;based sample of women with systemic lupus erythematosus&amp;quot;, Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, Criswell, LA. Arthritis Care &amp; Research 2010 [Epub ahead of print, Sep 7], PMID: 20824801, NIHMS in process.  In this study, we found that the prevalence of obesity in our female lupus subjects varied, depending on the measure used:  28% were classified as obese using a waist circumference definition (&gt;=88 cm), 29% using body mass index (BMI &gt;= 30 kg/m2), 41% by waist&#45;hip ratio (&gt;=0.85), and 50% using a criterion based on % body fat from DEXA.  Correspondence between the anthropometric and DEXA&#45;based measures was moderate.  We identified cut&#45;points for the anthropometric measures to better approximate DEXA estimates of % body fat:  BMI &gt;=26.8 kg/m2, waist circumference &gt;=84.75 cm, and waist&#45;hip ratio &gt;=0.80.  Comparing the ability of the new cut&#45;points to identify cardiovascular risk to that of the traditional cut&#45;points, we found that Framingham cardiovascular risk scores were significantly higher in women classified as obese by either traditional or revised criteria, suggesting that the traditional cut&#45;points exclude a significant number of at&#45;risk women.&lt;p&gt;
			  
			  Two abstracts have also been presented from the study during the past year.  The first, &amp;quot;Body composition, lower extremity strength, and fatigue in SLE,&amp;quot; was presented at the 2010 annual meeting of the American College of Rheumatology; the second, &amp;quot;Body composition, lower extremity strength, and disability in SLE,&amp;quot; was presented at the 2010 Aging Muscle Symposium.  Body composition has not previously been examined in relation to disability or fatigue in SLE.  In the first presentation, we reported that neither fat mass index (FMI; total fat mass,kg/height, m2) nor lean mass index (LMI; total lean mass, kg/height, m2) was significantly associated with fatigue severity.  However, when appendicular and trunk FMI were examined separately, greater trunk FMI was significantly associated with greater fatigue (?=0.25, p=0.01).  Muscle weakness was also significantly and independently associated with greater fatigue (extension: ?=&#45;0.04, p=0.03; flexion: ?=&#45;0.06, p=0.005).  In the second abstract, we found that greater FMI was associated with greater disability (?=1.6, p=0.05, R2=0.28), while LMI was not (p=0.6).  Lower extremity weakness was also associated with disability (extension: ? =&#45;0.47, p=0.05, R2=0.28; flexion: ? =&#45;0.89, p=0.04, R2=0.31).  In the combined models, both high FMI and low strength were independently associated with disability (extension: R2=0.31; flexion: R2=0.33), while LMI was not.&lt;p&gt;
			&lt;strong&gt;  C. Significance  &lt;/strong&gt;&lt;br /&gt;
			  The role of body composition in the development of disability in RA and SLE has not been well studied.  Inflammatory cytokines that are commonly elevated in RA and SLE appear to play a role in both body composition and disability in the general population; however, these interactions have not been systematically examined in RA and SLE.  Physical activity also appears to play a critical role in body composition, production of inflammatory cytokines, and maintenance of function.  In terms of clinical impact, the proposed study will:
			  &lt;ul&gt;
			  &lt;li&gt;collect information that will help identify individuals with RA and SLE who are at high risk of functional limitations, based on body composition and its potential interaction with other health status or treatment factors, so that prevention efforts can be appropriately focused; 
			  &lt;li&gt;provide the first comprehensive analysis of a constellation of potentially related factors in RA and SLE &#45; body composition, inflammatory markers, and physical activity &#45; and their association with disability;
			&lt;li&gt;provide a large scale examination of cognitive functioning in RA, an area in which very little research has been done, and elucidate the role of cognitive functional limitations in the development of disability in RA and SLE; and, perhaps most importantly,
			  &lt;li&gt;identify factors that are associated with avoidance of disability even after functional limitations occur, which can be translated into interventions to help patients with RA/SLE avoid or minimize disability.&lt;/ol&gt;
			  In addition, the proposed study will accumulate a unique database combining data from interviews, body composition assessments, physical performance testing, laboratory data, and cognitive function examinations that will have usefulness beyond the scope of the proposed project.&lt;p&gt;
			  &lt;strong&gt;D. Plans&lt;/strong&gt;&lt;br /&gt;
			  During the upcoming calendar year, our goal is to continue collecting follow&#45;up data.  We plan to submit an abstract (or abstracts) for the 2011 ACR/ARHP meeting and continue preparation of manuscripts.  We are currently preparing manuscripts using the baseline data that examine (1) correspondence among measures of body composition and obesity estimates for RA, (2) associations between body composition and measures of general inflammation and cardiovascular risk, and (3) associations between body composition and disability.&lt;p&gt;
			&lt;strong&gt;  E. Publications/Presentations&lt;/strong&gt;&lt;br /&gt;
			Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, Criswell, LA. Obesity and its measurement in a community&#45;based sample of women with systemic lupus erythematosus. &lt;em&gt;Arthritis Care &amp;amp; Research&lt;/em&gt; 2010 [Epub ahead of print, Sep 7], PMID: 20824801, NIHMS in process.
			  &lt;p&gt;&lt;br /&gt;
			    Katz P, Julian L, Yazdany J, Wing H, Kaplan S, Trupin L, Yelin E.&amp;nbsp; Body composition, lower extremity strength, and fatigue among women with SLE. &lt;em&gt;&amp;nbsp;Arthritis Rheum&lt;/em&gt; 2010; S261.&lt;br /&gt;
			    &lt;p&gt;Katz P, Yazdany J, Kaplan S, Wing H, Diskin R, Trupin L, Yelin E. Body composition, lower extremity strength, and disability in SLE.&amp;nbsp; Presented at the Aging Muscle Symposium, September 30, 2010, San Francisco, CA.&lt;br /&gt;
			    &lt;p&gt;Katz P, Wing H, Kaplan S, Diskin R, Julian L, Yazdany J, Criswell L, Yelin E.&amp;nbsp; Body composition and disability among women with RA and lupus. &lt;em&gt;Arthritis Rheum&lt;/em&gt; 2009; 60:S701.&lt;br /&gt;
			    &lt;p&gt;Katz P, Morris A, Trupin L, Yazdany J, Yelin E.&amp;nbsp; Disability in valued life activities among individuals with systemic lupus erythematosus. &lt;em&gt;Arthritis Rheum (Arthritis Care Res)&lt;/em&gt; 2008; 59: 465&#45;473&lt;br /&gt;
			    &lt;p&gt;Katz P, Morris A. Body composition and disability in valued life activities in RA and lupus. &lt;em&gt;Arthritis Rheum&lt;/em&gt; 2006; 54:2078.                     
			&lt;p&gt; &lt;strong&gt;F. Project&#45;Generated Resources&lt;/strong&gt;
			  &lt;br /&gt;
			  Not applicable
			  &lt;p&gt;&lt;strong&gt;Gender and Minority Inclusion&lt;/strong&gt;
			    &lt;br /&gt;
			    See the Methodology Core Unit Progress Report.
			  &lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 2 ./rheumatology/old/research/mcrc/project2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project2.html~</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			Project 2:  Body Composition and Disability in RA and SLE&lt;br&gt;
			(PI:  Patricia Katz, PhD)
			&lt;/b&gt;
			&lt;/center&gt;
			&lt;p&gt;
			&lt;img src=&quot;/rheum/images/mcrc/project2&#45;1.jpg&quot; align=left style=&quot;padding&#45;right: 8px&quot;&gt;
			
			The overarching aim of this study is to estimate the role of body composition in the development of functional limitations and disability in both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), within the context of a well&#45;established model of disablement. Use of this model will facilitate a greater understanding of the role of body composition in the development of disability, taking into account other disease, therapeutic, demographic, psychosocial, and behavioral factors that may contribute to or protect from disability. This project also represents the first attempt to characterize disability among persons with SLE across a wide range of life activities using the &quot;valued life activities&quot; model of disability.  Specific aims are to: (1) examine the role of body composition in development of functional limitations and disability in SLE and RA, using an existing model of disablement; (2) identify risk and protective factors that interact with body composition in the development of functional limitations and disability, or the maintenance of function and avoidance of disability, in RA and SLE; and (3) estimate the prevalence and incidence of disability in a wide range of life activities in a large group of individuals with SLE. 
			&lt;p&gt;
			Subjects for the proposed study are members of the existing UCSF RA Panel and Lupus Outcomes Study (LOS). Existing study protocols include annual telephone interviews with the cohorts through 2008, with an additional two years proposed in the Methodology Core of this application.  The proposed study builds upon this by adding project&#45;specific measures to the annual telephone interviews, and adding two in&#45;person assessments at the UCSF General Clinical Research Center (GCRC) for a subset of subjects from each cohort.  At the GCRC visit, we are conducting an assessment of body composition, conducting testing of muscle strength and physical function, obtaining blood samples for measurement of inflammatory and other markers, obtaining an estimate of habitual physical activity, and performing a cognitive function evaluation. Analyses, combining interview and home visit data, focus on 3 major areas &amp;mdash; (1) describing body composition findings in the 2 cohorts, (2) estimating the relationship between body composition and functional limitations and disability in the 2 cohorts; and (3) identifying factors that may modify or mediate the relationship between body composition and either functional limitations or disability. Analyses seek to identify the correlation between self&#45;reported information from interview data (e.g., body mass index calculated from self&#45;reported height and weight) with that gathered from the GCRC assessment.  The findings from this study will provide information that can assist in identifying individuals with RA and SLE who may be at greatest risk of disability, and estimating the effect of intervening factors on the development of disability.
			
			&lt;P&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			Data collection and management for this project are being handled by the Methodology Core Unit. Data for this project are collected both in the telephone interviews and through in&#45;person visits to the UCSF CTSI Clinical Research Center (CRC). From the telephone interview of the Lupus Outcomes Study, we submitted a manuscript addressing specific aim 3, estimating the prevalence and incidence of disability in a wide range of life activities. This manuscript was published Arthritis Care &amp; Research (see section E). 
			&lt;p&gt;
			We are recruiting a sample of individuals from both the RA Panel and the Lupus Outcomes Study who live in the greater Bay Area to participate in the CRC visit. In April 2007, we began to collect data in the CRC. Data being collected include assessments of body composition by DEXA, disability by self&#45;report questionnaires, functional limitations by muscle strength testing and performance tests, cognitive function by an extensive battery, and psychological status by a psychiatric screening interview. In addition, blood is collected to assess systemic inflammation as well as disease&#45;specific markers. 
			&lt;p&gt;
			As of 1/06/09, 197 subject visits have been completed, 90 from the RA Panel and 107 from the Lupus Outcomes Study. An additional 7 and 13 visits are currently scheduled for individuals  from the RA Panel and LOS, respectively. We are still behind in the number of visits we had hoped to complete. The primary reason that subjects have given for non&#45;participation is difficulty traveling to the University. This difficulty was compounded during a large portion of 2008 because of the high gas prices. Of the 58 individuals from the LOS and 74 from the RA Panel who have declined participation, almost 50% of each group reported that transportation problems were the reason they could not participate. We will continue to try to recruit participants for the CRC visits.
			&lt;p&gt;
			We presented preliminary data from the LOS cohort as part of a symposium on body composition and rheumatic disease at the 2008 annual meeting of the American College of Rheumatology.
			&lt;p&gt;
			One of the research assistants who conducted study visits left the University in December 2008. His replacement was hired and completed training by February 2008. We reported difficulties obtaining scheduling in the CRC in the last progress report; those difficulties have been resolved.
			
			
			&lt;p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 3 ./rheumatology/old/research/mcrc/project3.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project3.html</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			
			Project 3: SLE and Employment: The Impact of Individual and &lt;br&gt;
			Contextual
			Factors&lt;br&gt;
			
			(PI:  Edward Yelin, PhD)
			&lt;/b&gt;
			&lt;/center&gt;
			
			&lt;p&gt;
			&lt;img style=&quot;padding&#45;left: 6px&quot; src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/project3&#45;1.jpg&quot; align=right width=200&gt;
			
			&lt;strong&gt;A. Specific Aims&lt;br /&gt;
			&lt;/strong&gt;The study aims have not changed.  They are to:
			&lt;ol&gt;
			  &lt;li&gt;Describe the work dynamics of persons with SLE from onset through first interview and then prospectively through as many as seven more annual interviews;&lt;/li&gt;
			  &lt;li&gt;Compare the employment status of persons with SLE to that of similar persons without the condition;&lt;/li&gt;
			  &lt;li&gt;Assess the impact of specific constellations of disease manifestations or activity in SLE and work characteristics on employment outcomes, for example the impact of having cognitive impairment with jobs demanding high levels of cognitive skill; &lt;/li&gt;
			  &lt;li&gt;Evaluate the conjoint effect on employment of individual medical, demographic, and work characteristics and such community&#45;level variables as the average socioeconomic status, racial composition, and occupational and industrial mix of the local labor market;  and,&lt;/li&gt;
			  &lt;li&gt;Estimate the impact of individual&#45;level employment accommodations in reducing the work impacts of SLE. &lt;/li&gt;
			  &lt;li&gt;The principal data source for the project is the Lupus Outcomes Study (LOS).  In the LOS, 1,204 persons with SLE are being followed through annual structured telephone interviews conducted by trained survey workers, augmented by data on the SLE from a comprehensive review of medical charts and analysis of biological material from buccal DNA and/or blood samples.&lt;br /&gt;
			  &lt;/li&gt;
			&lt;/ol&gt;
			&lt;p&gt;&lt;strong&gt;B. Studies and Results&lt;br /&gt;
			  &lt;/strong&gt;Five papers from the project have been published.  The first, published in Arthritis Care &amp;amp; Research, provides a summary of the work history of persons with SLE from onset through the second interview as well as the factors affecting work loss in this population (see Yelin, et al., 2007, in publication list, below). The paper shows that the bulk of the reduced productivity of persons with SLE is due to total cessation of employment rather than reduced hours.  The paper also indicates that, among persons with SLE employed at disease onset, about 65 percent will have stopped working prior to age 65, the normal age of retirement. &lt;/p&gt;
			&lt;p&gt;A second paper, also published in Arthritis Care &amp;amp; Research, shows that persons with increasing levels of memory impairment have lower employment rates and higher rates of reporting an inability to work (see Panopalis, et al., 2007, in publication list, below).&lt;/p&gt;
			&lt;p&gt;In a third paper, Panopalis and colleagues (see Panopalis, et al., 2008 in publication list, below) described the economic impacts of lost and reduced employment as well as health care utilization.  They reported that among persons of working ages (18 through 64), productivity losses averaged $8,659 per year, while health care utilization averaged $12,643.  Older age, greater disease activity, and worse physical and mental health status were significant predictors of higher costs due to changes in work productivity.  We believe that this is the most systematic study of the economic impact of SLE in the literature. &lt;/p&gt;
			&lt;p&gt;In a fourth paper, (Yelin, et al., 2009 in the publication list, below), we do a purely prospective analysis of work dynamics from the first year of the LOS to the end of the third complete wave.  The analysis, unlike that for the first publication above, was able to use the medical data from the study to evaluate the impact of such variables on work outcomes.  The paper also compared work dynamics of LOS participants to an age&#45;matched population in the US as a whole, using the Survey of Income and Program Participation (SIPP).  At study initiation, 405 (50%) LOS participants were employed, of whom 96 (23.7%) experienced&lt;br /&gt;
			  work loss. In multivariate analysis, only advanced age predicted work loss. In comparison to the SIPP&lt;br /&gt;
			  sample, rates of work loss were only higher after age 55. Of the 404 LOS participants not employed, 82&lt;br /&gt;
			  (20.3%) experienced work entry. In multivariate analysis, only shorter duration of disease, better physical&lt;br /&gt;
			  functioning, and time since last employment predicted work entry. In comparison to SIPP, rates of work entry&lt;br /&gt;
			  were lower in every age group.  Thus, until age 55, low rates of employment among persons with SLE may be due to lower rates of work entry rather than higher rates of work loss. Beyond age 55, both high rates of work loss and low rates of work entry contribute to low rates of employment.&lt;/p&gt;
			&lt;p&gt;In the fifth paper, we reviewed the emerging literature concerning employment outcomes of persons with SLE and present estimates of the average employment rate among persons with SLE and of the time until work loss among such persons. &lt;/p&gt;
			&lt;p&gt;A sixth paper, A Longitudinal Study of the Impact of Specific Organ Manifestations on Work Loss among Persons with SLE, is nearing completion (the statistical estimations have been completed).  In this manuscript, we estimate the time until work loss among persons with a first incidence of thrombotic, neuropsychiatric, and musculoskeletal manifestations of SLE.  We also estimate the risk factors for such work loss.  Briefly, all three manifestations affect time until work loss, but the effects are especially pronounced for those experiencing thrombotic events.  Within a year of the incidence of a thrombotic event, those with such events are more than twice as likely to have stopped working as those without.  In a Cox regression, the factors increasing the hazard of work loss included advanced age, shorter job tenure, and the presence of thrombotic, neuropsychiatric, and musculoskeletal manifestations of SLE. &lt;br /&gt;
			  &lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;C. Significance&lt;br /&gt;
			  &lt;/strong&gt;Work disability, particularly in chronic diseases with onset in the early or mid stages of work life, has profound repercussions for the individual and family, including but not limited to loss of self&#45;esteem, loss of social network in the workplace, and loss of personal earnings and household income.&lt;/p&gt;
			&lt;p&gt;Rheumatic diseases in general and rheumatoid arthritis in particular have been the subject of numerous studies of the causes and consequences of work disability.  However, relatively few studies of work disability in systemic lupus erythematosus (SLE) have been conducted.  Even fewer have analyzed risk factors for work loss and none have done so prospectively.  None of the studies of employment outcomes among persons with SLE have evaluated the interaction of the medical, demographic, and work characteristics of such persons and their environments, despite a growing body of literature indicating that the local community and economy at large can have a profound impact on work outcomes.&lt;br /&gt;
			  &lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;D. Plans&lt;br /&gt;
			  &lt;/strong&gt;In the upcoming year, we will complete the estimations for Aim 4 in which we evaluate the conjoint impact of individual&#45; and community&#45;level characteristics on employment outcomes among persons with SLE, for example, the combination of personal poverty and living in communities with high concentrations of poverty.  In the last year two years, we completed an analysis that evaluated the conjoint effects of individual&#45; and community&#45;level characteristics on other kinds of outcomes in SLE (Trupin, et al., 2008) and on access to health care (Tonner, et al., 2010).  The latter analyses, though not directly related to this project, gives us confidence both in the statistical power for the employment paper, but also in the statistical approach used in the papers about the other outcomes and access to care, respectively. &lt;br /&gt;
			&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;E. Publications&lt;br /&gt;
			  &lt;/strong&gt;&lt;strong&gt;Papers&lt;br /&gt;
			  &lt;/strong&gt;Yelin E, Trupin L, Katz P, Criswell L, Yazdany J, Gillis J, Panopalis P.&amp;nbsp; Work dynamics among persons with SLE.&amp;nbsp; Arthritis Rheum (Arthritis Care Res) 2007; 57: 56&#45;63. PMCID: PMC2875125.&lt;br /&gt;
			  Panopalis P, Julian L, Yazdany J, Gillis J, Trupin L, Hersh A, Criswell L, Katz P, Yelin E.  Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum (Arthritis Care Res) 2007; 57: 1453&#45;1460. PMCID: PMC2875137.&lt;/p&gt;
			&lt;p&gt;Panopalis P, Yazdany J, Gillis J, Julian L, Trupin L, Hersh A, Criswell L, Katz P, Yelin E. Healthcare costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.  Arthritis and Rheumatism (Arthritis Care and Research) 2008; 59:1788&#45;1795. PMCID: PMC2875149&lt;/p&gt;
			&lt;p&gt;Yelin E, Tonner C,  Trupin L, Panopalis P, Yazdany J, Julian L, Katz P, Criswell L. Work loss and work entry among persons with SLE: comparisons to a national, matched sample.   Arthritis Rheum (Arthritis Care Res), 2009; 61(2):247&#45;258. PMCID: PMC2875188.&lt;/p&gt;
			&lt;p&gt;Yazdany J, Yelin E. Health&#45;related quality of life and employment among persons with systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36:15&#45;32. PMCID: PMC2833285.&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Manuscripts in Preparation&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;Yelin E, Tonner C, Trupin L, Julian L, Katz P, Yazdany J, Criswell L.  A Longitudinal Study of the Impact of Specific Organ Manifestations on Work Loss among Persons with SLE. &lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Presentations&lt;br /&gt;
			  &lt;/strong&gt;Panopalis P, Yazdany J, Gillis J, Julian L, Morris A, Katz P, Yelin E.  Cognitive function in systemic lupus erythematosus: impact on employment status.  Presented at the 70th annual meeting of the American College of Rheumatology; Washington, DC; 11/10&#45;15/06.  Arthritis Rheum  2006; 54(9&#45;supp): S120, #155.&lt;br /&gt;
			&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;F. Project&#45;Generated Resources&lt;br /&gt;
			  &lt;/strong&gt;Not applicable&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;Gender and Minority Inclusion&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;See attached table.&lt;/p&gt;
			&lt;p&gt; 
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 3 ./rheumatology/old/research/mcrc/project3.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project3.html~</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			
			Project 3: SLE and Employment: The Impact of Individual and &lt;br&gt;
			Contextual
			Factors&lt;br&gt;
			
			(PI:  Edward Yelin, PhD)
			&lt;/b&gt;
			&lt;/center&gt;
			
			&lt;p&gt;
			&lt;img style=&quot;padding&#45;left: 6px&quot; src=&quot;/rheum/images/mcrc/project3&#45;1.jpg&quot; align=right width=200&gt;
			
			The proposed project, &quot;SLE and Employment: The Impact of Individual and Contextual Factors&quot; has two principal aims: to describe the work dynamics of persons with SLE from the year of diagnosis (an average of 13 years before the study began) through 2010 and to assess the impact of characteristics of individuals with SLE (nature of their SLE, overall health status, demographics, and work history) and characteristics of the work, residential, and macroeconomic environment on employment outcomes.  Of note, the project assesses the impact of specific job accommodations on the work outcomes of SLE.
			
			
			&lt;br&gt;
			&lt;br clear=all&gt;
			&lt;img src=&quot;/rheum/images/mcrc/project3&#45;2.jpg&quot; style=&quot;padding&#45;right: 6px&quot; align=left width=200&gt;
			
			
			The principal data source for the project is the Lupus Outcomes Study (LOS).  In the LOS, about 1,175 persons with SLE are being followed through annual structured telephone interviews conducted by trained survey workers, augmented by data on the SLE from a comprehensive review of medical charts and analysis of biological material from buccal DNA and/or blood samples.  The LOS data are being augmented by contextual information on the nature of the local communities of the LOS participants matched to the interview data at the level of the Census block group, by data on the local labor market from the Bureau of Labor Statistics, and by data from the same source on the demand for labor in specific occupations and industries in the nation as a whole.  In addition, the March Supplement to the Census Bureau's Current Population Survey (CPS) is being used to develop models of labor force participation.  The models developed in the CPS are then applied to the LOS data to provide estimates of the labor force participation of persons with SLE in the presence or absence of their illness.
			&lt;p&gt;
			The project should provide the most systematic estimates of the work outcomes of SLE and of the factors affecting those outcomes.  The information should help persons with SLE understand their work prognoses and should assist health care providers and rehabilitation professionals in devising strategies to reduce the prevalence of work disability. 
			&lt;p&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			Four papers from the project have been published. The first, published in Arthritis Care &amp; Research, provides a summary of the work history of persons with SLE from onset through the second interview as well as the factors affecting work loss in this population (see Yelin, et al., 2007, in MCRC publication list). The paper shows that the bulk of the reduced productivity of persons with SLE is due to total cessation of employment rather than reduced hours. The paper also indicates that, among persons with SLE employed at disease onset, about 65 percent will have stopped working prior to age 65, the normal age of retirement.
			&lt;p&gt;
			A second paper, also published in Arthritis Care &amp; Research, shows that persons with increasing levels of memory impairment have lower employment rates and higher rates of reporting an inability to work (see Panopalis, et al., 2007, in MCRC publication list).
			&lt;p&gt;
			In a third paper, Panopalis and colleagues (see Panopalis, et al., 2008 in MCRC publication list) described the economic impacts of lost and reduced employment as well as health care utilization. They reported that among persons of working ages (18 through 64), productivity losses averaged \$8,659 per year, while health care utilization averaged \$12,643. Older age, greater disease activity, and worse physical and mental health status were significant predictors of higher costs due to changes in work productivity. We believe that this is the most systematic study of the economic impact of SLE in the literature.
			&lt;p&gt;
			In a fourth paper, now in press (Yelin, et al., 2008 in the MCRC publication list), we do a purely prospective analysis of work dynamics from the first year of the LOS to the end of the third complete wave. The analysis, unlike that for the first publication above, is able to use the medical data from the study to evaluate the impact of such variables on work outcomes. The paper also compares work dynamics of LOS participants to an age matched population in the US as a whole, using the Survey of Income and Program Participation (SIPP). At study initiation, 405 (50%) LOS participants were employed, of whom 96 (23.7%) experienced work loss. In multivariate analysis, only advanced age predicted work loss. In comparison to the SIPP sample, rates of work loss were only higher after age 55. Of the 404 LOS participants not employed, 82 (20.3%) experienced work entry. In multivariate analysis, only shorter duration of disease, better physical
			functioning, and time since last employment predicted work entry. In comparison to SIPP, rates of work entry were lower in every age group. Thus, until age 55, low rates of employment among persons with SLE may be due to lower rates of work entry rather than higher rates of work loss. Beyond age 55, both high rates of work loss and low rates of work entry contribute to low rates of employment.
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 4 ./rheumatology/old/research/mcrc/project4.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project4.html</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			Project 4: Do Mid&#45;Life Musculoskeletal Conditions Lead to Disability in the Elderly?&lt;br&gt;
			(PI:  Kenneth Covinsky, MD, MPH)
			&lt;/b&gt;
			&lt;/centeR&gt;
			&lt;p&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcrc/project4&#45;1.jpg&quot; align=right style=&quot;padding&#45;left: 8px&quot;&gt;
			
			&lt;br /&gt;
			&lt;strong&gt;A.	Specific Aims &lt;/strong&gt;
			&lt;p&gt;The aims of project 4 focus on the relationship between musculoskeletal conditions and symptoms on disability over the life course.  In past years, we have completed work showing (1) Arthritis in midlife strongly predicts later life disability; (2) Sociodemographic characteristics had little impact on this association; (3) Arthritis has a significant but modest impact on early retirement; and (4) Persons with pain have disability profiles similar to persons 2&#45;3 decades older without pain.  Over the past year, we have completed a project examining the patterns of pain in the last 2 years of life, with a focus on the impact of arthritis.  We have also begun to examine the longitudinal impact of pain on disability. &lt;br /&gt;
			  &lt;br /&gt;
			  &lt;strong&gt;B. Studies and Results&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;&lt;u&gt;1) Arthritis and Pain at the End of Life&lt;/u&gt;&lt;/p&gt;
			&lt;p&gt;The epidemiology of pain during the last years of life has not been well described.  Further, the impact of chronic conditions such as arthritis, that do not lead to death, but may have important impacts on quality of life towards the end of life are not well described.  Our objective was to describe the prevalence and correlates of pain during the last 2 years of life, with a focus on the impact of arthritis. &lt;/p&gt;
			&lt;p&gt;We used the Health and Retirement Study (HRS) to create a nationally representative cohort of decedents.  Our study included 4703 persons who died while enrolled in the HRS.  The survey interview closest to death was used. Each participant or proxy was interviewed once in the last 24 months of life and was classified into 1 of 24 cohorts on the basis of the number of months between the interview and death. The relationship between time before death and pain was modeled and was adjusted for age, sex, race or ethnicity, education level, net worth, income, terminal diagnosis category, presence of arthritis, and proxy status.  We defined clinically significant pain, as a report that the participant was &amp;quot;often troubled&amp;quot; by pain of at least moderate severity. &lt;/p&gt;
			&lt;p&gt;The mean age at death of the 4703 decedents was 75.7 years (SD, 10.8).  83.1% were white, 10.7% were black, 4.7% were Hispanic; and 52.3% were men. The adjusted prevalence of pain 24 months before death was 26% (95% CI, 23% to 30%). The prevalence remained flat until 4 months before death (28% [CI, 25% to 32%]), then it increased, reaching 46% (CI, 38% to 55%) in the last month of life. The prevalence of pain in the last month of life was 60% among patients with arthritis versus 26% among patients without arthritis (P &amp;lt; 0.001) and did not differ by terminal diagnosis category (cancer [45%], heart disease [48%], frailty [50%], sudden death [42%], or other causes [47%]; P = 0.195).&lt;/p&gt;
			&lt;p&gt;We conclude that although the prevalence of pain increases in the last 4 months of life, pain is present in more than one quarter of elderly persons during the last 2 years of life.  Furthermore, arthritis is strongly is strongly associated with pain at the end of life, and may be a more important determinant of pain than the condition resulting in death.  Efforts to improve pain control towards the end of life need to place greater focus on chronic conditions such as arthritis which have not traditionally been the focus of efforts to decrease the burden of pain towards the end of life.&lt;br /&gt;
			  &lt;br /&gt;
			  &lt;u&gt;2) Pain as a Predictor of Incident Disability in Older Persons&lt;/u&gt;&lt;/p&gt;
			&lt;p&gt;This study is a follow&#45;up to our previously published study demonstrating a very strong cross&#45;sectional relationship between pain and disability.  The goal of this study is to test the hypothesis that pain also predicts the development of subsequent disability in older persons.  We are using the HRS to compare the rates of new disabilities in activities of daily living (ADL) in persons with pain and without pain.  Contrary to our hypothesis, our preliminary results suggest that after accounting for baseline functional limitations, pain is not a predictor of progressive disability in ADL. &lt;/p&gt;
			&lt;p&gt;Over the next project year, we will be conducting further analyses to confirm this finding, and understand the reason for the highly discordant findings between our cross&#45;sectional and longitudinal study of the pain&#45;disability relationship.&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;C. Significance:&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;We have demonstrated that arthritis has significant impacts on functioning and well&#45;being throughout mid&#45;life and late life.  Earlier results of this project demonstrated that middle aged subjects with arthritis were at higher risk for developing limitations in mobility and ADL function as they progressed into later life. &lt;/p&gt;
			&lt;p&gt;Our most recent results suggest that arthritis may be an important determinant of quality of life towards the end of life.  Management of the chronic pain resulting from arthritis may be more important than managing the pain of the terminal condition at the end of life.  The implications of this study for the practice of Palliative Medicine were described on Pallimed, a widely read blog for Palliative Medicine providers by Dr. Brian McMichael  (http://www.pallimed.org/2010/11/cartography&#45;of&#45;eol&#45;pain.html#more): &lt;/p&gt;
			&lt;p&gt;&amp;ldquo;I have felt like arthritis is this incidental given, dwarfed by the likes of angina, dyspnea, acute fracture, and malignant pain, etc.; a kind of tell&#45;me&#45;something&#45;I&#45;don&amp;rsquo;t&#45;already&#45;know entity. It&amp;rsquo;s surprising to see this common, benign condition produce such a large overall, and then burgeoning burden of pain at end&#45;of&#45;life&amp;hellip;.Even in the setting of dominant, life&#45;limiting diagnoses, we must bear in mind, the burden of chronic, underlying, benign conditions like arthritis.&amp;rdquo;&lt;/p&gt;
			&lt;p&gt;D.  Plans:&lt;/p&gt;
			&lt;p&gt;Over the next year, we will continue examining the long term impact of pain on the progression of ADL disability in elders.  The vast majority of pain in this population is caused by arthritis.&lt;/p&gt;
			&lt;p&gt;We will also be examining the impact of hip fracture on long term disability outcomes in subjects enrolled in the Health and Retirement Study&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;E.  Publication:&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;Steinman M, McQuaid K, Covinsky K.  Age and rising rates of cyclooxygenase&#45;2 inhibitor use.  Results from a national survey.  J Gen Intern Med 2006; 21: 245&#45;250.&lt;/p&gt;
			&lt;p&gt;Sands LP, Xu H, Craig BA, Eng C, Covinsky KE.  Predicting change in functional status over quarterly intervals for older adults enrolled in the PACE community&#45;based long&#45;term care program.  Aging Clinical &amp;amp; Experimental Research  2008; 20(5):419&#45;27.  PMID only 19039283&lt;/p&gt;
			&lt;p&gt;Covinsky KE, Lindquist K, Dunlop DD, Gill TM, Yelin E.  Effect of arthritis in middle age on older&#45;age functioning.  J Am Geriatr Soc 2008; 56:23&#45;28 (On&#45;line early: PMID: 18184204)&lt;/p&gt;
			&lt;p&gt;Boyd CM, Landefeld CS, Counsell SR, Palmer RM, Fortinsky RH, Kresevic D, Burant C, Covinsky KE.&lt;br /&gt;
			  Recovery of activities of daily living in older adults after hospitalization for acute medical illness. J Am Geriatr Soc 2008; 56:2171&#45;2179&lt;br /&gt;
			  &amp;nbsp;&lt;br /&gt;
			  Lee SJ, Go AS, Lindquist K, Bertenthal D, Covinsky KE. Chronic conditions and mortality among the oldest old. Am J Public Health. 2008; 98:1209&#45;1214.&lt;/p&gt;
			&lt;p&gt;Covinsky KE, Lindquist K, Dunlop DD, Yelin E.  Pain, functional limitations, and aging.  J Am Geriatr Soc.  2009; 57:1556&#45;61.&lt;/p&gt;
			&lt;p&gt;Smith AK, Cenzer IS, Knight SJ, Puntillo KA, Widera E, Williams BA, Boscardin WJ, Covinsky KE.  The Epidemiology of pain during the last 2 years of life.  Ann Intern Med 2010;153:563&#45;569&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;F. Project&#45;Generated Resources&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;Not applicable&lt;/p&gt;
			&lt;p&gt;&lt;strong&gt;GENDER AND MINORITY INCLUSION&lt;/strong&gt;&lt;/p&gt;
			&lt;p&gt;See attached table.&lt;/p&gt;
			&lt;p&gt; 
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Project 4 ./rheumatology/old/research/mcrc/project4.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/old/research/mcrc/project4.html~</Path>
		<FileBody>
			
			
			&lt;centeR&gt;
			&lt;b&gt;
			Project 4: Do Mid&#45;Life Musculoskeletal Conditions Lead to Disability in the Elderly?&lt;br&gt;
			(PI:  Kenneth Covinsky, MD, MPH)
			&lt;/b&gt;
			&lt;/centeR&gt;
			&lt;p&gt;
			&lt;img src=&quot;/rheum/images/mcrc/project4&#45;1.jpg&quot; align=right style=&quot;padding&#45;left: 8px&quot;&gt;
			Difficulty with basic tasks such as walking a short distance or basic activities of daily living (ADL) rises rapidly with age and becomes common in old age.  These disabilities have detrimental effects on quality of life in older people, and are risk factors for other adverse outcomes including death and nursing home use.  Most disability in the elderly develops insidiously from the long term interaction of many risk factors.  Musculoskeletal conditions such as arthritis and back pain are important mediators of disability.  However, few studies have used long periods of follow&#45;up to examine the impact of mid&#45;life musculoskeletal conditions on later life disability.  Doing so is important because the impact of these conditions on disabilty is likely slow and progressive.  As a result, the full impact of these conditions on disability in the elderly is likely to be underestimated unless observation begins before the onset of old age, and continues for long time periods.  
			&lt;p&gt;
			In this project, we make innovative use of the population&#45;based Health and Retirement Study (HRS) to examine the impact of self&#45;reported mid&#45;life musculoskeletal conditions (arthritis and back pain) on later life functional limitations (walking difficulty and difficulty with ADL).  We are following 9759 subjects who were age 51&#45;61 when enrolled in 1992 and will range in age from 67&#45;77 by 2008.  At baseline, subjects reported the presence of symptomatic arthritis and back pain.  At each 2&#45;year follow&#45;up subjects report whether they have difficulty with walking various differences and up stairs and with activities of daily living (bathing, dressing, transferring, toileting, and eating).  We are undertaking a comprehensive series of aims to determine the impact of mid&#45;life musculoskeletal conditions on later life disability, the impact of other demographic characteristics and comorbid conditions on these relationships, and the impact of arthritis and back pain on other outcomes closely related to disabilty including death, nursing home use, caregiver burden, and retirement.  Our aims are to: (1) examine the impact of self&#45;reported symptomatic arthritis in mid&#45;life on late life disability, including difficulty performing basic activities of daily living and mobility difficulties; (2) examine the impact of back pain in mid&#45;life on disability; (3) examine whether the impact of arthritis and back pain on disability differs in demographic groups defined by race, gender, and socio&#45;economic status; (4) examine whether the impact of arthritis and back pain on disability differs depending on the presence of other comorbid medical conditions, obesity, and depression; (5) examine whether arthritis and back pain) are associated with outcomes that are common consequences of such as caregiver burden, nursing home placement, and death; and, (6) determine whether arthritis and back pain are associated with early retirement and whether early retirement identifies a subset of subjects with musculoskeletal conditions at particularly high risk for subsequent disability.
			&lt;p&gt;
			
			
			&lt;p&gt;
			&lt;b&gt;Progress since 5/1/2006 funding:&lt;/b&gt;&lt;br&gt;
			&lt;b&gt;(i) Background:&lt;/b&gt; Difficulty doing activities important to daily living becomes very common with old age. Functional limitations are also more common in those with pain. However, it is not clear how age and pain interact to influence the prevalence of functional limitations.
			&lt;p&gt;
			&lt;b&gt;(ii) Objective:&lt;/b&gt; To examine the relationship between functional limitations and pain across a spectrum of age, ranging from mid life to advanced old age.
			&lt;p&gt;
			&lt;b&gt;(iii) Design:&lt;/b&gt; Cross&#45;sectional study.
			&lt;p&gt;
			&lt;b&gt;(iv) Setting and Participants:&lt;/b&gt; 18,531 participants in the 2004 Health and Retirement Study (HRS), a nationally representative study of community living persons over the age of 50.
			&lt;p&gt;
			&lt;b&gt;(v) Measurements:&lt;/b&gt; Participants who reported that they were often troubled with pain and that the pain was either moderate or severe most of the time were defined as having significant pain. For each of 4 functional domains, we classified subjects according to their degree of functional limitation: mobility (able to jog one mile, able to walk several blocks, able to walk one block, unable to walk one block), stair climbing (able to climb several flights, able to climb one flight, not able to climb a flight), upper extremity tasks (able to do 3,2,1 or none), and ADL function (able to do without difficulty, had difficulty but able to do without help, needs help).
			&lt;p&gt;
			&lt;b&gt;(vi) Results:&lt;/b&gt; 24% of participants had significant pain. 81% of subjects with pain reported arthritis, suggesting that pain was predominantly related to musculoskeletal conditions. Across all 4 domains, participants with pain had much higher rates of functional limitations than subjects without pain. Participants with pain were similar in terms of their degree of functional limitation to participants 2&#45;3 decades older. For example, for mobility, among subjects 50&#45;59 without pain, 37% were able to jog 1 mile, 91% were able to walk several blocks, and 96% were able to walk 1 block without difficulty. In contrast, among subjects 50&#45;59 with pain, 9% were able to jog one mile, 50% were able to walk several blocks, and 69% were able to walk one block without  difficulty. Subjects 50&#45;59 with pain were similar in terms of mobility limitations to subjects 80&#45;89 years old without pain, among whom 4% were able to jog one mile, 55% were able to walk several blocks, and 72% were able to walk one block without difficulty. After adjustment for demographic characteristics, SES, comorbid conditions, depression, obesity, and health habits, across all 4 measures, participants with significant pain were at much higher risk for having functional limitations (adjusted ORs were 2.85 (95% CI 2.20&#45;3.69) for mobility, 2.84 (2.48&#45;3.26) for stair climbing, 3.96 (3.43&#45;4.58) for upper extremity, and 4.33 (3.71&#45;5.06) for ADL.
			&lt;p&gt;
			&lt;b&gt;(vii) Conclusion:&lt;/b&gt; Subjects with pain develop the functional limitations that are classically associated with aging at much earlier ages.
			&lt;p&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Basic and Translational ./rheumatology/research/basic_trans.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/basic_trans.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Division of Rheumatology has a long history of outstanding basic and translational research.   Much of this work has been supported by the National Institutes of Health, as well as by the Howard Hughes Medical Institute and the Rosalind Russell Medical Research Center for Arthritis.&lt;/p&gt;
			
			&lt;h3&gt;Current Research Areas:&lt;/h3&gt;
			
			&lt;a href=&quot;/research/immunology.html&quot;&gt;Immunology&lt;/a&gt;
			
			&lt;br/&gt;
			&lt;a href=&quot;/research/pain_mech.html&quot;&gt;Pain Mechanisms&lt;/a&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research Centers ./rheumatology/research/centers.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/centers.html</Path>
		<FileBody>
			
			&lt;a href=&quot;/research/mcrc.html&quot;&gt;
				&lt;p&gt;UCSF Multidisciplinary Clinical Research Center Program (MCRC)&lt;/p&gt;
			&lt;/a&gt;
			
			&lt;a href=&quot;/research/ncaaf.html&quot;&gt;
				&lt;p&gt;Northern California Chapter Arthritis Foundation Center of Excellence (NCCAF)&lt;/p&gt;
			&lt;/a&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical &amp;amp; Epidemiological Research ./rheumatology/research/clinical.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Clinical and epidemiological research within the UCSF Division of Rheumatology is an active and engaging enterprise. UCSF faculty members have leadership roles in a number of prominent clinical studies including the Rheumatoid Arthritis Observational Cohort Study, California Lupus Surveillance Project (CLSP), and the Sjögren’s International Collaboration Clinical Alliance (SICCA).&lt;/p&gt;
			
			&lt;h3&gt;Current Research Areas&lt;/h3&gt;
			
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/anky.html&quot;&gt;Ankylosing Spondylitis&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/genetics.html&quot;&gt;Genetics and Epidemiology of Autoimmune Disease&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/osteoarthritis.html&quot;&gt;Osteoarthritis&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/rheumatoid.html&quot;&gt;Rheumatoid Arthritis (RA)&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/scleroderma.html&quot;&gt;Scleroderma&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/sjogren.html&quot;&gt;Sj&amp;ouml;gren’s Syndrome&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/lupus.html&quot;&gt;Systemic Lupus Erythematosus (SLE)&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/research/clinical/vasculitis.html&quot;&gt;Vasculitis&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Health Services Research ./rheumatology/research/epi_health.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/epi_health.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Opportunities for getting involved in health services research continue to grow in the Division of Rheumatology at UCSF.  Several investigators are looking at health outcomes, quality of care, and projects aimed at improving patient&#45;doctor communication.&lt;/p&gt;
			
			&lt;h2&gt;Current Investigators Include:&lt;/h2&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=51513896a3f4e98dcd8dbc5d034f0db2&amp;name=KATZ%2CPATRICIA+P&quot;&gt;Patricia Katz, PhD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Katz’s research for the past decade has focused on redefining the measurement of disability in rheumatoid arthritis (RA) and lupus to include more of the everyday activities that people value, as well as examining the impact of such disability on psychological well&#45;being and quality of life.  More recently her research has focused on looking at the impacts of obesity and physical inactivity on disability in these same populations.  As a result of that work, she is also examining the impact of obesity and physical inactivity on other health outcomes among individuals with RA and lupus.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=7b6230ec9dcd3fdd84550511053841de&amp;name=MARGARETTEN%2CMARY+E&quot;&gt;Mary Margaretten, MD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Margaretten's primary research interest involves investigating the causes of depression in patients with rheumatoid arthritis (RA). Her long&#45;term goal is to develop an intervention to treat depression in patients with RA.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=0d2d533edff89b035e373298fdf90888&amp;name=SCHMAJUK%2CGABRIELA&quot;&gt;Gabriela Schmajuk, MD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Schmajuk’s research focus is on improving the access and quality of care in rheumatic diseases. Using large databases (including data from Medicare and the VA), she looks at medication use and medication monitoring in patients with rheumatoid arthritis and systemic lupus erythematosus.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=62810d36124bea448f4595f023ec7afc&amp;name=YAZDANY%2CJINOOS&quot;&gt;Jinoos Yazdany, MD, MPH&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Jinoos Yazdany's research focuses on improving the quality of health care delivered to patients with chronic rheumatic diseases.  Although recent therapeutic advances in rheumatology have greatly improved the outcomes of these once disabling and sometimes fatal diseases, many patients have not benefited from these innovations.  Dr. Yazdany's research program aims to improve health outcomes and ensure equity in health care delivery for patients with rheumatic disease through the development, application and implementation of quality measures.  Using a combination of clinical and health services research, her work tackles three key issues facing health care delivery in rheumatology:  1) a paucity of health care quality measurement tools; 2) lack of data about whether patients are receiving high quality, evidence&#45;based care; and 3) unknown prevalence and impact of unnecessary or inappropriate health care services.  She is co&#45;Chair of the American College of Rheumatology's (ACR) Quality Measures Subcommittee, a member of the ACR's Quality of Care Committee, co&#45;Chair of the ACR's Choosing Wisely Initiative and also serves on the Health Professional Council of the National Quality Forum.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=b3323c531ea2891f1413c9e0c8e9f00b&amp;name=YELIN%2CEDWARD+H&quot;&gt;Edward Yelin, PhD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Yelin’s research is focused on the reasons why members of racial and ethnic minorities and those from lower socioeconomic status backgrounds with systemic lupus erythematosus and rheumatoid arthritis have poorer access to care and poorer outcomes.  His work emphasizes the impact of changes in the health care system in the U.S. as well as changes in the economy on the disadvantaged.  Research conducted in collaboration with his colleagues Drs. Jinoos Yazdany and Jennifer Barton focuses on the effect of the interaction between health care providers and persons with SLE and RA as a cause of disparities in outcomes.  Lastly, together with his colleagues Drs. Lindsey Criswell, Patricia Katz and others, Dr. Yelin will be continuing his work as part of the Multidisciplinary Clinical Research Center (&lt;a href=&quot;http://rheumatology.medicine.ucsf.edu/research/mcrc/index.html&quot; target=&quot;_blank&quot;&gt;MCRC&lt;/a&gt;)&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Fellows Research ./rheumatology/research/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/fellows.html</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Funding Opportunities ./rheumatology/research/funding_opportunities.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/funding_opportunities.html</Path>
		<FileBody>
			
			&lt;h2&gt;Intramural&lt;/h2&gt;
			&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://rap.ucsf.edu/&quot;&gt;The UCSF Resource Allocation Program&lt;/a&gt;
			represents a collaborative effort among funding agencies at UCSF to provide a better and more streamlined application and review process.  Applications are received and reviewed during two cycles per year.&lt;/p&gt;
			
			&lt;p&gt;&lt;a href=&quot;http://bircwh.ucsf.edu/ &quot; target=&quot;_blank&quot;&gt;The UCSF Building Interdisciplinary Research Careers in Women’s Health (BIRCwH)&lt;/a&gt;K&#45;12 training program is eliciting a new round of applications for the 2013 Women’s Health scholarship program.&lt;/p&gt;
			
			&lt;h2&gt;Foundations and other non&#45;profit organizations&lt;/h2&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.rheumatology.org/foundation/awards/index.asp&quot;&gt;Rheumatology Research Foundation (formally known as the ACR Research and Education Foundation)&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.arthritis.org/research.php&quot;&gt;Arthritis Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.lupusresearch.org/&quot;&gt;Alliance for Lupus Research&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://curearthritis.org/&quot;&gt;Arthritis National Research Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.lupusresearchinstitute.org/&quot;&gt;Lupus Research Institute&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.srfcure.org/&quot;&gt;Scleroderma Research Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.scleroderma.org/site/PageServer?pagename=prof_research_apply&quot;&gt;Scleroderma Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.lupus.org/webmodules/webarticlesnet/templates/new_researchlfa.aspx?articleid=142&amp;zoneid=31&quot;&gt;Lupus Foundation of America&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.vasculitisfoundation.org&quot;&gt;Vasculitis Foundation&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;h2&gt;NIH and other federal funding sources&lt;/h2&gt;
			
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://www.niams.nih.gov/funding/Funding_Opportunities/default.asp&quot;&gt;NIAMS&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://www.niaid.nih.gov/researchfunding/ann/pages/opps.aspx&quot;&gt;NIAID&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://cdmrp.army.mil/funding/default.shtml&quot;&gt;Congressionally Directed Medical Research Program (Dept. of Defense)&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Funding Opportunities ./rheumatology/research/funding_oppurtunities.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/funding_oppurtunities.html</Path>
		<FileBody>
			
			&lt;h2&gt;Intramural&lt;/h2&gt;
			&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://rap.ucsf.edu/&quot;&gt;The UCSF Resource Allocation Program&lt;/a&gt;
			represents a collaborative effort among funding agencies at UCSF to provide a better and more streamlined application and review process.  Applications are received and reviewed during two cycles per year.&lt;/p&gt;
			
			&lt;p&gt;&lt;a href=&quot;http://bircwh.ucsf.edu/ &quot; target=&quot;_blank&quot;&gt;The UCSF Building Interdisciplinary Research Careers in Women’s Health (BIRCwH)&lt;/a&gt;K&#45;12 training program is eliciting a new round of applications for the 2013 Women’s Health scholarship program.&lt;/p&gt;
			
			&lt;h2&gt;Foundations and other non&#45;profit organizations&lt;/h2&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.rheumatology.org/foundation/awards/index.asp&quot;&gt;Rheumatology Research Foundation (formally known as the ACR Research and Education Foundation)&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.arthritis.org/research.php&quot;&gt;Arthritis Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.lupusresearch.org/&quot;&gt;Alliance for Lupus Research&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://curearthritis.org/&quot;&gt;Arthritis National Research Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.lupusresearchinstitute.org/&quot;&gt;Lupus Research Institute&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.srfcure.org/&quot;&gt;Scleroderma Research Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.scleroderma.org/site/PageServer?pagename=prof_research_apply&quot;&gt;Scleroderma Foundation&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.lupus.org/webmodules/webarticlesnet/templates/new_researchlfa.aspx?articleid=142&amp;zoneid=31&quot;&gt;Lupus Foundation of America&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.vasculitisfoundation.org&quot;&gt;Vasculitis Foundation&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;h2&gt;NIH and other federal funding sources&lt;/h2&gt;
			
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;http://www.niams.nih.gov/funding/Funding_Opportunities/default.asp&quot;&gt;NIAMS&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://www.niaid.nih.gov/researchfunding/ann/pages/opps.aspx&quot;&gt;NIAID&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;http://cdmrp.army.mil/funding/default.shtml&quot;&gt;Congressionally Directed Medical Research Program (Dept. of Defense)&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Immunology ./rheumatology/research/immunology.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/immunology.html</Path>
		<FileBody>
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=afeebd2da1ba32ecf886b2332ea76a43&amp;name=DAIKH%2CDAVID+I&quot; target=&quot;_blank&quot;&gt;David Daikh, MD, PhD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Dr. David Daikh is the Rheumatology Division Chief at the SFVA Medical Center, and director of the rheumatology fellowship program at UCSF.  Dr. Daikh’s research focuses on immune mechanisms of rheumatic disease, and he directs a core laboratory that serves a number of investigators at UCSF.  &lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=498948be744cb4aa804822b22b68b78a&amp;name=GROSS%2CANDREW+J&quot; target=&quot;_blank&quot;&gt;Andrew Gross, MD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Dr. Andrew Gross directs the Rheumatology Clinic at UCSF Medical Center and in that role he cares for patients with a wide range of rheumatic diseases.  Dr. Gross is also involved in facilitating research studies that serve as a bridge between basic science discoveries and results that can be applied to patients who suffer from autoimmune rheumatic disease.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=7b6230ec9dcd3fdd84550511053841de&amp;name=MARGARETTEN%2CMARY+E&quot; target=&quot;_blank&quot;&gt;Mehrdad Matloubian, MD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;The goal of Dr. Mehrdad Matloubian’s research is to understand how disease&#45;causing white blood cells find their way to sites of chronic inflammation, such as the joints in rheumatoid arthritis.  His hope is that a detailed understanding of the molecular factors that guide white blood cell movement the body will provide an opportunity for pharmaceutical intervention and treatment of many autoimmune diseases.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=60139bec23caaa3d1a7330e556a0f7b5&amp;name=NAKAMURA%2CMARY+C&quot; target=&quot;_blank&quot;&gt;Mary Nakamura, MD&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Dr. Mary Nakamura’s research focuses on a relatively new field called osteoimmunology, which refers to the study of interactions between the skeletal and immune systems.  Loss of bone or osteoporosis is a significant problem for patients due to aging but the process is also accelerated by inflammatory and autoimmune diseases yet can also be worsened during therapy for these diseases.  Dr. Nakamura’s research in the laboratory focuses on understanding mechanisms that regulate bone loss particularly due to autoimmune disease.  In translational studies she is interested in determining factors that predispose rheumatoid arthritis patients to local and systemic bone loss and how bony erosion can be better assessed in patients.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=ed21bb2e57488dc61360251d1859f6c1&amp;name=PETERLIN%2CBORIS+M&quot; target=&quot;_blank&quot;&gt;Matija Peterlin, MD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Dr. Matija Peterlin’s research focuses on how genes are regulated, which concerns primarily those involved in inflammation, autoimmunity, cancer and AIDS.  These studies have led to deep insights into basic science and are being translated to human therapy in all these areas.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=76c36c78eb66d8c73ab5976c7c4f3504&amp;name=SEAMAN%2CWILLIAM+E&quot; target=&quot;_blank&quot;&gt;William Seaman, MD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Dr. William E. Seaman's research interests include the regulation of immunity and autoimmunity, primarily using mice as a model for human disease.  After working in the lab for 35 years, he recently accepted the position of Associate Chair of Medicine for Research at UCSF.  A major goal in this position is to facilitate and expand the study of patients within the Department of Medicine, an area where Rheumatology has been a leader, thanks to support by the Rosalind Russell Arthritis Center.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=45455bd9c3cb9c9aa68bbc4de895daae&amp;name=WEISS%2CARTHUR&quot; target=&quot;_blank&quot;&gt;Arthur Weiss, MD, PhD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Lymphocytes are white blood cells that play central roles in most autoimmune diseases such as rheumatoid arthritis and lupus.  Dr. Weiss’ laboratory studies investigate how the intracellular molecular machinery in lymphocytes regulates normal and abnormal responses with an aim towards understanding what goes right during normal immune responses to infections and what goes wrong in autoimmune diseases.  Understanding these molecular mechanisms provides valuable information towards developing drugs that target such intracellular machinery.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=d020d9f9f54601fa149d1056712bb5ca&amp;name=ZIKHERMAN%2CJULIE&quot; target=&quot;_blank&quot;&gt;Julie Zikherman, MD:&lt;/a&gt;&lt;/h3&gt;
			&lt;p&gt;Dr. Julie Zikherman is interested in understanding why and how patients with autoimmune diseases such as lupus develop autoantibodies. Using genetic mouse models, she has taken advantage of a new genetic tool that “reports” when and where during and after their development critical signals are encountered by B cells, the source of antibodies.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research ./rheumatology/research/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/index.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Our research programs span the spectrum of the most fundamental research questions that underlie the pathogenesis of rheumatologic diseases to research involving clinical trials of new therapies as well as studies of health care delivery systems. &lt;/p&gt;
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/matloubain.jpg&quot; class=&quot;imgRight&quot;/&gt;
			&lt;p&gt;We now have unprecedented opportunities in basic and translational research as well as increased availability of new therapeutics to address questions related to rheumatologic diseases.  Our programs capitalize on strengths across all 4 of our UCSF&#45;affiliated rheumatology sites, ensuring that we take full advantage of the many opportunities that are now available through the Clinical and Translational Science Institute at UCSF.&lt;/p&gt;
			
			&lt;p&gt;These comprehensive research programs are being funded by a wide range of sources including the National Institutes of Health, the Arthritis Foundation, the Howard Hughes Medical Institute, philanthropic efforts and industry. Philanthropic support of research efforts and educational programs is coordinated by The &lt;a href=&quot;http://www.rosalindrussellcenter.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;Russell/Engleman Rheumatology Research Center&lt;/a&gt; which was established and sited at UCSF by an act of Congress.  We are committed to training the next generation of researchers to continue to make innovative contributions to the study of Rheumatology to ultimately improve clinical care for our patients.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Multidisciplinary Clinical Research Center ./rheumatology/research/mcrc.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/mcrc.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/rheumatology.ucsf.edu/files/images/mcr_2013_group.jpg&quot;/ class=&quot;image&quot; style=&quot;margin&#45;bottom:15px&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;The broad aim of the UCSF MCRC is to improve outcomes for persons with rheumatic diseases, with a special emphasis on differences in outcomes by race/ethnicity and socioeconomic status. This overarching aim is pursued by a comprehensive program of clinical research in the rheumatic diseases, including but not limited to that within the MCRC; by serving as a catalyst for such clinical research throughout UCSF; and by systematic training of clinical investigators in the rheumatic diseases.&lt;/p&gt;
			
			&lt;p&gt;The MCRC consists of an &lt;a href=&quot;administrative_unit.pdf&quot;&gt;Administrative Unit&lt;/a&gt;, &lt;a href=&quot;methodology_core_unit.pdf&quot;&gt;Methodology Core Unit&lt;/a&gt;, two five&#45;year projects, and a &lt;a href=&quot;dandf_study.pdf&quot;&gt;Development and Feasibility Study (D&amp;F)&lt;/a&gt;. The faculty members of the MCRC span three UCSF schools (Medicine, Nursing, and Dentistry) and UC, Davis and include representatives of eight discrete academic units, including the UCSF CTSA. The Center's Director and Associate Director are Drs. Edward Yelin and Lindsey Criswell, respectively. The Director of the Methodology Core Unit is Dr. Patricia Katz. The activities of the MCRC are guided on a day&#45;to&#45;day basis by an Executive Committee. Strategic oversight of the Center is provided by Internal (UCSF) and External Advisory Committees. The Center will also have a mentorship committee of our most senior former trainees, now all in academic medicine at UCSF and three other medical schools and a biotech firm, the Graduates' Council. The research of the MCRC is based on analysis of longitudinal primary data about two specific diseases, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The primary data, the Lupus Outcomes Study, and the Rheumatoid Arthritis Outcomes Study, are shared across MCRC projects. Design and implementation of these two datasets occurs in the Methodology Core Unit. The Core Unit is also responsible for biostatistical consulting and mentorship of faculty and fellows in emerging methods of analysis. The specific five&#45;year projects are: &lt;a href=&quot;genes_ancestry_sle.pdf&quot;&gt;Genetics, Ancestry, and SLE Outcomes&lt;/a&gt; (Lindsey Criswell, P.I); and &lt;a href=&quot;outcome_study_sle.pdf&quot;&gt;Health Care Factors Affecting Outcomes of Vulnerable Populations with SLE&lt;/a&gt; (Edward Yelin, P.I.). &lt;a href=&quot;dandf_study.pdf&quot;&gt;The D&amp;F Study is: The Development of a Tailored Symptom Assessment Tool to Enhance Patient&#45; Centered Care in RA&lt;/a&gt; (Jennifer Barton, P.I.).
			
					</FileBody>
	</node>
	<node>
		<Fname>
Overview of the Research Program of the NCCAF Center of Excellence ./rheumatology/research/ncaaf.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/ncaaf.html</Path>
		<FileBody>
			&lt;p class=&quot;introduction&quot;&gt;Simply bringing together faculty from the Divisions of Rheumatology at Stanford and UCSF led to proposals for projects with substantive involvement by investigators from both institutions.&lt;/p&gt;
			
			&lt;p&gt;For this initial phase of the Center of Excellence 8 such projects have been selected using the following criteria:&lt;/p&gt;
			
			&lt;ul&gt;
				&lt;li&gt;Research projects must be consistent with the Mission of the NCCAF Center of Excellence;&lt;/li&gt;
				&lt;li&gt;Research projects must focus on RA, JIA, and/or OA;&lt;/li&gt;
				&lt;li&gt;The work proposed must be original;&lt;/li&gt;
				&lt;li&gt;The experimental plan must be feasible and include metrics;&lt;/li&gt;
				&lt;li&gt;If the project is successful, the results should have a substantive impact on the field.&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;p&gt;The organization of the Research Proposal is thematic, with the goal of promoting synergistic interactions between investigators and between projects. The themes and projects build upon existing strengths and expertise in T&#45;cell biology, vascular biology, osteoimmunology, and clinical and translational studies of rheumatic diseases. Natural areas of collaboration stemmed from the complementary infrastructure investments made by the Stanford and UCSF Divisions of Rheumatology, notably the development of cutting&#45;edge antigen microarrays and high&#45;throughput multiplex analyses (Stanford) and development of the large, well&#45;characterized observational RA Cohort with dedicated RA clinics and a biorepository of samples linked to detailed clinical data (UCSF).
			&lt;/p&gt;
			
			&lt;h2&gt;Center Themes and Projects&lt;/h2&gt;
			
			&lt;/b&gt;&lt;/p&gt;
			
			&lt;ul&gt;
				&lt;li&gt;Theme 1. Disease progression in RA
					&lt;ul&gt;
					&lt;li&gt;Project 1.1: Isolation of the affinity&#45;matured autoantibodies in active rheumatoid arthritis&lt;/li&gt;
					&lt;li&gt;Project 1.2: Development of actionable biomarkers for rheumatoid arthritis.&lt;/li&gt;
					&lt;li&gt;Project 1.3: FCRL3 polymorphisms and RA disease progression&lt;/li&gt;
					&lt;li&gt;Project 1.4: T cell signaling signatures as biomarkers in rheumatoid arthritis&lt;/li&gt;
					&lt;/ul&gt;
				&lt;/li&gt;
			&lt;/ul&gt;
			
			
			&lt;ul&gt;
				&lt;li&gt;Theme 2. Cardiovascular disease in RA
				&lt;ul&gt;
					&lt;li&gt;Project 2.1: The Molecular Mechanisms of Vascular Endothelial Dysfunction in RA&lt;/li&gt;
					&lt;li&gt;Project 2.2: Immune Aging and Cardiovascular Disease in Rheumatoid Arthritis&lt;/li&gt;
				&lt;/ul&gt;
				&lt;li&gt;
			&lt;/ul&gt;
			
			&lt;ul&gt;&lt;li&gt;Theme 3. Role of osteoclasts and monocytes in joint damage in JIA and RA&lt;/li&gt;&lt;/ul&gt;
			
			&lt;ul&gt;&lt;li&gt;Theme 4. Role of inflammation in osteoarthritis&lt;/li&gt;&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Pain Mechanisms ./rheumatology/research/pain_mech.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/pain_mech.html</Path>
		<FileBody>
			&lt;h3&gt;&lt;a href=&quot;&quot; target=&quot;_blank&quot;&gt;Jon Levine, MD, PhD:&lt;/a&gt;&lt;/h3&gt;
			
			&lt;p&gt;Dr. Jon Levine’s research program focuses on understanding mechanisms underlying pain in rheumatic diseases.  His current research includes studies of the impact of stress on pain, the transition from acute to chronic pain and gender differences in pain.  The ultimate goal is to apply findings from these basic research studies to the important problem of pain management in rheumatic disease patients.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
How to Participate ./rheumatology/research/participate.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/participate.html~</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Publications ./rheumatology/research/publications.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/publications.html</Path>
		<FileBody>
			
			
			
			&lt;h3&gt;2015&lt;/h3&gt;
			
			&lt;p&gt;Predictors of long&#45;term renal outcome in lupus nephritis trials: lessons learned from the euro&#45;lupus nephritis cohort. Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M. Arthritis Rheumatol. 2015 May;67(5):1305&#45;13. doi: 10.1002/art.39026. PMID: 25605554
			&lt;/p&gt;&lt;p&gt;An In Vivo Reporter Reveals Active B Cell Receptor Signaling in the Germinal Center. James Mueller, Mehrdad Matloubian, and Julie Zikherman. J Immunol . 2015 Apr 1;194(7):2993&#45;7. 
			Neonatal handling (resilience) attenuates water&#45;avoidance stress induced enhancement of chronic mechanical hyperalgesia. Alvarez, P., Levine, J.D. and Green, P.G. Neurosci. Lett.  2015 Mar 30;591:207&#45;11. doi: 10.1016/j.neulet.2015.01.066.
			&lt;/p&gt;&lt;p&gt;Double&#45;blind randomized placebo&#45;controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione&#45;Schreiber LG, Callahan S, Goldmuntz EA, Keyes&#45;Elstein L, Oswald M, Gregersen PK, Diamond B. Arthritis Rheumatol. 2015 Mar 16. doi: 10.1002/art.39108. PMID: 25777546
			&lt;/p&gt;&lt;p&gt;Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Nakamura MC, Yenari MA. Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke. J Neurosci. 2015 Feb 25;35(8):3384&#45;96. 
			&lt;/p&gt;&lt;p&gt;Muscle Strength Predicts Changes in Physical Function in Women with Systemic Lupus Erythematosus. Andrews JS, Trupin L, Schmajuk G, Barton J, Margaretten M, Yazdany J, Yelin EH, Katz PP. Arthritis Care Res (Hoboken).  
			&lt;/p&gt;&lt;p&gt;Cyclin&#45;Dependent Kinase 12 Increases 3' End Processing of Growth Factor&#45;Induced c&#45;FOS Transcripts. Eifler TT, Shao W, Bartholomeeusen K, Fujinaga K, Jäger S, Johnson JR, Luo Z, Krogan NJ, Peterlin BM. Mol Cell Biol. 2015 Jan 15;35(2):468&#45;78. 
			&lt;/p&gt;&lt;p&gt;Andrews JS, Trupin L, Schmajuk G, Barton J, Margaretten M, Yazdany J, Yelin E, Katz P.  Muscle strength, muscle mass, and physical disability in women with systemic lupus erythematosus.  Arthritis Care &amp; Research 2015; 67:120&#45;127.  E&#45;pub 2014
			&lt;/p&gt;&lt;p&gt;Baker JF, Long J, Ibrahim S, Leonard MB, Katz P.  Men are at greater risk of lean mass deficits in rheumatoid arthritis.  Arthritis Care &amp; Research 2015; 67:112&#45;119. E&#45;pub 2014.
			&lt;/p&gt;&lt;p&gt;Plasma Membrane Mechanisms in a Preclinical Rat Model of Chronic Pain. Ferrari LF, Levine JD. J Pain. 2015 Jan;16(1):60&#45;6. 
			&lt;/p&gt;&lt;p&gt;Homocysteine&#45;induced attenuation of vascular endothelium&#45;dependent hyperalgesia in the rat. Joseph EK, Green PG, Ferrari LF, Levine JD. Neuroscience. 2015 Jan 22;284:678&#45;84. 
			Impact of surgical excision of lesions on pain in a rat model of endometriosis. Alvarez P, Giudice LC, Levine JD. Eur J Pain. 2015 Jan;19(1):103&#45;10. 
			&lt;/p&gt;&lt;p&gt;VARIATIONS IN POTASSIUM CHANNEL GENES ARE ASSOCIATED WITH DISTINCT TRAJECTORIES OF PERSISTENT BREAST PAIN FOLLOWING BREAST CANCER SURGERY. Langford DJ, Paul SM, West CM, Dunn LB, Levine JD, Kober KM, Dodd MJ, Miaskowski C, Aouizerat BE. Pain. 2015 Jan 14.
			&lt;/p&gt;&lt;p&gt;Accounting for the delay in the transition from acute to chronic pain: axonal and nuclear mechanisms. Ferrari LF, Bogen O, Reichling DB, Levine JD. J Neurosci. 2015 Jan 14;35(2):495&#45;507.
			&lt;/p&gt;&lt;p&gt;Efficiency gains for rheumatology consultation using a novel electronic referral system in a  safety net health setting. Scheibe MM, Imboden JB, Schmajuk G, Margaretten M, Graf JD, Chen AH, Yelin EH, Yazdany J.Arthritis Care Res (Hoboken). 2015 Jan 26. doi: 10.1002/acr.22559. PMID: 25623810 
			&lt;/p&gt;
			
			
			
			&lt;h3&gt;2014&lt;/h3&gt;
			
			&lt;/p&gt;&lt;p&gt;Lupus nephritis susceptibility Loci in women with systemic lupus erythematosus. Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, Alarcon&#45;Riquelme ME, Behrens TW, Criswell LA, Graham DC, Demirci FY, Edberg JC, Gaffney PM, Harley JB, Jacob CO, Kamboh MI, Kelly JA, Manzi S, Moser&#45;Sivils KL, Russell LP, Petri M, Tsao BP, Vyse TJ, Zidovetzki R, Kretzler M, Kimberly RP, Freedman BI, Graham RR, Langefeld CD; International Consortium for Systemic Lupus Erythematosus Genetics. J Am Soc Nephrol. 2014 Dec;25(12):2859&#45;70
			&lt;/p&gt;&lt;p&gt;Computer&#45;aided and manual quantifications of MRI synovitis, bone marrow edema&#45;like lesions, erosion and cartilage loss in rheumatoid arthritis of the wrist. Yang H, Rivoire J, Hoppe M, Srikhum W, Imboden J, Link TM, Li X. Skeletal Radiol. 2014 Dec 10. 
			&lt;/p&gt;&lt;p&gt;Visualization of Positive Transcription Elongation Factor b (P&#45;TEFb) activation in living cells. Fujinaga K, Luo Z, Schaufele F, Peterlin BM. J Biol Chem. 2014 Dec 9. 
			&lt;/p&gt;&lt;p&gt;Defining novel health&#45;related quality of life domains in lung transplantation: a qualitative analysis. Singer JP, Chen J, Katz PP, Blanc PD, Kagawa&#45;Singer M, Stewart AL. Qual Life Res. 2014 Dec 4
			&lt;/p&gt;&lt;p&gt;Preoperative Breast Pain Predicts Persistent Breast Pain and Disability Following Breast Cancer Surgery. Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, Hamolsky D, Mastick J, Paul SM, Cooper B, Kober K, Dodd M, Dunn L, Aouizerat B, Miaskowski C. J Pain Symptom Manage. 2014 Dec 16. pii: S0885&#45;3924(14)00915&#45;4. 
			&lt;/p&gt;&lt;p&gt;Persistent arm pain is distinct from persistent breast pain following breast cancer surgery. Langford DJ, Paul SM, West C, Abrams G, Elboim C, Levine JD, Hamolsky D, Luce JA, Kober KM, Neuhaus JM, Cooper BA, Aouizerat BE, Miaskowski C. J Pain. 2014 Dec;15(12):1238&#45;47. doi: 10.1016/j.jpain.2014.08.013.
			&lt;/p&gt;&lt;p&gt;Persistent breast pain following breast cancer surgery is associated with persistent sensory changes, pain interference, and functional impairments. Langford DJ, Paul SM, West C, Levine JD, Hamolsky D, Elboim C, Schmidt BL, Cooper BA, Abrams G, Aouizerat BE, Miaskowski C. J Pain. 2014 Dec;15(12):1227&#45;37. 
			&lt;/p&gt;&lt;p&gt;Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain. Alvarez P, Bogen O, Levine JD. Pain. 2014 Dec;155(12):2680&#45;6. 
			&lt;/p&gt;&lt;p&gt;CRB2 Mutations Produce a Phenotype Resembling Congenital Nephrosis, Finnish type, with Cerebral Ventriculomegaly and Raised Alpha&#45;Fetoprotein. Slavotinek A, Kaylor J, Pierce H, Cahr M, DeWard SJ, Schneidman&#45;Duhovny D, Alsadah A, Salem F, Schmajuk G, Mehta L. Am J Hum Genet. 2014 Dec 30. 
			&lt;/p&gt;&lt;p&gt;Reply to letter to the editor. Deodhar A, Sieper J, Reveille JD, van der Heijde D, Gensler LS, Landewe R. Arthritis Rheumatol. 2014 Nov 21. 
			&lt;/p&gt;&lt;p&gt;The associations of leg lean mass with foot pain, posture and function in the Framingham foot study. McLean RR, Dufour AB, Katz PP, Hillstrom HJ, Hagedorn TJ, Hannan MT. J Foot Ankle Res. 2014 Nov 12;7(1):46. 
			&lt;/p&gt;&lt;p&gt;Body composition and mortality after adult lung transplantation in the United States. Singer JP, Peterson ER, Snyder ME, Katz PP, Golden JA, D'Ovidio F, Bacchetta M, Sonett JR, Kukreja J, Shah L, Robbins H, Van Horn K, Shah RJ, Diamond JM, Wickersham N, Sun L, Hays S, Arcasoy SM, Palmer SM, Ware LB, Christie JD, Lederer DJ.Am J Respir Crit Care Med. 2014 Nov 1;190(9):1012&#45;21.
			&lt;/p&gt;&lt;p&gt;Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. ACCESS Trial Group. Arthritis Rheumatol. 2014 Nov;66(11):3096&#45;104. doi: 10.1002/art.38790.
			&lt;/p&gt;&lt;p&gt;Relationships between driving distance, rheumatoid arthritis diagnosis, and disease&#45;modifying antirheumatic drug receipt. Polinski JM, Brookhart MA, Ayanian JZ, Katz JN, Kim SC, Lii J, Tonner C, Yelin E, Solomon DH. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1634&#45;43. 
			&lt;/p&gt;&lt;p&gt;Spontaneous, drug&#45;induced, and drug&#45;free remission in peripheral and axial spondyloarthritis. Poddubnyy D, Gensler LS. Best Pract Res Clin Rheumatol. 2014 Oct;28(5):807&#45;818. 
			&lt;/p&gt;&lt;p&gt;The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos&#45;Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst&#45;Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewé RB. Arthritis Rheumatol. 2014 Oct;66(10):2649&#45;56. 
			&lt;/p&gt;&lt;p&gt;Pauci&#45;immune glomerulonephritis in individuals with disease associated with levamisole&#45;adulterated cocaine: a series of 4 cases. Carlson AQ, Tuot DS, Jen KY, Butcher B, Graf J, Sam R, Imboden JB. Medicine (Baltimore). 2014 Oct;93(17):290&#45;7.
			&lt;/p&gt;&lt;p&gt;Depletion of B&#45;cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. Hsue PY, Scherzer R, Grunfeld C, Imboden J, Wu Y, Del Puerto G, Nitta E, Shigenaga J, Schnell Heringer A, Ganz P, Graf J. J Am Heart Assoc. 2014 Oct 21;3(5):e001267.
			&lt;/p&gt;&lt;p&gt;Infection is the leading cause of hospital mortality in patients with dermatomyositis/polymyositis: Data from a population&#45;based study. Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J, Margaretten M, Katz PP, Yelin EH, Yazdany J. Arthritis Care Res (Hoboken). 2014 Oct 20. 
			&lt;/p&gt;&lt;p&gt;CCR2 deficiency impairs macrophage infiltration and improves cognitive function after traumatic brain injury.Hsieh CL, Niemi EC, Wang SH, Lee CC, Bingham D, Zhang J, Cozen ML, Charo I, Huang EJ, Liu J,Nakamura MC. J Neurotrauma. 2014 Oct 15;31(20):1677&#45;88. 
			&lt;/p&gt;&lt;p&gt;Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis. Yazdany J, Tonner C, Schmajuk G, Lin GA, Trivedi AN. Arthritis Care Res (Hoboken). 2014 Oct;66(10):1447&#45;55. 
			&lt;/p&gt;&lt;p&gt;Using Medicare data to understand low&#45;value health care: the case of intra&#45;articular hyaluronic acid injections. Schmajuk G, Bozic KJ, Yazdany J. JAMA Intern Med. 2014 Oct;174(10):1702&#45;4. 
			&lt;/p&gt;&lt;p&gt;Thirty&#45;day hospital readmissions in systemic lupus erythematosus: predictors and hospital&#45; and state&#45;level variation. Yazdany J, Marafino BJ, Dean ML, Bardach NS, Duseja R, Ward MM, Dudley RA. Arthritis Rheumatol. 2014 Oct;66(10):2828&#45;36. 
			&lt;/p&gt;&lt;p&gt;Correlation of structural abnormalities of the wrist and metacarpophalangeal joints evaluated by high&#45;resolution peripheral quantitative computed tomography, 3 Tesla magnetic resonance imaging and conventional radiographs in rheumatoid arthritis. Lee CH, Srikhum W, Burghardt AJ, Virayavanich W, Imboden JB, Link TM, Li X. Int J Rheum Dis. 2014 Oct 8. 
			&lt;/p&gt;&lt;p&gt;A sharp T&#45;cell antigen receptor signaling threshold for T&#45;cell proliferation. Au&#45;Yeung BB, Zikherman J, Mueller JL, Ashouri JF, Matloubian M, Cheng DA, Chen Y, Shokat KM, Weiss A. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3679&#45;88. 
			&lt;/p&gt;&lt;p&gt;The IRF5&#45;TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Kottyan LC, Zoller EE, Bene J, Lu X, Kelly JA, Rupert AM, Lessard CJ, Vaughn SE, Marion M, Weirauch MT, Namjou B, Adler A, Rasmussen A, Glenn S, Montgomery CG, Hirschfield GM, Xie G, Coltescu C, Amos C, Li H, Ice JA, Nath SK, Mariette X, Bowman S; for UK Primary Sjögren's Syndrome Registry, Rischmueller M, Lester S, Brun JG, Gøransson LG, Harboe E, Omdal R, Cunninghame&#45;Graham DS, Vyse T, Miceli&#45;Richard C, Brennan MT, Lessard JA, Wahren&#45;Herlenius M, Kvarnström M, Illei GG, Witte T, Jonsson R, Eriksson P, Nordmark G, Ng WF; for UK Primary Sjögren's Syndrome Registry, Anaya JM, Rhodus NL, Segal BM, Merrill JT, James JA, Guthridge JM, Hal Scofield R, Alarcon&#45;Riquelme M, Bae SC, Boackle SA, Criswell LA, Gilkeson G, Kamen DL, Jacob CO, Kimberly R, Brown E, Edberg J, Alarcón GS, Reveille JD, Vilá LM, Petri M, Ramsey&#45;Goldman R, Freedman BI, Niewold T, Stevens AM, Tsao BP, Ying J, Mayes MD, Gorlova OY, Wakeland W, Radstake T, Martin E, Martin J, Siminovitch K, Moser Sivils KL, Gaffney PM, Langefeld CD, Harley JB, Kaufman KM.Hum Mol Genet. 2014 Sep 8. pii: ddu455. 
			&lt;/p&gt;&lt;p&gt;Preferential association of a functional variant in complement receptor 2 with antibodies to double&#45;stranded DNA. Zhao J, Giles BM, Taylor RL, Yette GA, Lough KM, Ng HL, Abraham LJ, Wu H, Kelly JA, Glenn SB, Adler AJ, Williams AH, Comeau ME, Ziegler JT, Marion M, Alarcón&#45;Riquelme ME, Alarcón GS, Anaya JM, Bae SC, Kim D, Lee HS, Criswell LA, Freedman BI, Gilkeson GS, Guthridge JM, Jacob CO, James JA, Kamen DL, Merrill JT, Sivils KM, Niewold TB, Petri MA, Ramsey&#45;Goldman R, Reveille JD, Scofield RH, Stevens AM, Vilá LM, Vyse TJ, Kaufman KM, Harley JB, Langefeld CD, Gaffney PM, Brown EE, Edberg JC, Kimberly RP, Ulgiati D, Tsao BP, Boackle SA; for the BIOLUPUS and GENLES Networks. Ann Rheum Dis. 2014 Sep 1. pii: annrheumdis&#45;2014&#45;205584. doi: 10.1136/annrheumdis&#45;2014&#45;205584. 
			&lt;/p&gt;&lt;p&gt;New population&#45;based reference values for spinal mobility measures based on the 2009&#45;2010 National Health and Nutrition Examination Survey. Assassi S, Weisman MH, Lee M, Savage L, Diekman L, Graham TA, Rahbar MH, Schall JI, Gensler LS, Deodhar AA, Clegg DO, Colbert RA, Reveille JD. Arthritis Rheumatol. 2014 Sep;66(9):2628&#45;37. 
			&lt;/p&gt;&lt;p&gt;Bone structure and perfusion quantification of bone marrow edema pattern in the wrist of patients with rheumatoid arthritis: a multimodality study. Teruel JR, Burghardt AJ, Rivoire J, Srikhum W, Noworolski SM, Link TM, Imboden JB, Li X. J Rheumatol. 2014 Sep;41(9):1766&#45;73. 
			&lt;/p&gt;&lt;p&gt;Side of cancer does not influence limb volumes in women prior to breast cancer surgery. Smoot B, Paul SM, Aouizerat BE, Elboim C, Levine JD, Abrams G, Hamolsky D, Neuhaus J, Schmidt B, West C, Topp K, Miaskowski C. Lymphat Res Biol. 2014 Sep;12(3):189&#45;93. 
			&lt;/p&gt;&lt;p&gt;Chakraborty AK, Weiss A.  Insights into the initiation of TCR signaling.  Nat. Immunol.  2014  Sept; 15(9)798&#45;807 
			&lt;/p&gt;&lt;p&gt;Schim van der Loeff I, Hsu LY, Saini M, Weiss A, Seddon B.  Zap70 is essential for long&#45;term survival of naive CD8 T cells.  J Immunol  2014  Sep 15;193(6):2873&#45;2880  
			&lt;/p&gt;&lt;p&gt;Application and feasibility of systemic lupus erythematosus reproductive health care quality indicators at a public urban rheumatology clinic. Quinzanos I, Davis L, Keniston A, Nash A, Yazdany J, Fransen R, Hirsh J, Zell J. Lupus. 2014 Sep 29. 
			&lt;/p&gt;&lt;p&gt;Interactions between patients, providers, and health systems and technical quality of care. Yelin E, Yazdany J, Tonner C, Trupin L, Criswell LA, Katz P, Schmajuk G. Arthritis Care Res (Hoboken). 2014 Aug 6. doi: 10.1002/acr.22427. 
			&lt;/p&gt;&lt;p&gt;MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Zhou X, Wang J, Zou H, Ward MM, Weisman MH, Espitia MG, Xiao X, Petersdorf E, Mignot E, Martin J, Gensler LS, Scheet P, Reveille JD. Ann Rheum Dis. 2014 Aug;73(8):1552&#45;7.
			&lt;/p&gt;&lt;p&gt;Temporal and geospatial trends in male factor infertility with assisted reproductive technology in the United States from 1999&#45;2010. Odisho AY, Nangia AK, Katz PP, Smith JF. Fertil Steril. 2014 Aug;102(2):469&#45;75. 
			&lt;/p&gt;&lt;p&gt;Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. Yazdany J, Trupin L, Schmajuk G, Katz PP, Yelin EH. BMJ Qual Saf. 2014 Aug;23(8):659&#45;66. 
			&lt;/p&gt;&lt;p&gt;Reactivation of latent HIV&#45;1 by new semi&#45;synthetic ingenol esters. Pandeló José D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TB, Bacchi Rabay AF, Pianowski Filho LF, Dudycz LW, Ranga U, Peterlin BM, Pianowski LF, Tanuri A, Aguiar RS. Virology. 2014 Aug;462&#45;463:328&#45;39. doi: 10.1016/j.virol.2014.05.033. 
			&lt;/p&gt;&lt;p&gt;Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, Steinman MA. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1159&#45;66. 
			&lt;/p&gt;&lt;p&gt;Post&#45;marketing experiences with belimumab in the treatment of SLE patients. Askanase AD, Yazdany J, Molta CT. Rheum Dis Clin North Am. 2014 Aug;40(3):507&#45;17
			&lt;/p&gt;&lt;p&gt;Rheumatoid arthritis quality measures and radiographic progression. Desai SP, Liu CC, Tory H, Norton T, Frits M, Lillegraven S, Weinblatt M, Coblyn J, Yazdany J, Shadick N, Solomon DH. Semin Arthritis Rheum. 2014 Aug;44(1):9&#45;13. 
			&lt;/p&gt;&lt;p&gt;Muscle Strength, Muscle Mass, and Physical Disability in Women with Systemic Lupus Erythematosus. Andrews JS, Trupin L, Schmajuk G, Barton J, Margaretten M, Yazdany J, Yelin EH, Katz PP. Arthritis Care Res (Hoboken). 2014 Jul 21. doi: 10.1002/acr.22399.
			&lt;/p&gt;&lt;p&gt;Quantitative and temporal requirements revealed for Zap70 catalytic activity during T cell development. Au&#45;Yeung BB, Melichar HJ, Ross JO, Cheng DA, Zikherman J, Shokat KM, Robey EA, Weiss A. Nat Immunol. 2014 Jul;15(7):687&#45;94. 
			&lt;/p&gt;&lt;p&gt;Lifetime medical costs of knee osteoarthritis management in the United States: Impact of extending indications for total knee arthroplasty. Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, Katz JN. Arthritis Care Res (Hoboken). 2014 Jul 21. 
			&lt;/p&gt;&lt;p&gt;Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. Yelin E, Tonner C, Kim SC, Katz JN, Ayanian JZ, Brookhart MA, Solomon DH. Arthritis Care Res (Hoboken). 2014 Jul;66(7):980&#45;9
			&lt;/p&gt;&lt;p&gt;A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus. Kaiser R, Tang LF, Taylor KE, Sterba K, Nititham J, Brown EE, Edberg JC, McGwin G Jr, Alarcón GS, Ramsey&#45;Goldman R, Reveille JD, Vilá LM, Petri M, Rauch J, Miller E, Mesznik K, Kwok PY, Kimberly RP, Salmon JE, Criswell LA. Arthritis Rheumatol. 2014 Jul;66(7):1882&#45;7. doi: 10.1002/art.38520.
			&lt;/p&gt;&lt;p&gt;Genetic analysis of the structure and function of 7SK small nuclear ribonucleoprotein (snRNP) in cells. Fujinaga K, Luo Z, Peterlin BM. J Biol Chem. 2014 Jul 25;289(30):21181&#45;90.
			&lt;/p&gt;&lt;p&gt;Spine fractures in ankylosing spondylitis: a case report and review of imaging as well as predisposing factors to falls and fractures. Fatemi G, Gensler LS, Learch TJ, Weisman MH. Semin Arthritis Rheum. 2014 Aug;44(1):20&#45;4. 
			&lt;/p&gt;&lt;p&gt;ATP release mechanisms of endothelial cell&#45;mediated stimulus&#45;dependent hyperalgesia. Joseph EK, Green PG, Levine JD. J Pain. 2014 Jul;15(7):771&#45;7. 
			&lt;/p&gt;&lt;p&gt;Does the antihyperalgesic disruptor of endothelial cells, octoxynol&#45;9, alter nociceptor function? Chen X, Green PG, Levine JD. J Neurophysiol. 2014 Jul 15;112(2):463&#45;6. 
			&lt;/p&gt;&lt;p&gt;Screening the role of pronociceptive molecules in a rodent model of endometriosis pain. Alvarez P, Levine JD. J Pain. 2014 Jul;15(7):726&#45;33. 
			&lt;/p&gt;&lt;p&gt;Longitudinal validation of the Brief Index of Lupus Damage. Katz P, Trupin L, Rush S, Yazdany J. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1057&#45;62. 
			&lt;/p&gt;&lt;p&gt;Barton JL, Trupin L, Tonner C, Imboden J, Katz P, Schillinger D, Yelin E.  English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis.  Journal of Rheumatology 2014; 41:1290&#45;1297
			&lt;/p&gt;&lt;p&gt;The &quot;Prediction of Alcohol Withdrawal Severity Scale&quot; (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Maldonado JR, Sher Y, Ashouri JF, Hills&#45;Evans K, Swendsen H, Lolak S, Miller AC. Alcohol. 2014 Jun;48(4):375&#45;90. 
			&lt;/p&gt;&lt;p&gt;Distinct phases in the positive selection of CD8+ T cells distinguished by intrathymic migration and T&#45;cell receptor signaling patterns. Ross JO, Melichar HJ, Au&#45;Yeung BB, Herzmark P, Weiss A, Robey EA. Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2550&#45;8. 
			&lt;/p&gt;&lt;p&gt;Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome. Gong YZ, Nititham J, Taylor K, Miceli&#45;Richard C, Sordet C, Wachsmann D, Bahram S, Georgel P, Criswell LA, Sibilia J, Mariette X, Alsaleh G, Gottenberg JE. J Autoimmun. 2014 Jun;51:57&#45;66. doi: 10.1016/j.jaut.2013.11.003. 
			&lt;/p&gt;&lt;p&gt;Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter&#45;proximal pausing of RNA polymerase II on the HIV long terminal repeat. Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J. Mol Cell Biol. 2014 Jun;34(11):1911&#45;28. 
			&lt;/p&gt;&lt;p&gt;Katz P, Trupin L, Rush S, Yazdany J. Longitudinal validation of the Brief Index of Lupus Damage (BILD). Arthritis Care &amp; Research 2014; 66:1057&#45;1062.
			&lt;/p&gt;&lt;p&gt;Drenkard C, Yazdany J, Trupin L, Katz PP, Dunlop&#45;Thomas C, Bao G, Lim SS. Validity of a self&#45;administered version of the Brief Index of Lupus Damage in a predominantly African American systemic lupus erythematosus cohort.  Arthritis Care &amp; Research 2014; 66:888&#45;896.
			&lt;/p&gt;&lt;p&gt;Role for monocyte chemoattractant protein&#45;1 in the induction of chronic muscle pain in the rat. Alvarez P, Green PG, Levine JD. Pain. 2014 Jun;155(6):1161&#45;7.
			&lt;/p&gt;&lt;p&gt;Identification of patient subgroups and risk factors for persistent arm/shoulder pain following breast cancer surgery. Miaskowski C, Paul SM, Cooper B, West C, Levine JD, Elboim C, Hamolsky D, Abrams G, Luce J, Dhruva A, Langford DJ, Merriman JD, Kober K, Baggott C, Leutwyler H, Aouizerat BE. Eur J Oncol Nurs. 2014 Jun;18(3):242&#45;53. 
			&lt;/p&gt;&lt;p&gt;Elevated Risk for Autoimmune Disorders in Iraq and Afghanistan Veterans with Posttraumatic Stress Disorder.O'Donovan A, Cohen BE, Seal KH, Bertenthal D, Margaretten M, Nishimi K, Neylan TC. Biol Psychiatry. 2014 Jun 28. pii: S0006&#45;3223(14)00457&#45;0. 
			&lt;/p&gt;&lt;p&gt;Efficacy and safety of atacicept for prevention of flares in patients with moderate&#45;to&#45;severe systemic lupus erythematosus (SLE): 52&#45;week data (APRIL&#45;SLE randomised trial). Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Ann Rheum Dis. 2014 Jun 20. pii: annrheumdis&#45;2013&#45;205067. doi: 10.1136/annrheumdis&#45;2013&#45;205067.
			&lt;/p&gt;&lt;p&gt;Challenges in understanding the role of pregnancy morbidity in cardiovascular risk in SLE. Simard JF, Yazdany J. Lupus Sci Med. 2014 Jun 10;1(1):e000035. 
			&lt;/p&gt;&lt;p&gt;Validity of a self&#45;administered version of the brief index of lupus damage in a predominantly African American systemic lupus erythematosus cohort. Drenkard C, Yazdany J, Trupin L, Katz PP, Dunlop&#45;Thomas C, Bao G, Lim SS. Arthritis Care Res (Hoboken). 2014 Jun;66(6):888&#45;96. 
			&lt;/p&gt;&lt;p&gt;Ann Rheum Dis. 2014 Jun;73(6):1060&#45;6.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.  Cottrell TR, Wise RA, Wigley FM, Boin F.
			&lt;/p&gt;&lt;p&gt;Pak2 is required for actin cytoskeleton remodeling, TCR signaling, and normal thymocyte development and maturation. Phee H, Au&#45;Yeung BB, Pryshchep O, O'Hagan KL, Fairbairn SG, Radu M, Kosoff R, Mollenauer M, Cheng D, Chernoff J, Weiss A. Elife. 2014 May 13;3:e02270. 
			&lt;/p&gt;&lt;p&gt;Development and validation of a lung transplant&#45;specific disability questionnaire. Singer JP, Blanc PD, Dean YM, Hays S, Leard L, Kukreja J, Golden J, Katz PP. Thorax. 2014 May;69(5):437&#45;42. doi: 10.1136/thoraxjnl&#45;2013&#45;204557. 
			&lt;/p&gt;&lt;p&gt;Educational and vocational outcomes of adults with childhood&#45; and adult&#45;onset systemic lupus erythematosus: nine years of followup. Lawson EF, Hersh AO, Trupin L, von Scheven E, Okumura MJ, Yazdany J, Yelin EH. Arthritis Care Res (Hoboken). 2014 May;66(5):717&#45;24.
			&lt;/p&gt;&lt;p&gt;MHC associations with clinical and autoantibody manifestations in European SLE. Morris DL, Fernando MM, Taylor KE, Chung SA, Nititham J, Alarcón&#45;Riquelme ME, Barcellos LF, Behrens TW, Cotsapas C, Gaffney PM, Graham RR, Pons&#45;Estel BA, Gregersen PK, Harley JB, Hauser SL, Hom G, Langefeld CD, Noble JA, Rioux JD, Seldin MF; Systemic Lupus Erythematosus Genetics Consortium, Vyse TJ, Criswell LA. Genes Immun. 2014 Apr;15(4):210&#45;7. doi: 10.1038/gene.2014.6. 
			&lt;/p&gt;&lt;p&gt;Genetic, genomic and epigenetic studies as tools for elucidating disease pathogenesis in primary Sjögren's syndrome. Miceli&#45;Richard C, Criswell LA. Expert Rev Clin Immunol. 2014 Apr;10(4):437&#45;44. doi: 10.1586/1744666X.2014.901888. Review.
			&lt;/p&gt;&lt;p&gt;Two functional lupus&#45;associated BLK promoter variants control cell&#45;type&#45; and developmental&#45;stage&#45;specific transcription. Guthridge JM, Lu R, Sun H, Sun C, Wiley GB, Dominguez N, Macwana SR, Lessard CJ, Kim&#45;Howard X, Cobb BL, Kaufman KM, Kelly JA, Langefeld CD, Adler AJ, Harley IT, Merrill JT, Gilkeson GS, Kamen DL, Niewold TB, Brown EE, Edberg JC, Petri MA, Ramsey&#45;Goldman R, Reveille JD, Vilá LM, Kimberly RP, Freedman BI, Stevens AM, Boackle SA, Criswell LA, Vyse TJ, Behrens TW, Jacob CO, Alarcón&#45;Riquelme ME, Sivils KL, Choi J, Joo YB, Bang SY, Lee HS, Bae SC, Shen N, Qian X, Tsao BP, Scofield RH, Harley JB, Webb CF, Wakeland EK, James JA, Nath SK, Graham RR, Gaffney PM. Am J Hum Genet. 2014 Apr 3;94(4):586&#45;98. doi: 10.1016/j.ajhg.2014.03.008.
			&lt;/p&gt;&lt;p&gt;Release of positive transcription elongation factor b (P&#45;TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide&#45;inducible protein (HEXIM1) transcription. Liu P, Xiang Y, Fujinaga K, Bartholomeeusen K, Nilson KA, Price DH, Peterlin BM. J Biol Chem. 2014 Apr 4;289(14):9918&#45;25.
			&lt;/p&gt;&lt;p&gt;Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, Stone MA, Corr M, Gensler LS, Gladman D, Morgan A, Marzo&#45;Ortega H, Ward MM; SPARCC (Spondyloarthritis Research Consortium of Canada), TASC (Australo&#45;Anglo&#45;American Spondyloarthritis Consortium),, Learch TJ, Reveille JD, Brown MA, Weisman MH. Ann Rheum Dis. 2014 Apr 10.
			&lt;/p&gt;&lt;p&gt;Proteome&#45;wide analysis and CXCL4 in systemic sclerosis. Su R, Schmajuk G. N Engl J Med. 2014 Apr 17;370(16):1562. 
			&lt;/p&gt;&lt;p&gt;Wang H, Flach H, Onizawa M, Wei L, McManus MT, Weiss A. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia&#45;regulated microRNA miR&#45;210. Nat Immunol. 2014 Apr; 15(4):393&#45;401.
			&lt;/p&gt;&lt;p&gt;Limnander A, Zikherman J, Lau T, Leitges M, Weiss A, Roose JP. Protein kinase cd promotes transitional B cell&#45;negative selection and limits proximal B cell receptor signaling to enforce tolerance. Mol Cell Biol. 2014 Apr; 34(8):1474&#45;85.
			&lt;/p&gt;&lt;p&gt;Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Arthritis Care Res (Hoboken). 2014 Apr;66(4):617&#45;24. 
			&lt;/p&gt;&lt;p&gt;Protein kinase Cδ promotes transitional B cell&#45;negative selection and limits proximal B cell receptor signaling to enforce tolerance. Limnander A, Zikherman J, Lau T, Leitges M, Weiss A, Roose JP. Mol Cell Biol. 2014 Apr;34(8):1474&#45;85. 
			&lt;/p&gt;&lt;p&gt;Distinct structural and catalytic roles for Zap70 in formation of the immunological synapse in CTL. Jenkins MR, Stinchcombe JC, Au&#45;Yeung BB, Asano Y, Ritter AT, Weiss A, Griffiths GM. Elife. 2014 Mar 4;3:e01310. 
			&lt;/p&gt;&lt;p&gt;Second messengers mediating the expression of neuroplasticity in a model of chronic pain in the rat. Ferrari LF, Bogen O, Levine JD. J Pain. 2014 Mar;15(3):312&#45;20. 
			&lt;/p&gt;&lt;p&gt;Variations in potassium channel genes are associated with breast pain in women prior to breast cancer surgery. Langford DJ, West C, Elboim C, Cooper BA, Abrams G, Paul SM, Schmidt BL, Levine JD, Merriman JD, Dhruva A, Neuhaus J, Leutwyler H, Baggott C, Sullivan CW, Aouizerat BE, Miaskowski C. J Neurogenet. 2014 Mar&#45;Jun;28(1&#45;2):122&#45;35. 
			&lt;/p&gt;&lt;p&gt;Bone and the innate immune system. Charles JF, Nakamura MC. Curr Osteoporos Rep. 2014 Mar;12(1):1&#45;8. 
			&lt;/p&gt;&lt;p&gt;Interprofessional communication skills training for serious illness: evaluation of a small&#45;group, simulated patient intervention. Bays AM, Engelberg RA, Back AL, Ford DW, Downey L, Shannon SE, Doorenbos AZ, Edlund B, Christianson P, Arnold RW, O'Connor K, Kross EK, Reinke LF,Cecere Feemster L, Fryer&#45;Edwards K, Alexander SC, Tulsky JA, Curtis JR. J Palliat Med. 2014 Feb;17(2):159&#45;66. 
			&lt;/p&gt;&lt;p&gt;End&#45;stage renal disease in African Americans with lupus nephritis is associated with APOL1. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey&#45;Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis–End‐Stage Renal Disease Consortium.  Arthritis Rheumatol. 2014 Feb;66(2):390&#45;6. doi: 10.1002/art.38220
			&lt;/p&gt;&lt;p&gt;Genetics of rheumatoid arthritis contributes to biology and drug discovery. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli&#45;Richard C, Bang SY, Lee HS, Martin J, Gonzalez&#45;Gay MA, Rodriguez&#45;Rodriguez L, Rantapää&#45;Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M; RACI consortium; GARNET consortium, Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM. Nature. 2014 Feb 20;506(7488):376&#45;81. doi: 10.1038/nature12873. 
			&lt;/p&gt;&lt;p&gt;Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti&#45;nuclear antibody production in Lyn&#45;deficient mice. Hua Z, Gross AJ, Lamagna C, Ramos&#45;Hernández N, Scapini P, Ji M, Shao H, Lowell CA, Hou B, DeFranco AL. J Immunol. 2014 Feb 1;192(3):875&#45;85.
			&lt;/p&gt;&lt;p&gt;Annual average ambient particulate matter exposure estimates, measured home particulate matter, and hair nicotine are associated with respiratory outcomes in adults with asthma. Balmes JR, Cisternas M, Quinlan PJ, Trupin L, Lurmann FW, Katz PP, Blanc PD. Environ Res. 2014 Feb;129:1&#45;10. 
			&lt;/p&gt;&lt;p&gt;Responding to clinicians who fail to follow patient safety practices: perceptions of physicians, nurses, trainees, and patients. Driver TH, Katz PP, Trupin L, Wachter RM. J Hosp Med. 2014 Feb;9(2):99&#45;105. 
			Out&#45;of&#45;pocket fertility patient expense: data from a multicenter prospective infertility cohort. Wu AK, Odisho AY, Washington SL 3rd, Katz PP, Smith JF. J Urol. 2014 Feb;191(2):427&#45;32. 
			&lt;/p&gt;&lt;p&gt;Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery. Stephens K, Cooper BA, West C, Paul SM, Baggott CR, Merriman JD, Dhruva A, Kober KM, Langford DJ, Leutwyler H, Luce JA, Schmidt BL, Abrams GM, Elboim C, Hamolsky D, Levine JD, Miaskowski C, Aouizerat BE. J Pain. 2014 Feb;15(2):169&#45;80. 
			&lt;/p&gt;&lt;p&gt;CIITA: a master regulator of adaptive immunity shows its innate side in the bone. Nakamura MC. J Bone Miner Res. 2014 Feb;29(2):287&#45;9.
			&lt;/p&gt;&lt;p&gt;Tan YX, Manz BN, Freedman TS, Zhang C, Shokat KM, Weiss A. Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling. Nat Immunol. 2014 Feb; 15(2):186&#45;94.
			&lt;/p&gt;&lt;p&gt;Nucleic Acids Res. 2014 Feb;42(3):1757&#45;71. Stress&#45;induced changes in gene interactions in human cells. Nayak RR1, Bernal WE, Lee JW, Kearns MJ, Cheung VG.
			&lt;/p&gt;&lt;p&gt;Iwashima M, Irving BA, van Oers NS, Chan AC, Weiss A.  Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases.  Science  1994  Feb 25;263(5150):1136&#45;1139.
			&lt;/p&gt;&lt;p&gt;Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Bernatsky S, Ramsey&#45;Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, Jacobsen S, Manzi S, Ginzler EM, Isenberg D, Rahman A, Gordon C, Ruiz&#45;Irastorza G, Yelin E, Bae SC, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero&#45;Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, Sturfelt GK, Blanco I, Feldman CH, Dreyer L, Patel NM, St Pierre Y, Clarke AE. Ann Rheum Dis. 2014 Jan;73(1):138&#45;42. doi: 10.1136/annrheumdis&#45;2012&#45;202099.
			&lt;/p&gt;&lt;p&gt;Development and validation of the spondyloarthritis radiography module for calibration of readers using the modified Stoke Ankylosing Spondylitis Spine Score. Maksymowych WP, Learch T, Lambert RG, Ward M, Haroon N, Inman R, Salonen D, Gensler LS, Weisman MH. Arthritis Care Res (Hoboken). 2014 Jan;66(1):55&#45;62. 
			&lt;/p&gt;&lt;p&gt;Ectopic endometrium&#45;derived leptin produces estrogen&#45;dependent chronic pain in a rat model of endometriosis. Alvarez P, Bogen O, Chen X, Giudice LC, Levine JD. Neuroscience. 2014 Jan 31;258:111&#45;20. 
			&lt;/p&gt;&lt;p&gt;NOP receptor mediates anti&#45;analgesia induced by agonist&#45;antagonist opioids. Gear RW, Bogen O, Ferrari LF, Green PG, Levine JD. Neuroscience. 2014 Jan 17;257:139&#45;48. 
			&lt;/p&gt;&lt;p&gt;Jenkins MR, Stinchcombe JC, Ritter AT, Au&#45;Yeung BB, Weiss A, Griffiths GM.  Distinct structural and catalytic roles for Zap70 in formation of the immunological synapse in CTL.  Elife. 2014 Jan 1;3:e01310. doi: 10.7554/eLife.01310. 
			&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Trials ./rheumatology/research/trials.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/trials.html</Path>
		<FileBody>
			
			&lt;p&gt;Content goes here.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Ankylosing Spondylitis ./rheumatology/research/clinical/anky.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/anky.html</Path>
		<FileBody>
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=bc5b1e3f809e1eac458c90f77451d8bd&amp;name=GENSLER%2CLIANNE+S.&quot;&gt;Lianne Gensler, MD:&lt;/a&gt;&lt;/h3&gt;
			
			&lt;p&gt;Dr. Lianne Gensler is the Ankylosing Spondylitis (AS) Clinic Director and performs research in AS and related fields. Currently, she is enrolling patients in 2 observational studies to better understand outcomes in patients with AS.  One of these is in collaboration with other investigators to better understand the genetic contributions towards the disease.  She is also studying a survey tool to identify patients with AS early, with the hope of reducing the current delay to diagnosis of 5&#45;10 years.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Genetics and Epidemiology of Autoimmune Disease ./rheumatology/research/clinical/genetics.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/genetics.html</Path>
		<FileBody>
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=c8efd73be3ebada424ea407e082dc9ec&amp;name=CRISWELL%2CLINDSEY+A&quot;&gt;Lindsey Criswell, MD, MPH, DSc:&lt;/a&gt;&lt;/h3&gt;
			
			&lt;p&gt;Dr. Lindsey Criswell’s research focuses on identifying the genes that contribute to risk and severity of systemic lupus erythematosus, rheumatoid arthritis, and related diseases.  Through this work, Dr. Criswell and her collaborators have helped to define biologic pathways that contribute to the development of these disorders.  Ultimately, this work will inform the development of new treatments for these disorders and provide better diagnostic and prognostic tools.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Systemic Lupus Erythematosus (SLE) ./rheumatology/research/clinical/lupus.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/lupus.html</Path>
		<FileBody>
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=4dc744193bb4e2395adc2c92000c06bf&amp;name=DALL%27ERA%2CMARIA+C&quot;&gt;Maria Dall’Era, MD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Dall’Era is the Director of the UCSF Lupus Clinic, which cares for over 200 patients with systemic lupus erythematosus from all over Northern California.  Her research focuses on the design and conduct of clinical trials in order to develop safer and more effective medications for the treatment of lupus. Her work also looks at the symptoms, clinical course, treatments, and outcomes of lupus patients in a prospective registry.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=c8efd73be3ebada424ea407e082dc9ec&amp;name=CRISWELL%2CLINDSEY+A&quot;&gt;Lindsey Criswell, MD, MPH, DSc&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Lindsey Criswell’s lupus research focuses on identifying the genes that contribute to the risk and severity of the disease.  Through this work, Dr. Criswell and her collaborators have helped to define biologic pathways that contribute to the development of SLE.  Ultimately, this work will inform the development of new treatments and provide better diagnostic and prognostic tools.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=7e4fdef0fe0606ffda3a16629b518d8a&amp;name=WOFSY%2CDAVID&quot;&gt;David Wofsy, MD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. David Wofsy conducts clinical trials of new therapies designed to translate recent advances in basic research into safe and effective new treatments for people with severe rheumatic diseases, including in particular systemic lupus erythematosus (SLE).  Within the past two years, this work has culminated in the demonstration of effective new approaches to induce and maintain remission in people with life&#45;threatening kidney disease due to SLE.  This work is based in large part on pioneering basic research conducted at the Rosalind Russell Center by Drs. Wofsy and Daikh.  This research has already contributed to the approval of a new drug for rheumatoid arthritis, which is also currently under investigation for use in SLE patients.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=62810d36124bea448f4595f023ec7afc&amp;name=YAZDANY%2CJINOOS&quot;&gt;Jinoos Yazdany, MD, MPH&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;A key focus of Jinoos Yazdany's lupus research program has been examining the quality of health care delivered to patients with lupus.  In 2009, with lupus experts from around the United States, she spearheaded the development of the first quality measure set for lupus.  Subsequently, she has gone on to apply these measures to understand health care quality for patients with lupus.  Her work has highlighted gaps in care for the condition, disparities in quality for vulnerable populations such as the uninsured, and also identified preventable medication errors.  Dr. Yazdany's research has been informed by her experiences as a physician caring for patients with lupus.  She currently co&#45;Directs the Lupus Clinic at UCSF, and also the Lupus Clinic at San Francisco General Hospital.  In 2011, she was awarded the Mary Betty Stevens Young Investigator Prize from the Lupus Foundation of America.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Osteoarthritis ./rheumatology/research/clinical/osteoarthritis.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/osteoarthritis.html</Path>
		<FileBody>
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=63b2160b29065ca1794286f7030b6bff&amp;name=CHAGANTI%2CRAMANI+KRISHNA&quot;&gt;Krishna Chaganti, MD, MS:&lt;/a&gt;&lt;/h3&gt;
			
			&lt;p&gt;Dr. Chaganti’s primary focus is on clinical patient care.  She sees general rheumatology patients on the Parnassus campus and osteoarthritis patients at the Orthopedic Institute at Mission Bay. She has been actively engaged in collaborative research regarding the epidemiology of osteoarthritis, using established multicenter databases based at UCSF and elsewhere.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Rheumatoid Arthritis (RA) ./rheumatology/research/clinical/rheumatoid.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/rheumatoid.html</Path>
		<FileBody>
			
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=8b413233a93e914828059f859a6a1b23&amp;name=GRAF%2CJONATHAN+D&quot;&gt;Jon Graf, MD:&lt;/a&gt;&lt;/h3&gt;
			
			&lt;p&gt;Dr. Graf is the Director of the Rheumatoid Arthritis (RA) Clinic at San Francisco General Hospital and co&#45;director of the UCSF RA cohort.  His research focuses on clinical and translational studies of RA, including studies that look at novel therapeutics, biomarkers, and cardiovascular risk in patients with RA.  Dr. Graf is also a very talented clinician educator and he has received many teaching awards for his contributions in this area.&lt;/p&gt;
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=b80afbe9d11c18bd53766169d66127b9&amp;name=IMBODEN%2CJOHN+B&quot;&gt;John Imboden, MD:&lt;/a&gt;&lt;/h3&gt;
			
			&lt;p&gt;Dr. Imboden is the Rheumatology Division Chief at San Francisco General Hospital.  He is also the founder of the UCSF RA Cohort.  Dr. Imboden’s research interests relate broadly to immune mechanisms in rheumatic disease, spanning from basic laboratory research to studies in humans with RA and other rheumatic disorders. &lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Scleroderma ./rheumatology/research/clinical/scleroderma.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/scleroderma.html</Path>
		<FileBody>
			
			&lt;h4&gt;UCSF Scleroderma Cohort Study&lt;/h4&gt;
			
			&lt;p&gt;The UCSF Scleroderma Cohort Study is a collaborative effort between leading experts in the departments of Rheumatology (Drs. &lt;a href=&quot;http://profiles.ucsf.edu/andrew.gross&quot; target=&quot;new&quot;&gt;Gross&lt;/a&gt; and &lt;a href=&quot;http://profiles.ucsf.edu/lianne.gensler&quot; target=&quot;new&quot;&gt;Gensler&lt;/a&gt;), Dermatology (Drs. &lt;a href=&quot;http://profiles.ucsf.edu/anna.haemel&quot; target=&quot;new&quot;&gt;Haemel&lt;/a&gt; and &lt;a href=&quot;http://profiles.ucsf.edu/kari.connolly&quot; target=&quot;new&quot;&gt;Connolly&lt;/a&gt;), and Pulmonology (Drs. &lt;a href=&quot;http://profiles.ucsf.edu/paul.wolters&quot; target=&quot;new&quot;&gt;Wolters&lt;/a&gt; and &lt;a href=&quot;http://profiles.ucsf.edu/jeffrey.golden&quot; target=&quot;new&quot;&gt;Golden&lt;/a&gt;). The purpose of this study is to develop a prospective cohort of patients with autoimmune cutaneous and rheumatic diseases in order to assess changes in clinical manifestations, disease activity, disease damage, quality of life, and disability over time. &lt;/p&gt;
			
			&lt;p&gt;With this information, we plan to better understand the pathophysiology of rheumatic diseases and evaluate the effects of current therapies in hopes to one day, develop even better treatments to help patients.&lt;/p&gt; 
			
			&lt;p&gt;Although the set of causes of these autoimmune diseases is unknown, it is thought that a gene&#45;environment interaction is necessary. This database will serve to collect clinical information that will be used in conjunction with tissue and or sample collection protocols to determine whether certain clinical manifestations correlate with specific genetic markers. Lastly, we hope to establish a pool of potential patients for enrollment in future studies.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Sj&amp;ouml;gren’s Syndrome ./rheumatology/research/clinical/sjogren.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/sjogren.html</Path>
		<FileBody>
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=c8efd73be3ebada424ea407e082dc9ec&amp;name=CRISWELL%2CLINDSEY+A&quot;&gt;Lindsey Criswell, MD, MPH, DSc&lt;/a&gt; and &lt;a href=&quot;/faculty/index.html?key=6306c7779a08f08c80b5c6a57dc97f4a&amp;name=SACK%2CKENNETH+E&quot;&gt;Ken Sack, MD&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Drs. Criswell and Sack are contributing to research efforts in Sjögren’s Syndrome through their participation in the NIH&#45;funded Sjögren’s International Collaboration Clinical Alliance (&lt;a href=&quot;http://sicca.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;SICCA&lt;/a&gt;).  In addition to extensive clinical information, a bank of salivary gland tissue, blood and other biospecimens have been obtained from over 3,000 participants and are made available to worldwide investigators.  These studies have led to the development of new classification criteria for Sjögren’s Syndrome.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Vasculitis (Giant Cell Arteritis, Polyarteritis Nodosa, Wegener’s Granulomatosis) ./rheumatology/research/clinical/vasculitis.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./rheumatology/research/clinical/vasculitis.html</Path>
		<FileBody>
			
			&lt;h3&gt;&lt;a href=&quot;/faculty/index.html?key=214ecee2bb05a12e95c5802e7a2ed5fa&amp;name=CHUNG%2CSHARON+A.&quot;&gt;Sharon Chung, MD, MAS&lt;/a&gt;:&lt;/h3&gt;
			
			&lt;p&gt;Dr. Chung’s research and clinical program focuses on the study of vasculitis, a group of life&#45;threatening diseases caused by inflammation of the blood vessels.  As the director of the UCSF Vasculitis Clinic, she works with other UCSF specialists to provide expert care in diagnosing and treating these rare and intensively complex diseases.  Dr. Chung also leads state&#45;of&#45;the&#45;art genetic and epigenetic research studies, and collaborates with national and international research networks, to help identify the biologic mechanisms that lead to vasculitis in order to develop less toxic treatments and more informative diagnostic tests. &lt;/p&gt;
			
					</FileBody>
	</node>
</nodes>